

# 2023 Payment Policies

MVP Health Care<sup>®</sup> policy and procedure guidelines.

Updated May 11, 2023

# **MVP Payment Policies**

# Table of Contents

#### Click on a policy name to view.

After-Hours Allergy Testing and Serum Preparation Claims **Evaluation and Management** Arthroscopic, Endoscopic, and other Non Gastro **Intestinal Scope Procedures** Article 28 Split Billing **Audiology Services** Audio-Only (Vermont Only) Behavioral Health Non-Licensed Provider (Vermont Only) **Consistency of Denials Contrast Materials** COVID-19 Lab Testing **Default Pricing** Diabetic Management and Nutritional Counseling **Diagnosis Matching Edits Durable Medical Equipment** Elective Delivery for Providers and Facilities **Emergency Department - Physician** EyeMed Payment Policy Eye Wear Coverage Home Infusion Incident to Guidelines Infusion Policy Interpreter Services JW and JZ Modifiers Laboratory Services Locum Tenens Mental Health and Substance Use Disorder

Mid-Level Payment Policy Modifier Policy for Physician Multiple Surgery - VT Facilities Only NDC Policy Nurse Practitioner (NP)/Physician Assistant (PA)/ Clinical Nurse Specialists (CNS) Billing in a Skilled Nursing Facility, Nursing Facility, Inpatient Setting **Observation Status for Facility and Provider** Occupational Therapy (OT) Personal Care/Consumer Directed Personal Assistance Services - Service Units Billing Physical Therapy (PT) Preoperative Lab Testing **Preventive Health Care** Radiology Radiopharmaceuticals **Robotic and Computer Assisted Surgery** Services Not Separately Reimbursed Speech Therapy (ST) Surgical Supplies Telehealth Transitional Care Management **Unlisted CPT Code** Urgent Care Vaccine Administration (Vermont Only) Virtual Check-ins and Interpersonal Telephone/ Internet/Electronic Health Record Consultation Viscosupplementation of the Knee: Non-Coverage for Medicaid Managed Care (MMC) Plans **Implantable Devices** 



# After-Hours

Last Reviewed Date: March 1, 2023

#### AFTER-HOURS

Policy Reimbursement Guidelines Notification/Prior Authorization Requests References History

# Policy

After-hour codes are used when a provider performs services in the office outside of normal business hours. MVP has determined normal business hours to mean 8: am – 6:00 pm EST, Monday through Friday. In accordance with Centers for Medicare and Medicaid Services (CMS) guidelines, MVP reimburses the following after-hours codes as inclusive with the Evaluation and Management (E&M) code that is billed. These CPT codes are not payable if they are the only CPT procedure(s) listed on the claim.

### **Reimbursement Guidelines**

| Code  | Description  | Reimbursement Guidelines  |
|-------|--|---|
| 99050 | Service(s) provided in the office at times<br>other than regularly scheduled office<br>hours, or days when the office is normally<br>closed (e.g., holidays, Saturday or<br>Sunday), in addition to basic service. | This code must be billed with an E&M to be reimbursable This code will not be reimbursable when submitted with preventive visit codes.  |
| 99051 | Service(s) provided in the office during<br>regularly scheduled evening, weekend,<br>or holiday office hours, in addition to<br>basic service  | This code must be billed with an E&M code and is considered inclusive<br>to the E&M. MVP does not reimburse separately for this code for<br>Commercial and Medicare products. For Medicaid/HARP products,<br>MVP will reimburse this code at the Medicaid rate. |
| 99053 | Service(s) provided between 10:00<br>pm and 8:00 am at 24-hour facility, in<br>addition to basic service   | This code must be billed with an E&M code and is considered inclusive to the E&M. MVP does not reimburse separately for this code.  |
| 99056 | Service(s) typically provided in the office,<br>provided out of the office at request of<br>patient, in addition to basic service  | This code must be billed with an E&M code and is considered inclusive to the E&M. MVP does not reimburse separately for this code.  |
| 99058 | Service(s) provided on an emergency<br>basis in the office, which disrupts other<br>scheduled office services, in addition to<br>basic service   | This code must be billed with an E&M code and is considered inclusive to the E&M. MVP does not reimburse separately for this code.  |
| 99060 | Service(s) provided on an emergency<br>basis, out of the office, which disrupts<br>other scheduled office services, in<br>addition to basic service  | This code must be billed with an E&M code and is considered inclusive to the E&M. MVP does not reimburse separately for this code.  |

# **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.



# References

NYS Department of Health: <u>health.ny.gov/health\_care/medicaid/program/update/2008/2008-10.htm#enh</u>

| October 15, 2018 | New policy, approved                         |
|------------------|--|
| December 1, 2020 | Policy reviewed and approved without changes |
| March 1, 2022    | Policy reviewed and approved with changes    |
| March 1, 2023    | Policy reviewed and approved with no changes |



# Allergy Testing and Serum Preparation Claims

## ALLERGY TESTING AND SERUM PREPARATION CLAIMS Policy Billing/Coding Guidelines Notification/Prior Authorization Requests References History

Last Reviewed Date: March 1, 2023

### Policy

MVP will reimburse for allergy testing and serum preparation. The tests and units of doses are limited per Member every calendar year as outlined below:

# **Billing/Coding Guidelines**

| Code  | Description  | Rule   |
|-------|--|--|
| 95165 | Professional services for the<br>supervision of preparation and<br>provision of antigens for allergen<br>immunotherapy; single or multiple<br>antigens   | <ul> <li>Number of units/doses must be specified on the claim</li> <li>First Year: Reimbursement is limited to 40 units/doses per claim and 160 units/doses per calendar year</li> <li>Subsequent Years: Reimbursement is limited to 30 units per claim and 120 units/doses per calendar year</li> </ul> |
| 95004 | Percutaneous tests (scratch, puncture,<br>and prick) with allergenic extracts,<br>immediate type reaction, including<br>test interpretation and report   | Number of tests must be specified on the claim     Reimbursement is limited to 80 units per calendar year  |
| 95024 | Intracutaneous (intradermal) tests<br>with allergenic extracts, immediate<br>type reaction, including test<br>interpretation and report  | <ul> <li>Number of tests must be specified on the claim</li> <li>Reimbursement is limited to 40 units per calendar year</li> </ul>   |
| 95027 | Intracutaneous (intradermal) tests,<br>sequential and incremental, with<br>allergenic extracts for airborne<br>allergens, immediate type reaction,<br>including test interpretation and<br>report, specify number of tests | <ul> <li>Number of tests must be specified on the claim</li> <li>Reimbursement is limited to 40 units per calendar year</li> </ul>   |
| 95028 | Intracutaneous (intradermal) tests<br>with allergenic extracts, delayed type<br>reaction, including reading  | <ul> <li>Number of tests must be specified on the claim</li> <li>Reimbursement is limited to 30 units per calendar year</li> </ul>   |

# **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must confirm Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into the Providers account at <u>mvphealthcare.com</u>.



### References

1. Noridian Healthcare Solutions, LLC. Local Coverage Determination (LCD): Allergy Testing (L34313). Original Effective Date 10/01/2015. Revision Effective Date 10/01/2019. Available: https://www.cms.gov/medicare-coverage-database/ search.aspx

2. Noridian Healthcare Solutions, LLC. Local Coverage Article: Billing and Coding: Allergy Testing (A57181). Original Effective Date 10/01/2019. Available: https://www.cms.gov/ medicare-coverage-database/search.aspx

| December 1, 2018  | New Policy approved                          |
|-------------------|--|
| September 1, 2019 | Policy reviewed and approved with no changes |
| July 1, 2020      | Policy reviewed and approved with changes    |
| December 1, 2020  | Policy reviewed and approved with changes    |
| December 1, 2021  | Policy reviewed and approved with changes    |
| March 1, 2022     | Policy reviewed and approved with changes    |
| March 1, 2023     | Policy reviewed and approved with no changes |



# Evaluation and Management

Last Reviewed Date: March 1, 2023

# EVALUATION AND MANAGEMENT Policy Definitions Notification/Prior Authorization Requests E&M Codes and Preventive Services/Medicine E&M Codes and Sexual Assault Forensic Exam Billing/Coding Guidelines Critical Care Services History

# Policy

MVP will reimburse for "Medically Necessary" Evaluation / Management (E&M) services. MVP recognizes AMA's definition of CPT codes and follows the CMS 1995/1997 documentation guidelines for E&M services. In addition, MVP will follow the CMS 2021 E&M Coding Guidelines "Office and Other Outpatient Services." Medical records may be periodically requested to ensure appropriate documentation and accuracy of services billed. Member eligibility and benefit specifics should be verified prior to providing services.

# Definitions

#### **Medical Necessity**

**AMA's Definition:** "Health care services or procedures that a prudent physician would provide to a patient for the purpose of preventing, diagnosing, or treating an illness, injury, or disease or its symptoms in a manner that is (a) in accordance with generally accepted standards of medical practice; (b) clinically appropriate in terms of type, frequency, extent, site, and duration; and (c) not primarily for the economic benefit of the health plans and purchases for the convenience of the patient, treating physician or other health care provider."

**CMS/Medicare Definition:** "Medical necessity is the overarching criterion for payment in addition to the individual documentation requirements of a CPT code. It would not be medically necessary or appropriate to bill a higher level of evaluation and management service when a lower level of service is warranted. The volume of documentation should not be the primary influence upon which a specific level of service is billed. Documentation should support the level of service being reported."

**MVP's Definition:** "Medically Necessary" or "Medical Necessity" means health care services that are: (a) necessary to prevent, diagnose, correct or cure conditions in the person that cause acute suffering, endanger life, result in illness or infirmity, interfere with such person's capacity for normal activity, or threaten some significant handicap; and (b) recommended by the Member's treating provider; and (c) determined by MVP's or its designee to meet the following criteria, which may be subject to external review:

- 1. the services are appropriate and consistent with the diagnosis and treatment of the Member's medical condition;
- 2. the services are not primarily for the convenience of the Member, the Member's family, or the provider;
- 3. the services are required for the direct care and treatment of that condition;
- 4. the services are provided in accordance with general standards of good medical practice, as evidenced by reports in peer reviewed medical literature; reports and guidelines as published by nationally recognized health care organizations that include supporting scientific data; and, any other relevant information brought to MVP's attention; and
- 5. the services are provided in a safe, appropriate and cost-effective setting given the nature of the diagnosis and severity of symptoms.



# The reason for the visit (chief complaint) MUST necessitate the need to perform and document the extent of HPI, Exam, and Medical Decision Making involved in order to appropriately manage the Member's care today.

#### **New Patient**

MVP follows the American Medical Association's definition of a new patient as one who has not received any professional services from the same provider, or other qualified health care professional of the exact same specialty and sub-specialty, who belongs to the same group Participating Provider Group (same tax ID), within the past three years.

#### Significant E&M Service

A significant service at minimum warrants the need for an expanded problem focused examination.

E&M services which provide reassurance, monitoring, continue meds, refills, and/or are problem- focused (minor rash, bug bite) will not be considered significant.

#### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

#### **E&M Codes and Preventive Services/Medicine**

If the claim indicates the primary reason for the visit was for preventive services, then the claim will be reimbursed in accordance with state and federal regulations.

There should be no co-pays/co-insurance/cost share taken at the time of the service unless the specific product is excluded from Federal Health Care Reform. For the full policy regarding billing and reimbursement of preventive services, please refer to MVP Payment Policy identified as <u>Preventive Health Care Policy</u>.

#### **Payment of Evaluation and Management for Preventive and Sick Visits**

Effective May 1, 2023, In accordance with industry standards, sick E&M visits (99202-99205, and 99211-99215) billed on the same date-of-service and by the same Provider as a preventive E&M visit will be reduced by 50% for the overlapping practice expense component, regardless of the presence of a 25 modifier.

#### **E&M Codes and Sexual Assault Forensic Exam**

If the claim indicates the primary reason for the exam is a diagnosis related to sexual assault or sexual abuse, the claim will be reimbursed in accordance with the New York State Office of Victims Services mandated regulations for victims of sexual assault and the forensic exam. This mandate, which is applicable to the New York Fully Insured and select ASO groups, should be billed with applicable CPT codes as outlined in the mandate located at: <u>ovs.ny.gov/sites/default/</u><u>files/general-form/fre-ppt-6-4-18.pdf.</u> There should be no co-pay/co-insurance/cost share or deductible taken at time of service or applied unless the product is excluded.

#### **Billing/Coding Guidelines**

#### Multiple E&M Services on the Same Day

MVP allows one E&M CPT code per day of service per physician group, per specialty.



| Code        | Description   | Rule   |
|-------------|---|--|
| 99381-99387 | Preventative Medicine<br>Evaluation and Management<br>of an individual. | <ul> <li>MVP will reimburse for a preventive medicine visit; however will not reimburse for an office visit procedure including the following codes when performed on the same day as the preventive visits: 99201-99215, 92015, 92081, 92551, 92552, 92553, 92555, 92556, 92557, 92567, 99172, 99173, 95930, and 99174.</li> <li>See member benefits to determine if these codes are reimbursable.</li> </ul> |
| 99391-99397 | Preventative Medicine<br>Evaluation and Management<br>of an individual. | MVP will reimburse for a preventive medicine visit; however will not reimburse<br>for an office visit procedure including the following codes when performed on the<br>same day as the preventive visits: 99202-99215, 92015, 92081, 92551, 92552, 92553,<br>92555, 92556, 92557, 92567, 99172, 99173, 95930, and 99174.<br>• See member benefits to determine if these codes are reimbursable.                |

# Routine Screening Services Billed with E&M

| Code             | Description                                   | Rule  |
|------------------|---|---|
| G0102            | Manual rectal neoplasm                        | <ul> <li>MVP will <b>not</b> reimburse separately for this procedure on the same day as an E&amp;M<br/>Office/Clinic/Outpatient Service – 99202–99215.</li> </ul>   |
|                  | screening                                     | • MVP will reimburse for this procedure when it is the sole service provided.   |
| 36415            | Collection of venous blood<br>by venipuncture | • MVP will <b>not</b> reimburse separately for this procedure on the same day as an E&M<br>Office/Clinic/Outpatient Service – 99202–99215 when the lab is performed in the<br>office. MVP will reimburse separately for this procedure when the Lab work is sent<br>to an external lab and billed with a modifier CG. |
|                  |   | • MVP will reimburse for this procedure when it is the sole service provided.   |
| 36416            | Collection of capillary blood                 | <ul> <li>MVP will not reimburse separately for this procedure on the same day as an E&amp;M<br/>Office/Clinic/Outpatient Service – 99202–99215.</li> </ul>  |
| 36416            | specimen i.e., finger, heel,<br>ear stick     | <ul> <li>MVP will reimburse for this procedure when it is the sole service provided and<br/>modifier CG is submitted.</li> </ul>  |
| 99000 &<br>99001 | Lab specimen handling services                | <ul> <li>MVP will not reimburse separately for this procedure on the same day as an E&amp;M<br/>Office/Clinic/Outpatient Service – 99202–99215.</li> </ul>  |
| 99001            | Services                                      | • MVP will reimburse for this procedure when it is the sole service provided.   |
| Q0091            | Collection of pap smear                       | <ul> <li>MVP will <b>not</b> reimburse separately for this procedure on the same day as an E&amp;M<br/>Office/Clinic/Outpatient Service – 99202–99215.</li> </ul>   |
|                  | specimen                                      | • MVP will reimburse for this procedure when it is the sole service provided.   |
| 92567            | Tympanometry (impedance testing)              | • MVP will <b>not</b> reimburse separately for this procedure on the same day as an E&M Office/Clinic/Outpatient Service – 99202–99215.   |
|                  | testing)                                      | • MVP will reimburse for this procedure when it is the sole service provided.   |
| 94760 &<br>94761 | Pulse Oximetry Testing                        | • MVP will <b>not</b> Reimburse separately for this procedure on the same day as an E&M Office/Clinic/Outpatient Service.   |



#### Smoking Cessation Billed with E&M

| Code   | Description                     | Rule   |
|--|---------------------------------|--|
| 99406, 99407,<br>G0376, G0375,<br>S9453, S9075 | Smoking Cessation<br>Counseling | <ul> <li>MVP will <b>not</b> reimburse for these procedure codes.</li> <li>Exception: Please check the member benefits to determine if this is a covered benefit.</li> </ul> |

#### E&M Billed During a Global Period

MVP will **not** separately reimburse for any E&M service when reported with major surgical procedure within a global period unless there is a "significant" problem which arises which is not considered a normal complication of recovery or an "unrelated" problem not associated with the procedure performed.

In alignment with CMS guidelines, Modifier 24 must be appended on the E&M service. Modifier 24 states: Unrelated evaluation and management service by the same physician or other qualified health care professional during a postoperative period.

MVP will **not** separately reimburse for an E&M services billed with minor procedures that have a 10-day post-op period. Note: Services billed on day 11 that appear to be related to the procedure performed can be subject to internal review.

# For Non-Face-to-Face Evaluation and Management Services, Please refer to <u>MVP's Virtual Check-in</u>, <u>Telehealth</u> and <u>Telemental Health Payment Policies</u>

#### **Diabetes Education**

| Code  | Description  | Rule  |
|-------|--|---|
| 98960 | Education and training<br>for self-management of<br>Diabetes | <ul> <li>MVP will reimburse for these services when the service is billed alone.</li> <li>MVP will <b>not</b> reimburse for these codes when billed with an E&amp;M office visit code (example: 99211-99215). The services will deny as bundled to the office visit.</li> </ul> |

#### **Osteopathic Manipulation**

| Code                                    | Description              | Rule  |
|---|--------------------------|---|
| 98925, 98926,<br>98927, 98928,<br>98929 | Osteopathic Manipulation | <ul> <li>MVP will <b>not</b> reimburse for these sevices.</li> <li><b>Exception:</b> Refer to your contractual agreement to determine if there is an exception for these services.</li> </ul> |

#### **Immunization Administration**

| Code  | Description                             | Rule  |
|---|---|---|
| 90460, 90461,<br>90471, 90472,<br>90473, 90474,<br>G0008, G0009,<br>G0010 | Immunization<br>administration services | MVP will only reimburse for immunization administration services when billed with a Z23 diagnosis code. |



# **Modifier 25**

| Code   | Description               | Rule   |
|--|---------------------------|--|
| 95115, 95117,<br>95120, 95125,<br>95130-95134,<br>95144-95149,<br>95165, 95170 | Allergy Injections        | MVP will only reimburse for allergy injections in conjunction with an E&M visit,<br>Inpatient visit, or Emergency Room visit when billed with a modifier 25. Refer to<br>CPT code guidelines for billing with Modifier 25 and to the medical policy for <u>Allergy</u><br><u>Testing and Serum Preparation Claims.</u> |
| 96900, 96902,<br>96904, 96910,<br>96912, 96913,<br>96920-96922                 | PUVA, UBA, UVA treatments | MVP will only reimburse for dermatological procedures in conjunction with an E&M visit, Inpatient visit, or Emergency Room visit when billed with Modifier 25.   |
| 99201 - 99499  | E&M visits                | Refer to the <u>MVP Modifier Payment Policy</u> regarding payment of two E&M visits on the same day with a modifier 25.  |

### Prenatal E&M Visit

| Code  | Description                        | Rule   |
|---|------------------------------------|--|
| 99201-99215   | 1st Prenatal E&M visit             | The 1st prenatal visit is global to the total OB Delivery charges with the entire global OB allowable amount reimbursed on the Global delivery claim.    |
| 59425 for<br>visits 4-6 or<br>59426 for 7+<br>visits  | Antepartum Care                    | Antepartum Care billed without indicating the number of prenatal visits will not be reimbursed.  |
| 59400, 59410,<br>59510, 59515,<br>59610, 59614,<br>59618, 59620,<br>59812, 59820,<br>59821, 59830,<br>59840, 59841,<br>59850, 59851,<br>59852, 59855,<br>59856, 59857 | Obstetric care and antepartum care | The 1st prenatal visit is global to the total OB Delivery charges with the entire global<br>OB allowable amount reimbursed on the Global delivery claim. |

# Inpatient Visit

| Code Description Rule |                                    | Rule   |
|-----------------------|------------------------------------|--|
| 99201 - 99499         | Evaluation and<br>Management Codes | When two Inpatient Physician E&M codes are billed on the same date of service, for the same/related condition, and by the same provider, the second E&M code will be denied. |

# **After-Hours Visits**

| Code          | Description               | Rule   |  |
|---------------|---------------------------|--|--|
| 99051 - 99060 | E&M After-Hour Procedures | Refer to the <u>MVP After-Hours Payment Policy</u> for guidelineson these codes. Please refer to your contractual agreement to determine if this rule applies. |  |



| Code  | Description      | Rule  |  |
|-------|------------------|---|--|
| 99050 | After-Hours Code | MVP will reimburse for this code without review unless submitted with preventative visit codes 99381-99397. Please refer to your contractual agreement to determine if this rule applies. |  |

# **Urgent Care Visits**

| Code          | Description  | Rule  |  |
|---------------|--|---|--|
| 99201 - 99499 | Evaluation and Management<br>Codes billed as urgent care | MVP will <b>not</b> reimburse for these codes when an Urgent Care visit is billed with Well Child Care, Routine Diagnoses, or Routine Services such as Immunizations. |  |

# **Consultation Visits**

| Code   | Description   | Rule  |  |
|--|---|---|--|
| 99241-99245  | Office/Outpatient<br>Consultation Procedures        | MVP follows CMS Guidelines regarding the use of consultations and does <b>not</b> reimburse for these codes.  |  |
| 99251-99255Inpatient Consultation<br>ProceduresMVP follows CMS Guidelines regarding the use of consu<br>reimburse for these codes. |   | MVP follows CMS Guidelines regarding the use of consultations and does <b>not</b> reimburse for these codes.  |  |
| 99218-99220;<br>99234- 99235,  |   | • Only the provider who " <b>orders</b> " the observation services can bill observation codes.  |  |
| 99236 and<br>discharge<br>code 99217   | Hospital Observation Codes                          | • Bill with the appropriate observation codes which are based on components for observation. The codes must meet the component requirements set forth by the CPT code guidelines.   |  |
|  |   | • An Initial Consultation in the hospital should be billed as an initial hospital visit.<br>An AI modifier should be affixed to this code if the physician is the "principle<br>physician of record" (i.e. admitting/attending) and is not performing a<br>consultation.        |  |
| 99221-99223  | Initial Hospital Visit                              | • MVP will allow one (1) visit per provider related to the same condition or diagnosis per day. The "volume of documentation" should not be the primary influence upon which a specific level of service is billed. Documentation should support the level of service reported. |  |
|  |   | <ul> <li>The duration of a visit is an ancillary factor and does not "control" the level of<br/>the service to be billed unless more than 50% of the allowable time by setting<br/>occurs and this needs to be documented.</li> </ul>   |  |
|  |   | <ul> <li>These are timed and component-based codes. They must meet the components<br/>and time requirements set forth by the CPT code guidelines.</li> </ul>  |  |
|  | Evaluation and Management within the Emergency Room | • MVP does <b>not</b> reimburse for consultations. Please use the following codes to indicate that this is an evaluation and management service in place of a consultation in the Emergency room.   |  |
| 99281-99288  |   | • MVP will reimburse for these codes if the ER attending provides services and sends the Member home.   |  |
|  |   | <ul> <li>MVP will reimburse for these codes If a provider goes to the ER (must be present         – no phone) to render a consultation service to determine if a member should be         admitted.</li> </ul>  |  |



| Code                   | Description  | Rule   |  |
|------------------------|--|--|--|
| 99221-99223            | Evaluation and Management<br>within the Emergency Room<br>In the Emergency Room<br>with an inpatient admission   | <ul> <li>MVP will reimburse for these codes if a provider goes to the ER (must be present – no phone) to render a service and admits the Member. Modifier AI must be affixed to the claim. (I.e. when you are the attending/admitting provider).</li> <li>MVP will reimburse for these codes if the ER attending admits the Member. Modifier AI must be affixed to the claim (i.e. when you are the attending/admitting provider).</li> </ul>  |  |
| 99211-99215            | Office or other outpatient<br>visit for the evaluation<br>and management of an<br>established patient  | MVP will reimburse for these codes as set forth by the CPT Code guidelines. MVP<br>will reimburse these codes for established patients who do not meet the CPT<br>Code guidelines for a "New" patient. Consultations are not reimbursed by MVP.<br>Providers should use these codes when providing a consultation and documenting<br>as such.  |  |
| 99211                  | Office or other outpatient<br>visit for the evaluation<br>and management of an<br>established patient that may<br>not require the presence<br>of a physician. Usually, the<br>presenting problem(s) are<br>minimal | <ul> <li>MVP will reimburse as follows:</li> <li>When the patient visit is part of an established physician plan of care requiring medically necessary follow-up.</li> <li>RNs or qualified ancillary staff cannot code higher than a 99211 for E&amp;M services.</li> <li>RNs or qualified ancillary staff cannot bill new problems or new patient visit code 99201.</li> <li>A Provider and a RN or qualified ancillary staff cannot both bill for an E&amp;M office visit within the same day.</li> </ul> |  |
| 99304, 99305,<br>99306 | Initial Skilled Nursing<br>Facility Visit  | <ul> <li>MVP will reimburse for these codes as set forth by the CPT Code guidelines.</li> <li>Consultations are not reimbursed by MVP. Providers should use these codes when providing a consultation and documenting as such.</li> <li>If performing the initial evaluation Modifier "AI" must be affixed to the claim which will identify you as the "Principal Physician of Record" (e.g. admitting/attending SNF provider) vs. a provider rendering "specialty care."</li> </ul>                         |  |
| 99307-99310            | Follow-up Skilled Nursing<br>Facility Visit  | MVP will reimburse for these codes as set forth by the CPT Code guidelines .<br>Consultations are not reimbursed by MVP. Providers should use these codes when<br>providing a consultation and documenting as such.  |  |

# **Discharge Services**

| Code Description |  | Rule   |  |
|------------------|--|--|--|
| 00738            | Inpatient Standard<br>Discharge instructions<br>typically 0-30 min   | <ul> <li>These are timed and component based codes. They must meet the components<br/>and time requirements set forth by the CPT code guidelines.</li> </ul>   |  |
| 99238            |  | <ul> <li>For discharge services, please follow the state mandate on required<br/>documentation prior to discharging a Member.</li> </ul>   |  |
| 99239            | Inpatient discharge planning<br>exceeds 30 minutes and is<br>generally considered not a<br>typical discharge | <ul> <li>These are timed and component based codes. They must meet the components<br/>and time requirements set forth by the CPT code guidelines.</li> </ul>   |  |
|                  |  | • For discharge services, please follow the state mandate on required documentation prior to discharging a Member. Provider must note "time" in the note that was spent above/beyond 30 minutes and provide explanation as to why the discharge was not typical. |  |
| 00217            | Observation Discharge of a<br>Member   | <ul> <li>These are timed and component based codes. They must meet the components<br/>and time requirements set forth by the CPT code guidelines.</li> </ul>   |  |
| 99217            |  | <ul> <li>For discharge services, please follow the state mandate on required<br/>documentation prior to discharging a Member.</li> </ul>   |  |



| Code        | Description   | Rule   |  |
|-------------|---|--|--|
|             | Observation or Inpatient<br>Hospital Care where an<br>Admission and Discharge are<br>done on the same day | <ul> <li>These are timed and component-based codes. They must meet the components<br/>and time requirements set forth by the CPT code guidelines.</li> </ul> |  |
| 99234-99236 |   | <ul> <li>Don't allow a discharge code and a regular E&amp;M subsequent inpatient code or<br/>observation code on the same day.</li> </ul>                    |  |
|             |   | <ul> <li>For discharge services, please follow the state mandate on required<br/>documentation prior to discharging a Member.</li> </ul>                     |  |

# **Critical Care Services**

Critically ill is defined as:

A critical illness or injury that **acutely impairs** one or more **vital** organ systems indicating a **high probability** of **"imminent"** or **"life threatening"** deterioration" in the Member's condition. Examples of vital organ system failure include, but are not limited to, central nervous system failure, circulatory failure, shock, renal, hepatic, metabolic and/ or respiratory failure.

- "The time spent engaged in work directly related to the individual patient's care whether that time was spent at the immediate bedside or elsewhere on the floor or unit.";
- Time spent does not need to be continuous;
- The key is for the provider to be "immediately" available to the Member;
- Time billed is "per calendar day";
- Time **must be documented** in the medical record;
- Billable time can be time spent at the bedside, reviewing test results, discussing the case w/staff, family (if Member is unable or clinically incompetent to participate);
- Time spent performing procedures below during critical care do not count towards critical care time;
  - If an additional specialist assists with services while providing critical care (i.e. Vascular Surgeon performs a vascular access procedure) the specialist will be paid for their services.
  - In this situation a critical care physician should not count the time performing this procedure as part of the services they have provided.

# Family Discussion cannot be billed as part of critically ill services. **Examples of family discussions which do not count toward critical care time include:**

- Regular or periodic updates of the Member's condition;
- Emotional support for the family;
- Answering questions regarding the Member's condition to provide reassurance;
- Telephone calls to family members and surrogate decision makers must meet the same conditions as face-to-face meetings;
- Time involved in activities that do not directly contribute to the treatment of the Member, and therefore may not be counted towards critical care time, include teaching sessions with residents whether conducted on rounds or in other venues;
- Non Critically III or Injured Members in a Critical Care Unit;
- Members admitted to a critical care unit because **no other hospital beds** were available.



| Code                          | Description  | Rule   |  |
|-------------------------------|--|--|--|
| 93561 &<br>93562              | Interpretation of cardiac output measurements  | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by physician providing the critical care services.   |  |
| 94760, 94761,<br>94762        | Pulse Oximetry   | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by a physician providing the critical care services.   |  |
| 71045 and<br>71046            | Chest x-rays, professional component   | Time spent performing this procedure does NOT count toward critical care time<br>and cannot be billed separately by a physician providing the critical care services.  |  |
| 99090                         | Blood gases, and<br>information data stored in<br>computers (e.g., ECGs, blood<br>pressures, hematologic data) | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by a physician providing the critical care services.   |  |
| 43752 &<br>43753              | Gastric intubation   | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by a physician providing the critical care services.   |  |
| 92953                         | Transcutaneous pacing  | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by physician providing the critical care services.   |  |
| 94002-94004,<br>94660, 94662  | Ventilator management  | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by a physician providing the critical care services.   |  |
| 36000, 36410,<br>36415, 36591 | Vascular access procedures   | Time spent performing this procedure does NOT count toward critical care time and cannot be billed separately by a physician providing the critical care services.   |  |
| 92950                         | CPR  | MVP will reimburse for this procedure separately from critical care services.  |  |
| 31500                         | Endotracheal intubation  | MVP will reimburse for this procedure separately from critical care services.  |  |
| 36555, 36556                  | Central line placement   | MVP will reimburse for this procedure separately from critical care services.  |  |
| 36680                         | Intraosseous placement   | MVP will reimburse for this procedure separately from critical care services.  |  |
| 32551                         | Tube thoracostomy  | MVP will reimburse for this procedure separately from critical care services.  |  |
| 33210                         | Temporary transvenous pacemaker  | MVP will reimburse for this procedure separately from critical care services.  |  |
| 93010                         | Electrocardiogram - routine<br>ECG with at least 12 leads;<br>interpretation and report<br>only                | MVP will reimburse for this procedure separately from critical care services.  |  |
| 99291 & 99292                 | Critical Care, Evaluation &<br>Management of the critically<br>ill or critically injured<br>Member:            | <ul> <li>MVP will not reimburse for this code if the time spent with the Member is less than 30 minutes.</li> <li>30-74 minutes code 99291 once.</li> <li>75 - 104 minutes code 99291 once and 99292 x 1.</li> <li>105-134 minutes code 99291 once and 99292 x 2.</li> <li>135-164 minutes code 99291 once and 99292 x 3.</li> <li>165-194 minutes code 99291 once and 99292 x 4.</li> <li>These codes should be used when transporting a critically ill patient.</li> </ul> |  |



| December 1, 2022  | Policy approved                           |
|-------------------|---|
| September 1, 2022 | Policy reviewed and approved with changes |
| March 1, 2023     | Policy reviewed and approved with changes |



# Arthroscopic, Endoscopic, and other Non Gastro Intestinal Scope Procedures

ARTHROSCOPIC, ENDOSCOPIC, AND OTHER NON GASTRO INTESTINAL SCOPE PROCEDURES Policy

Notification/Prior Authorization Requests Billing/Coding Guidelines History

Last Reviewed Date: March 1, 2023

#### **Policy**

When multiple Arthroscopic, Endoscopic, and other Non Gastro Intestinal Scope Procedures within the same code family are performed on the same date of service, the procedure with the highest RVU will be reimbursed according to the provider fee schedule. The reimbursement of additional procedure will follow the Medicare reimbursement methodology by reducing payment for secondary procedures within the same CPT code family. This reimbursement rule follows Medicare methodology and applies to all product lines. This reimbursement rule does not apply to procedures in different code families; however, other reimbursement rules such as multiple procedure reimbursement reduction may apply.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

The endoscopy code families are defined in Medicare's RBRVS fee schedule. This reimbursement rule applies to gastroenterology code families including:

- Biliary Endoscopy
- Anoscopy
- Colonoscopy
- Sigmoidoscopy
- Small Bowel Endoscopy ERCP
- Esophagogastroduoenoscopy
- Esophagoscopy
- Shoulder Arthroscopy
- Elbow Arthroscopy
- Wrist Arthroscopy
- Knee Arthroscopy
- Laryngoscopy w/operating microscope
- Bronchoscope/wash
- Esophagoscopy flexible brush



- Diagnostic laparoscopy
- Cystoscopy
- Cystourethroscopy & or Pyeloscopy
- Hysteroscopy diagnostic separate procedure

- June 1, 2018 New policy, approved
- June 1, 2020 Policy reviewed and approved with no changes
- March 1, 2022 Policy reviewed and approved with no changes
- March 1, 2023 Policy reviewed and approved with no changes

#### **MVP Health Care Payment Policy**



# Article 28 Split Billing

Last Reviewed Date: September 1, 2022

# ARTICLE 28 SPLIT BILLING Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines History

# Policy

MVP recognizes split billing arrangements as outlined below. In order for MVP to agree to a split billing arrangement, the billing entity must be structured so that it would meet the requirements of Article 28 guidelines in New York or its equivalent in other states.

MVP Commercial/ASO and Exchange products are not eligible for split billing arrangements.

This policy is limited to Article 28 providers who participate with our Medicare and/or Medicaid/Government Programs (Medicaid Managed Care and Child Health Plus).

### Definitions

#### **Split Billing reimbursement**

A structure whereby there are two separate charges, one for professional and one for technical reimbursement.

Professional reimbursements are for the physician/physician practice and technical reimbursements are for the facility.

#### Professional

Billable services provided by physician, such as provider consultation and physician interpretation of an x-ray, lab, CT Scan, or MRI. Payment is made to the provider group.

#### Technical

Billable services provided in a facility setting such as but not limited to lab, x-rays, evaluation and management services, procedures, and any other non-professional (providers) services. Reimbursement is made to the hospital.

#### **Global reimbursement**

A structure under which one bill is generated to represent both the professional and technical services. The service is billed and reimbursed at a global rate that includes one global payment for the professional and technical components. Typically, all reimbursements go to the physician practice, unless the providers are employed by the hospital.

#### "Split billing" or "Facility-Based" or "Hospital-Based"

The Hospital incurs costs associated with employing the physicians and in turn receives technical component reimbursement for services conducted by the physicians in the hospital setting.

The physicians are paid at the professional fee rate consistent with facility based RVU's.

The technical component and the professional component associated with each service is billed separately.

#### "Global" or "Non-Facility" or "Private Practice"

A service is billed and reimbursed at a global rate that includes one global payment for both the professional and technical components. The combined payment is designed to compensate physicians operating in a private practice and covers overhead and technical expenses associated with operating the practice.



One bill is generated which combines the professional and technical components.

No additional payments will be made to facilities under this payment methodology.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **General Guidelines**

MVP Commercial/ASO and Exchange products are not eligible for split billing arrangements.

When billing under a split billing arrangement, the Hospital incurs all expenses related to the employed providers practice (rental expense, operating cost). The Hospital would receive the technical reimbursement.

Provider claims would be generated with a facility place of service instead of a non-facility place of service, such as office. For example, a physician claim would be submitted with a place of service 22 for outpatient location instead of place of service 11 for office.

Procedure codes on the MVP In-Office Only list are not reimbursed under a split billing arrangement regardless of product unless an authorization is obtained. If an authorization is obtained, reimbursement may be allowed for Medicare and Medicaid products.

| June 1, 2017      | Policy approved                              |
|-------------------|--|
| March 1, 2020     | Policy reviewed and approved with no changes |
| June 1, 2020      | Policy reviewed and approved with no changes |
| September 1, 2021 | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



# Audiology Services

Last Reviewed Date: March 1, 2023

#### AUDIOLOGY SERVICES

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Examples for Ordering Audiological Testing Designation of Time 15 Minute Codes References History

#### Policy

Audiology is the prevention, identification, and evaluation of hearing disorders; the selection and evaluation of hearing aids; and the rehabilitation of individuals with hearing impairment. Audiological services, including function tests, are performed to provide medical diagnosis and treatment of the auditory system.

### Definitions

Audiological diagnostic testing refers to tests of the audiological and vestibular systems, including hearing, balance, auditory processing, tinnitus, and diagnostic programming of certain prosthetic devices, performed by qualified audiologists.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Audiologists may not bill using Evaluation and Management (E&M) CPT codes 99201 – 99499.

Audiologists may not bill removal of impacted cerumen (separate procedure, one or both ears) under CPT codes 69209 and 69210. Cerumen removal is included in the relative value for each diagnostic test. If a physician is needed to remove impacted cerumen on the same day as a diagnlostic test, the physician bills code G0268.

The reimbursement for hearing aids includes the initial evaluation and all follow-up tests and adjustments, which may be required to properly fit the hearing aids.

Audiometric test codes assume that both ears are tested. If only one ear is tested, modifier 52 should be billed to indicate less than the normal procedure.

#### **Examples for Ordering Audiological Testing**

Examples of appropriate reasons for ordering audiological diagnostic tests include, but are not limited to:

- Evaluation of suspected change in hearing, tinnitus, or balance
- Evaluation of the cause of disorders of hearing, tinnitus, or balance
- Determination of the effect of medication, surgery, or other treatment



- Re-evaluation to follow-up changes in hearing, tinnitus, or balance that may be caused by established diagnoses that place the patient at probable risk for a change in status including, but not limited to otosclerosis, atelectatic tympanic membrane, tympanosclerosis, cholesteatoma, resolving middle ear infection, Meniére's disease, sudden idiopathic sensorineural hearing loss, autoimmune inner ear disease, acoustic neuroma, demyelinating diseases, ototoxicity secondary to medications, or genetic vascular and viral conditions
- Failure of a screening test
- · Diagnostic analysis of cochlear or brainstem implant and programming
- · Audiology diagnostic tests before and periodically after implantation of auditory prosthetic devices

#### **Designation of Time**

The CPT procedures for audiology do not include time designations except for the five codes listed below. If the CPT descriptor has no time designation, the procedure is billed as a session without regard to time.

When calculating time attributed to the audiology evaluation codes activities such as counseling, establishment of interventional goals, or evaluating potential for remediation not included as diagnostic tests, the time spent on these activities should not be included in billing for:

- 92620 (evaluation of central auditory function, with report; initial 60 minutes)
- 92621 (evaluation of central auditory function, with report; each additional 15 minutes)
- 92626 (evaluation of auditory rehabilitation status; first hour)
- 92627 (evaluation of auditory rehabilitation status; each additional 15 minutes)
- 92640 (diagnostic analysis with programming of auditory brainstem implant, per hour).

Note: A timed code is billed only if testing is at least 51 percent of the time designated in the code's descriptor.

#### **15 Minute Codes**

For CPT codes designated as 15 minutes, multiple coding represents minimum face-to-face treatment, as follows:

| 1 unit:  | 8 minutes to < 23 minutes  | 4 units: | 53 minutes to < 68 minutes |
|----------|----------------------------|----------|----------------------------|
| 2 units: | 23 minutes to < 38 minutes | 5 units: | 68 minutes to < 83 minutes |
| 3 units: | 38 minutes to < 53 minutes | 6 units: | 83 minutes to < 98 minutes |

#### References

CMS Therapy Services ASHA Medicare CPT Coding Rules for Audiology Services

| December1, 2018  | New policy approved                          |
|------------------|--|
| December 1, 2020 | Policy reviewed and approved with no changes |
| March 1, 2022    | Policy reviewed and approved with no changes |
| March 1, 2023    | Policy reviewed and approved with no changes |

#### **MVP Health Care Payment Policy**



# Audio-Only (Vermont Only)

Last Reviewed Date - June 1, 2021

**Related Policies –** 

Telehealth Payment Policy Telemental Health Payment Policy Virtual Check-ins Payment Policy

#### AUDIO ONLY (VT ONLY)

Policy Definitions Notifications/Prior Authorization Request Billing/Coding Guidelines Reimbursement Guidelines History

# Policy

MVP covers telephone (audio-only) services in the State of Vermont and will reimburse for telephone-only and equivalent, to in-person codes when provided through audio-only means.

# Definitions

**Current Procedural Terminology (CPT)** - Medical code set that is used to report medical, surgical, and diagnostic procedures and services to entities such as physicians, health insurance companies, and accreditation organizations.

**Evaluation Management (E&M) Codes** - Coding is the use of CPT<sup>®</sup> codes from the range 99202-99499 to represent services provided by a physician or other qualified health care professional. As the name E/M indicates, these medical codes apply to visits and services that involve evaluating and managing patient health.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required, and the Benefit Interpretation Manual for MVP's clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **Medical Claims**

| Procedure Codes  | CPT Code Description  | Place of Service | Modifier |
|--|---|------------------|----------|
| In-person CPT codes<br>performed through audio<br>only means |   | 99               | V3       |
| E&M Codes  | CPT Code Description  | Place of Service | Modifier |
| 99441  | Telephone E/M service; 5-10 minutes<br>of medical discussion  | 99               | N/A      |
| 99442  | Telephone E/M service; 11-20<br>minutes of medical discussion | 99               | N/A      |
| 99443  | Telephone E/M service; 21-30<br>minutes of medical discussion | 99               | N/A      |



#### Non-Physician/APRN Behavioral Health Claims

| Procedure Codes   | Place of Service | Modifier |
|---|------------------|----------|
| In-person CPT codes outlined in provider contract delivered through audio only means. | 99               | V3       |

- Non-Physician/APRN Behavioral Health Providers will be reimbursed for all codes outlined in their contract when delivered through audio-only
- Non-Physician/APRN Behavioral Health Providers are not eligible to bill, and will not be reimbursed, for CPT codes 99441-99443
- Modifier V3 is required to be in the first position on codes for equivalent to in person delivered through audio-only means

#### **Reimbursement Guidelines**

Reimbursement for covered services will be at 75% of the medical providers physician fee schedule.

#### **History**

December 1, 2021 – New policy, approved June 1, 2022 – Policy reviewed an approved with changes



# Behavioral Health Non-Licensed Provider (Vermont Only)

BEHAVIORAL HEALTH NON-LICENSED PROVIDER (VERMONT ONLY) Policy Definitions Notifications/Prior Authorization Billing/Coding Guidelines Reimbursement Guidelines References

Last Review Date: New Policy, effective July 1, 2021

### Policy

In Vermont, reimbursement for services supplied by a Qualified Non-Licensed Psychotherapist can be billed and reimbursed when under the direct supervision of a Qualified Licensed Psychotherapist. MVP Medicare Advantage products are excluded from this policy.

History

#### **Definitions**

**Qualified Licensed Practitioner**: A Provider who is licensed and credentialed by MVP and is acting within the scope of his/her practice.

**Qualified Non-Licensed Practitioner**: A Provider that is actively working towards licensure as specified by his or her profession.

**Supervised Billing**: A Qualified Licensed Practitioner can bill for covered clinical services within his or her scope of practice provided by a Qualified Non-Licensed Practitioner when the Qualified Non-Licensed Practitioner is under the direct supervision of the Qualified Licensed Practitioner.

# **Notifications/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Qualified Non-Licensed Practitioners registered on the roster of Non-Licensed & Non-Certified Psychotherapists per VT state statute should bill supervised billing eligible claims to MVP as follows:

- In Box 24j of the CMS 1500 form, list the NPI and taxonomy code of the supervising licensed clinician appropriate to the degree of the unlicensed provider.
- In Box 31 of the CMS 1500 form, list the name and degree/title of the supervising provider.
  - o The supervising clinician must be a licensed practitioner with the same degree level (i.e., Masters or Doctorate) as the unlicensed clinician.

One of the following modifiers must be appended to the billed CPT codes:

| Modifier | Practitioner Level    | Rule  |
|----------|-----------------------|---|
| но       | Master's degree level | This is required when the claim is for supervised billing when the eligible unlicensed practitioner rendering the service is a Master's degree level. |



| Modifier | Practitioner Level | Rule   |
|----------|--------------------|--|
| HP       | Doctorate level    | This is required when the claim is for supervised billing when the eligible unlicensed practitioner rendering the service is a Doctorate degree level. |

# **Reimbursement Guidelines**

#### **Non-Reimbursable Services**

- These are services performed by a non-licensed provider who cannot practice independently and is not actively working toward licensure.
- MVP Medicare Members are not eligible to receive services performed by a non-licensed provider even under the supervision of a licensed provider.

#### References

https://sos.vermont.gov/media/0jyhuiuj/amh-rules-adopted-final-sos-jan-2015.pdf https://legislature.vermont.gov/statutes/fullchapter/26/078

9.103-supervised-billing-adopted-rule.pdf (vermont.gov)

#### History

June 1, 2021 New Policy, Approved



# Consistency of Denials

# CONSISTENCY OF DENIALS Policy

Notifications/Prior Authorization Requests History

Last Reviewed Date: March 1, 2023

**Related Policy: Radiology** 

# Policy

MVP requires authorizations for select services as identified in MVP's Utilization Management Guides. When an authorization is required, this authorization applies to all Technical, Professional, Global and/or Facility claims submitted for the service. If service(s) requiring an authorization are provided without prior approval, then all technical, professional, global and/or facility claims associated with those services will be denied administratively.

MVP will apply this administrative denial to Outpatient Surgical Services.

MVP will apply this administrative denial to the Radiology code set as defined in the Radiology Payment Policy.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

| September 1, 2022 | New policy, approved                         |
|-------------------|--|
| March 1, 2022     | Policy reviewed and approved with no changes |
| March 1, 2023     | Policy reviewed and approved with no changes |



# Contrast Materials

Last Reviewed Date: September 1, 2022

# CONTRAST MATERIALS Policy Definitions Notification/Prior Authorization Requests

**Billing/Coding Guidelines** 

History

# Policy

MVP Health Care has determined that the cost of ionic contrast is included in the fee paid for CT and other contrast enhanced exams. Additional payment for this material is no longer warranted. MVP will deny claims for contrast materials for Commercial, Exchange, and Medicaid products.

### Definitions

Reimbursement for non-ionic contrast was initially significantly more costly than the ionic contrast agent, and its use was limited to occasional patients based on sensitivity to ionic contrast. This basis for payment no longer applies, as the cost of non-ionic contrast has approached that of ionic contrast. In addition, non-ionic contrast material has become routinely used regardless of patient history. Therefore, MVP considers such use of both contrast material as part of the underlying examination and will consider them inclusive to the primary procedure fee and not separately reimbursable.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Providers will not be reimbursed separately for contrast material for the codes listed below. This will apply to all participating providers (physicians, hospitals, and other facilities) for all MVP Commercial, Exchange, and Medicaid products:

#### **HCPCS Code: Gadolinium**

Injection, gadolinium-based magnetic reso-nance contrast A9579 agent, not otherwise specified (NOS), per ml **HCPCS Code: Non-Ionic, Low Osmolar Contrast** Low osmolar contrast material, 400 or greater mg/ml iodine Q9951 concentration, per ml Low osmolar contrast material, 100-199 mg/ml iodine Q9965 concentration, per ml Low osmolar contrast material, 200-299 mg/ml iodine Q9966 concentration, per ml Low osmolar contrast material, 300-399 mg/ml iodine Q9967 concentration, per ml



#### HCPCS Code: Non-Ionic, Low Osmolar Contrast

| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine<br>concentration, per ml   |
|-------|---|
| Q9959 | High osmolar contrast material, 150-199 mg/ml iodine<br>concentration, per ml     |
| Q9960 | High osmolar contrast material, 200-249 mg/ml iodine<br>concentration, per ml     |
| Q9961 | High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml        |
| Q9962 | High osmolar contrast material, 300-349 mg/ml iodine concentration, per ml        |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml        |
| Q9964 | High osmolar contrast material, 400 or greater mg/ml iodine concentration, per ml |
|       |   |

| December 1, 2016  | Policy approved                              |
|-------------------|--|
| December 1, 2021  | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



# COVID-19 Lab Testing

Last Reviewed Date - June 1, 2022

**Related Policies – Preoperative Lab Testing** 

### Policy

MVP will provide coverage for COVID-19 diagnostic/viral testing as well as antibody testing. The testing must be medically appropriate for the diagnosis and treatment of COVID-19.

### Definitions

This policy is to define the coverage, reimbursement and billing guidelines for COVID-19 viral and antibody testing. This policy applies to participating and non-participating practitioners, facilities, laboratories and pharmacies and all lines of business.

# **Billing/Coding Guidelines**

MVP encourages health care providers to use reliable FDA-authorized tests. A virus/antigen detection (diagnostic) test determines if a person is currently infected with COVID-19. An antibody (serology) test may determine if a person has been exposed to COVID-19, and according to the FDA, this test should not be used to diagnose a current infection.

Applicable COVID-19 codes can be found in CPT codes as published by the AMA, or HCPCS codes as published by CMS.

Providers should follow CDC ICD–10–CM Official Coding Guidelines when selecting a diagnosis code to ensure proper reporting.

#### **Reimbursement Guidelines**

Testing that is ordered or performed solely for purposes of pandemic control or re-opening the economy, and not based on a determination by a provider that the test is medically appropriate for the diagnosis and treatment of an individual member, is not covered. This includes tests performed on an asymptomatic individual solely to assess health status as required by parties such as a government/public health agency, employer, common carrier, school, camp, or when ordered upon the request of a member solely to facilitate the member's desire to self-assess COVID-19 immune status.

#### The following diagnosis codes will be denied when submitted for COVID-19 testing.

| Primary Diagnosis Code | Primary Diagnosis Code Description                                 |
|------------------------|--|
| Z02.0                  | Encounter for examination for admission to educational institution |
| Z02.1                  | Medical diagnosis of encounter for pre-employment examination      |
| Z02.4                  | Encounter for examination for driving license                      |
| Z02.5                  | Encounter for examination for participation in sport               |
| Z02.79                 | A diagnosis of encounter for issue of other medical certificate    |
| Z02.89                 | Encounter for other administrative examinations                    |

#### COVID-19 LAB TESTING

Policy Definitions Billing/Coding Guidelines Reimbursement Guidelines Notifications/Prior Authorization Requests References History



| Primary Diagnosis Code | Primary Diagnosis Code Description                                  |
|------------------------|---|
| Z02.9                  | Encounter for administrative examinations, unspecified              |
| Z56.89                 | Specify a medical diagnosis of other problems related to employment |
| Z56.9                  | a medical diagnosis of unspecified problems related to employment   |

Claims will be reviewed post-payment. A post-payment review may result in no change to the initial determination or a revised determination. Post-payment reviews are to ensure claim/billing accuracy and completeness, and are not medical necessity reviews.

These services are subject to audit and policy updates at MVP's discretion. Commercial Plan Members will be held liable for claims that deny based upon this policy. Providers will bear responsibility for testing claim denials of Medicare Advantage and Medicaid Managed Care Members.

MVP will cover the testing when required by applicable law and regulation.

Examples of services not reimbursable per administrative policy are below. These codes are examples of inappropriate diagnoses received by MVP and are not all inclusive.

| Primary Diagnosis Code | Primary Diagnosis Code Description  |
|------------------------|---|
| Z03.818                | Encounter for observation for suspected exposure to other biological agents ruled out |
| 276                    | Persons encountering health services in other circumstances                           |
| Z01.89                 | Encounter for other specified special examinations                                    |
| Z13.9                  | Encounter for screening, unspecified  |
| Z71.89                 | Other specified counseling  |
| Z71.82                 | Exercise counseling   |
| R68.89                 | Other general symptoms and signs  |
| B34.9                  | Viral infection, unspecified  |
| E55.9                  | Vitamin D deficiency, unspecified   |
| Z03.89                 | Encounter for observation for other suspected diseases and conditions ruled out       |
| E03.9                  | Hypothyroidism, unspecified   |
| Z56.5                  | Uncongenial work environment  |
| Z00.00                 | Encounter for general adult medical examination without abnormal findings             |
| K21.9                  | Gastro-esophageal reflux disease without esophagitis                                  |
| E11.9                  | Type 2 diabetes mellitus without complications  |
| R10.9                  | Unspecified abdominal pain  |
| N23                    | Unspecified renal colic   |



| Primary Diagnosis Code | Primary Diagnosis Code Description   |
|------------------------|--|
| N39.0                  | Urinary tract infection, site not specified  |
| R73.03                 | Prediabetes  |
| M54.5                  | Low back pain  |
| E78.2                  | Mixed hyperlipidemia   |
| R07.89                 | Other chest pain   |
| K62.89                 | Other specified diseases of anus and rectum  |
| N89.8                  | Other specified noninflammatory disorders of vagina  |
| M25.50                 | Pain in unspecified joint  |
| Z20.818                | Contact with and (suspected) exposure to other bacterial communicable diseases                             |
| R42                    | Dizziness and giddiness  |
| Z09                    | Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm |
| K80.00                 | Calculus of gallbladder with acute cholecystitis without obstruction                                       |
| R07.9                  | Chest pain, unspecified  |
| N93.9                  | Abnormal uterine and vaginal bleeding, unspecified   |
| K29.00                 | Acute gastritis without bleeding   |
| 124.9                  | Acute ischemic heart disease, unspecified  |
| 024.419                | Gestational diabetes mellitus in pregnancy, unspecified control  |
| E78.5                  | Hyperlipidemia, unspecified  |
| E16.2                  | Hypoglycemia, unspecified  |
| J11.1                  | Influenza due to unidentified influenza virus with other respiratory manifestations                        |
| Z29.9                  | Encounter for prophylactic measures, unspecified   |
| Z119                   | Encounter for screening for infectious and parasitic diseases, unspecified                                 |

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.



#### References

CMS Guidelines https://www.cms.gov/outreach-education/partner-resources/coronavirus-covid-19-partner-toolkit

AMA Resources <u>https://www.ama-assn.org/delivering-care/public-health/covid-19-2019-novel-coronavirus-resource-center-physicians</u>

CDC Interim Guidelines for COVID-19 Antibody Testing: <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html#anchor\_1590264293982</u>

American Medical Association's Serological Testing for SARS-CoV-2 Antibodies: <u>https://www.ama-assn.org/delivering-care/public-health/serological-testing-sars-cov-2-antibodies</u>

Infectious Diseases Society of America's IDSA COVID19 Antibody Testing Primer: <u>https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-covid-19-antibody-testing-primer.pdf</u>

Association of Public Health Laboratories and Council of State and Territorial Epidemiologists, Public Health Considerations: Serologic Testing for COVID-19, Version 1 – May 7, 2020: <u>https://www.aphl.org/programs/preparedness/Crisis-Management/Documents/Serologic-Testing-for-COVID-19.pdf</u>

#### **History**

December 1, 2020New policy, approvedJune 1, 2022Policy reviewed and approved with no change



# Default Pricing

#### DEFAULT PRICING

Policy Notifications/Prior Authorization Requests Reimbursement Guidelines History

Last Reviewed Date: March 1, 2023

# Policy

When a reimbursement rate has not been assigned by MVP, by the parties' executed contract, by Centers for Medicare and Medicaid Services (CMS), or by NYS Medicaid, one will be established based upon a gap pricing method that is an acceptable industry standard. If there is not an accepted industry standard, MVP will reimburse according to default pricing based upon a percentage of billed charges ("Default Pricing"). . If a code does not have an assigned rate, the default rate will be applied.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also confirm Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

#### **Reimbursement Guidelines**

Under Default Pricing, MVP will pay up to 30% of billed charges unless otherwise provided for in the parties executed contract, or assigned by Centers for Medicare & Medicaid Services or NYS Medicaid.

| September 1, 2022 | New policy, approved                         |
|-------------------|--|
| March 1, 2022     | Policy reviewed and approved with changes    |
| March 1, 2023     | Policy reviewed and approved with no changes |



# Diabetic Management and Nutritional Counseling

Last Reviewed Date: December 1, 2022

### DIABETIC MANAGEMENT AND NUTRITIONAL COUNSELING Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Reimbursement Guidelines References

History

# Policy

#### **Nutritional Counseling**

Nutritional Counseling is reimbursable when medically necessary for chronic diseases in which dietary adjustment has a therapeutic role. Nutritional counseling must be prescribed by a physician or qualified non-physician practitioner and furnished by a provider (e.g., licensed nutritionist, registered dietician, or other qualified licensed health professionals such as nurses who are trained in nutrition) recognized under the plan.

#### **Diabetic Management**

Diabetic Management encompasses education and management as medically necessary for the diagnosis and treatment of diabetes, including Type I or Type II, gestational, and/or insulin or non-insulin dependent diabetes.

Diabetic self-management education is considered medically necessary when the member has a diagnosis of diabetes and management services have been prescribed by a physician or qualified non-physician practitioner. These services must be provided by a licensed healthcare professional (e.g., registered dietician, registered nurse, or other health professional) who is a certified diabetes educator (CDE).

# Definitions

#### **Nutritional Counseling**

Medical nutrition therapy provided by a registered dietitian involves the assessment of the person's overall nutritional status, followed by the assignment of individualized diet, counseling, and/or specialized nutrition therapies to treat a chronic illness or condition.

#### **Diabetic Management**

Diabetes self-management education (DSME) is the process through which persons with or at risk for diabetes develop and use the knowledge and skill required to reach their self-defined diabetes goals (American Association of Diabetes Educators [AADE], 2008. The national standards for DSME state that DSME is an interactive, collaborative, ongoing process that involves the person with diabetes and the educator (Funnell, et. al., 2011). The individual with diabetes needs the knowledge and skills to make informed choices, to facilitate self-directed behavior changes, and, ultimately, to reduce the risk of complications. Documentation should include:

- Assessment of the individual's specific education needs
- The individual's specific diabetes self-management goals
- Education and behavioral intervention directed toward helping the individual achieve identified self-management goals
- Evaluation of the individual's attainment of identified self-management goals



#### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>myphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **General Guidelines**

Services rendered by a nutritionist, dietician, or certified diabetes educator must be billed under their individual provider number.

#### **Nutritional Counseling**

For Nutritional Counseling, the following CPT/HCPCS codes are considered reimbursable:

| 97802 | Medical nutritional therapy; initial assessment and intervention, individual, face-to-face with the patient, each 15 minutes   |
|-------|--|
| 97803 | Re-assessment and intervention, individual, face-to-face with the patient, each 15 minutes   |
| 97804 | Group (2 or more individuals(s)), each 30 minutes  |
| G0270 | Medical nutritional therapy; re-assessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face-to-face with the patient, each 15 minutes     |
| G0271 | Medical nutritional therapy; re-assessment and subsequent interventions(s) following second referral in the same<br>year for change in diagnosis, medical condition, or treatment regimen (including additional hours needed for renal<br>disease), group, (2 or more individuals), each<br>30 minutes |

Nutritional Counseling for codes 97802-97804, G0270-G0271 is limited to the following diagnoses for Medicare MSA plans only. All other plans have no diagnosis code restrictions:

| ICD-10 CM | CMS reserves the right to add or remove diagnosis codes associated with its NCDs to implement those NCDs in the most efficient manner within the confines of the policy. |
|-----------|--|
| E08.00    | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)  |
| E08.01    | Diabetes mellitus due to underlying condition with hyperosmolarity with coma   |
| E08.10    | Diabetes mellitus due to underlying condition with ketoacidosis without coma   |
| E08.11    | Diabetes mellitus due to underlying condition with ketoacidosis with coma  |
| E08.22    | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease   |
| E08.29    | Diabetes mellitus due to underlying condition with other diabetic kidney complication  |
| E08.3211  | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye  |



| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,<br>left eye       |
|----------|---|
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral         |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye      |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye       |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral      |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, right eye  |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, left eye   |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, bilateral  |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye  |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye   |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral  |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye       |
| E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye        |
| E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral       |
| E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, right eye |
| E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, left eye  |
| E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, bilateral |
| E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye                 |
| E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye                  |
| E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral                 |



| E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye     |
|----------|--|
| E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye      |
| E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral     |
| E08.3531 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye  |
| E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E08.3541 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, right eye                 |
| E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, left eye                  |
| E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, bilateral                 |
| E08.3551 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye  |
| E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye   |
| E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral  |
| E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye                                     |
| E08.3592 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye                                      |
| E08.3593 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral                                     |
| E08.37X1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye   |
| E08.37X2 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye  |
| E08.37X3 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral   |
| E08.40   | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified  |
| E08.41   | Diabetes mellitus due to underlying condition with diabetic mononeuropathy   |
| E08.42   | Diabetes mellitus due to underlying condition with diabetic polyneuropathy   |
| E08.43   | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy   |
| E08.44   | Diabetes mellitus due to underlying condition with diabetic amyotrophy   |
| E08.49   | Diabetes mellitus due to underlying condition with other diabetic neurological complication  |
| E08.51   | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene   |



| E08.52   | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene                               |
|----------|---|
| E08.59   | Diabetes mellitus due to underlying condition with other circulatory complications  |
| E08.610  | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy   |
| E08.618  | Diabetes mellitus due to underlying condition with other diabetic arthropathy   |
| E08.620  | Diabetes mellitus due to underlying condition with diabetic dermatitis  |
| E08.621  | Diabetes mellitus due to underlying condition with foot ulcer   |
| E08.622  | Diabetes mellitus due to underlying condition with other skin ulcer   |
| E08.628  | Diabetes mellitus due to underlying condition with other skin complications   |
| E08.630  | Diabetes mellitus due to underlying condition with periodontal disease  |
| E08.638  | Diabetes mellitus due to underlying condition with other oral complications   |
| E08.641  | Diabetes mellitus due to underlying condition with hypoglycemia with coma   |
| E08.649  | Diabetes mellitus due to underlying condition with hypoglycemia without coma  |
| E08.69   | Diabetes mellitus due to underlying condition with other specified complication   |
| E08.8    | Diabetes mellitus due to underlying condition with unspecified complications  |
| E08.9    | Diabetes mellitus due to underlying condition without complications   |
| E09.00   | Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar<br>coma (NKHHC) |
| E09.01   | Drug or chemical induced diabetes mellitus with hyperosmolarity with coma   |
| E09.10   | Drug or chemical induced diabetes mellitus with ketoacidosis without coma   |
| E09.11   | Drug or chemical induced diabetes mellitus with ketoacidosis with coma  |
| E09.22   | Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease   |
| E09.29   | Drug or chemical induced diabetes mellitus with other diabetic kidney complication  |
| E09.321  | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema                 |
| E09.3211 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema,<br>right eye   |
| E09.3212 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema,<br>left eye    |
| E09.3213 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema,<br>bilateral   |
| E09.329  | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema              |
| E09.3291 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye   |
|          |   |



| E09.3292 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without<br>macular edema, left eye   |
|----------|---|
| E09.3293 | Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral     |
| E09.331  | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema               |
| E09.3311 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye    |
| E09.3312 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye     |
| E09.3313 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral    |
| E09.339  | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema            |
| E09.3391 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E09.3392 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye  |
| E09.3393 | Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E09.341  | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema                 |
| E09.3411 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,<br>right eye   |
| E09.3412 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,<br>left eye    |
| E09.3413 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,<br>bilateral   |
| E09.349  | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema              |
| E09.3491 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye   |
| E09.3492 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye    |
| E09.3493 | Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E09.351  | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema                           |
| E09.3511 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye                |
| E09.3512 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye                 |
| E09.3513 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral                |



| E09.3521 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye                           |
|----------|---|
| E09.3522 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye                            |
| E09.3523 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral                           |
| E09.3531 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye                       |
| E09.3532 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye                        |
| E09.3533 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral                       |
| E09.3541 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E09.3542 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye  |
| E09.3543 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E09.3551 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |
| E09.3552 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye   |
| E09.3553 | Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral  |
| E09.359  | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema  |
| E09.3591 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye   |
| E09.3592 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |
| E09.3593 | Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral   |
| E09.37X1 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye   |
| E09.37X2 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye  |
| E09.37X3 | Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral   |
| E09.40   | Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified  |
| E09.41   | Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy   |
| E09.42   | Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy   |
| E09.43   | Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy   |
| E09.44   | Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy   |
|          |   |



| E09.49   | Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication |
|----------|--|
| E09.51   | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene                          |
| E09.52   | Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene                             |
| E09.59   | Drug or chemical induced diabetes mellitus with other circulatory complications  |
| E09.610  | Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy   |
| E09.618  | Drug or chemical induced diabetes mellitus with other diabetic arthropathy   |
| E09.620  | Drug or chemical induced diabetes mellitus with diabetic dermatitis  |
| E09.621  | Drug or chemical induced diabetes mellitus with foot ulcer   |
| E09.622  | Drug or chemical induced diabetes mellitus with other skin ulcer   |
| E09.628  | Drug or chemical induced diabetes mellitus with other skin complications   |
| E09.630  | Drug or chemical induced diabetes mellitus with periodontal disease  |
| E09.638  | Drug or chemical induced diabetes mellitus with other oral complications   |
| E09.641  | Drug or chemical induced diabetes mellitus with hypoglycemia with coma   |
| E09.649  | Drug or chemical induced diabetes mellitus with hypoglycemia without coma  |
| E09.65   | Drug or chemical induced diabetes mellitus with hyperglycemia  |
| E09.69   | Drug or chemical induced diabetes mellitus with other specified complication   |
| E09.8    | Drug or chemical induced diabetes mellitus with unspecified complications  |
| E09.9    | Drug or chemical induced diabetes mellitus without complications   |
| E10.10   | Type 1 diabetes mellitus with ketoacidosis without coma  |
| E10.11   | Type 1 diabetes mellitus with ketoacidosis with coma   |
| E10.21   | Type 1 diabetes mellitus with diabetic nephropathy   |
| E10.22   | Type 1 diabetes mellitus with diabetic chronic kidney disease  |
| E10.29   | Type 1 diabetes mellitus with other diabetic kidney complication   |
| E10.3211 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye                   |
| E10.3212 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye                    |
| E10.3213 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral                   |
| E10.3291 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye                |
| E10.3292 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye                 |
| E10.3293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral                |



| E10.3311 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye  |
|----------|---|
| E10.3312 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye   |
| E10.3313 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye   |
| E10.3392 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye  |
| E10.3393 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E10.3411 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye  |
| E10.3412 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye   |
| E10.3413 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3491 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye   |
| E10.3492 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye  |
| E10.3493 | Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E10.3511 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye  |
| E10.3512 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye   |
| E10.3513 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3521 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye                           |
| E10.3522 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye                            |
| E10.3523 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral                           |
| E10.3531 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye                       |
| E10.3532 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye                        |
| E10.3533 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral                       |
| E10.3541 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E10.3542 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye  |
| E10.3543 | Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E10.3551 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |



| E10.3552 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye                 |
|----------|---|
| E10.3553 | Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral                |
| E10.3591 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye |
| E10.3592 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |
| E10.3593 | Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral |
| E10.37X1 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye     |
| E10.37X2 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye      |
| E10.37X3 | Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral     |
| E10.40   | Type 1 diabetes mellitus with diabetic neuropathy, unspecified                                    |
| E10.41   | Type 1 diabetes mellitus with diabetic mononeuropathy   |
| E10.42   | Type 1 diabetes mellitus with diabetic polyneuropathy   |
| E10.43   | Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy                                 |
| E10.44   | Type 1 diabetes mellitus with diabetic amyotrophy   |
| E10.49   | Type 1 diabetes mellitus with other diabetic neurological complication                            |
| E10.51   | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene                     |
| E10.52   | Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene                        |
| E10.59   | Type 1 diabetes mellitus with other circulatory complications                                     |
| E10.610  | Type 1 diabetes mellitus with diabetic neuropathic arthropathy                                    |
| E10.618  | Type 1 diabetes mellitus with other diabetic arthropathy  |
| E10.620  | Type 1 diabetes mellitus with diabetic dermatitis   |
| E10.621  | Type 1 diabetes mellitus with foot ulcer  |
| E10.622  | Type 1 diabetes mellitus with other skin ulcer  |
| E10.628  | Type 1 diabetes mellitus with other skin complications  |
| E10.630  | Type 1 diabetes mellitus with periodontal disease   |
| E10.638  | Type 1 diabetes mellitus with other oral complications  |
| E10.641  | Type 1 diabetes mellitus with hypoglycemia with coma  |
| E10.649  | Type 1 diabetes mellitus with hypoglycemia without coma   |
| E10.65   | Type 1 diabetes mellitus with hyperglycemia   |
| E10.69   | Type 1 diabetes mellitus with other specified complication  |
|          |   |



| E10.8    | Type 1 diabetes mellitus with unspecified complications   |
|----------|---|
| E10.9    | Type 1 diabetes mellitus without complications  |
| E11.00   | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)      |
| E11.01   | Type 2 diabetes mellitus with hyperosmolarity with coma   |
| E11.21   | Type 2 diabetes mellitus with diabetic nephropathy  |
| E11.22   | Type 2 diabetes mellitus with diabetic chronic kidney disease   |
| E11.29   | Type 2 diabetes mellitus with other diabetic kidney complication  |
| E11.3211 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye        |
| E11.3212 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye         |
| E11.3213 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral        |
| E11.329  | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema                |
| E11.3291 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye     |
| E11.3292 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye      |
| E11.3293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral     |
| E11.331  | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema               |
| E11.3311 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye    |
| E11.3312 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye     |
| E11.3313 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral    |
| E11.339  | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema            |
| E11.3391 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |
| E11.3392 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye  |
| E11.3393 | Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |
| E11.341  | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema                 |
| E11.3411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye      |
| E11.3412 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye       |
| E11.3413 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral      |
| E11.349  | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema              |
| E11.3491 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye   |
| E11.3492 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye    |
|          |   |



| E11.3493 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral   |
|----------|---|
| E11.3511 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye  |
| E11.3512 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye   |
| E11.3513 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral  |
| E11.3521 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye                           |
| E11.3522 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye                            |
| E11.3523 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral                           |
| E11.3531 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye                       |
| E11.3532 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye                        |
| E11.3533 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral                       |
| E11.3541 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
| E11.3542 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye  |
| E11.3543 | Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E11.3551 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |
| E11.3552 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye   |
| E11.3553 | Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral  |
| E11.3591 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye   |
| E11.3592 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |
| E11.3593 | Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral   |
| E11.37X1 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye   |
| E11.37X2 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye  |
| E11.37X3 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral   |
| E11.40   | Type 2 diabetes mellitus with diabetic neuropathy, unspecified  |
| E11.41   | Type 2 diabetes mellitus with diabetic mononeuropathy   |
| E11.42   | Type 2 diabetes mellitus with diabetic polyneuropathy   |
|          |   |



| E11.43   | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy   |
|----------|---|
| E11.44   | Type 2 diabetes mellitus with diabetic amyotrophy   |
| E11.49   | Type 2 diabetes mellitus with other diabetic neurological complication  |
| E11.51   | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene                                     |
| E11.52   | Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene  |
| E11.59   | Type 2 diabetes mellitus with other circulatory complications   |
| E11.610  | Type 2 diabetes mellitus with diabetic neuropathic arthropathy  |
| E11.618  | Type 2 diabetes mellitus with other diabetic arthropathy  |
| E11.620  | Type 2 diabetes mellitus with diabetic dermatitis   |
| E11.621  | Type 2 diabetes mellitus with foot ulcer  |
| E11.622  | Type 2 diabetes mellitus with other skin ulcer  |
| E11.628  | Type 2 diabetes mellitus with other skin complications  |
| E11.630  | Type 2 diabetes mellitus with periodontal disease   |
| E11.638  | Type 2 diabetes mellitus with other oral complications  |
| E11.641  | Type 2 diabetes mellitus with hypoglycemia with coma  |
| E11.649  | Type 2 diabetes mellitus with hypoglycemia without coma   |
| E11.65   | Type 2 diabetes mellitus with hyperglycemia   |
| E11.69   | Type 2 diabetes mellitus with other specified complication  |
| E11.8    | Type 2 diabetes mellitus with unspecified complications   |
| E11.9    | Type 2 diabetes mellitus without complications  |
| E13.00   | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) |
| E13.01   | Other specified diabetes mellitus with hyperosmolarity with coma  |
| E13.10   | Other specified diabetes mellitus with ketoacidosis without coma  |
| E13.11   | Other specified diabetes mellitus with ketoacidosis with coma   |
| E13.21   | Other specified diabetes mellitus with diabetic nephropathy   |
| E13.22   | Other specified diabetes mellitus with diabetic chronic kidney disease  |
| E13.29   | Other specified diabetes mellitus with other diabetic kidney complication   |
| E13.3211 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye   |
| E13.3212 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye    |
|          |   |



| E13.3213 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral                                   |
|----------|---|
| E13.3291 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye                                |
| E13.3292 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye                                 |
| E13.3293 | Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral                                |
| E13.3311 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye                               |
| E13.3312 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye                                |
| E13.3313 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral                               |
| E13.3391 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye                            |
| E13.3392 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye                             |
| E13.3393 | Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral                            |
| E13.3411 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye                                 |
| E13.3412 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye                                  |
| E13.3413 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral                                 |
| E13.3491 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye                              |
| E13.3492 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye                               |
| E13.3493 | Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral                              |
| E13.3511 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye   |
| E13.3512 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye  |
| E13.3513 | Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral   |
| E13.3521 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye        |
| E13.3522 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye         |
| E13.3523 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral        |
| E13.3531 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye    |
| E13.3532 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not<br>involving the macula, left eye  |
| E13.3533 | Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not<br>involving the macula, bilateral |



| E13.3541 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |
|----------|--|
| E13.3542 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye  |
| E13.3543 | Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |
| E13.3551 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |
| E13.3552 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye   |
| E13.3553 | Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral  |
| E13.3591 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye   |
| E13.3592 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |
| E13.3593 | Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral   |
| E13.37X1 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, right eye   |
| E13.37X2 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, left eye  |
| E13.37X3 | Other specified diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral   |
| E13.40   | Other specified diabetes mellitus with diabetic neuropathy, unspecified  |
| E13.41   | Other specified diabetes mellitus with diabetic mononeuropathy   |
| E13.42   | Other specified diabetes mellitus with diabetic polyneuropathy   |
| E13.43   | Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy   |
| E13.44   | Other specified diabetes mellitus with diabetic amyotrophy   |
| E13.49   | Other specified diabetes mellitus with other diabetic neurological complication  |
| E13.51   | Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene   |
| E13.52   | Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene  |
| E13.59   | Other specified diabetes mellitus with other circulatory complications   |
| E13.610  | Other specified diabetes mellitus with diabetic neuropathic arthropathy  |
| E13.618  | Other specified diabetes mellitus with other diabetic arthropathy  |
| E13.620  | Other specified diabetes mellitus with diabetic dermatitis   |
| E13.621  | Other specified diabetes mellitus with foot ulcer  |
| E13.622  | Other specified diabetes mellitus with other skin ulcer  |
| E13.628  | Other specified diabetes mellitus with other skin complications  |
| E13.630  | Other specified diabetes mellitus with periodontal disease   |
|          |  |



| E13.638 | Other specified diabetes mellitus with other oral complications  |
|---------|--|
| E13.641 | Other specified diabetes mellitus with hypoglycemia with coma  |
| E13.649 | Other specified diabetes mellitus with hypoglycemia without coma   |
| E13.65  | Other specified diabetes mellitus with hyperglycemia   |
| E13.69  | Other specified diabetes mellitus with other specified complication  |
| E13.8   | Other specified diabetes mellitus with unspecified complications   |
| E13.9   | Other specified diabetes mellitus without complications  |
| 112.9   | Hypertensive chronic kidney disease with state 1-4 chronic kidney disease, or unspecified chronic kidney disease |
| N18.1   | Chronic kidney disease, stage 1  |
| N18.2   | Chronic kidney disease, stage 2 (mild)   |
| N18.31  | Chronic kidney disease, stage 3a (CMS: only for a GFR <51)   |
| N18.32  | Chronic kidney disease, stage 3b   |
| N18.4   | Chronic kidney disease, stage 4 (severe)   |
| N18.5   | Chronic kidney disease, stage 5 (severe)   |
| 024.011 | Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester   |
| 024.012 | Pre-existing type 1 diabetes mellitus, in pregnancy, second trimester  |
| 024.013 | Pre-existing type 1 diabetes mellitus, in pregnancy, third trimester   |
| 024.03  | Pre-existing type 1 diabetes mellitus, in the puerperium   |
| 024.111 | Pre-existing type 2 diabetes mellitus, in pregnancy, first trimester   |
| 024.112 | Pre-existing type 2 diabetes mellitus, in pregnancy, second trimester  |
| 024.113 | Pre-existing type 2 diabetes mellitus, in pregnancy, third trimester   |
| 024.13  | Pre-existing type 2 diabetes mellitus, in the puerperium   |
| 024.410 | Gestational diabetes mellitus in pregnancy, diet controlled  |
| 024.414 | Gestational diabetes mellitus in pregnancy, insulin controlled   |
| 024.415 | Gestational diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs                                |
| 024.419 | Gestational diabetes mellitus in pregnancy, unspecified control  |
| 024.420 | Gestational diabetes mellitus in childbirth, diet controlled   |
| 024.424 | Gestational diabetes mellitus in childbirth, insulin controlled  |
| 024.425 | Gestational diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs                               |
|         |  |



| 024.429 | Gestational diabetes mellitus in childbirth, unspecified control                   |
|---------|--|
| 024.430 | Gestational diabetes mellitus in the puerperium, diet controlled                   |
| 024.434 | Gestational diabetes mellitus in the puerperium, insulin controlled                |
| 024.435 | Gestational diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs |
| 024.439 | Gestational diabetes mellitus in the puerperium, unspecified control               |
| 024.811 | Other pre-existing diabetes mellitus in pregnancy, first trimester                 |
| 024.812 | Other pre-existing diabetes mellitus in pregnancy, second trimester                |
| 024.813 | Other pre-existing diabetes mellitus in pregnancy, third trimester                 |
| 024.83  | Other pre-existing diabetes mellitus in the puerperium                             |
| Z48.22  | Encounter for aftercare following kidney transplant                                |

Nutritional Counseling is not reimbursed for the following services:

- Commercial diet plans, weight management programs or any foods or services related to such plans or programs
- Gym membership programs
- Holistic therapy
- Nutritional counseling when offered by health resorts, recreational programs, camps, wilderness programs, outdoor programs
- Skill programs, relaxation or lifestyle programs, including any services provided in conjunction with, or as part of, such
- Supplemental fasting
- Treatment by a physical therapist for weight loss

#### **Diabetic Management**

For Diabetic Management the following CPT/HCPCS codes are considered reimbursable:

| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes                |
|-------|--|
| G0109 | Diabetes outpatient self-management training services, group session (2 or more), per 30 minutes |

Diabetic Management for codes G0108 and G0109 is limited to the following diagnoses for Medicare MSA plans only. All other Plans will reimburse ICD-10 in range E08-E09:

| ICD-10 CM | CMS reserves the right to add or remove codes associated with its NCDs to implement those NCDs in the most efficient manner within the confines of the policy. |
|-----------|--|
| E08.00    | Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar<br>coma (NKHHC)                               |
| E08.21    | Diabetes mellitus due to underlying condition with diabetic nephropathy  |



| E08.22   | Diabetes mellitus due to underlying condition with diabetic chronic kidney disease  |
|----------|---|
| E08.29   | Diabetes mellitus due to underlying condition with other diabetic kidney complication   |
| E08.311  | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema                                |
| E08.319  | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema                             |
| E08.3211 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye           |
| E08.3212 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,<br>left eye         |
| E08.3213 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,<br>bilateral        |
| E08.3291 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye        |
| E08.3292 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye         |
| E08.3293 | Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral        |
| E08.3311 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, right eye    |
| E08.3312 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, left eye     |
| E08.3313 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular<br>edema, bilateral    |
| E08.3391 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular<br>edema, right eye |
| E08.3392 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular<br>edema, left eye  |
| E08.3393 | Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular<br>edema, bilateral |
| E08.3411 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,<br>right eye      |
| E08.3412 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,<br>left eye       |
| E08.3413 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral         |
| E08.3491 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, right eye   |
| E08.3492 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, left eye    |



| E08.3493 | Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular<br>edema, bilateral                        |
|----------|--|
| E08.3511 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye  |
| E08.3512 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye   |
| E08.3513 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral  |
| E08.3521 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye     |
| E08.3522 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye      |
| E08.3523 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral     |
| E08.3531 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |
| E08.3532 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye  |
| E08.3533 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |
| E08.3541 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, right eye                 |
| E08.3542 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, left eye                  |
| E08.3543 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment, bilateral                 |
| E08.3551 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye  |
| E08.3552 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye   |
| E08.3553 | Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral  |
| E08.3591 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye                                     |
| E08.3592 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye                                      |
| E08.3593 | Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral                                     |
| E08.36   | Diabetes mellitus due to underlying condition with diabetic cataract   |
| E08.37X1 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye   |
| E08.37X2 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye  |
| E08.37X3 | Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral   |
| E08.39   | Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication  |



| E08.40  | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified  |
|---------|--|
| E08.41  | Diabetes mellitus due to underlying condition with diabetic mononeuropathy   |
| E08.42  | Diabetes mellitus due to underlying condition with diabetic polyneuropathy   |
| E08.43  | Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy                                     |
| E08.44  | Diabetes mellitus due to underlying condition with diabetic amyotrophy   |
| E08.49  | Diabetes mellitus due to underlying condition with other diabetic neurological complication                                |
| E08.51  | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene                         |
| E08.52  | Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene                            |
| E08.59  | Diabetes mellitus due to underlying condition with other circulatory complications   |
| E08.610 | Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy  |
| E08.618 | Diabetes mellitus due to underlying condition with other diabetic arthropathy  |
| E08.620 | Diabetes mellitus due to underlying condition with diabetic dermatitis   |
| E08.621 | Diabetes mellitus due to underlying condition with foot ulcer  |
| 508.622 | Diabetes mellitus due to underlying condition with other skin ulcer  |
| E08.628 | Diabetes mellitus due to underlying condition with other skin complications  |
| E08.630 | Diabetes mellitus due to underlying condition with periodontal disease   |
| E08.638 | Diabetes mellitus due to underlying condition with other oral complications  |
| E08.649 | Diabetes mellitus due to underlying condition with hypoglycemia without coma   |
| E08.65  | Diabetes mellitus due to underlying condition with hyperglycemia   |
| E08.69  | Diabetes mellitus due to underlying condition with other specified complication  |
| E08.8   | Diabetes mellitus due to underlying condition with unspecified complications   |
| E08.9   | Diabetes mellitus due to underlying condition without complications  |
| E09.00  | Drug or chemical induced Diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) |
| E09.21  | Drug or chemical induced Diabetes mellitus with diabetic nephropathy   |
| E09.22  | Drug or chemical induced Diabetes mellitus with diabetic chronic kidney disease  |
| E09.29  | Drug or chemical induced Diabetes mellitus with other diabetic kidney complication   |
| E09.311 | Drug or chemical induced Diabetes mellitus with unspecified diabetic retinopathy with macular edema                        |
| E09.319 | Drug or chemical induced Diabetes mellitus with unspecified diabetic retinopathy without macular edema                     |
|         |  |



| E09.3211 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right<br>eye        |
|----------|--|
| E09.3212 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye            |
| E09.3213 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema,<br>bilateral        |
| E09.3291 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye        |
| E09.3292 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema,<br>left eye      |
| E09.3293 | Drug or chemical induced Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema,<br>bilateral     |
| E09.3311 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye       |
| E09.3312 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema,<br>left eye     |
| E09.3313 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema,<br>bilateral    |
| E09.3391 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular<br>edema, right eye |
| E09.3392 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular<br>edema, left eye  |
| E09.3393 | Drug or chemical induced Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular<br>edema, bilateral |
| E09.3411 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,<br>right eye      |
| E09.3412 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left<br>eye       |
| E09.3413 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,<br>bilateral      |
| E09.3491 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye      |
| E09.3492 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye       |
| E09.3493 | Drug or chemical induced Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral      |
| E09.3511 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye                   |
| E09.3512 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye                    |



| E09.3513 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral   |
|----------|--|
| E09.3521 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment<br>involving the macula, right eye     |
| E09.3522 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye         |
| E09.3523 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral        |
| E09.3531 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye    |
| E09.3532 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye     |
| E09.3533 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment<br>not involving the macula, bilateral |
| E09.3541 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment, right eye                    |
| E09.3542 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment, left eye                     |
| E09.3543 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment, bilateral                    |
| E09.3551 | Drug or chemical induced Diabetes mellitus with stable proliferative diabetic retinopathy, right eye   |
| E09.3552 | Drug or chemical induced Diabetes mellitus with stable proliferative diabetic retinopathy, left eye  |
| E09.3553 | Drug or chemical induced Diabetes mellitus with stable proliferative diabetic retinopathy, bilateral   |
| E09.3591 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye  |
| E09.3592 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye   |
| E09.3593 | Drug or chemical induced Diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral  |
| E09.36   | Drug or chemical induced Diabetes mellitus with diabetic cataract  |
| E09.37X1 | Drug or chemical induced Diabetes mellitus with diabetic macular edema, resolved following treatment, right eye  |
| E09.37X2 | Drug or chemical induced Diabetes mellitus with diabetic macular edema, resolved following treatment, left eye   |
| E09.37X3 | Drug or chemical induced Diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral  |
| E09.39   | Drug or chemical induced Diabetes mellitus with other diabetic ophthalmic complication   |
| E09.40   | Drug or chemical induced Diabetes mellitus with neurological complications with diabetic neuropathy, unspecified   |
| E09.41   | Drug or chemical induced Diabetes mellitus with neurological complications with diabetic mononeuropathy  |
| E09.42   | Drug or chemical induced Diabetes mellitus with neurological complications with diabetic polyneuropathy  |



| E09.43   | Drug or chemical induced Diabetes mellitus with neurological complications with diabetic autonomic (poly)<br>neuropathy  |
|----------|--|
| E09.44   | Drug or chemical induced Diabetes mellitus with neurological complications with diabetic amyotrophy                      |
| E09.49   | Drug or chemical induced Diabetes mellitus with neurological complications with other diabetic neurological complication |
| E09.51   | Drug or chemical induced Diabetes mellitus with diabetic peripheral angiopathy without gangrene                          |
| E09.52   | Drug or chemical induced Diabetes mellitus with diabetic peripheral angiopathy with gangrene                             |
| E09.59   | Drug or chemical induced Diabetes mellitus with other circulatory complications  |
| E09.610  | Drug or chemical induced Diabetes mellitus with diabetic neuropathic arthropathy   |
| E09.618  | Drug or chemical induced Diabetes mellitus with other diabetic arthropathy   |
| E09.620  | Drug or chemical induced Diabetes mellitus with diabetic dermatitis  |
| E09.621  | Drug or chemical induced Diabetes mellitus with foot ulcer   |
| E09.622  | Drug or chemical induced Diabetes mellitus with other skin ulcer   |
| E09.628  | Drug or chemical induced Diabetes mellitus with other skin complications   |
| E09.630  | Drug or chemical induced Diabetes mellitus with periodontal disease  |
| E09.638  | Drug or chemical induced Diabetes mellitus with other oral complications   |
| E09.649  | Drug or chemical induced Diabetes mellitus with hypoglycemia without coma  |
| E09.65   | Drug or chemical induced Diabetes mellitus with hyperglycemia  |
| E09.69   | Drug or chemical induced Diabetes mellitus with other specified complication   |
| E09.8    | Drug or chemical induced Diabetes mellitus with unspecified complications  |
| E09.9    | Drug or chemical induced Diabetes mellitus without complications   |
| E10.21   | Type 1 Diabetes mellitus with diabetic nephropathy   |
| E10.22   | Type 1 Diabetes mellitus with diabetic chronic kidney disease  |
| E10.29   | Type 1 Diabetes mellitus with other diabetic kidney complication   |
| E10.311  | Type 1 Diabetes mellitus with unspecified diabetic retinopathy with macular edema  |
| E10.319  | Type 1 Diabetes mellitus with unspecified diabetic retinopathy without macular edema                                     |
| E10.3211 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye                   |
| E10.3212 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye                    |
| E10.3213 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral                   |
| E10.3291 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye                |



| E10.3292 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye  |
|----------|---|
| E10.3293 | Type 1 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E10.3311 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye  |
| E10.3312 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye   |
| E10.3313 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3391 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye   |
| E10.3392 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye  |
| E10.3393 | Type 1 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E10.3411 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye  |
| E10.3412 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye   |
| E10.3413 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3491 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye   |
| E10.3492 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye  |
| E10.3493 | Type 1 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral   |
| E10.3511 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye  |
| E10.3512 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye   |
| E10.3513 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral  |
| E10.3521 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye                             |
| E10.3522 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye                              |
| E10.3523 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral                             |
| E10.3531 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye                         |
| E10.3532 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye                          |
| E10.3533 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral                         |
| E10.3541 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye   |
| E10.3542 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and<br>rhegmatogenous retinal detachment, left eye |



| E10.3543 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |  |  |
|----------|---|--|--|
| E10.3551 | Type 1 Diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |  |  |
| E10.3552 | Type 1 Diabetes mellitus with stable proliferative diabetic retinopathy, left eye   |  |  |
| E10.3553 | Type 1 Diabetes mellitus with stable proliferative diabetic retinopathy, bilateral  |  |  |
| E10.3591 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye   |  |  |
| E10.3592 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |  |  |
| E10.3593 | Type 1 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral   |  |  |
| E10.36   | Type 1 Diabetes mellitus with diabetic cataract   |  |  |
| E10.37X1 | Type 1 Diabetes mellitus with diabetic macular edema, resolved following treatment, right eye   |  |  |
| E10.37X2 | Type 1 Diabetes mellitus with diabetic macular edema, resolved following treatment, left eye  |  |  |
| E10.37X3 | Type 1 Diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral   |  |  |
| E10.39   | Type 1 Diabetes mellitus with other diabetic ophthalmic complication  |  |  |
| E10.40   | Type 1 Diabetes mellitus with diabetic neuropathy, unspecified  |  |  |
| E10.41   | Type 1 Diabetes mellitus with diabetic mononeuropathy   |  |  |
| E10.42   | Type 1 Diabetes mellitus with diabetic polyneuropathy   |  |  |
| E10.43   | Type 1 Diabetes mellitus with diabetic autonomic (poly)neuropathy   |  |  |
| E10.44   | Type 1 Diabetes mellitus with diabetic amyotrophy   |  |  |
| E10.49   | Type 1 Diabetes mellitus with other diabetic neurological complication  |  |  |
| E10.51   | Type 1 Diabetes mellitus with diabetic peripheral angiopathy without gangrene   |  |  |
| E10.52   | Type 1 Diabetes mellitus with diabetic peripheral angiopathy with gangrene  |  |  |
| E10.59   | Type 1 Diabetes mellitus with other circulatory complications   |  |  |
| E10.610  | Type 1 Diabetes mellitus with diabetic neuropathic arthropathy  |  |  |
| E10.618  | Type 1 Diabetes mellitus with other diabetic arthropathy  |  |  |
| E10.620  | Type 1 Diabetes mellitus with diabetic dermatitis   |  |  |
| E10.621  | Type 1 Diabetes mellitus with foot ulcer  |  |  |
| E10.622  | Type 1 Diabetes mellitus with other skin ulcer  |  |  |
| E10.628  | Type 1 Diabetes mellitus with other skin complications  |  |  |
| E10.630  | Type 1 Diabetes mellitus with periodontal disease   |  |  |
| E10.638  | Type 1 Diabetes mellitus with other oral complications  |  |  |



| E10.649  | Type 1 Diabetes mellitus with hypoglycemia without coma   |  |  |  |
|----------|---|--|--|--|
| E10.65   | Type 1 Diabetes mellitus with hyperglycemia   |  |  |  |
| E10.69   | Type 1 Diabetes mellitus with other specified complication  |  |  |  |
| E10.8    | Type 1 Diabetes mellitus with unspecified complications   |  |  |  |
| E10.9    | Type 1 Diabetes mellitus without complications  |  |  |  |
| E11.00   | Type 2 Diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)      |  |  |  |
| E11.21   | Type 2 Diabetes mellitus with diabetic nephropathy  |  |  |  |
| E11.22   | Type 2 Diabetes mellitus with diabetic chronic kidney disease   |  |  |  |
| E11.29   | Type 2 Diabetes mellitus with other diabetic kidney complication  |  |  |  |
| E11.311  | Type 2 Diabetes mellitus with unspecified diabetic retinopathy with macular edema                             |  |  |  |
| E11.319  | Type 2 Diabetes mellitus with unspecified diabetic retinopathy without macular edema                          |  |  |  |
| E11.3211 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye        |  |  |  |
| E11.3212 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye         |  |  |  |
| E11.3213 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral        |  |  |  |
| E11.3291 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye     |  |  |  |
| E11.3292 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye      |  |  |  |
| E11.3293 | Type 2 Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral     |  |  |  |
| E11.3311 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye    |  |  |  |
| E11.3312 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye     |  |  |  |
| E11.3313 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral    |  |  |  |
| E11.3391 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye |  |  |  |
| E11.3392 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye  |  |  |  |
| E11.3393 | Type 2 Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral |  |  |  |
| E11.3411 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye      |  |  |  |
| E11.3412 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye       |  |  |  |
| E11.3413 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral      |  |  |  |
| E11.3491 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye   |  |  |  |
| E11.3492 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye    |  |  |  |
| E11.3493 | Type 2 Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral   |  |  |  |
|          |   |  |  |  |



| E11.3511 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye  |  |  |  |
|----------|---|--|--|--|
| E11.3512 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye   |  |  |  |
| E11.3513 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral  |  |  |  |
| E11.3521 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye                           |  |  |  |
| E11.3522 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye                            |  |  |  |
| E11.3523 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral                           |  |  |  |
| E11.3531 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye                       |  |  |  |
| E11.3532 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye                        |  |  |  |
| E11.3533 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral                       |  |  |  |
| E11.3541 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye |  |  |  |
| E11.3542 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye  |  |  |  |
| E11.3543 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral |  |  |  |
| E11.3551 | Type 2 Diabetes mellitus with stable proliferative diabetic retinopathy, right eye  |  |  |  |
| E11.3552 | Type 2 Diabetes mellitus with stable proliferative diabetic retinopathy, left eye   |  |  |  |
| E11.3553 | Type 2 Diabetes mellitus with stable proliferative diabetic retinopathy, bilateral  |  |  |  |
| E11.3591 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye   |  |  |  |
| E11.3592 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye  |  |  |  |
| E11.3593 | Type 2 Diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral   |  |  |  |
| E11.36   | Type 2 Diabetes mellitus with diabetic cataract   |  |  |  |
| E11.37X1 | Type 2 Diabetes mellitus with diabetic macular edema, resolved following treatment, right eye   |  |  |  |
| E11.37X2 | Type 2 Diabetes mellitus with diabetic macular edema, resolved following treatment, left eye  |  |  |  |
| E11.37X3 | Type 2 Diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral   |  |  |  |
| E11.39   | Type 2 Diabetes mellitus with other diabetic ophthalmic complication  |  |  |  |
| E11.40   | Type 2 Diabetes mellitus with diabetic neuropathy, unspecified  |  |  |  |
| E11.41   | Type 2 Diabetes mellitus with diabetic mononeuropathy   |  |  |  |
|          |   |  |  |  |



| E11.42   | Type 2 Diabetes mellitus with diabetic polyneuropathy  |  |  |
|----------|--|--|--|
| E11.43   | Type 2 Diabetes mellitus with diabetic autonomic (poly)neuropathy  |  |  |
| E11.44   | Type 2 Diabetes mellitus with diabetic amyotrophy  |  |  |
| E11.49   | Type 2 Diabetes mellitus with other diabetic neurological complication   |  |  |
| E11.51   | Type 2 Diabetes mellitus with diabetic peripheral angiopathy without gangrene  |  |  |
| E11.52   | Type 2 Diabetes mellitus with diabetic peripheral angiopathy with gangrene   |  |  |
| E11.59   | Type 2 Diabetes mellitus with other circulatory complications  |  |  |
| E11.610  | Type 2 Diabetes mellitus with diabetic neuropathic arthropathy   |  |  |
| E11.618  | Type 2 Diabetes mellitus with other diabetic arthropathy   |  |  |
| E11.620  | Type 2 Diabetes mellitus with diabetic dermatitis  |  |  |
| E11.621  | Type 2 Diabetes mellitus with foot ulcer   |  |  |
| E11.622  | Type 2 Diabetes mellitus with other skin ulcer   |  |  |
| E11.628  | Type 2 Diabetes mellitus with other skin complications   |  |  |
| E11.630  | Type 2 Diabetes mellitus with periodontal disease  |  |  |
| E11.638  | Type 2 Diabetes mellitus with other oral complications   |  |  |
| E11.649  | Type 2 Diabetes mellitus with hypoglycemia without coma  |  |  |
| E11.65   | Type 2 Diabetes mellitus with hyperglycemia  |  |  |
| E11.69   | Type 2 Diabetes mellitus with other specified complication   |  |  |
| E11.8    | Type 2 Diabetes mellitus with unspecified complications  |  |  |
| E11.9    | Type 2 Diabetes mellitus without complications   |  |  |
| E13.00   | Other specified Diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma<br>(NKHHC) |  |  |
| E13.21   | Other specified Diabetes mellitus with diabetic nephropathy  |  |  |
| E13.22   | Other specified Diabetes mellitus with diabetic chronic kidney disease   |  |  |
| E13.29   | Other specified Diabetes mellitus with other diabetic kidney complication  |  |  |
| E13.311  | Other specified Diabetes mellitus with unspecified diabetic retinopathy with macular edema                           |  |  |
| E13.319  | Other specified Diabetes mellitus with unspecified diabetic retinopathy without macular edema                        |  |  |
| E13.3211 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye      |  |  |
| E13.3212 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye       |  |  |
| E13.3213 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral      |  |  |
|          |  |  |  |



| E13.3291 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye                             |  |  |
|----------|--|--|--|
| E13.3292 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye                              |  |  |
| E13.3293 | Other specified Diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral                             |  |  |
| E13.3311 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye                            |  |  |
| E13.3312 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye                             |  |  |
| E13.3313 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral                            |  |  |
| E13.3391 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye                         |  |  |
| E13.3392 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left<br>eye                       |  |  |
| E13.3393 | Other specified Diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral                         |  |  |
| E13.3411 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye                              |  |  |
| E13.3412 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye                               |  |  |
| E13.3413 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral                              |  |  |
| E13.3491 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye                           |  |  |
| E13.3492 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye                            |  |  |
| E13.3493 | Other specified Diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral                           |  |  |
| E13.3511 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye  |  |  |
| E13.3512 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye   |  |  |
| E13.3513 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral  |  |  |
| E13.3521 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye     |  |  |
| E13.3522 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye      |  |  |
| E13.3523 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving th macula, bilateral      |  |  |
| E13.3531 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye |  |  |
| E13.3532 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye  |  |  |
| E13.3533 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral |  |  |



| E13.3541 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment<br>and rhegmatogenous retinal detachment, right eye |  |  |
|----------|---|--|--|
| E13.3542 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye     |  |  |
| E13.3543 | Other specified Diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral    |  |  |
| E13.3551 | Other specified Diabetes mellitus with stable proliferative diabetic retinopathy, right eye   |  |  |
| E13.3552 | Other specified Diabetes mellitus with stable proliferative diabetic retinopathy, left eye  |  |  |
| E13.3553 | Other specified Diabetes mellitus with stable proliferative diabetic retinopathy, bilateral   |  |  |
| E13.3591 | Other specified Diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye  |  |  |
| E13.3592 | Other specified Diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye   |  |  |
| E13.3593 | Other specified Diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral  |  |  |
| E13.36   | Other specified Diabetes mellitus with diabetic cataract  |  |  |
| E13.37X1 | Other specified Diabetes mellitus with diabetic macular edema, resolved following treatment, right eye  |  |  |
| E13.37X2 | Other specified Diabetes mellitus with diabetic macular edema, resolved following treatment, left eye   |  |  |
| E13.37X3 | Other specified Diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral  |  |  |
| E13.39   | Other specified Diabetes mellitus with other diabetic ophthalmic complication   |  |  |
| E13.40   | Other specified Diabetes mellitus with diabetic neuropathy, unspecified   |  |  |
| E13.41   | Other specified Diabetes mellitus with diabetic mononeuropathy  |  |  |
| E13.42   | Other specified Diabetes mellitus with diabetic polyneuropathy  |  |  |
| E13.43   | Other specified Diabetes mellitus with diabetic autonomic (poly)neuropathy  |  |  |
| E13.44   | Other specified Diabetes mellitus with diabetic amyotrophy  |  |  |
| E13.49   | Other specified Diabetes mellitus with other diabetic neurological complication   |  |  |
| E13.51   | Other specified Diabetes mellitus with diabetic peripheral angiopathy without gangrene  |  |  |
| E13.52   | Other specified Diabetes mellitus with diabetic peripheral angiopathy with gangrene   |  |  |
| E13.59   | Other specified Diabetes mellitus with other circulatory complications  |  |  |
| E13.610  | Other specified Diabetes mellitus with diabetic neuropathic arthropathy   |  |  |
| E13.618  | Other specified Diabetes mellitus with other diabetic arthropathy   |  |  |
| E13.620  | Other specified Diabetes mellitus with diabetic dermatitis  |  |  |
| E13.621  | Other specified Diabetes mellitus with foot ulcer   |  |  |
| E13.622  | Other specified Diabetes mellitus with other skin ulcer   |  |  |



| E13.628 | Other specified Diabetes mellitus with other skin complications                    |  |  |
|---------|--|--|--|
| E13.630 | Other specified Diabetes mellitus with periodontal disease                         |  |  |
| E13.638 | Other specified Diabetes mellitus with other oral complications                    |  |  |
| E13.649 | Other specified Diabetes mellitus with hypoglycemia without coma                   |  |  |
| E13.65  | Other specified Diabetes mellitus with hyperglycemia                               |  |  |
| E13.69  | Other specified Diabetes mellitus with other specified complication                |  |  |
| E13.8   | Other specified Diabetes mellitus with unspecified complications                   |  |  |
| E13.9   | Other specified Diabetes mellitus without complications                            |  |  |
| 024.011 | Pre-existing type 1 Diabetes mellitus, in pregnancy, first trimester               |  |  |
| 024.012 | Pre-existing type 1 Diabetes mellitus, in pregnancy, second trimester              |  |  |
| 024.013 | Pre-existing type 1 Diabetes mellitus, in pregnancy, third trimester               |  |  |
| 024.03  | Pre-existing type 1 Diabetes mellitus, in the puerperium                           |  |  |
| 024.111 | Pre-existing type 2 Diabetes mellitus, in pregnancy, first trimester               |  |  |
| 024.112 | Pre-existing type 2 Diabetes mellitus, in pregnancy, second trimester              |  |  |
| 024.113 | Pre-existing type 2 Diabetes mellitus, in pregnancy, third trimester               |  |  |
| 024.13  | Pre-existing type 2 Diabetes mellitus, in the puerperium                           |  |  |
| 024.410 | Gestational Diabetes mellitus in pregnancy, diet controlled                        |  |  |
| 024.414 | Gestational Diabetes mellitus in pregnancy, insulin controlled                     |  |  |
| 024.415 | Gestational Diabetes mellitus in pregnancy, controlled by oral hypoglycemic drugs  |  |  |
| 024.419 | Gestational Diabetes mellitus in pregnancy, unspecified control                    |  |  |
| 024.420 | Gestational Diabetes mellitus in childbirth, diet controlled                       |  |  |
| 024.424 | Gestational Diabetes mellitus in childbirth, insulin controlled                    |  |  |
| 024.425 | Gestational Diabetes mellitus in childbirth, controlled by oral hypoglycemic drugs |  |  |
| 024.429 | Gestational Diabetes mellitus in childbirth, unspecified control                   |  |  |
| 024.430 | Gestational Diabetes mellitus in the puerperium, diet controlled                   |  |  |
| 024.434 | Gestational Diabetes mellitus in the puerperium, insulin controlled                |  |  |
| 024.435 | Gestational Diabetes mellitus in puerperium, controlled by oral hypoglycemic drugs |  |  |
| 024.439 | Gestational Diabetes mellitus in the puerperium, unspecified control               |  |  |
|         | Other pre-existing Diabetes mellitus in pregnancy, first trimester                 |  |  |



| 024.812 | Other pre-existing Diabetes mellitus in pregnancy, second trimester |  |
|---------|---|--|
| 024.813 | Other pre-existing Diabetes mellitus in pregnancy, third trimester  |  |
| 024.83  | Other pre-existing Diabetes mellitus in the puerperium              |  |

## **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

## References

MVP Credentialing and Recredentialing of Practitioners

CMS National and Local Coverages Indexes: <u>cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx</u> <u>cms.gov/medicare-coverage-database/details/ncd-details.aspx?ncdid=252</u>

# History

| June 1, 2017      | Policy approved                              |
|-------------------|--|
| June 1, 2020      | Policy reviewed and approved with no changes |
| September 1, 2021 | Policy reviewed and approved with changes    |
| December 1, 2022  | Policy reviewed and approved with no changes |



# Diagnosis Matching Edits

Last Reviewed Date: December 1, 2022

#### DIAGNOSIS MATCHING EDITS

| Policy                                    |
|---|
| Definitions                               |
| Notification/Prior Authorization Requests |
| Billing/Coding Guidelines                 |
| References                                |
| Appendix                                  |
| History                                   |

# Policy

MVP Health Care follows the diagnosis matching edits in accordance with Medicare Local Coverage Determinations (LCD) or National Coverage Determinations (NCD), in addition to guidelines established by Physician Medical Societies for the procedures listed in the policy. This policy applies to all lines of business and all claims including, but not limited to, physicians, hospitals, and ambulatory surgery centers. For more information on Medicare Local Coverage Determinations please visit the Center for Medicare & Medicaid services website at <u>cms.gov/medicare-coverage-database/overview-and-quick-search.aspx</u>

# Definitions

#### Medical Necessity (CMS Medicare's definition)

Medical necessity is the overarching criterion for payment in addition to the individual documentation requirements of a CPT code. It would not be medically necessary or appropriate to bill a higher level of evaluation and management service when a lower level of service is warranted. The volume of documentation should not be the primary influence upon which a specific level of service is billed. Documentation should support the level of service being reported.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Participating Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Participating Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **Transthoracic Echocardiography**

To access the appropriate diagnoses to be used with these Procedure codes, use Document ID #L33577 – Contract # 13282 or Article A56781 on the CMS website.

| Code                                | Description   | Rule   |
|-------------------------------------|---|--|
| 93303<br>93304<br>C8921<br>C8922    | Transthoracic<br>echocardiography for<br>congenital cardiac<br>anomalies; Group 2 | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due<br/>to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> <li>Pediatric Cardiology Specialty is excluded from this edit</li> </ul> |
| 93306-93308<br>C8923-C8924<br>C8929 | Real time transthoracic<br>echocardiography; Group 1                              | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes.</li> <li>Pediatric Cardiology Specialty is excluded from this edit</li> </ul>        |



| Code                          | Description  | Rule   |
|-------------------------------|--|--|
| 93308<br>C8924                | Echocardiography,<br>transthoracic, real-time with<br>image documentation (2D),<br>includes M-mode recording,<br>when performed, follow-up<br>or limited study. Group 3                    | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> <li>Pediatric Cardiology Specialty is excluded from this edit</li> </ul> |
| 93350-93352<br>C8928<br>C8930 | Echocardiography,<br>transthoracic, real-time with<br>image documentation (2D),<br>includes M-mode recording,<br>when performed, during rest<br>and cardiovascular stress<br>test. Group 4 | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> <li>Pediatric Cardiology Specialty is excluded from this edit</li> </ul> |

## Facet Joint Injections, Medical Branch Blocks, and Facet Joint Radiofrequency Neurotomy

To access the appropriate diagnoses to be used with these Procedure codes, use Document ID #35936 – Contract # 13282 or Article A57826 on the CMS website.

| Code                                      | Description  | Rule  |
|---|--|---|
| 64490-64495                               | Diagnostic or Therapeutic<br>agent injections with image<br>guidance. Cervical,Thoracic,<br>Lumbar, or Sacral    | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due to<br/>medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul> |
| 64633<br>64634<br>64635<br>64636<br>64625 | Destruction by neurolytic<br>agent, paravertebral facet<br>joint nerve; Cervical,<br>Thoracic, Lumbar, or Sacral | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due to<br/>medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul> |

#### Nerve Conduction Studies and electromyography

To access the appropriate diagnoses to be used with these Procedure codes use Document ID # L35098– Contract # 13282 or Article A57668 on the CMS website.

| Code   | Description   | Rule  |
|--|---|---|
| 51785, 92265,<br>95860, 95861,<br>95863, 95864,<br>95865, 95866,<br>95867, 95868,<br>95872, 95870,<br>95872, 95873,<br>95874, 95885,<br>95886, 95887,<br>95905, 95907,<br>95908, 95909,<br>95910, 95911,<br>95912, 95913<br>95933, G0255 | Nerve Conduction Studies<br>(NCS) and Electromyography<br>Group 1 | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due<br/>to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul> |



| Code  | Description                               | Rule  |
|-------|---|---|
| 95937 | Neuromuscular Junction<br>Testing Group 2 | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due<br/>to medical necessity.</li> </ul> |
|       |   | <ul> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul>  |

#### **Corneal Pachymetry**

To access the appropriate diagnoses to be used with these Procedure codes, useDocument ID # L33630 corneal pachymetry - Contract # 13282 or Article A56548 on the CMS website.

| Code  | Description   | Rule  |
|-------|---|---|
| 76514 | Ophthalmic ultrasound,<br>diagnostic; corneal<br>pachymetry, unilateral or<br>bilateral (determination of<br>corneal thickness) | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance<br/>with the Medicare Local Coverage Determination or the claim will be denied due to<br/>medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul> |

#### **Visual Fields Testing**

To access the appropriate diagnoses to be used with these Procedure codes use Document ID # L33574 – Contract # 13282 or Article A56551 on the CMS website.

| Code  | Description                   | Rule  |
|-------|-------------------------------|---|
| 92081 | Visual field examination,     | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance</li></ul> |
| 92082 | unilateral or bilateral, with | with the Medicare Local Coverage Determination or the claim will be denied due to               |
| 92083 | interpretation and report     | medical necessity. <li>The Upstate New York Local Coverage Determinations for these codes</li>  |

#### Antibody Herpes Simplex Virus (Type 1 and Type 2)

Only an appropriate diagnoses should be used with these procedure codes in accordance with the United States Preventive Services Task Force, and the American Academy of Family Physicians. Please see <u>Appendix</u> for the appropriate diagnosis codes.

| Code  | Description             | Rule   |
|-------|-------------------------|--|
| 86695 | Herpes Simplex, type 1  | MVP requires the correct diagnosis be submitted with the claim in accordance with the American Academy of Family Physicians or the claim will be denied due to medical necessity |
| 86696 | Herpies Simplex, type 2 | MVP requires the correct diagnosis be submitted with the claim in accordance with clinical guidance.   |



#### Vitamin D 25 and Vitamin D1.25

To access the appropriate diagnoses to be used with these Procedure codes, use Document ID LCD #L 37535 – Contract # 13201 or Article A57736 on the CMS website.

| Code  | Description   | Rule  |
|-------|---|---|
| 82306 | Vitamin D 25 hydroxy<br>includes fraction if<br>performed   | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Upstate New York Local Coverage Determinations for these codes</li> </ul> |
| 82652 | Vitamin D 1.25 hydroxy<br>includes fraction if<br>performed |   |

#### **Erythrocyte Sedimentation Rate RBC Automated**

To access the appropriate diagnoses to be used with procedure codes in accordance with the American Society for Clinical Pathology Refer to the <u>Appendix</u> for appropriate diagnosis codes.

| Code  | Description                                   | Rule   |
|-------|---|--|
| 85652 | Sedimentation rate;<br>erythrocyte; automated | MVP requires the correct diagnosis be submitted with the claim in accordance<br>with the American Society for Clinical Pathology or the claim will be denied due to<br>medical due to medical necessity. |

## Gammaglobulin IGE, Allergen Spec IGE, Crude Allergan Extract and Allergen Spec IGE Recombinant/ Purified component, (each)

To access the appropriate diagnoses to be used with procedure codes in accordance with the American Academy of Allergy, Asthma & Immunology. Refer to the <u>Appendix</u> for the appropriate diagnosis codes.

| Code  | Description  | Rule   |
|-------|--|--|
| 82785 | Assay of Gammaglobulin IGE   | MVP requires the correct diagnosis be submitted with the claim in accordance with clinical guidance. |
| 86003 | Allergen Specific<br>IGE ; quantitative or<br>semiquantitative, crude<br>allergen extract, each            |  |
| 86008 | Allergen Specific<br>IGE quantitative or<br>semiquantitative,<br>recombinant/purified<br>component, (each) |  |

#### **Folic Acid**

Only an appropriate diagnoses should be used with these procedure codes in accordance with the American Society for Clinical Pathology. Refer to the <u>Appendix</u> for appropriate diagnosis codes.

| Code  | Description               | Rule   |
|-------|---------------------------|--|
| 82746 | Assay of Folic Acid Serum | MVP requires the correct diagnosis be submitted with the claim in accordance with clinical guidance. |



### Cyanocobalamin-Vitamin B12

To access the appropriate diagnoses to be used with these Procedure codes, use Document ID #L34914 – Novitas Solutions Inc. on the CMS website.

| Code  | Description                    | Rule  |
|-------|--------------------------------|---|
| 82607 | Cyanocobalamin-<br>Vitamin B12 | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Novitas Solutions Inc. Local Coverage Determinations for this code – see reference below</li> </ul> |

#### **Gonadotropin Follicle Stimulating Hormone**

To access the appropriate diagnoses to be used with these procedure codes in accordance with the American Society for Reproductive Medicine. Refer to the <u>Appendix</u> for appropriate diagnosis codes.

| Code  | Description                          | Rule   |
|-------|--------------------------------------|--|
| 83001 | Gonadotropin Follicle<br>Stimulating | MVP requires the correct diagnosis be submitted with the claim in accordance with the American Society for Reproductive Medicine or the claim will be denied due to medical necessity. |

## Thyroid Stimulating Hormone Testing (TSH)

To access the appropriate diagnoses to be used with these Procedure codes, use National Coverage Determination Publication ID # 100-3 Manual Section # 190.22 on the CMS website.

| Code  | Description   | Rule  |
|-------|---|---|
| 84443 | Thyroid stimulating hormone (TSH)   | <ul> <li>MVP requires the correct diagnosis be submitted with the claim in accordance with the Medicare Local Coverage Determination or the claim will be denied due to medical necessity.</li> <li>The Novitas Solutions Inc. Local Coverage Determinations for this code – see reference below</li> </ul> |
| 84436 | Thyroxine; total  |   |
| 84439 | Free -thyroxine; total  |   |
| 84479 | Thyroid hormone (TS or T4)<br>uptake or thyroid hormone<br>binding ratio (THBR) |   |

#### Triiodothyronine

To access the appropriate diagnoses to be used with procedure codes in accordance with the American Society for Clinical Pathology & the Endocrine Society. Refer to the <u>Appendix</u> for appropriate diagnosis codes.

| Code  | Description                                | Rule   |
|-------|--|--|
| 84480 | Assay of Triiodothyronine<br>T3; Total TT3 | MVP requires the correct diagnosis be submitted with the claim or the claim will be denied due to medical necessity. Refer to the <u>Appendix</u> for appropriate diagnosis codes. |
| 84481 | Assay of Triiodothyronine<br>Free          | Refer to the <u>Appendix</u> for appropriate diagnosis codes.  |



# References

Medicare Coverage Database Advanced Search: <u>cms.gov/medicare-coverage-database/search/advanced-search.aspx</u>

## Appendix

This Appendix contains the reimbursable diagnosis codes for the laboratory services listed below.

#### **Laboratory Services**

- Follicle Stimulating Hormone
- Herpes Simplex Virus
- Gammaglobulin IGE
- Erythrocyte Sedimentation Rate
- Folic Acid
- Triiodothyronine -T3 Free
- Triiodothyronine -T3 Total

#### **Follicle Stimulating Hormone**

| Code   | Description  |  |  |
|--------|--|--|--|
| C50112 | Malignant neoplasm of central portion of left female breast                            |  |  |
| C50211 | Malignant neoplasm of upper-inner quadrant of right female breast                      |  |  |
| C50212 | Malignant neoplasm of upper-inner quadrant of left female breast                       |  |  |
| C50411 | Malignant neoplasm of upper-outer quadrant of right female breast                      |  |  |
| C50412 | Malignant neoplasm of upper-outer quadrant of left female breast                       |  |  |
| C50512 | Malignant neoplasm of lower-outer quadrant of left female breast                       |  |  |
| C50811 | Malignant neoplasm of overlapping sites of right female breast                         |  |  |
| C50911 | Malignant neoplasm of unspecified site of right female breast                          |  |  |
| C50911 | Malignant neoplasm of unspecified site of right female breast                          |  |  |
| C50912 | Malignant neoplasm of unspecified site of left female breast                           |  |  |
| C50919 | Malignant neoplasm of unspecified site of unspecified female breast                    |  |  |
| C569   | Malignant neoplasm of unspecified ovary  |  |  |
| C719   | Malignant neoplasm of brain, unspecified   |  |  |
| C73    | Malignant neoplasm of thyroid gland  |  |  |
| C773   | Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes      |  |  |
| C8330  | Diffuse large B-cell lymphoma, unspecified site  |  |  |
| D0512  | Intraductal carcinoma in situ of left breast   |  |  |
| D352   | Benign neoplasm of pituitary gland   |  |  |
| D497   | Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system |  |  |
| D6862  | Lupus anticoagulant syndrome   |  |  |
| E032   | Hypothyroidism due to medicaments and other exogenous substances                       |  |  |
| E038   | Other specified hypothyroidism   |  |  |



| Code   | Description   |
|--------|---|
| E039   | Hypothyroidism, unspecified                                   |
| E063   | Autoimmune thyroiditis  |
| E0789  | Other specified disorders of thyroid                          |
| E079   | Disorder of thyroid, unspecified                              |
| E10649 | Type 1 diabetes mellitus with hypoglycemia without coma       |
| E1065  | Type 1 diabetes mellitus with hyperglycemia                   |
| E1159  | Type 2 diabetes mellitus with other circulatory complications |
| E221   | Hyperprolactinemia  |
| E230   | Hypopituitarism   |
| E236   | Other disorders of pituitary gland                            |
| E237   | Disorder of pituitary gland, unspecified                      |
| E240   | Pituitary-dependent Cushing's disease                         |
| E241   | Nelson's syndrome   |
| E271   | Primary adrenocortical insufficiency                          |
| E2740  | Unspecified adrenocortical insufficiency                      |
| E278   | Other specified disorders of adrenal gland                    |
| E280   | Estrogen excess   |
| E282   | Polycystic ovarian syndrome                                   |
| E28310 | Symptomatic premature menopause                               |
| E28319 | Asymptomatic premature menopause                              |
| E2839  | Other primary ovarian failure                                 |
| E288   | Other Ovarian dysfunction                                     |
| E289   | Ovarian dysfunction, unspecified                              |
| E349   | Endocrine disorder, unspecified                               |
| F520   | Hypoactive sexual desire disorder                             |
| L680   | Hirsutism   |
| M069   | Rheumatoid arthritis, unspecified                             |
| M3500  | Sicca syndrome, unspecified                                   |
| N800   | adenomyosis   |
| N803   | Endometriosis of pelvic peritoneum                            |
| N809   | Endometriosis, unspecified                                    |
| N910   | Primary amenorrhea  |
| N911   | Secondary amenorrhea  |
| N912   | Amenorrhea, unspecified                                       |
| N914   | Secondary oligomenorrhea                                      |
| N915   | Oligomenorrhea, unspecified                                   |
| N920   | Excessive and frequent menstruation with regular cycle        |



| Code   | Description  |
|--------|--|
| N921   | Excessive and frequent menstruation with irregular cycle   |
| N925   | Other specified irregular menstruation   |
| N926   | Irregular menstruation, unspecified  |
| N938   | Other specified abnormal uterine and vaginal bleeding  |
| N939   | Abnormal uterine and vaginal bleeding, unspecified   |
| N9489  | Other specified conditions associated with female genital organs and menstrual cycle                       |
| N96    | Recurrent pregnancy loss   |
| N970   | female infertility with anovulation  |
| N971   | female infertility, tubal  |
| N978   | Female infertility of other origin   |
| N979   | Female infertility, unspecified  |
| 00990  | Supervision of high-risk pregnancy, unspecified, unspecified trimester                                     |
| R6882  | Decreased libido   |
| R871   | Abnormal level of hormones in specimens from female genital organs   |
| R891   | Abnormal level of hormones in specimens from other organs, systems, and tissues                            |
| R946   | Abnormal results of thyroid function studies   |
| Z01818 | Encounter for other preprocedural examination  |
| Z08    | Encounter for follow-up examination after completed treatment for malignant neoplasm                       |
| Z09    | Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm |
| Z1329  | Encounter for screening for other suspected endocrine disorder   |
| Z3141  | Encounter for fertility testing  |
| Z3149  | Encounter for other procreative investigation and testing  |
| Z3169  | Encounter for other general counseling and advice on procreation   |
| Z3183  | Encounter for assisted reproductive fertility procedure cycle  |
| Z3189  | Encounter for other procreative management   |
| Z331   | Pregnant state, incidental   |
| Z5112  | Encounter for antineoplastic immunotherapy   |
| Z5181  | Encounter for therapeutic drug level monitoring  |
| Z79818 | Long term (current) use of other agents affecting estrogen receptors and estrogen levels                   |
| Z79899 | Other long term (current) drug therapy   |
| Z853   | Personal history of malignant neoplasm of breast   |
| E1165  | Type 2 diabetes mellitus with hyperglycemia  |
| E119   | Type 2 diabetes mellitus without complications   |
| B181   | Chronic viral hepatitis B without delta-agent  |
| B1910  | Unspecified viral hepatitis B without hepatic coma   |
| B1920  | Unspecified viral hepatitis C without hepatic coma   |
| B20    | Human immunodeficiency virus [HIV] disease   |



| Code   | Description  |
|--------|--|
| D251   | Intramural leiomyoma of uterus   |
| D259   | Leiomyoma of uterus, unspecified   |
| E033   | Postinfectious hypothyroidism  |
| E041   | Nontoxic single thyroid nodule   |
| E042   | Nontoxic multinodular goiter   |
| E213   | Hyperparathyroidism, unspecified   |
| E890   | Postprocedural hypothyroidism  |
| F3281  | Premenstrual dysphoric disorder  |
| F329   | Major depressive disorder, single episode, unspecified                     |
| F331   | Major depressive disorder, recurrent, moderate                             |
| F39    | Unspecified mood [affective] disorder                                      |
| F410   | Panic disorder [episodic paroxysmal anxiety]                               |
| F419   | Anxiety disorder, unspecified  |
| G43709 | Chronic migraine without aura, not intractable, without status migrainosus |
| G43909 | Migraine, unspecified, not intractable, without status migrainosus         |
| K7210  | Chronic hepatic failure without coma                                       |
| K900   | Celiac disease   |
| L638   | Other alopecia areata  |
| L639   | Alopecia areata, unspecified   |
| L650   | Telogen effluvium  |
| L658   | Other specified nonscarring hair loss                                      |
| L659   | Nonscarring hair loss, unspecified   |
| L682   | Localized hypertrichosis   |
| L700   | Acne vulgaris  |
| L709   | Acne, unspecified  |
| N6452  | Nipple discharge   |
| N6459  | Other signs and symptoms in breast   |
| N761   | Subacute and chronic vaginitis   |
| N83202 | Unspecified ovarian cyst, left side  |
| N83209 | Unspecified ovarian cyst, unspecified side                                 |
| N840   | Polyp of corpus uteri  |
| N841   | Polyp of cervix uteri  |
| N8500  | Endometrial hyperplasia, unspecified                                       |
| N859   | Noninflammatory disorder of uterus, unspecified                            |
| N898   | Other specified noninflammatory disorders of vagina                        |
| N943   | Premenstrual tension syndrome  |
| N944   | Primary dysmenorrhea   |



| Code    | Description  |
|---------|--|
| N946    | Dysmenorrhea, unspecified  |
| R102    | Pelvic and perineal pain   |
| R1030   | Lower abdominal pain, unspecified  |
| R1904   | Left lower quadrant abdominal swelling, mass, and lump   |
| R1909   | Other intra-abdominal and pelvic swelling, mass, and lump  |
| R232    | Flushing   |
| R3129   | Other microscopic hematuria  |
| R430    | Anosmia  |
| R531    | Weakness   |
| R5381   | Other malaise  |
| R5382   | Chronic fatigue, unspecified   |
| R5383   | Other fatigue  |
| R61     | Generalized hyperhidrosis  |
| R630    | Anorexia   |
| R700    | Elevated erythrocyte sedimentation rate  |
| R7303   | Prediabetes  |
| R7309   | Other abnormal glucose   |
| R748    | Abnormal levels of other serum enzymes   |
| R7989   | Other specified abnormal findings of blood chemistry   |
| R799    | Abnormal finding of blood chemistry, unspecified   |
| R87810  | Cervical high risk human papillomavirus (HPV) DNA test positive  |
| R9389   | Abnormal findings on diagnostic imaging of other specified body structures   |
| R945    | Abnormal results of liver function studies   |
| T783XXA | Angioneurotic edema, initial encounter   |
| Z0000   | Encounter for general adult medical examination without abnormal findings  |
| Z0001   | Encounter for general adult medical examination with abnormal findings   |
| Z01411  | Encounter for gynecological examination (general) (routine) with abnormal findings   |
| Z01419  | Encounter for gynecological examination (general) (routine) without abnormal findings  |
| Z0189   | Encounter for other specified special examinations   |
| Z1231   | Encounter for screening mammogram for malignant neoplasm of breast   |
| Z124    | Encounter for screening for malignant neoplasm of cervix   |
| Z1273   | Encounter for screening for malignant neoplasm of ovary  |
| Z130    | Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the<br>immune mechanism |
| Z13228  | Encounter for screening for other metabolic disorders  |
| Z170    | Estrogen receptor positive status [ER+]  |
| Z3009   | Encounter for other general counseling and advice on contraception   |
| Z3041   | Encounter for surveillance of contraceptive pills  |



| Code   | Description  |
|--------|--|
| Z3042  | Encounter for surveillance of injectable contraceptive                 |
| Z30430 | Encounter for insertion of intrauterine contraceptive device           |
| Z30431 | Encounter for routine checking of intrauterine contraceptive device    |
| Z30432 | Encounter for removal of intrauterine contraceptive device             |
| Z3200  | Encounter for pregnancy test, result unknown                           |
| Z3202  | Encounter for pregnancy test, result negative                          |
| Z510   | Encounter for antineoplastic radiation therapy                         |
| Z6832  | Body mass index (BMI) 32.0-32.9, adult                                 |
| Z7689  | Persons encountering health services in other specified circumstances  |
| Z8041  | Family history of malignant neoplasm of ovary                          |
| Z8639  | Personal history of other endocrine, nutritional and metabolic disease |
| Z8742  | Personal history of other diseases of the female genital tract         |
| Z9013  | Acquired absence of bilateral breasts and nipples                      |
| Z975   | Presence of (intrauterine) contraceptive device                        |
| Z9884  | Bariatric surgery status   |
| C9000  | Multiple myeloma not having achieved remission                         |
| D329   | Benign neoplasm of meninges, unspecified                               |
| D500   | Iron deficiency anemia secondary to blood loss (chronic)               |
| D509   | Iron deficiency anemia, unspecified                                    |
| D519   | Vitamin B12 deficiency anemia, unspecified                             |
| D563   | Thalassemia minor  |
| D649   | Anemia, unspecified  |
| D751   | Secondary polycythemia   |
| E0500  | Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm  |
| E0590  | Thyrotoxicosis, unspecified without thyrotoxic crisis or storm         |
| E061   | Subacute thyroiditis   |
| E639   | Nutritional deficiency, unspecified                                    |
| E6601  | Morbid (severe) obesity due to excess calories                         |
| E663   | Overweight   |
| E669   | Obesity, unspecified   |
| E7800  | Pure hypercholesterolemia, unspecified                                 |
| E782   | Mixed hyperlipidemia   |
| E785   | Hyperlipidemia, unspecified  |
| E83110 | Hereditary hemochromatosis   |
| E83118 | Other hemochromatosis  |
| E8350  | Unspecified disorder of calcium metabolism                             |
| E875   | Hyperkalemia   |



| Code  | Description   |
|-------|---|
| 14891 | Unspecified atrial fibrillation   |
| 1959  | Hypotension, unspecified  |
| J449  | Chronic obstructive pulmonary disease, unspecified                              |
| L293  | Anogenital pruritus, unspecified  |
| L298  | Other pruritus  |
| L299  | Pruritus, unspecified   |
| L400  | Psoriasis vulgaris  |
| M791  | Myalgia   |
| M7910 | Myalgia, unspecified site   |
| Q281  | Other malformations of precerebral vessels                                      |
| R42   | Dizziness and giddiness   |
| R51   | Headache  |
| G629  | Polyneuropathy, unspecified   |
| G8929 | Other chronic pain  |
| 110   | Essential (primary) hypertension  |
| 12510 | Atherosclerotic heart disease of native coronary artery without angina pectoris |
| K529  | Noninfective gastroenteritis and colitis, unspecified                           |
| R631  | Polydipsia  |
| R634  | Abnormal weight loss  |
| R635  | Abnormal weight gain  |
| E15   | Nondiabetic hypoglycemic coma   |
| E162  | Hypoglycemia, unspecified   |
| N200  | Calculus of kidney  |
| N3090 | Cystitis, unspecified without hematuria   |
| N368  | Other specified disorders of urethra  |
| N390  | Urinary tract infection, site not specified                                     |
| N644  | Mastodynia  |
| R000  | Tachycardia, unspecified  |
| R002  | Palpitations  |
| R52   | Pain, unspecified   |
| H1830 | Unspecified corneal membrane change   |
| N3010 | Interstitial cystitis (chronic) without hematuria                               |
| N760  | Acute vaginitis   |
| N930  | Postcoital and contact bleeding   |
| R300  | Dysuria   |
| R309  | Painful micturition, unspecified  |
|       |   |



## Herpes Simplex Virus

| Code    | Description  |
|---------|--|
| Z135    | Encounter for screening for eye and ear disorders                                    |
| Z0442   | Encounter for examination and observation following alleged child rape               |
| Z01411  | Encounter for gynecological examination (general) (routine) with abnormal findings   |
| Z0001   | Encounter for general adult medical examination with abnormal findings               |
| T7421XA | Adult sexual abuse, confirmed, initial encounter                                     |
| S1012XA | Blister (nonthermal) of throat, initial encounter                                    |
| S00521A | Blister (nonthermal) of lip, initial encounter                                       |
| R051    | Acute cough  |
| R052    | Subacute cough   |
| R053    | Chronic cough  |
| R054    | Cough syncope  |
| R058    | Other specified cough  |
| R059    | Cough unspecified  |
| R945    | Abnormal results of liver function studies   |
| R599    | Enlarged lymph nodes, unspecified  |
| R591    | Generalized enlarged lymph nodes   |
| R509    | Fever, unspecified   |
| R29818  | Other symptoms and signs involving the nervous system                                |
| R29810  | Facial weakness  |
| R221    | Localized swelling, mass and lump, neck  |
| R21     | Rash and other nonspecific skin eruption   |
| R202    | Paresthesia of skin  |
| R102    | Pelvic and perineal pain   |
| 099353  | Diseases of the nervous system complicating pregnancy, third trimester               |
| 00993   | Supervision of high-risk pregnancy, unspecified, third trimester                     |
| 00992   | Supervision of high-risk pregnancy, unspecified, second trimester                    |
| 00991   | Supervision of high-risk pregnancy, unspecified, first trimester                     |
| O0990   | Supervision of high-risk pregnancy, unspecified, unspecified trimester               |
| O09899  | Supervision of other high-risk pregnancies, unspecified trimester                    |
| 009893  | Supervision of other high-risk pregnancies, third trimester                          |
| 009892  | Supervision of other high-risk pregnancies, second trimester                         |
| 009891  | Supervision of other high-risk pregnancies, first trimester                          |
| N9489   | Other specified conditions associated with female genital organs and menstrual cycle |
| N9089   | Other specified noninflammatory disorders of vulva and perineum                      |
| N907    | Vulvar cyst  |
| N898    | Other specified noninflammatory disorders of vagina                                  |
|         |  |



| N7681Mucositis (ulcerative) of vagina and vulvaN766Ulceration of vulvaN765Ulceration of vaginaN762Acute vulvitisN760Acute vaginitisN5089Other specified disorders of the male genital organsN50819Testicular pain, unspecifiedN492Inflammatory disorders of scrotum |  |
|---|--|
| N765Ulceration of vaginaN762Acute vulvitisN760Acute vaginitisN5089Other specified disorders of the male genital organsN50819Testicular pain, unspecifiedN492Inflammatory disorders of scrotum   |  |
| N762Acute vulvitisN760Acute vaginitisN5089Other specified disorders of the male genital organsN50819Testicular pain, unspecifiedN492Inflammatory disorders of scrotum   |  |
| N760       Acute vaginitis         N5089       Other specified disorders of the male genital organs         N50819       Testicular pain, unspecified         N492       Inflammatory disorders of scrotum  |  |
| N5089       Other specified disorders of the male genital organs         N50819       Testicular pain, unspecified         N492       Inflammatory disorders of scrotum   |  |
| N50819     Testicular pain, unspecified       N492     Inflammatory disorders of scrotum  |  |
| N492         Inflammatory disorders of scrotum  |  |
|   |  |
|   |  |
| N489 Disorder of penis, unspecified   |  |
| N4889         Other specified disorders of penis  |  |
| N485 Ulcer of penis   |  |
| N481 Balanitis  |  |
| N368         Other specified disorders of urethra   |  |
| M792 Neuralgia and neuritis, unspecified  |  |
| L989         Disorder of the skin and subcutaneous tissue, unspecified  |  |
| L309 Dermatitis, unspecified  |  |
| L293 Anogenital pruritus, unspecified   |  |
| L089 Local infection of the skin and subcutaneous tissue, unspecified   |  |
| K759 Inflammatory liver disease, unspecified  |  |
| K6289         Other specified diseases of anus and rectum   |  |
| K146 Glossodynia  |  |
| K1379         Other lesions of oral mucosa  |  |
| K1370         Unspecified lesions of oral mucosa  |  |
| K130 Diseases of lips   |  |
| K121         Other forms of stomatitis  |  |
| K120         Recurrent oral aphthae   |  |
| K068         Other specified disorders of gingiva and edentulous alveolar ridge   |  |
| H15012     Anterior scleritis, left eye   |  |
| H109 Unspecified conjunctivitis   |  |
| <b>G9009</b> Other idiopathic peripheral autonomic neuropathy   |  |
| G629 Polyneuropathy, unspecified  |  |
| G510 Bell's palsy   |  |
| E299   Testicular dysfunction, unspecified  |  |
| D849 Immunodeficiency, unspecified  |  |
| B349 Viral infection, unspecified   |  |
| B20   Human immunodeficiency virus [HIV] disease  |  |
| B189         Chronic viral hepatitis, unspecified   |  |



| Code  | Description   |
|-------|---|
| B179  | Acute viral hepatitis, unspecified                      |
| B009  | Herpesviral infection, unspecified                      |
| B009  | Herpesviral infection, unspecified                      |
| B0089 | Other herpesviral infection                             |
| B0052 | Herpesviral keratitis                                   |
| B002  | Herpesviral gingivostomatitis and pharyngotonsillitis   |
| B001  | Herpesviral vesicular dermatitis                        |
| B000  | Eczema herpeticum                                       |
| A64   | Unspecified sexually transmitted disease                |
| A609  | Anogenital herpesviral infection, unspecified           |
| A601  | Herpesviral infection of perianal skin and rectum       |
| A6009 | Herpesviral infection of other urogenital tract         |
| A6004 | Herpesviral vulvovaginitis                              |
| A6002 | Herpesviral infection of other male genital organs      |
| A6000 | Herpesviral infection of urogenital system, unspecified |

## Gammaglobulin IGE

| Code   | Description  |
|--------|--|
| B4481  | Allergic bronchopulmonary aspergillosis                    |
| B449   | Aspergillosis, unspecified                                 |
| B49    | Unspecified mycosis  |
| H01119 | Allergic dermatitis of unspecified eye, unspecified eyelid |
| H1010  | Acute atopic conjunctivitis, unspecified eye               |
| H1013  | Acute atopic conjunctivitis, bilateral                     |
| H1030  | Unspecified acute conjunctivitis, unspecified eye          |
| H1032  | Unspecified acute conjunctivitis, left eye                 |
| H1033  | Unspecified acute conjunctivitis, bilateral                |
| H10403 | Unspecified chronic conjunctivitis, bilateral              |
| H1045  | Other chronic allergic conjunctivitis                      |
| H6503  | Acute serous otitis media, bilateral                       |
| H6523  | Chronic serous otitis media, bilateral                     |
| H68103 | Unspecified obstruction of Eustachian tube, bilateral      |
| H6990  | Unspecified Eustachian tube disorder, unspecified ear      |
| H6992  | Unspecified Eustachian tube disorder, left ear             |
| J0100  | Acute maxillary sinusitis, unspecified                     |
| J0140  | Acute pansinusitis, unspecified                            |
| J0141  | Acute recurrent pansinusitis                               |



| Code  | Description   |
|-------|---|
| J0190 | Acute sinusitis, unspecified                                    |
| J0191 | Acute recurrent sinusitis, unspecified                          |
| J028  | Acute pharyngitis due to other specified organisms              |
| J029  | Acute pharyngitis, unspecified                                  |
| J0390 | Acute tonsillitis, unspecified                                  |
| J208  | Acute bronchitis due to other specified organisms               |
| J209  | Acute bronchitis, unspecified                                   |
| J300  | Vasomotor rhinitis  |
| J301  | Allergic rhinitis due to pollen                                 |
| J302  | Other seasonal allergic rhinitis                                |
| J305  | Allergic rhinitis due to food                                   |
| J3081 | Allergic rhinitis due to animal (cat) (dog) hair and dander     |
| J3089 | Other allergic rhinitis   |
| J309  | Allergic rhinitis, unspecified                                  |
| J310  | Chronic rhinitis  |
| J311  | Chronic nasopharyngitis   |
| J320  | Chronic maxillary sinusitis                                     |
| J321  | Chronic frontal sinusitis                                       |
| J322  | Chronic ethmoidal sinusitis                                     |
| J324  | Chronic pansinusitis  |
| J328  | Other chronic sinusitis   |
| J329  | Chronic sinusitis, unspecified                                  |
| J339  | Nasal polyp, unspecified  |
| J343  | Hypertrophy of nasal turbinates                                 |
| J3489 | Other specified disorders of nose and nasal sinuses             |
| J3503 | Chronic tonsillitis and adenoiditis                             |
| J353  | Hypertrophy of tonsils with hypertrophy of adenoids             |
| J392  | Other diseases of pharynx                                       |
| J40   | Bronchitis, not specified as acute or chronic                   |
| J411  | Mucopurulent chronic bronchitis                                 |
| J441  | Chronic obstructive pulmonary disease with (acute) exacerbation |
| J449  | Chronic obstructive pulmonary disease, unspecified              |
| J4520 | Mild intermittent asthma, uncomplicated                         |
| J4521 | Mild intermittent asthma with (acute) exacerbation              |
| J4530 | Mild persistent asthma, uncomplicated                           |
| J4531 | Mild persistent asthma with (acute) exacerbation                |
| J4540 | Moderate persistent asthma, uncomplicated                       |



| Code   | Description  |
|--------|--|
| J4541  | Moderate persistent asthma with (acute) exacerbation         |
| J4550  | Severe persistent asthma, uncomplicated                      |
| J4551  | Severe persistent asthma with (acute) exacerbation           |
| J4552  | Severe persistent asthma with status asthmaticus             |
| J45901 | Unspecified asthma with (acute) exacerbation                 |
| J45909 | Unspecified asthma, uncomplicated                            |
| J45990 | Exercise induced bronchospasm                                |
| J45991 | Cough variant asthma   |
| J45998 | Other asthma   |
| J470   | Bronchiectasis with acute lower respiratory infection        |
| J479   | Bronchiectasis, uncomplicated                                |
| J679   | Hypersensitivity pneumonitis due to unspecified organic dust |
| J8410  | Pulmonary fibrosis, unspecified                              |
| J84112 | Idiopathic pulmonary fibrosis                                |
| J849   | Interstitial pulmonary disease, unspecified                  |
| J9601  | Acute respiratory failure with hypoxia                       |
| J9801  | Acute bronchospasm   |
| J984   | Other disorders of lung                                      |
| J988   | Other specified respiratory disorders                        |
| K120   | Recurrent oral aphthae                                       |
| K1370  | Unspecified lesions of oral mucosa                           |
| K146   | Glossodynia  |
| K200   | Eosinophilic esophagitis                                     |
| K210   | Gastro-esophageal reflux disease with esophagitis            |
| K219   | Gastro-esophageal reflux disease without esophagitis         |
| K2900  | Acute gastritis without bleeding                             |
| K2970  | Gastritis, unspecified, without bleeding                     |
| K5221  | food protein induced enterocolitis                           |
| K5229  | Other allergic and dietetic gastroenteritis and colitis      |
| K52832 | Lymphocytic colitis  |
| K529   | Noninfective gastroenteritis and colitis, unspecified        |
| K9049  | Malabsorption due to intolerance, not elsewhere classified   |
| K909   | Intestinal malabsorption, unspecified                        |
| L2081  | Atopic neurodermatitis                                       |
| L2082  | Flexural eczema  |
| L2083  | Infantile (acute) (chronic) eczema                           |
| L2084  | Intrinsic (allergic) eczema                                  |



| Code    | Description   |
|---------|---|
| L2089   | Other atopic dermatitis   |
| L209    | Atopic dermatitis, unspecified  |
| L230    | Allergic contact dermatitis due to metals                             |
| L237    | Allergic contact dermatitis due to plants, except food                |
| L2389   | Allergic contact dermatitis due to other agents                       |
| L239    | Allergic contact dermatitis, unspecified cause                        |
| L259    | Unspecified contact dermatitis, unspecified cause                     |
| L272    | Dermatitis due to ingested food                                       |
| L290    | Pruritus ani  |
| L293    | Anogenital pruritus, unspecified                                      |
| L298    | Other pruritus  |
| L299    | Pruritus, unspecified   |
| L309    | Dermatitis, unspecified   |
| L400    | Psoriasis vulgaris  |
| L500    | Allergic urticaria  |
| L501    | Idiopathic urticaria  |
| L502    | Urticaria due to cold and heat  |
| L503    | Dermatographic urticaria  |
| L506    | Contact urticaria   |
| L508    | Other urticaria   |
| L509    | Urticaria, unspecified  |
| L710    | Perioral dermatitis   |
| R040    | Epistaxis   |
| R05     | Cough   |
| R051    | Acute cough   |
| R052    | Subacute cough  |
| R053    | Chronic cough   |
| R054    | Cough syncope   |
| R058    | Other specified cough   |
| R059    | Cough unspecified   |
| R062    | Wheezing  |
| R0981   | Nasal congestion  |
| R0982   | Postnasal drip  |
| S30861A | Insect bite (nonvenomous) of abdominal wall, initial encounter        |
| S40869A | Insect bite (nonvenomous) of unspecified upper arm, initial encounter |
| S60561A | Insect bite (nonvenomous) of right hand, initial encounter            |
| T360X5A | Adverse effect of penicillins, initial encounter                      |



| Code           | Description   |
|----------------|---|
| T63421A        | Toxic effect of venom of ants, accidental (unintentional), initial encounter                            |
| T63441A        | Toxic effect of venom of bees, accidental (unintentional), initial encounter                            |
| T63441D        | Toxic effect of venom of bees, accidental (unintentional), subsequent encounter                         |
| T63444A        | Toxic effect of venom of bees, undetermined, initial encounter  |
| T63451A        | Toxic effect of venom of hornets, accidental (unintentional), initial encounter                         |
| T63461D        | Toxic effect of venom of wasps, accidental (unintentional), subsequent encounter                        |
| T63481A        | Toxic effect of venom of other arthropod, accidental (unintentional), initial encounter                 |
| T6391XA        | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), initial encounter |
| T6391XS        | Toxic effect of contact with unspecified venomous animal, accidental (unintentional), sequela           |
| T65811A        | Toxic effect of latex, accidental (unintentional), initial encounter                                    |
| T7800XA        | Anaphylactic reaction due to unspecified food, initial encounter  |
| T7800XD        | Anaphylactic reaction due to unspecified food, subsequent encounter                                     |
| T7800XS        | Anaphylactic reaction due to unspecified food, sequela  |
| T7801XA        | Anaphylactic reaction due to peanuts, initial encounter   |
| T7801XD        | Anaphylactic reaction due to peanuts, subsequent encounter  |
| T7802XA        | Anaphylactic reaction due to shellfish (crustaceans), initial encounter                                 |
| T7802XD        | Anaphylactic reaction due to shellfish (crustaceans), subsequent encounter                              |
| T7803XS        | Anaphylactic reaction due to other fish, sequela  |
| T7804XD        | Anaphylactic reaction due to fruits and vegetables, subsequent encounter                                |
| T7805XA        | Anaphylactic reaction due to tree nuts and seeds, initial encounter                                     |
| T7805XD        | Anaphylactic reaction due to tree nuts and seeds, subsequent encounter                                  |
| T7807XD        | Anaphylactic reaction due to milk and dairy products, subsequent encounter                              |
| T7808XA        | Anaphylactic reaction due to eggs, initial encounter  |
| T7808XD        | Anaphylactic reaction due to eggs, subsequent encounter   |
| T781XXA        | Other adverse food reactions, not elsewhere classified, initial encounter                               |
| T781XXD        | Other adverse food reactions, not elsewhere classified, subsequent encounter                            |
| T781XXS        | Other adverse food reactions, not elsewhere classified, sequela   |
| T782XXA        | Anaphylactic shock, unspecified, initial encounter  |
| T782XXD        | Anaphylactic shock, unspecified, subsequent encounter   |
| T782XXS        | Anaphylactic shock, unspecified, sequela  |
| <b>T783XXA</b> | Angioneurotic edema, initial encounter  |
| T783XXD        | Angioneurotic edema, subsequent encounter   |
| T7840XA        | Allergy, unspecified, initial encounter   |
| T7840XD        | Allergy, unspecified, subsequent encounter  |
| T7840XS        | Allergy, unspecified, sequela   |
| T7849XA        | Other allergy, initial encounter  |
| T7849XS        | Other allergy, sequela  |



| Code   | Description  |
|--------|--|
| Z0182  | Encounter for allergy testing  |
| Z0189  | Encounter for other specified special examinations                                 |
| Z572   | Occupational exposure to dust  |
| Z579   | Occupational exposure to unspecified risk factor                                   |
| Z77118 | Contact with and (suspected) exposure to other environmental pollution             |
| Z77120 | Contact with and (suspected) exposure to mold (toxic)                              |
| Z8619  | Personal history of other infectious and parasitic diseases                        |
| Z87892 | Personal history of anaphylaxis  |
| Z880   | Allergy status to penicillin   |
| Z881   | Allergy status to other antibiotic agents' status                                  |
| Z888   | Allergy status to other drugs, medicaments, and biological substances status       |
| Z889   | Allergy status to unspecified drugs, medicaments, and biological substances status |
| Z91010 | Allergy to peanuts   |
| Z91011 | Allergy to milk products   |
| Z91012 | Allergy to eggs  |
| Z91013 | Allergy to seafood   |
| Z91018 | Allergy to other foods   |
| Z91030 | Bee allergy status   |
| Z91038 | Other insect allergy status  |
| Z91040 | Latex allergy status   |
| Z9109  | Other allergy status, other than to drugs and biological substances                |

## Erythrocyte Sedimentation Rate

| Code  | Description  |
|-------|--|
| C029  | Malignant neoplasm of tongue, unspecified                              |
| C099  | Malignant neoplasm of tonsil, unspecified                              |
| C169  | Malignant neoplasm of stomach, unspecified                             |
| C182  | Malignant neoplasm of ascending colon                                  |
| C187  | Malignant neoplasm of sigmoid colon                                    |
| C189  | Malignant neoplasm of colon, unspecified                               |
| C210  | Malignant neoplasm of anus, unspecified                                |
| C220  | Liver cell carcinoma   |
| C229  | Malignant neoplasm of liver, not specified as primary or secondary     |
| C3411 | Malignant neoplasm of upper lobe, right bronchus, or lung              |
| C3412 | Malignant neoplasm of upper lobe, left bronchus, or lung               |
| C3490 | Malignant neoplasm of unspecified part of unspecified bronchus or lung |
| C4022 | Malignant neoplasm of long bones of left lower limb                    |



| Code   | Description   |
|--------|---|
| C419   | Malignant neoplasm of bone and articular cartilage, unspecified         |
| C4330  | Malignant melanoma of unspecified part of face                          |
| C4359  | Malignant melanoma of other part of trunk                               |
| C439   | Malignant melanoma of skin, unspecified                                 |
| C44309 | Unspecified malignant neoplasm of skin of other parts of face           |
| C4491  | Basal cell carcinoma of skin, unspecified                               |
| C481   | Malignant neoplasm of specified parts of peritoneum                     |
| C50111 | Malignant neoplasm of central portion of right female breast            |
| C50112 | Malignant neoplasm of central portion of left female breast             |
| C50211 | Malignant neoplasm of upper-inner quadrant of right female breast       |
| C50212 | Malignant neoplasm of upper-inner quadrant of left female breast        |
| C50311 | Malignant neoplasm of lower-inner quadrant of right female breast       |
| C50312 | Malignant neoplasm of lower-inner quadrant of left female breast        |
| C50411 | Malignant neoplasm of upper-outer quadrant of right female breast       |
| C50412 | Malignant neoplasm of upper-outer quadrant of left female breast        |
| C50511 | Malignant neoplasm of lower-outer quadrant of right female breast       |
| C50519 | Malignant neoplasm of lower-outer quadrant of unspecified female breast |
| C50811 | Malignant neoplasm of overlapping sites of right female breast          |
| C50812 | Malignant neoplasm of overlapping sites of left female breast           |
| C50911 | Malignant neoplasm of unspecified site of right female breast           |
| C50912 | Malignant neoplasm of unspecified site of left female breast            |
| C50919 | Malignant neoplasm of unspecified site of unspecified female breast     |
| C539   | Malignant neoplasm of cervix uteri, unspecified                         |
| C541   | Malignant neoplasm of endometrium                                       |
| C549   | Malignant neoplasm of corpus uteri, unspecified                         |
| C562   | Malignant neoplasm of left ovary  |
| C574   | Malignant neoplasm of uterine adnexa, unspecified                       |
| C61    | Malignant neoplasm of prostate  |
| C649   | Malignant neoplasm of unspecified kidney, except renal pelvis           |
| C662   | Malignant neoplasm of left ureter                                       |
| C679   | Malignant neoplasm of bladder, unspecified                              |
| C720   | Malignant neoplasm of spinal cord                                       |
| C779   | Secondary and unspecified malignant neoplasm of lymph node, unspecified |
| C782   | Secondary malignant neoplasm of pleura                                  |
| C787   | Secondary malignant neoplasm of liver and intrahepatic bile duct        |
| C7951  | Secondary malignant neoplasm of bone                                    |
| C800   | Disseminated malignant neoplasm, unspecified                            |



| Code  | Description   |
|-------|---|
| C8100 | Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site                     |
| C8104 | Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb |
| C8110 | Nodular sclerosis Hodgkin lymphoma, unspecified site                                  |
| C8111 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck               |
| C8112 | Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes                         |
| C8114 | Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb              |
| C8170 | Other Hodgkin lymphoma, unspecified site  |
| C8172 | Other Hodgkin lymphoma, intrathoracic lymph nodes                                     |
| C8178 | Other Hodgkin lymphoma, lymph nodes of multiple sites                                 |
| C8190 | Hodgkin lymphoma, unspecified, unspecified site                                       |
| C8191 | Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck                    |
| C8192 | Hodgkin lymphoma, unspecified, intrathoracic lymph nodes                              |
| C8194 | Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb                   |
| C8197 | Hodgkin lymphoma, unspecified, spleen   |
| C8199 | Hodgkin lymphoma, unspecified, extranodal and solid organ sites                       |
| C8207 | Follicular lymphoma grade I, spleen   |
| C8209 | Follicular lymphoma grade I, extranodal and solid organ sites                         |
| C8210 | Follicular lymphoma grade II, unspecified site  |
| C8211 | Follicular lymphoma grade II, lymph nodes of head, face, and neck                     |
| C8226 | Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes                   |
| C8251 | Diffuse follicle center lymphoma, lymph nodes of head, face, and neck                 |
| C8258 | Diffuse follicle center lymphoma, lymph nodes of multiple sites                       |
| C8280 | Other types of follicular lymphoma, unspecified site                                  |
| C8290 | Follicular lymphoma, unspecified, unspecified site                                    |
| C8300 | Small cell B-cell lymphoma, unspecified site  |
| C8330 | Diffuse large B-cell lymphoma, unspecified site                                       |
| C8333 | Diffuse large B-cell lymphoma, intra-abdominal lymph nodes                            |
| C8338 | Diffuse large B-cell lymphoma, lymph nodes of multiple sites                          |
| C8339 | Diffuse large B-cell lymphoma, extranodal and solid organ sites                       |
| C8388 | Other non-follicular lymphoma, lymph nodes of multiple sites                          |
| C8400 | Mycosis fungoides, unspecified site   |
| C8448 | Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites             |
| C84A3 | Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes                   |
| C8510 | Unspecified B-cell lymphoma, unspecified site   |
| C8580 | Other specified types of non-Hodgkin lymphoma, unspecified site                       |
| C8589 | Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites       |
| C8590 | Non-Hodgkin lymphoma, unspecified, unspecified site                                   |



| Code   | Description   |
|--------|---|
| C8591  | Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck    |
| C8593  | Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes            |
| C880   | Waldenström macroglobulinemia   |
| C9000  | Multiple myeloma not having achieved remission                            |
| C9001  | Multiple myeloma in remission   |
| C9002  | Multiple myeloma in relapse   |
| C9110  | Chronic lymphocytic leukemia of B-cell type not having achieved remission |
| C9111  | Chronic lymphocytic leukemia of B-cell type in remission                  |
| C9112  | Chronic lymphocytic leukemia of B-cell type in relapse                    |
| C9140  | Hairy cell leukemia not having achieved remission                         |
| C9141  | Hairy cell leukemia, in remission   |
| C9190  | Lymphoid leukemia, unspecified not having achieved remission              |
| C91Z0  | Other lymphoid leukemia not having achieved remission                     |
| C91Z2  | Other lymphoid leukemia, in relapse                                       |
| C9200  | Acute myeloblastic leukemia, not having achieved remission                |
| C946   | Myelodysplastic disease, not classified                                   |
| D376   | Neoplasm of uncertain behavior of liver, gallbladder, and bile ducts      |
| D392   | Neoplasm of uncertain behavior of placenta                                |
| D3A00  | Benign carcinoid tumor of unspecified site                                |
| D3A019 | Benign carcinoid tumor of the small intestine, unspecified portion        |
| D550   | Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency         |
| D560   | Alpha thalassemia   |
| D563   | Thalassemia minor   |
| D5700  | Hb-SS disease with crisis, unspecified                                    |
| D582   | Other hemoglobinopathies  |
| D61810 | Antineoplastic chemotherapy induced pancytopenia                          |
| D61818 | Other pancytopenia  |
| D619   | Aplastic anemia, unspecified  |
| D62    | Acute posthemorrhagic anemia  |
| D630   | Anemia in neoplastic disease  |
| D631   | Anemia in chronic kidney disease  |
| D638   | Anemia in other chronic diseases classified elsewhere                     |
| D6481  | Anemia due to antineoplastic chemotherapy                                 |
| D6489  | Other specified anemias   |
| D649   | Anemia, unspecified   |
| D680   | Von Willebrand's disease  |
| D682   | Hereditary deficiency of other clotting factors                           |



| Code   | Description   |
|--------|---|
| D684   | Acquired coagulation factor deficiency  |
| D6859  | Other primary thrombophilia   |
| D6861  | Antiphospholipid syndrome   |
| D6862  | Lupus anticoagulant syndrome  |
| D6869  | Other thrombophilia   |
| D688   | Other specified coagulation defects   |
| D689   | Coagulation defect, unspecified   |
| D690   | Allergic purpura  |
| D692   | Other nonthrombocytopenic purpura   |
| D693   | Immune thrombocytopenic purpura   |
| D696   | Thrombocytopenia, unspecified   |
| D698   | Other specified hemorrhagic conditions  |
| D699   | Hemorrhagic condition, unspecified  |
| D702   | Other drug-induced agranulocytosis  |
| D708   | Other neutropenia   |
| D709   | Neutropenia, unspecified  |
| D71    | Functional disorders of polymorphonuclear neutrophils                               |
| D721   | Eosinophilia  |
| D72819 | Decreased white blood cell count, unspecified                                       |
| D72820 | Lymphocytosis (symptomatic)   |
| D72821 | Monocytosis (symptomatic)   |
| D72823 | Leukemoid reaction  |
| D72824 | Basophilia  |
| D72828 | Other elevated white blood cell count   |
| D72829 | Elevated white blood cell count, unspecified  |
| D7289  | Other specified disorders of white blood cells                                      |
| D729   | Disorder of white blood cells, unspecified  |
| D751   | Secondary polycythemia  |
| D7589  | Other specified diseases of blood and blood-forming organs                          |
| D801   | Nonfamilial hypogammaglobulinemia   |
| D802   | Selective deficiency of immunoglobulin A [IgA]                                      |
| D809   | Immunodeficiency with predominantly antibody defects, unspecified                   |
| D824   | Hyperimmunoglobulin E [IgE] syndrome  |
| D831   | Common variable immunodeficiency with predominant immunoregulatory T-cell disorders |
| D839   | Common variable immunodeficiency, unspecified                                       |
| D841   | Defects in the complement system  |
| D849   | Immunodeficiency, unspecified   |



| Code    | Description  |
|---------|--|
| D860    | Sarcoidosis of lung  |
| D862    | Sarcoidosis of lung with sarcoidosis of lymph nodes  |
| D863    | Sarcoidosis of skin  |
| D8687   | Sarcoid myositis   |
| D8689   | Sarcoidosis of other sites   |
| D869    | Sarcoidosis, unspecified   |
| D890    | Polyclonal hypergammaglobulinemia  |
| D891    | Cryoglobulinemia   |
| D892    | Hypergammaglobulinemia, unspecified  |
| D8989   | Other specified disorders involving the immune mechanism, not elsewhere classified                           |
| D899    | Disorder involving the immune mechanism, unspecified   |
| E0821   | Diabetes mellitus due to underlying condition with diabetic nephropathy                                      |
| E0842   | Diabetes mellitus due to underlying condition with diabetic polyneuropathy                                   |
| E099    | Drug or chemical induced diabetes mellitus without complications   |
| E1010   | Type 1 diabetes mellitus with ketoacidosis without coma  |
| E1029   | Type 1 diabetes mellitus with other diabetic kidney complication   |
| E10319  | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema                         |
| E103293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral    |
| E1040   | Type 1 diabetes mellitus with diabetic neuropathy, unspecified   |
| E10621  | Type 1 diabetes mellitus with foot ulcer   |
| E10622  | Type 1 diabetes mellitus with other skin ulcer   |
| E1065   | Type 1 diabetes mellitus with hyperglycemia  |
| E108    | Type 1 diabetes mellitus with unspecified complications  |
| E109    | Type 1 diabetes mellitus without complications   |
| E1121   | Type 2 diabetes mellitus with diabetic nephropathy   |
| E1122   | Type 2 diabetes mellitus with diabetic chronic kidney disease  |
| E1129   | Type 2 diabetes mellitus with other diabetic kidney complication   |
| E113219 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye |
| E113293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral    |
| E1140   | Type 2 diabetes mellitus with diabetic neuropathy, unspecified   |
| E1142   | Type 2 diabetes mellitus with diabetic polyneuropathy  |
| E1149   | Type 2 diabetes mellitus with other diabetic neurological complication                                       |
| E1151   | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene                                |
| E1159   | Type 2 diabetes mellitus with other circulatory complications  |
| E11610  | Type 2 diabetes mellitus with diabetic neuropathic arthropathy   |
| E11621  | Type 2 diabetes mellitus with foot ulcer   |
| E11622  | Type 2 diabetes mellitus with other skin ulcer   |



| Code   | Description  |
|--------|--|
| E11628 | Type 2 diabetes mellitus with other skin complications                 |
| E1165  | Type 2 diabetes mellitus with hyperglycemia                            |
| E1169  | Type 2 diabetes mellitus with other specified complication             |
| E118   | Type 2 diabetes mellitus with unspecified complications                |
| E119   | Type 2 diabetes mellitus without complications                         |
| E1310  | Other specified diabetes mellitus with ketoacidosis without coma       |
| E13621 | Other specified diabetes mellitus with foot ulcer                      |
| E13628 | Other specified diabetes mellitus with other skin complications        |
| E138   | Other specified diabetes mellitus with unspecified complications       |
| E139   | Other specified diabetes mellitus without complications                |
| E161   | Other hypoglycemia   |
| E162   | Hypoglycemia, unspecified  |
| E213   | Hyperparathyroidism, unspecified                                       |
| E221   | Hyperprolactinemia   |
| E230   | Hypopituitarism  |
| E232   | Diabetes insipidus   |
| E233   | Hypothalamic dysfunction, not elsewhere classified                     |
| E237   | Disorder of pituitary gland, unspecified                               |
| E249   | Cushing's syndrome, unspecified  |
| E270   | Other adrenocortical overactivity                                      |
| E2740  | Unspecified adrenocortical insufficiency                               |
| E279   | Disorder of adrenal gland, unspecified                                 |
| E700   | Classical phenylketonuria  |
| E7204  | Cystinosis   |
| E7210  | Disorders of sulfur-bearing amino-acid metabolism, unspecified         |
| E849   | Cystic fibrosis, unspecified   |
| E854   | Organ-limited amyloidosis  |
| E8581  | Light chain (AL) amyloidosis   |
| E859   | Amyloidosis, unspecified   |
| E8809  | Other disorders of plasma-protein metabolism, not elsewhere classified |
| E8840  | Mitochondrial metabolism disorder, unspecified                         |
| G0491  | Myelitis, unspecified  |
| G060   | Intracranial abscess and granuloma                                     |
| G061   | Intraspinal abscess and granuloma                                      |
| G062   | Extradural and subdural abscess, unspecified                           |
| G10    | Huntington's disease   |
| G114   | Hereditary spastic paraplegia  |



| Code   | Description  |
|--------|--|
| G20    | Parkinson's disease  |
| G255   | Other chorea   |
| G2579  | Other drug induced movement disorders                                      |
| G2581  | Restless legs syndrome   |
| G2582  | Stiff-man syndrome   |
| G35    | Multiple sclerosis   |
| G379   | Demyelinating disease of central nervous system, unspecified               |
| G43001 | Migraine without aura, not intractable, with status migrainosus            |
| G43009 | Migraine without aura, not intractable, without status migrainosus         |
| G43011 | Migraine without aura, intractable, with status migrainosus                |
| G43019 | Migraine without aura, intractable, without status migrainosus             |
| G43101 | Migraine with aura, not intractable, with status migrainosus               |
| G43109 | Migraine with aura, not intractable, without status migrainosus            |
| G43111 | Migraine with aura, intractable, with status migrainosus                   |
| G43409 | Hemiplegic migraine, not intractable, without status migrainosus           |
| G43701 | Chronic migraine without aura, not intractable, with status migrainosus    |
| G43709 | Chronic migraine without aura, not intractable, without status migrainosus |
| G43711 | Chronic migraine without aura, intractable, with status migrainosus        |
| G43719 | Chronic migraine without aura, intractable, without status migrainosus     |
| G43809 | Other migraine, not intractable, without status migrainosus                |
| G43811 | Other migraine, intractable, with status migrainosus                       |
| G43819 | Other migraine, intractable, without status migrainosus                    |
| G43901 | Migraine, unspecified, not intractable, with status migrainosus            |
| G43909 | Migraine, unspecified, not intractable, without status migrainosus         |
| G43919 | Migraine, unspecified, intractable, without status migrainosus             |
| G43A0  | Cyclical vomiting, in migraine, not intractable                            |
| G43B0  | Ophthalmoplegic migraine, not intractable                                  |
| G44001 | Cluster headache syndrome, unspecified, intractable                        |
| G44009 | Cluster headache syndrome, unspecified, not intractable                    |
| G44019 | Episodic cluster headache, not intractable                                 |
| G44021 | Chronic cluster headache, intractable                                      |
| G44031 | Episodic paroxysmal hemicrania, intractable                                |
| G44039 | Episodic paroxysmal hemicrania, not intractable                            |
| G44049 | Chronic paroxysmal hemicrania, not intractable                             |
| G441   | Vascular headache, not elsewhere classified                                |
| G44201 | Tension-type headache, unspecified, intractable                            |
| G44209 | Tension-type headache, unspecified, not intractable                        |



| Code   | Description  |
|--------|--|
| G44219 | Episodic tension-type headache, not intractable                  |
| G44229 | Chronic tension-type headache, not intractable                   |
| G44319 | Acute post-traumatic headache, not intractable                   |
| G44329 | Chronic post-traumatic headache, not intractable                 |
| G4440  | Drug-induced headache, not elsewhere classified, not intractable |
| G4451  | Hemicrania continua  |
| G4452  | New daily persistent headache (NDPH)                             |
| G4453  | Primary thunderclap headache                                     |
| G4459  | Other complicated headache syndrome                              |
| G4482  | Headache associated with sexual activity                         |
| G4489  | Other headache syndrome  |
| G450   | Vertebro-basilar artery syndrome                                 |
| G453   | Amaurosis fugax  |
| G454   | Transient global amnesia   |
| G459   | Transient cerebral ischemic attack, unspecified                  |
| G500   | Trigeminal neuralgia   |
| G501   | Atypical facial pain   |
| G509   | Disorder of trigeminal nerve, unspecified                        |
| G510   | Bell's palsy   |
| G529   | Cranial nerve disorder, unspecified                              |
| G540   | Brachial plexus disorders  |
| G545   | Neuralgic amyotrophy   |
| G549   | Nerve root and plexus disorder, unspecified                      |
| G587   | Mononeuritis multiplex   |
| G589   | Mononeuropathy, unspecified                                      |
| G600   | Hereditary motor and sensory neuropathy                          |
| G603   | Idiopathic progressive neuropathy                                |
| G608   | Other hereditary and idiopathic neuropathies                     |
| G609   | Hereditary and idiopathic neuropathy, unspecified                |
| G610   | Guillain-Barre syndrome  |
| G6181  | Chronic inflammatory demyelinating polyneuritis                  |
| G6189  | Other inflammatory polyneuropathies                              |
| G619   | Inflammatory polyneuropathy, unspecified                         |
| G621   | Alcoholic polyneuropathy   |
| G6289  | Other specified polyneuropathies                                 |
| G629   | Polyneuropathy, unspecified                                      |
| G63    | Polyneuropathy in diseases classified elsewhere                  |



| Code   | Description   |
|--------|---|
| G7000  | Myasthenia gravis without (acute) exacerbation                            |
| G719   | Primary disorder of muscle, unspecified                                   |
| G7241  | Inclusion body myositis [IBM]   |
| G7249  | Other inflammatory and immune myopathies, not elsewhere classified        |
| G7289  | Other specified myopathies  |
| G729   | Myopathy, unspecified   |
| G801   | Spastic diplegic cerebral palsy   |
| G809   | Cerebral palsy, unspecified   |
| G8220  | Paraplegia, unspecified   |
| G8250  | Quadriplegia, unspecified   |
| G8310  | Monoplegia of lower limb affecting unspecified side                       |
| G909   | Disorder of the autonomic nervous system, unspecified                     |
| G919   | Hydrocephalus, unspecified  |
| G92    | Toxic encephalopathy  |
| G920   | Immune effector cell-associated neurotoxicity syndrome                    |
| G9200  | Immune effector cell-associated neurotoxicity syndrome, grade unspecified |
| G9201  | Immune effector cell-associated neurotoxicity syndrome, grade 1           |
| G9202  | Immune effector cell-associated neurotoxicity syndrome, grade 2           |
| G9203  | Immune effector cell-associated neurotoxicity syndrome, grade 3           |
| G9204  | Immune effector cell-associated neurotoxicity syndrome, grade 4           |
| G9205  | Immune effector cell-associated neurotoxicity syndrome, grade 5           |
| G928   | Other toxic encephalopathy  |
| G929   | Unspecified toxic encephaloopathy   |
| G932   | Benign intracranial hypertension  |
| G933   | Postviral fatigue syndrome  |
| G9340  | Encephalopathy, unspecified   |
| G9341  | Metabolic encephalopathy  |
| G9349  | Other encephalopathy  |
| G935   | Compression of brain  |
| G9389  | Other specified disorders of brain  |
| G959   | Disease of spinal cord, unspecified                                       |
| G988   | Other disorders of nervous system   |
| H019   | Unspecified inflammation of eyelid  |
| H02401 | Unspecified ptosis of right eyelid  |
| H02402 | Unspecified ptosis of left eyelid   |
| H0266  | Xanthelasma of left eye, unspecified eyelid                               |
| H04123 | Dry eye syndrome of bilateral lacrimal glands                             |



| Code   | Description                                       |
|--------|---|
| H04129 | Dry eye syndrome of unspecified lacrimal gland    |
| H05013 | Cellulitis of bilateral orbits                    |
| H05113 | Granuloma of bilateral orbits                     |
| H0520  | Unspecified exophthalmos                          |
| H05223 | Edema of bilateral orbit                          |
| H15001 | Unspecified scleritis, right eye                  |
| H15002 | Unspecified scleritis, left eye                   |
| H15003 | Unspecified scleritis, bilateral                  |
| H15009 | Unspecified scleritis, unspecified eye            |
| H15012 | Anterior scleritis, left eye                      |
| H15013 | Anterior scleritis, bilateral                     |
| H15039 | Posterior scleritis, unspecified eye              |
| H15101 | Unspecified episcleritis, right eye               |
| H15103 | Unspecified episcleritis, bilateral               |
| H15112 | Episcleritis periodica fugax, left eye            |
| H159   | Unspecified disorder of sclera                    |
| H16001 | Unspecified corneal ulcer, right eye              |
| H16002 | Unspecified corneal ulcer, left eye               |
| H16072 | Perforated corneal ulcer, left eye                |
| H16203 | Unspecified keratoconjunctivitis, bilateral       |
| H1712  | Central corneal opacity, left eye                 |
| H2000  | Unspecified acute and subacute iridocyclitis      |
| H20012 | Primary iridocyclitis, left eye                   |
| H20013 | Primary iridocyclitis, bilateral                  |
| H20019 | Primary iridocyclitis, unspecified eye            |
| H20021 | Recurrent acute iridocyclitis, right eye          |
| H20022 | Recurrent acute iridocyclitis, left eye           |
| H2012  | Chronic iridocyclitis, left eye                   |
| H2013  | Chronic iridocyclitis, bilateral                  |
| H209   | Unspecified iridocyclitis                         |
| H3022  | Posterior cyclitis, left eye                      |
| H3023  | Posterior cyclitis, bilateral                     |
| H3093  | Unspecified chorioretinal inflammation, bilateral |
| H31001 | Unspecified chorioretinal scars, right eye        |
| H3411  | Central retinal artery occlusion, right eye       |
| H3412  | Central retinal artery occlusion, left eye        |
| H3413  | Central retinal artery occlusion, bilateral       |



| Code    | Description  |
|---------|--|
| H34231  | Retinal artery branch occlusion, right eye   |
| H34232  | Retinal artery branch occlusion, left eye  |
| H348112 | Central retinal vein occlusion, right eye, stable  |
| H348130 | Central retinal vein occlusion, bilateral, with macular edema                                    |
| H348320 | Tributary (branch) retinal vein occlusion, left eye, with macular edema                          |
| H348321 | Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization             |
| H348392 | Tributary (branch) retinal vein occlusion, unspecified eye, stable                               |
| H35062  | Retinal vasculitis, left eye   |
| H35069  | Retinal vasculitis, unspecified eye  |
| H353221 | Exudative age-related macular degeneration, left eye, with active choroidal neovascularization   |
| H353222 | Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization |
| H35352  | Cystoid macular degeneration, left eye   |
| H35353  | Cystoid macular degeneration, bilateral  |
| H3552   | Pigmentary retinal dystrophy   |
| H3581   | Retinal edema  |
| H43392  | Other vitreous opacities, left eye   |
| H4389   | Other disorders of vitreous body   |
| H44001  | Unspecified purulent endophthalmitis, right eye  |
| H44119  | Panuveitis, unspecified eye  |
| H44139  | Sympathetic uveitis, unspecified eye   |
| H44539  | Leucocoria, unspecified eye  |
| H44811  | Hemophthalmos, right eye   |
| H4602   | Optic papillitis, left eye   |
| H4612   | Retrobulbar neuritis, left eye   |
| H469    | Unspecified optic neuritis   |
| H47011  | Ischemic optic neuropathy, right eye   |
| H47012  | Ischemic optic neuropathy, left eye  |
| H47013  | Ischemic optic neuropathy, bilateral   |
| H47019  | Ischemic optic neuropathy, unspecified eye   |
| H4710   | Unspecified papilledema  |
| H47211  | Primary optic atrophy, right eye   |
| H47293  | Other optic atrophy, bilateral   |
| H47512  | Disorders of visual pathways in (due to) inflammatory disorders, left side                       |
| H4901   | Third [oculomotor] nerve palsy, right eye  |
| H4902   | Third [oculomotor] nerve palsy, left eye   |
| H4910   | Fourth [trochlear] nerve palsy, unspecified eye  |
| H4911   | Fourth [trochlear] nerve palsy, right eye  |



| Code   | Description  |
|--------|--|
| H4912  | Fourth [trochlear] nerve palsy, left eye                   |
| H4913  | Fourth [trochlear] nerve palsy, bilateral                  |
| H4920  | Sixth [abducent] nerve palsy, unspecified eye              |
| H4921  | Sixth [abducent] nerve palsy, right eye                    |
| H4922  | Sixth [abducent] nerve palsy, left eye                     |
| H5022  | Vertical strabismus, left eye                              |
| H53121 | Transient visual loss, right eye                           |
| H53122 | Transient visual loss, left eye                            |
| H53123 | Transient visual loss, bilateral                           |
| H53129 | Transient visual loss, unspecified eye                     |
| H53131 | Sudden visual loss, right eye                              |
| H53132 | Sudden visual loss, left eye                               |
| H53143 | Visual discomfort, bilateral                               |
| H5316  | Psychophysical visual disturbances                         |
| H5319  | Other subjective visual disturbances                       |
| H532   | Diplopia   |
| H5340  | Unspecified visual field defects                           |
| H53411 | Scotoma involving central area, right eye                  |
| H53451 | Other localized visual field defect, right eye             |
| H53459 | Other localized visual field defect, unspecified eye       |
| H53461 | Homonymous bilateral field defects, right side             |
| H538   | Other visual disturbances                                  |
| H539   | Unspecified visual disturbance                             |
| H543   | Unqualified visual loss, both eyes                         |
| H5440  | Blindness, one eye, unspecified eye                        |
| H5461  | Unqualified visual loss, right eye, normal vision left eye |
| H5462  | Unqualified visual loss, left eye, normal vision right eye |
| H547   | Unspecified visual loss                                    |
| H5710  | Ocular pain, unspecified eye                               |
| H5711  | Ocular pain, right eye                                     |
| H5712  | Ocular pain, left eye                                      |
| H5713  | Ocular pain, bilateral                                     |
| H578   | Other specified disorders of eye and adnexa                |
| H579   | Unspecified disorder of eye and adnexa                     |
| H60392 | Other infective otitis externa, left ear                   |
| H60501 | Unspecified acute noninfective otitis externa, right ear   |
| H61031 | Chondritis of right external ear                           |



| Code   | Description   |
|--------|---|
| H61032 | Chondritis of left external ear   |
| H61033 | Chondritis of external ear, bilateral   |
| H61039 | Chondritis of external ear, unspecified ear   |
| H7010  | Chronic mastoiditis, unspecified ear  |
| H70212 | Acute petrositis, left ear  |
| H7090  | Unspecified mastoiditis, unspecified ear  |
| H7093  | Unspecified mastoiditis, bilateral  |
| H7192  | Unspecified cholesteatoma, left ear   |
| H8110  | Benign paroxysmal vertigo, unspecified ear  |
| H8113  | Benign paroxysmal vertigo, bilateral  |
| H8120  | Vestibular neuronitis, unspecified ear  |
| H8122  | Vestibular neuronitis, left ear   |
| H81391 | Other peripheral vertigo, right ear   |
| H8309  | Labyrinthitis, unspecified ear  |
| H903   | Sensorineural hearing loss, bilateral   |
| H9041  | Sensorineural hearing loss, unilateral, right ear, with unrestricted hearing on the contralateral side  |
| H9042  | Sensorineural hearing loss, unilateral, left ear, with unrestricted hearing on the contralateral side   |
| H9121  | Sudden idiopathic hearing loss, right ear   |
| H9122  | Sudden idiopathic hearing loss, left ear  |
| H9123  | Sudden idiopathic hearing loss, bilateral   |
| H918X1 | Other specified hearing loss, right ear   |
| H918X2 | Other specified hearing loss, left ear  |
| H9190  | Unspecified hearing loss, unspecified ear   |
| H9191  | Unspecified hearing loss, right ear   |
| H9193  | Unspecified hearing loss, bilateral   |
| H9313  | Tinnitus, bilateral   |
| H9319  | Tinnitus, unspecified ear   |
| H93A9  | Pulsatile tinnitus, unspecified ear   |
| 100    | Rheumatic fever without heart involvement   |
| 1110   | Hypertensive heart disease with heart failure   |
| 1129   | Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease                                  |
| 1130   | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease      |
| 11310  | Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease |
| 1309   | Acute pericarditis, unspecified   |
| 1313   | Pericardial effusion (noninflammatory)  |
| 1319   | Disease of pericardium, unspecified   |
|        |   |



| I339 Acute a   | nd subacute infective endocarditis<br>nd subacute endocarditis, unspecified<br>rditis, valve unspecified |
|----------------|--|
|                |  |
| 139 Endoca     | rditis valve unspecified   |
| ISO ENUOCA     |  |
| I400 Infectiv  | e myocarditis  |
| I420 Dilated   | cardiomyopathy   |
| I422 Other h   | ypertrophic cardiomyopathy   |
| I428 Other c   | ardiomyopathies  |
| I429 Cardior   | nyopathy, unspecified  |
| I442 Atriove   | ntricular block, complete  |
| I5020 Unspec   | ified systolic (congestive) heart failure  |
| I5021 Acute s  | ystolic (congestive) heart failure   |
| I5022 Chronic  | c systolic (congestive) heart failure  |
| I5030 Unspec   | ified diastolic (congestive) heart failure   |
| I5031 Acute d  | iastolic (congestive) heart failure  |
| I5032 Chronic  | : diastolic (congestive) heart failure   |
| I5033 Acute o  | n chronic diastolic (congestive) heart failure   |
| I5042 Chronic  | combined systolic (congestive) and diastolic (congestive) heart failure                                  |
| I5043 Acute o  | n chronic combined systolic (congestive) and diastolic (congestive) heart failure                        |
| I509 Heart fa  | ailure, unspecified  |
| I514 Myocar    | ditis, unspecified   |
| I517 Cardior   | negaly   |
| I519 Heart d   | isease, unspecified  |
| I610 Nontra    | umatic intracerebral hemorrhage in hemisphere, subcortical   |
| I619 Nontra    | umatic intracerebral hemorrhage, unspecified   |
| I6200 Nontra   | umatic subdural hemorrhage, unspecified  |
| l63412 Cerebra | al infarction due to embolism of left middle cerebral artery   |
| l6350 Cerebra  | al infarction due to unspecified occlusion or stenosis of unspecified cerebral artery                    |
| l63511 Cerebra | al infarction due to unspecified occlusion or stenosis of right middle cerebral artery                   |
| I639 Cerebra   | al infarction, unspecified   |
| l6783 Posteri  | or reversible encephalopathy syndrome  |
| I6789 Other c  | erebrovascular disease   |
| I679 Cerebro   | ovascular disease, unspecified   |
| I682 Cerebra   | al arteritis in other diseases classified elsewhere  |
| I7300 Raynau   | d's syndrome without gangrene  |
| I7301 Raynau   | d's syndrome with gangrene   |
| I7381 Erythro  | melalgia   |
| I773 Arterial  | fibromuscular dysplasia  |



| Code   | Description  |
|--------|--|
| 1776   | Arteritis, unspecified   |
| 1880   | Nonspecific mesenteric lymphadenitis   |
| 1889   | Nonspecific lymphadenitis, unspecified                                       |
| 1890   | Lymphedema, not elsewhere classified   |
| 1951   | Orthostatic hypotension  |
| 1959   | Hypotension, unspecified   |
| 196    | Gangrene, not elsewhere classified   |
| 1998   | Other disorder of circulatory system   |
| 1999   | Unspecified disorder of circulatory system                                   |
| J9610  | Chronic respiratory failure, unspecified whether with hypoxia or hypercapnia |
| K111   | Hypertrophy of salivary gland  |
| K1120  | Sialoadenitis, unspecified   |
| K1121  | Acute sialoadenitis  |
| K117   | Disturbances of salivary secretion   |
| K118   | Other diseases of salivary glands  |
| K119   | Disease of salivary gland, unspecified                                       |
| K120   | Recurrent oral aphthae   |
| K121   | Other forms of stomatitis  |
| K1230  | Oral mucositis (ulcerative), unspecified                                     |
| K130   | Diseases of lips   |
| K1370  | Unspecified lesions of oral mucosa   |
| K1379  | Other lesions of oral mucosa   |
| K141   | Geographic tongue  |
| K146   | Glossodynia  |
| K200   | Eosinophilic esophagitis   |
| K5000  | Crohn's disease of small intestine without complications                     |
| K50011 | Crohn's disease of small intestine with rectal bleeding                      |
| K50012 | Crohn's disease of small intestine with intestinal obstruction               |
| K50014 | Crohn's disease of small intestine with abscess                              |
| K50018 | Crohn's disease of small intestine with other complication                   |
| K50019 | Crohn's disease of small intestine with unspecified complications            |
| K5010  | Crohn's disease of large intestine without complications                     |
| K50111 | Crohn's disease of large intestine with rectal bleeding                      |
| K50113 | Crohn's disease of large intestine with fistula                              |
| K50118 | Crohn's disease of large intestine with other complication                   |
| K50119 | Crohn's disease of large intestine with unspecified complications            |
| K5080  | Crohn's disease of both small and large intestine without complications      |



| Code   | Description  |
|--------|--|
| K50811 | Crohn's disease of both small and large intestine with rectal bleeding           |
| K50812 | Crohn's disease of both small and large intestine with intestinal obstruction    |
| K50813 | Crohn's disease of both small and large intestine with fistula                   |
| K50814 | Crohn's disease of both small and large intestine with abscess                   |
| K50818 | Crohn's disease of both small and large intestine with other complication        |
| K50819 | Crohn's disease of both small and large intestine with unspecified complications |
| K5090  | Crohn's disease, unspecified, without complications                              |
| K50911 | Crohn's disease, unspecified, with rectal bleeding                               |
| K50913 | Crohn's disease, unspecified, with fistula                                       |
| K50918 | Crohn's disease, unspecified, with other complication                            |
| K50919 | Crohn's disease, unspecified, with unspecified complications                     |
| K5100  | Ulcerative (chronic) pancolitis without complications                            |
| K51011 | Ulcerative (chronic) pancolitis with rectal bleeding                             |
| K51018 | Ulcerative (chronic) pancolitis with other complication                          |
| K51019 | Ulcerative (chronic) pancolitis with unspecified complications                   |
| K5120  | Ulcerative (chronic) proctitis without complications                             |
| K51211 | Ulcerative (chronic) proctitis with rectal bleeding                              |
| K51219 | Ulcerative (chronic) proctitis with unspecified complications                    |
| K5130  | Ulcerative (chronic) rectosigmoiditis without complications                      |
| K51311 | Ulcerative (chronic) rectosigmoiditis with rectal bleeding                       |
| K5150  | Left sided colitis without complications   |
| K51511 | Left sided colitis with rectal bleeding  |
| K51518 | Left sided colitis with other complication                                       |
| K5180  | Other ulcerative colitis without complications                                   |
| K51818 | Other ulcerative colitis with other complication                                 |
| K51819 | Other ulcerative colitis with unspecified complications                          |
| K5190  | Ulcerative colitis, unspecified, without complications                           |
| K51911 | Ulcerative colitis, unspecified with rectal bleeding                             |
| K51918 | Ulcerative colitis, unspecified with other complication                          |
| K51919 | Ulcerative colitis, unspecified with unspecified complications                   |
| K5221  | Food protein-induced enterocolitis syndrome                                      |
| K5222  | Food protein-induced enteropathy   |
| K5229  | Other allergic and dietetic gastroenteritis and colitis                          |
| K523   | Indeterminate colitis  |
| K5281  | Eosinophilic gastritis or gastroenteritis  |
| K5282  | Eosinophilic colitis   |
| K52831 | Collagenous colitis  |



| Code   | Description  |
|--------|--|
| K52832 | Lymphocytic colitis                                      |
| K52839 | Microscopic colitis, unspecified                         |
| K5289  | Other specified noninfective gastroenteritis and colitis |
| K529   | Noninfective gastroenteritis and colitis, unspecified    |
| K551   | Chronic vascular disorders of intestine                  |
| K559   | Vascular disorder of intestine, unspecified              |
| K6389  | Other specified diseases of intestine                    |
| K639   | Disease of intestine, unspecified                        |
| K654   | Sclerosing mesenteritis                                  |
| K900   | Celiac disease   |
| K9041  | Non-celiac gluten sensitivity                            |
| L109   | Pemphigus, unspecified                                   |
| L120   | Bullous pemphigoid                                       |
| L121   | Cicatricial pemphigoid                                   |
| L139   | Bullous disorder, unspecified                            |
| L2084  | Intrinsic (allergic) eczema                              |
| L2089  | Other atopic dermatitis                                  |
| L209   | Atopic dermatitis, unspecified                           |
| L218   | Other seborrheic dermatitis                              |
| L219   | Seborrheic dermatitis, unspecified                       |
| L400   | Psoriasis vulgaris                                       |
| L401   | Generalized pustular psoriasis                           |
| L403   | Pustulosis palmaris et plantaris                         |
| L404   | Guttate psoriasis  |
| L4050  | Arthropathic psoriasis, unspecified                      |
| L4052  | Psoriatic arthritis mutilans                             |
| L4053  | Psoriatic spondylitis                                    |
| L4059  | Other psoriatic arthropathy                              |
| L408   | Other psoriasis  |
| L409   | Psoriasis, unspecified                                   |
| L413   | Small plaque parapsoriasis                               |
| L433   | Subacute (active) lichen planus                          |
| L438   | Other lichen planus                                      |
| L500   | Allergic urticaria                                       |
| L501   | Idiopathic urticaria                                     |
| L503   | Dermatographic urticaria                                 |
| L508   | Other urticaria  |



| Code   | Description  |
|--------|--|
| L509   | Urticaria, unspecified   |
| L511   | Stevens-Johnson syndrome   |
| L519   | Erythema multiforme, unspecified   |
| L52    | Erythema nodosum   |
| L539   | Erythematous condition, unspecified  |
| L88    | Pyoderma gangrenosum   |
| L921   | Necrobiosis lipoidica, not elsewhere classified  |
| L928   | Other granulomatous disorders of the skin and subcutaneous tissue  |
| L930   | Discoid lupus erythematosus  |
| L931   | Subacute cutaneous lupus erythematosus   |
| L932   | Other local lupus erythematosus  |
| L940   | Localized scleroderma [morphea]  |
| L941   | Linear scleroderma   |
| L943   | Sclerodactyly  |
| L949   | Localized connective tissue disorder, unspecified  |
| L959   | Vasculitis limited to the skin, unspecified  |
| L97128 | Non-pressure chronic ulcer of left thigh with other specified severity                                   |
| L97312 | Non-pressure chronic ulcer of right ankle with fat layer exposed   |
| L97319 | Non-pressure chronic ulcer of right ankle with unspecified severity                                      |
| L97409 | Non-pressure chronic ulcer of unspecified heel and midfoot with unspecified severity                     |
| L97412 | Non-pressure chronic ulcer of right heel and midfoot with fat layer exposed                              |
| L97429 | Non-pressure chronic ulcer of left heel and midfoot with unspecified severity                            |
| L97503 | Non-pressure chronic ulcer of other part of unspecified foot with necrosis of muscle                     |
| L97509 | Non-pressure chronic ulcer of other part of unspecified foot with unspecified severity                   |
| L97511 | Non-pressure chronic ulcer of other part of right foot limited to breakdown of skin                      |
| L97512 | Non-pressure chronic ulcer of other part of right foot with fat layer exposed                            |
| L97514 | Non-pressure chronic ulcer of other part of right foot with necrosis of bone                             |
| L97519 | Non-pressure chronic ulcer of other part of right foot with unspecified severity                         |
| L97522 | Non-pressure chronic ulcer of other part of left foot with fat layer exposed                             |
| L97524 | Non-pressure chronic ulcer of other part of left foot with necrosis of bone                              |
| L97526 | Non-pressure chronic ulcer of other part of left foot with bone involvement without evidence of necrosis |
| L97529 | Non-pressure chronic ulcer of other part of left foot with unspecified severity                          |
| L97818 | Non-pressure chronic ulcer of other part of right lower leg with other specified severity                |
| L97829 | Non-pressure chronic ulcer of other part of left lower leg with unspecified severity                     |
| L97909 | Non-pressure chronic ulcer of unspecified part of unspecified lower leg with unspecified severity        |
| L97911 | Non-pressure chronic ulcer of unspecified part of right lower leg limited to breakdown of skin           |
| L97919 | Non-pressure chronic ulcer of unspecified part of right lower leg with unspecified severity              |



| Code   | Description  |
|--------|--|
| L982   | Febrile neutrophilic dermatosis [Sweet]  |
| L98499 | Non-pressure chronic ulcer of skin of other sites with unspecified severity                              |
| L989   | Disorder of the skin and subcutaneous tissue, unspecified  |
| M0230  | Reiter's disease, unspecified site   |
| M0239  | Reiter's disease, multiple sites   |
| M0280  | Other reactive arthropathies, unspecified site   |
| M041   | Periodic fever syndromes   |
| M048   | Other autoinflammatory syndromes   |
| M05161 | Rheumatoid lung disease with rheumatoid arthritis of right knee  |
| M0520  | Rheumatoid vasculitis with rheumatoid arthritis of unspecified site                                      |
| M0540  | Rheumatoid myopathy with rheumatoid arthritis of unspecified site  |
| M0569  | Rheumatoid arthritis of multiple sites with involvement of other organs and systems                      |
| M0570  | Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement     |
| M05711 | Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement       |
| M05732 | Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement           |
| M05741 | Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement           |
| M05749 | Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement     |
| M05771 | Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement |
| M05772 | Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement  |
| M0579  | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement       |
| M0580  | Other rheumatoid arthritis with rheumatoid factor of unspecified site                                    |
| M05841 | Other rheumatoid arthritis with rheumatoid factor of right hand  |
| M0589  | Other rheumatoid arthritis with rheumatoid factor of multiple sites                                      |
| M059   | Rheumatoid arthritis with rheumatoid factor, unspecified   |
| M0600  | Rheumatoid arthritis without rheumatoid factor, unspecified site   |
| M06032 | Rheumatoid arthritis without rheumatoid factor, left wrist   |
| M06041 | Rheumatoid arthritis without rheumatoid factor, right hand   |
| M06062 | Rheumatoid arthritis without rheumatoid factor, left knee  |
| M06072 | Rheumatoid arthritis without rheumatoid factor, left ankle, and foot                                     |
| M0609  | Rheumatoid arthritis without rheumatoid factor, multiple sites   |
| M061   | Adult-onset Still's disease  |
| M06249 | Rheumatoid bursitis, unspecified hand  |
| M0630  | Rheumatoid nodule, unspecified site  |
| M064   | Inflammatory polyarthropathy   |
| M0680  | Other specified rheumatoid arthritis, unspecified site   |
| M06841 | Other specified rheumatoid arthritis, right hand   |
| M06871 | Other specified rheumatoid arthritis, right ankle, and foot  |
|        |  |



| Code   | Description  |
|--------|--|
| M06872 | Other specified rheumatoid arthritis, left ankle, and foot               |
| M0688  | Other specified rheumatoid arthritis, vertebrae                          |
| M0689  | Other specified rheumatoid arthritis, multiple sites                     |
| M069   | Rheumatoid arthritis, unspecified  |
| M0760  | Enteropathic arthropathies, unspecified site                             |
| M0800  | Unspecified juvenile rheumatoid arthritis of unspecified site            |
| M0829  | Juvenile rheumatoid arthritis with systemic onset, multiple sites        |
| M083   | Juvenile rheumatoid polyarthritis (seronegative)                         |
| M0840  | Pauciarticular juvenile rheumatoid arthritis, unspecified site           |
| M0880  | Other juvenile arthritis, unspecified site                               |
| M0889  | Other juvenile arthritis, multiple sites                                 |
| M0890  | Juvenile arthritis, unspecified, unspecified site                        |
| M1000  | Idiopathic gout, unspecified site  |
| M10021 | Idiopathic gout, right elbow   |
| M10031 | Idiopathic gout, right wrist   |
| M10061 | Idiopathic gout, right knee  |
| M10062 | Idiopathic gout, left knee   |
| M10071 | Idiopathic gout, right ankle, and foot                                   |
| M10072 | Idiopathic gout, left ankle, and foot                                    |
| M10079 | Idiopathic gout, unspecified ankle, and foot                             |
| M1009  | Idiopathic gout, multiple sites  |
| M1010  | Lead-induced gout, unspecified site                                      |
| M10249 | Drug-induced gout, unspecified hand                                      |
| M1040  | Other secondary gout, unspecified site                                   |
| M10472 | Other secondary gout, left ankle, and foot                               |
| M109   | Gout, unspecified  |
| M1120  | Other chondrocalcinosis, unspecified site                                |
| M11232 | Other chondrocalcinosis, left wrist                                      |
| M11239 | Other chondrocalcinosis, unspecified wrist                               |
| M11261 | Other chondrocalcinosis, right knee                                      |
| M1129  | Other chondrocalcinosis, multiple sites                                  |
| M1180  | Other specified crystal arthropathies, unspecified site                  |
| M1230  | Palindromic rheumatism, unspecified site                                 |
| M1239  | Palindromic rheumatism, multiple sites                                   |
| M1280  | Other specific arthropathies, not elsewhere classified, unspecified site |
| M12811 | Other specific arthropathies, not elsewhere classified, right shoulder   |
| M12849 | Other specific arthropathies, not elsewhere classified, unspecified hand |



| Code    | Description   |
|---------|---|
| M129    | Arthropathy, unspecified  |
| M130    | Polyarthritis, unspecified  |
| M1310   | Monoarthritis, not elsewhere classified, unspecified site               |
| M13111  | Monoarthritis, not elsewhere classified, right shoulder                 |
| M13161  | Monoarthritis, not elsewhere classified, right knee                     |
| M13162  | Monoarthritis, not elsewhere classified, left knee                      |
| M13171  | Monoarthritis, not elsewhere classified, right ankle and foot           |
| M1380   | Other specified arthritis, unspecified site                             |
| M13832  | Other specified arthritis, left wrist                                   |
| M13839  | Other specified arthritis, unspecified wrist                            |
| M13841  | Other specified arthritis, right hand                                   |
| M13842  | Other specified arthritis, left hand                                    |
| M13849  | Other specified arthritis, unspecified hand                             |
| M13851  | Other specified arthritis, right hip                                    |
| M13861  | Other specified arthritis, right knee                                   |
| M13862  | Other specified arthritis, left knee                                    |
| M13872  | Other specified arthritis, left ankle, and foot                         |
| M1388   | Other specified arthritis, other site                                   |
| M1389   | Other specified arthritis, multiple sites                               |
| M14672  | Charcôt's joint, left ankle and foot                                    |
| M150    | Primary generalized (osteo)arthritis                                    |
| M151    | Heberden's nodes (with arthropathy)                                     |
| M154    | Erosive (osteo)arthritis  |
| M158    | Other polyosteoarthritis  |
| M159    | Polyosteoarthritis, unspecified   |
| M160    | Bilateral primary osteoarthritis of hip                                 |
| M180    | Bilateral primary osteoarthritis of first carpometacarpal joints        |
| M1990   | Unspecified osteoarthritis, unspecified site                            |
| M1993   | Secondary osteoarthritis, unspecified site                              |
| M1A00X0 | Idiopathic chronic gout, unspecified site, without tophus (tophi)       |
| M1A0710 | Idiopathic chronic gout, right ankle, and foot, without tophus (tophi)  |
| M1A09X0 | Idiopathic chronic gout, multiple sites, without tophus (tophi)         |
| M1A09X1 | Idiopathic chronic gout, multiple sites, with tophus (tophi)            |
| M1A1720 | Lead-induced chronic gout, left ankle, and foot, without tophus (tophi) |
| M1A9XX0 | Chronic gout, unspecified, without tophus (tophi)                       |
| M272    | Inflammatory conditions of jaws   |
| M300    | Polyarteritis nodosa  |



| Code  | Description  |
|-------|--|
| M301  | Polyarteritis with lung involvement [Churg-Strauss]                    |
| M302  | Juvenile polyarteritis   |
| M310  | Hypersensitivity angiitis  |
| M3130 | Wegener's granulomatosis without renal involvement                     |
| M3131 | Wegener's granulomatosis with renal involvement                        |
| M314  | Aortic arch syndrome [Takayasu]  |
| M315  | Giant cell arteritis with polymyalgia rheumatica                       |
| M316  | Other giant cell arteritis   |
| M317  | Microscopic polyangiitis   |
| M318  | Other specified necrotizing vasculopathies                             |
| M320  | Drug-induced systemic lupus erythematosus                              |
| M3210 | Systemic lupus erythematosus, organ, or system involvement unspecified |
| M3212 | Pericarditis in systemic lupus erythematosus                           |
| M3214 | Glomerular disease in systemic lupus erythematosus                     |
| M3219 | Other organ or system involvement in systemic lupus erythematosus      |
| M328  | Other forms of systemic lupus erythematosus                            |
| M329  | Systemic lupus erythematosus, unspecified                              |
| M3310 | Other dermatomyositis, organ involvement unspecified                   |
| M3320 | Polymyositis, organ involvement unspecified                            |
| M3322 | Polymyositis with myopathy   |
| M3390 | Dermatopolymyositis, unspecified, organ involvement unspecified        |
| M3392 | Dermatopolymyositis, unspecified with myopathy                         |
| M3393 | Dermatopolymyositis, unspecified without myopathy                      |
| M3399 | Dermatopolymyositis, unspecified with other organ involvement          |
| M340  | Progressive systemic sclerosis   |
| M341  | CR(E)ST syndrome   |
| M3489 | Other systemic sclerosis   |
| M349  | Systemic sclerosis, unspecified  |
| M3500 | Sicca syndrome, unspecified  |
| M3501 | Sicca syndrome with keratoconjunctivitis                               |
| M3502 | Sicca syndrome with lung involvement                                   |
| M3509 | Sicca syndrome with other organ involvement                            |
| M351  | Other overlap syndromes  |
| M352  | Behçet's disease   |
| M353  | Polymyalgia rheumatica   |
| M355  | Multifocal fibrosclerosis  |
| M357  | Hypermobility syndrome   |



| Code    | Description   |
|---------|---|
| M358    | Other specified systemic involvement of connective tissue                         |
| M359    | Systemic involvement of connective tissue, unspecified                            |
| M368    | Systemic disorders of connective tissue in other diseases classified elsewhere    |
| N049    | Nephrotic syndrome with unspecified morphologic changes                           |
| N052    | Unspecified nephritic syndrome with diffuse membranous glomerulonephritis         |
| N057    | Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis         |
| N059    | Unspecified nephritic syndrome with unspecified morphologic changes               |
| N069    | Isolated proteinuria with unspecified morphologic lesion                          |
| N10     | Acute pyelonephritis  |
| N12     | Tubulo-interstitial nephritis, not specified as acute or chronic                  |
| N179    | Acute kidney failure, unspecified   |
| N182    | Chronic kidney disease, stage 2 (mild)  |
| N183    | Chronic kidney disease, stage 3 (moderate)  |
| N184    | Chronic kidney disease, stage 4 (severe)  |
| N185    | Chronic kidney disease, stage 5   |
| N186    | End stage renal disease   |
| N189    | Chronic kidney disease, unspecified   |
| N200    | Calculus of kidney  |
| N2889   | Other specified disorders of kidney and ureter                                    |
| N289    | Disorder of kidney and ureter, unspecified  |
| N3001   | Acute cystitis with hematuria   |
| N3010   | Interstitial cystitis (chronic) without hematuria                                 |
| N3090   | Cystitis, unspecified without hematuria   |
| N3289   | Other specified disorders of bladder  |
| N342    | Other urethritis  |
| N368    | Other specified disorders of urethra  |
| N399    | Disorder of urinary system, unspecified   |
| N710    | Acute inflammatory disease of uterus  |
| N730    | Acute parametritis and pelvic cellulitis  |
| N738    | Other specified female pelvic inflammatory diseases                               |
| N739    | Female pelvic inflammatory disease, unspecified                                   |
| 0368210 | Fetal anemia and thrombocytopenia, first trimester, not applicable or unspecified |
| 099012  | Anemia complicating pregnancy, second trimester                                   |
| R051    | Acute cough   |
| R052    | Subacute cough  |
| R053    | Chronic cough   |
| R054    | Cough syncope   |



| Code    | Description  |
|---------|--|
| R058    | Other specified cough  |
| R059    | Cough unspecified  |
| R29818  | Other symptoms and signs involving the nervous system  |
| R29898  | Other symptoms and signs involving the musculoskeletal system  |
| R2990   | Unspecified symptoms and signs involving the nervous system  |
| R2991   | Unspecified symptoms and signs involving the musculoskeletal system  |
| R51     | Headache   |
| R634    | Abnormal weight loss   |
| R768    | Other specified abnormal immunological findings in serum   |
| R769    | Abnormal immunological finding in serum, unspecified   |
| R779    | Abnormality of plasma protein, unspecified   |
| T883XXD | Malignant hyperthermia due to anesthesia, subsequent encounter   |
| Z08     | Encounter for follow-up examination after completed treatment for malignant neoplasm                       |
| Z09     | Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm |
| Z4732   | Aftercare following explantation of hip joint prosthesis   |
| Z4781   | Encounter for orthopedic aftercare following surgical amputation   |
| Z4789   | Encounter for other orthopedic aftercare   |
| Z4822   | Encounter for aftercare following kidney transplant  |
| Z4823   | Encounter for aftercare following liver transplant   |
| Z48812  | Encounter for surgical aftercare following surgery on the circulatory system                               |
| Z48815  | Encounter for surgical aftercare following surgery on the digestive system                                 |
| Z4889   | Encounter for other specified surgical aftercare   |
| Z5111   | Encounter for antineoplastic chemotherapy  |
| Z5112   | Encounter for antineoplastic immunotherapy   |

# Folic Acid

| Code | Description   |
|------|---|
| D510 | Vitamin B12 deficiency anemia due to intrinsic factor deficiency                          |
| D511 | Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria |
| D513 | Other dietary vitamin B12 deficiency anemia   |
| D518 | Other vitamin B12 deficiency anemias  |
| D519 | Vitamin B12 deficiency anemia, unspecified  |
| D528 | Other folate deficiency anemias   |
| D529 | Folate deficiency anemia, unspecified   |
| D531 | Other megaloblastic anemias, not elsewhere classified                                     |
| D538 | Other specified nutritional anemias   |
| D539 | Nutritional anemia, unspecified   |



| Code    | Description   |
|---------|---|
| D649    | Anemia, unspecified   |
| D696    | Thrombocytopenia, unspecified   |
| D8689   | Sarcoidosis of other sites  |
| D869    | Sarcoidosis, unspecified  |
| E08311  | Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema          |
| E0840   | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified                             |
| E088    | Diabetes mellitus due to underlying condition with unspecified complications                                    |
| E089    | Diabetes mellitus due to underlying condition without complications   |
| E1010   | Type 1 diabetes mellitus with ketoacidosis without coma   |
| E1022   | Type 1 diabetes mellitus with diabetic chronic kidney disease   |
| E1029   | Type 1 diabetes mellitus with other diabetic kidney complication  |
| E10319  | Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema                            |
| E103293 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral       |
| E103299 | Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye |
| E103391 | Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye   |
| E1040   | Type 1 diabetes mellitus with diabetic neuropathy, unspecified  |
| E1042   | Type 1 diabetes mellitus with diabetic polyneuropathy   |
| E1049   | Type 1 diabetes mellitus with other diabetic neurological complication  |
| E10621  | Type 1 diabetes mellitus with foot ulcer  |
| E10649  | Type 1 diabetes mellitus with hypoglycemia without coma   |
| E1065   | Type 1 diabetes mellitus with hyperglycemia   |
| E108    | Type 1 diabetes mellitus with unspecified complications   |
| E109    | Type 1 diabetes mellitus without complications  |
| E1100   | Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)        |
| E1110   | Type 2 diabetes mellitus with ketoacidosis without coma   |
| E1121   | Type 2 diabetes mellitus with diabetic nephropathy  |
| E1122   | Type 2 diabetes mellitus with diabetic chronic kidney disease   |
| E1129   | Type 2 diabetes mellitus with other diabetic kidney complication  |
| E11319  | Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema                            |
| E113293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral       |
| E113411 | Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye        |
| E1136   | Type 2 diabetes mellitus with diabetic cataract   |
| E1137X3 | Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral                   |
| E1139   | Type 2 diabetes mellitus with other diabetic ophthalmic complication  |
| E1140   | Type 2 diabetes mellitus with diabetic neuropathy, unspecified  |
| E1141   | Type 2 diabetes mellitus with diabetic mononeuropathy   |
| E1142   | Type 2 diabetes mellitus with diabetic polyneuropathy   |



| Code   | Description   |
|--------|---|
| E1143  | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy   |
| E1149  | Type 2 diabetes mellitus with other diabetic neurological complication  |
| E1151  | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene   |
| E1159  | Type 2 diabetes mellitus with other circulatory complications   |
| E11610 | Type 2 diabetes mellitus with diabetic neuropathic arthropathy  |
| E11621 | Type 2 diabetes mellitus with foot ulcer  |
| E1165  | Type 2 diabetes mellitus with hyperglycemia   |
| E1169  | Type 2 diabetes mellitus with other specified complication  |
| E118   | Type 2 diabetes mellitus with unspecified complications   |
| E119   | Type 2 diabetes mellitus without complications  |
| E1300  | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma<br>(NKHHC)  |
| E1322  | Other specified diabetes mellitus with diabetic chronic kidney disease  |
| E138   | Other specified diabetes mellitus with unspecified complications  |
| E139   | Other specified diabetes mellitus without complications   |
| E538   | Deficiency of other specified B group vitamins  |
| E539   | Vitamin B deficiency, unspecified   |
| E569   | Vitamin deficiency, unspecified   |
| E639   | Nutritional deficiency, unspecified   |
| E7211  | Homocystinuria  |
| E7212  | Methylenetetrahydrofolate reductase deficiency  |
| F0390  | Unspecified dementia without behavioral disturbance   |
| F509   | Eating disorder, unspecified  |
| G309   | Alzheimer's disease, unspecified  |
| G40109 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus     |
| G40209 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not<br>intractable, without status epilepticus |
| G40219 | Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures,<br>intractable, without status epilepticus     |
| G40309 | Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus  |
| G40409 | Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus   |
| G40804 | Other epilepsy, intractable, without status epilepticus   |
| G4089  | Other seizures  |
| G40901 | Epilepsy, unspecified, not intractable, with status epilepticus   |
| G40909 | Epilepsy, unspecified, not intractable, without status epilepticus  |
| G40911 | Epilepsy, unspecified, intractable, with status epilepticus   |
| G40919 | Epilepsy, unspecified, intractable, without status epilepticus  |
| G40B09 | Juvenile myoclonic epilepsy, not intractable, without status epilepticus  |



| Code   | Description   |
|--------|---|
| G609   | Hereditary and idiopathic neuropathy, unspecified                         |
| G629   | Polyneuropathy, unspecified   |
| G63    | Polyneuropathy in diseases classified elsewhere                           |
| G7000  | Myasthenia gravis without (acute) exacerbation                            |
| H44139 | Sympathetic uveitis, unspecified eye                                      |
| H44539 | Leucocoria, unspecified eye   |
| H4612  | Retrobulbar neuritis, left eye  |
| H463   | Toxic optic neuropathy  |
| H469   | Unspecified optic neuritis  |
| K120   | Recurrent oral aphthae  |
| K121   | Other forms of stomatitis   |
| K1230  | Oral mucositis (ulcerative), unspecified                                  |
| K130   | Diseases of lips  |
| K1379  | Other lesions of oral mucosa  |
| K140   | Glossitis   |
| K141   | Geographic tongue   |
| K146   | Glossodynia   |
| K149   | Disease of tongue, unspecified  |
| K5000  | Crohn's disease of small intestine without complications                  |
| K50011 | Crohn's disease of small intestine with rectal bleeding                   |
| K50018 | Crohn's disease of small intestine with other complication                |
| K5010  | Crohn's disease of large intestine without complications                  |
| K50111 | Crohn's disease of large intestine with rectal bleeding                   |
| K50118 | Crohn's disease of large intestine with other complication                |
| K50119 | Crohn's disease of large intestine with unspecified complications         |
| K5080  | Crohn's disease of both small and large intestine without complications   |
| K50811 | Crohn's disease of both small and large intestine with rectal bleeding    |
| K50813 | Crohn's disease of both small and large intestine with fistula            |
| K50818 | Crohn's disease of both small and large intestine with other complication |
| K5090  | Crohn's disease, unspecified, without complications                       |
| K50913 | Crohn's disease, unspecified, with fistula                                |
| K50919 | Crohn's disease, unspecified, with unspecified complications              |
| K5100  | Ulcerative (chronic) pancolitis without complications                     |
| K51011 | Ulcerative (chronic) pancolitis with rectal bleeding                      |
| K5120  | Ulcerative (chronic) proctitis without complications                      |
| K51211 | Ulcerative (chronic) proctitis with rectal bleeding                       |
| K5130  | Ulcerative (chronic) rectosigmoiditis without complications               |



| Code   | Description  |
|--------|--|
| K51311 | Ulcerative (chronic) rectosigmoiditis with rectal bleeding                             |
| K51419 | Inflammatory polyps of colon with unspecified complications                            |
| K5180  | Other ulcerative colitis without complications   |
| K51818 | Other ulcerative colitis with other complication                                       |
| K5190  | Ulcerative colitis, unspecified, without complications                                 |
| K51911 | Ulcerative colitis, unspecified with rectal bleeding                                   |
| K51918 | Ulcerative colitis, unspecified with other complication                                |
| K51919 | Ulcerative colitis, unspecified with unspecified complications                         |
| K523   | Indeterminate colitis  |
| K52831 | Collagenous colitis  |
| K52832 | Lymphocytic colitis  |
| K5289  | Other specified noninfective gastroenteritis and colitis                               |
| K529   | Noninfective gastroenteritis and colitis, unspecified                                  |
| K900   | Celiac disease   |
| K9049  | Malabsorption due to intolerance, not elsewhere classified                             |
| K9089  | Other intestinal malabsorption   |
| K909   | Intestinal malabsorption, unspecified  |
| K912   | Postsurgical malabsorption, not elsewhere classified                                   |
| K929   | Disease of digestive system, unspecified   |
| L2089  | Other atopic dermatitis  |
| L209   | Atopic dermatitis, unspecified   |
| L219   | Seborrheic dermatitis, unspecified   |
| L282   | Other prurigo  |
| L298   | Other pruritus   |
| L299   | Pruritus, unspecified  |
| L301   | Dyshidrosis [pompholyx]  |
| L309   | Dermatitis, unspecified  |
| L400   | Psoriasis vulgaris   |
| L401   | Generalized pustular psoriasis   |
| L4050  | Arthropathic psoriasis, unspecified  |
| L4059  | Other psoriatic arthropathy  |
| L409   | Psoriasis, unspecified   |
| L439   | Lichen planus, unspecified   |
| L499   | Exfoliation due to erythematous condition involving 90 or more percent of body surface |
| L819   | Disorder of pigmentation, unspecified  |
| L930   | Discoid lupus erythematosus  |
| L989   | Disorder of the skin and subcutaneous tissue, unspecified                              |



| Code   | Description  |
|--------|--|
| M0579  | Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement |
| M05849 | Other rheumatoid arthritis with rheumatoid factor of unspecified hand                              |
| M0589  | Other rheumatoid arthritis with rheumatoid factor of multiple sites                                |
| M059   | Rheumatoid arthritis with rheumatoid factor, unspecified   |
| M06041 | Rheumatoid arthritis without rheumatoid factor, right hand   |
| M0609  | Rheumatoid arthritis without rheumatoid factor, multiple sites                                     |
| M064   | Inflammatory polyarthropathy   |
| M0680  | Other specified rheumatoid arthritis, unspecified site   |
| M069   | Rheumatoid arthritis, unspecified  |
| M0829  | Juvenile rheumatoid arthritis with systemic onset, multiple sites                                  |
| M1000  | Idiopathic gout, unspecified site  |
| M10031 | Idiopathic gout, right wrist   |
| M10472 | Other secondary gout, left ankle, and foot   |
| M109   | Gout, unspecified  |
| M119   | Crystal arthropathy, unspecified   |
| M129   | Arthropathy, unspecified   |
| M130   | Polyarthritis, unspecified   |
| M3210  | Systemic lupus erythematosus, organ, or system involvement unspecified                             |
| M3214  | Glomerular disease in systemic lupus erythematosus   |
| M328   | Other forms of systemic lupus erythematosus  |
| M329   | Systemic lupus erythematosus, unspecified  |
| M3390  | Dermatopolymyositis, unspecified, organ involvement unspecified                                    |
| M3392  | Dermatopolymyositis, unspecified with myopathy   |
| M349   | Systemic sclerosis, unspecified  |
| M3500  | Sicca syndrome, unspecified  |
| M3501  | Sicca syndrome with keratoconjunctivitis   |
| M353   | Polymyalgia rheumatica   |
| M359   | Systemic involvement of connective tissue, unspecified   |
| M450   | Ankylosing spondylitis of multiple sites in spine  |
| M455   | Ankylosing spondylitis of thoracolumbar region   |
| M461   | Sacroiliitis, not elsewhere classified   |
| M4690  | Unspecified inflammatory spondylopathy, site unspecified   |
| N186   | End stage renal disease  |
| N19    | Unspecified kidney failure   |
| 00901  | Supervision of pregnancy with history of infertility, first trimester                              |
| 009291 | Supervision of pregnancy with other poor reproductive or obstetric history, first trimester        |
| 00940  | Supervision of pregnancy with grand multiparity, unspecified trimester                             |



| Code    | Description   |
|---------|---|
| 00942   | Supervision of pregnancy with grand multiparity, second trimester                               |
| 00943   | Supervision of pregnancy with grand multiparity, third trimester                                |
| 009521  | Supervision of elderly multigravida, first trimester  |
| 009522  | Supervision of elderly multigravida, second trimester   |
| 009523  | Supervision of elderly multigravida, third trimester  |
| O09893  | Supervision of other high-risk pregnancies, third trimester                                     |
| 00992   | Supervision of high-risk pregnancy, unspecified, second trimester                               |
| 00993   | Supervision of high-risk pregnancy, unspecified, third trimester                                |
| 010912  | Unspecified pre-existing hypertension complicating pregnancy, second trimester                  |
| 0163    | Unspecified maternal hypertension, third trimester  |
| 024011  | Pre-existing type 1 diabetes mellitus, in pregnancy, first trimester                            |
| 024919  | Unspecified diabetes mellitus in pregnancy, unspecified trimester                               |
| 026843  | Uterine size-date discrepancy, third trimester  |
| 026891  | Other specified pregnancy related conditions, first trimester                                   |
| O26893  | Other specified pregnancy related conditions, third trimester                                   |
| 02691   | Pregnancy related conditions, unspecified, first trimester                                      |
| O358XX0 | Maternal care for other (suspected) fetal abnormality and damage, not applicable or unspecified |
| O3680X0 | Pregnancy with inconclusive fetal viability, not applicable or unspecified                      |
| 0368210 | Fetal anemia and thrombocytopenia, first trimester, not applicable or unspecified               |
| 099011  | Anemia complicating pregnancy, first trimester  |
| 099012  | Anemia complicating pregnancy, second trimester   |
| 099013  | Anemia complicating pregnancy, third trimester  |
| 099019  | Anemia complicating pregnancy, unspecified trimester  |
| 099281  | Endocrine, nutritional, and metabolic diseases complicating pregnancy, first trimester          |
| 099841  | Bariatric surgery status complicating pregnancy, first trimester                                |
| 099842  | Bariatric surgery status complicating pregnancy, second trimester                               |
| 099843  | Bariatric surgery status complicating pregnancy, third trimester                                |
| R200    | Anesthesia of skin  |
| R202    | Paresthesia of skin   |
| R203    | Hyperesthesia   |
| R208    | Other disturbances of skin sensation  |
| R209    | Unspecified disturbances of skin sensation  |
| R231    | Pallor  |
| R233    | Spontaneous ecchymoses  |
| R238    | Other skin changes  |
| R269    | Unspecified abnormalities of gait and mobility  |
| R413    | Other amnesia   |



| Code   | Description   |
|--------|---|
| Z1321  | Encounter for screening for nutritional disorder                                  |
| Z3401  | Encounter for supervision of normal first pregnancy, first trimester              |
| Z3402  | Encounter for supervision of normal first pregnancy, second trimester             |
| Z3403  | Encounter for supervision of normal first pregnancy, third trimester              |
| Z3481  | Encounter for supervision of other normal pregnancy, first trimester              |
| Z3482  | Encounter for supervision of other normal pregnancy, second trimester             |
| Z3483  | Encounter for supervision of other normal pregnancy, third trimester              |
| Z3490  | Encounter for supervision of normal pregnancy, unspecified, unspecified trimester |
| Z3491  | Encounter for supervision of normal pregnancy, unspecified, first trimester       |
| Z3492  | Encounter for supervision of normal pregnancy, unspecified, second trimester      |
| Z3493  | Encounter for supervision of normal pregnancy, unspecified, third trimester       |
| Z369   | Encounter for antenatal screening, unspecified                                    |
| Z79899 | Other long term (current) drug therapy  |
| Z940   | Kidney transplant status  |
| Z941   | Heart transplant status   |
| Z944   | Liver transplant status   |
| Z9884  | Bariatric surgery status  |
| Z992   | Dependence on renal dialysis  |

# Triiodothyroxine-T3 Free

| Code  | Description  |
|-------|--|
| C73   | Malignant neoplasm of thyroid gland  |
| C7989 | Secondary malignant neoplasm of other specified sites                                  |
| C799  | Secondary malignant neoplasm of unspecified site                                       |
| D34   | Benign neoplasm of thyroid gland   |
| D497  | Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system |
| D510  | Vitamin B12 deficiency anemia due to intrinsic factor deficiency                       |
| D539  | Nutritional anemia, unspecified  |
| D6489 | Other specified anemias  |
| D649  | Anemia, unspecified  |
| D8989 | Other specified disorders involving the immune mechanism, not elsewhere classified     |
| E009  | Congenital iodine-deficiency syndrome, unspecified                                     |
| E010  | Iodine-deficiency related diffuse (endemic) goiter                                     |
| E02   | Subclinical iodine-deficiency hypothyroidism   |
| E030  | Congenital hypothyroidism with diffuse goiter  |
| E031  | Congenital hypothyroidism without goiter   |
| E032  | Hypothyroidism due to medicaments and other exogenous substances                       |



| Code    | Description   |
|---------|---|
| E034    | Atrophy of thyroid (acquired)   |
| E038    | Other specified hypothyroidism  |
| E039    | Hypothyroidism, unspecified   |
| E040    | Nontoxic diffuse goiter   |
| E041    | Nontoxic single thyroid nodule  |
| E042    | Nontoxic multinodular goiter  |
| E049    | Nontoxic goiter, unspecified  |
| E0500   | Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm                                     |
| E0510   | Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm                        |
| E0520   | Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm                          |
| E0521   | Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm                             |
| E0530   | Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm                             |
| E0540   | Thyrotoxicosis factitia without thyrotoxic crisis or storm  |
| E0580   | Other thyrotoxicosis without thyrotoxic crisis or storm   |
| E0590   | Thyrotoxicosis, unspecified without thyrotoxic crisis or storm  |
| E0591   | Thyrotoxicosis, unspecified with thyrotoxic crisis or storm   |
| E060    | Acute thyroiditis   |
| E061    | Subacute thyroiditis  |
| E063    | Autoimmune thyroiditis  |
| E065    | Other chronic thyroiditis   |
| E069    | Thyroiditis, unspecified  |
| E0789   | Other specified disorders of thyroid  |
| E079    | Disorder of thyroid, unspecified  |
| E1029   | Type 1 diabetes mellitus with other diabetic kidney complication  |
| E1040   | Type 1 diabetes mellitus with diabetic neuropathy, unspecified  |
| E1051   | Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene                             |
| E1065   | Type 1 diabetes mellitus with hyperglycemia   |
| E108    | Type 1 diabetes mellitus with unspecified complications   |
| E109    | Type 1 diabetes mellitus without complications  |
| E1121   | Type 2 diabetes mellitus with diabetic nephropathy  |
| E1122   | Type 2 diabetes mellitus with diabetic chronic kidney disease   |
| E1129   | Type 2 diabetes mellitus with other diabetic kidney complication  |
| E113293 | Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral |
| E1140   | Type 2 diabetes mellitus with diabetic neuropathy, unspecified  |
| E1142   | Type 2 diabetes mellitus with diabetic polyneuropathy   |
| E1159   | Type 2 diabetes mellitus with other circulatory complications   |
| E1165   | Type 2 diabetes mellitus with hyperglycemia   |



| Code   | Description   |  |
|--------|---|--|
| E1169  | Type 2 diabetes mellitus with other specified complication  |  |
| E118   | Type 2 diabetes mellitus with unspecified complications   |  |
| E119   | Type 2 diabetes mellitus without complications  |  |
| E1300  | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) |  |
| E139   | Other specified diabetes mellitus without complications   |  |
| E209   | Hypoparathyroidism, unspecified   |  |
| E220   | Acromegaly and pituitary gigantism  |  |
| E221   | Hyperprolactinemia  |  |
| E229   | Hyperfunction of pituitary gland, unspecified   |  |
| E230   | Hypopituitarism   |  |
| E278   | Other specified disorders of adrenal gland  |  |
| E279   | Disorder of adrenal gland, unspecified  |  |
| E28310 | Symptomatic premature menopause   |  |
| E2839  | Other primary ovarian failure   |  |
| E291   | Testicular hypofunction   |  |
| E7800  | Pure hypercholesterolemia, unspecified  |  |
| E781   | Pure hyperglyceridemia  |  |
| E782   | Mixed hyperlipidemia  |  |
| E784   | Other hyperlipidemia  |  |
| E7841  | Elevated Lipoprotein(a)   |  |
| E7849  | Other hyperlipidemia  |  |
| E785   | Hyperlipidemia, unspecified   |  |
| E8351  | Hypocalcemia  |  |
| E8352  | Hypercalcemia   |  |
| E871   | Hypo-osmolality and hyponatremia  |  |
| E890   | Postprocedural hypothyroidism   |  |
| E892   | Postprocedural hypoparathyroidism   |  |
| F3130  | Bipolar disorder, current episode depressed, mild or moderate severity, unspecified                               |  |
| F3132  | Bipolar disorder, current episode depressed, moderate   |  |
| F314   | Bipolar disorder, current episode depressed, severe, without psychotic features                                   |  |
| F315   | Bipolar disorder, current episode depressed, severe, with psychotic features                                      |  |
| F3160  | Bipolar disorder, current episode mixed, unspecified  |  |
| F3170  | Bipolar disorder, currently in remission, most recent episode unspecified   |  |
| F3181  | Bipolar II disorder   |  |
| F319   | Bipolar disorder, unspecified   |  |
| F322   | Major depressive disorder, single episode, severe without psychotic features                                      |  |
| F3281  | Premenstrual dysphoric disorder   |  |



| Code   | Description   |
|--------|---|
| F3289  | Other specified depressive episodes   |
| F329   | Major depressive disorder, single episode, unspecified  |
| F330   | Major depressive disorder, recurrent, mild  |
| F331   | Major depressive disorder, recurrent, moderate  |
| F332   | Major depressive disorder, recurrent severe without psychotic features  |
| F333   | Major depressive disorder, recurrent, severe with psychotic symptoms  |
| F339   | Major depressive disorder, recurrent, unspecified   |
| F341   | Dysthymic disorder  |
| F3481  | Disruptive mood dysregulation disorder  |
| F3489  | Other specified persistent mood disorders   |
| F39    | Unspecified mood [affective] disorder   |
| F410   | Panic disorder [episodic paroxysmal anxiety]  |
| F411   | Generalized anxiety disorder  |
| F418   | Other specified anxiety disorders   |
| F419   | Anxiety disorder, unspecified   |
| G250   | Essential tremor  |
| G3184  | Mild cognitive impairment, so stated  |
| G4700  | Insomnia, unspecified   |
| G4730  | Sleep apnea, unspecified  |
| G4739  | Other sleep apnea   |
| G479   | Sleep disorder, unspecified   |
| G5603  | Carpal tunnel syndrome, bilateral upper limbs   |
| G609   | Hereditary and idiopathic neuropathy, unspecified   |
| G933   | Post viral fatigue syndrome   |
| H0520  | Unspecified exophthalmos  |
| H05242 | Constant exophthalmos, left eye   |
| H4900  | Third [oculomotor] nerve palsy, unspecified eye   |
| H4920  | Sixth [abducent] nerve palsy, unspecified eye   |
| H4922  | Sixth [abducent] nerve palsy, left eye  |
| 110    | Essential (primary) hypertension  |
| 1129   | Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic<br>kidney disease                               |
| 11310  | Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease |
| J9691  | Respiratory failure, unspecified with hypoxia   |
| K5090  | Crohn's disease, unspecified, without complications   |
| K582   | Mixed irritable bowel syndrome  |
| K5900  | Constipation, unspecified   |



| Code   | Description  |
|--------|--|
| L299   | Pruritus, unspecified  |
| L601   | Onycholysis  |
| L608   | Other nail disorders   |
| L630   | Alopecia (capitis) totalis   |
| L639   | Alopecia areata, unspecified   |
| L649   | Androgenic alopecia, unspecified   |
| L658   | Other specified nonscarring hair loss  |
| L659   | Nonscarring hair loss, unspecified   |
| L80    | Vitiligo   |
| M3210  | Systemic lupus erythematosus, organ, or system involvement unspecified                       |
| M329   | Systemic lupus erythematosus, unspecified  |
| M3500  | Sicca syndrome, unspecified  |
| M3501  | Sicca syndrome with keratoconjunctivitis   |
| M359   | Systemic involvement of connective tissue, unspecified                                       |
| M360   | Dermato(poly)myositis in neoplastic disease  |
| M797   | Fibromyalgia   |
| M818   | Other osteoporosis without current pathological fracture                                     |
| N910   | Primary amenorrhea   |
| N911   | Secondary amenorrhea   |
| N912   | Amenorrhea, unspecified  |
| N914   | Secondary oligomenorrhea   |
| N915   | Oligomenorrhea, unspecified  |
| N920   | Excessive and frequent menstruation with regular cycle                                       |
| N925   | Other specified irregular menstruation   |
| N926   | Irregular menstruation, unspecified  |
| N945   | Secondary dysmenorrhea   |
| N946   | Dysmenorrhea, unspecified  |
| O905   | Postpartum thyroiditis   |
| O99280 | Endocrine, nutritional, and metabolic diseases complicating pregnancy, unspecified trimester |
| 099281 | Endocrine, nutritional, and metabolic diseases complicating pregnancy, first trimester       |
| O99282 | Endocrine, nutritional, and metabolic diseases complicating pregnancy, second trimester      |
| O99283 | Endocrine, nutritional, and metabolic diseases complicating pregnancy, third trimester       |
| R000   | Tachycardia, unspecified   |
| R001   | Bradycardia, unspecified   |
| R002   | Palpitations   |
| R0600  | Dyspnea, unspecified   |
| R0609  | Other forms of dyspnea   |



| Code           | Description   |  |
|----------------|---|--|
| R0683          | Snoring   |  |
| R070           | Pain in throat  |  |
| R1310          | Dysphagia, unspecified  |  |
| R194           | Change in bowel habit   |  |
| R197           | Diarrhea, unspecified   |  |
| R200           | Anesthesia of skin  |  |
| R202           | Paresthesia of skin   |  |
| R208           | Other disturbances of skin sensation  |  |
| R251           | Tremor, unspecified   |  |
| R252           | Cramp and spasm   |  |
| R270           | Ataxia, unspecified   |  |
| R279           | Unspecified lack of coordination  |  |
| R404           | Transient alteration of awareness   |  |
| R410           | Disorientation, unspecified   |  |
| R413           | Other amnesia   |  |
| R4182          | Altered mental status, unspecified  |  |
| R4189          | Other symptoms and signs involving cognitive functions and awareness                      |  |
| R419           | Unspecified symptoms and signs involving cognitive functions and awareness                |  |
| R4582          | Worries   |  |
| R490           | Dysphonia   |  |
| R509           | Fever, unspecified  |  |
| R52            | Pain, unspecified   |  |
| R531           | Weakness  |  |
| R5381          | Other malaise   |  |
| R5382          | Chronic fatigue, unspecified  |  |
| R5383          | Other fatigue   |  |
| R600           | Localized edema   |  |
| R609           | Edema, unspecified  |  |
| R61            | Generalized hyperhidrosis   |  |
| R634           | Abnormal weight loss  |  |
| R635           | Abnormal weight gain  |  |
|                | Abnormal weight gain  |  |
| R6889          | Abnormal weight gain Other general symptoms and signs                                     |  |
| R6889<br>R7303 | Other general symptoms and signs Prediabetes  |  |
|                | Other general symptoms and signs  |  |
| R7303          | Other general symptoms and signs Prediabetes  |  |
| R7303<br>R946  | Other general symptoms and signs Prediabetes Abnormal results of thyroid function studies |  |



| Code   | Description   |  |
|--------|---|--|
| Z85850 | Personal history of malignant neoplasm of thyroid   |  |
| Z862   | Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism |  |
| Z8639  | Personal history of other endocrine, nutritional and metabolic disease  |  |

# Triiodothyronine-T3 Total

| Principal Diagnosis | Principal Diagnosis Description  |
|---------------------|--|
| C569                | Malignant neoplasm of unspecified ovary  |
| C7989               | Secondary malignant neoplasm of other specified sites                                  |
| C7A8                | Other malignant neuroendocrine tumors  |
| D34                 | Benign neoplasm of thyroid gland   |
| D352                | Benign neoplasm of pituitary gland   |
| D497                | Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system |
| D510                | Vitamin B12 deficiency anemia due to intrinsic factor deficiency                       |
| D539                | Nutritional anemia, unspecified  |
| D6489               | Other specified anemias  |
| D649                | Anemia, unspecified  |
| D8989               | Other specified disorders involving the immune mechanism, not elsewhere classified     |
| E010                | Iodine-deficiency related diffuse (endemic) goiter                                     |
| E011                | Iodine-deficiency related multinodular (endemic) goiter                                |
| E018                | Other iodine-deficiency related thyroid disorders and allied conditions                |
| E02                 | Subclinical iodine-deficiency hypothyroidism   |
| E030                | Congenital hypothyroidism with diffuse goiter  |
| E031                | Congenital hypothyroidism without goiter   |
| E032                | Hypothyroidism due to medicaments and other exogenous substances                       |
| E033                | Postinfectious hypothyroidism  |
| E034                | Atrophy of thyroid (acquired)  |
| E038                | Other specified hypothyroidism   |
| E039                | Hypothyroidism, unspecified  |
| E040                | Nontoxic diffuse goiter  |
| E041                | Nontoxic single thyroid nodule   |
| E042                | Nontoxic multinodular goiter   |
| E048                | Other specified nontoxic goiter  |
| E049                | Nontoxic goiter, unspecified   |
| E0500               | Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm                  |
| E0501               | Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm                     |
| E0520               | Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm       |



| Principal Diagnosis | Principal Diagnosis Description   |
|---------------------|---|
| E0521               | Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm       |
| E0540               | Thyrotoxicosis factitia without thyrotoxic crisis or storm                          |
| E0580               | Other thyrotoxicosis without thyrotoxic crisis or storm                             |
| E0590               | Thyrotoxicosis, unspecified without thyrotoxic crisis or storm                      |
| E0591               | Thyrotoxicosis, unspecified with thyrotoxic crisis or storm                         |
| E061                | Subacute thyroiditis  |
| E063                | Autoimmune thyroiditis  |
| E064                | Drug-induced thyroiditis  |
| E069                | Thyroiditis, unspecified  |
| E071                | Dyshormogenetic goiter  |
| E0789               | Other specified disorders of thyroid  |
| E079                | Disorder of thyroid, unspecified  |
| E0810               | Diabetes mellitus due to underlying condition with ketoacidosis without coma        |
| E0840               | Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified |
| E089                | Diabetes mellitus due to underlying condition without complications                 |
| E099                | Drug or chemical induced diabetes mellitus without complications                    |
| E1010               | Type 1 diabetes mellitus with ketoacidosis without coma                             |
| E1021               | Type 1 diabetes mellitus with diabetic nephropathy                                  |
| E1040               | Type 1 diabetes mellitus with diabetic neuropathy, unspecified                      |
| E1042               | Type 1 diabetes mellitus with diabetic polyneuropathy                               |
| E10621              | Type 1 diabetes mellitus with foot ulcer  |
| E1065               | Type 1 diabetes mellitus with hyperglycemia   |
| E1069               | Type 1 diabetes mellitus with other specified complication                          |
| E108                | Type 1 diabetes mellitus with unspecified complications                             |
| E109                | Type 1 diabetes mellitus without complications                                      |
| E1121               | Type 2 diabetes mellitus with diabetic nephropathy                                  |
| E1122               | Type 2 diabetes mellitus with diabetic chronic kidney disease                       |
| E1129               | Type 2 diabetes mellitus with other diabetic kidney complication                    |
| E1140               | Type 2 diabetes mellitus with diabetic neuropathy, unspecified                      |
| E1142               | Type 2 diabetes mellitus with diabetic polyneuropathy                               |
| E1143               | Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy                   |
| E1151               | Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene       |
| E1159               | Type 2 diabetes mellitus with other circulatory complications                       |
| E11610              | Type 2 diabetes mellitus with diabetic neuropathic arthropathy                      |
| E1165               | Type 2 diabetes mellitus with hyperglycemia   |
| E1169               | Type 2 diabetes mellitus with other specified complication                          |
| E118                | Type 2 diabetes mellitus with unspecified complications                             |



| Principal Diagnosis | Principal Diagnosis Description   |
|---------------------|---|
| E119                | Type 2 diabetes mellitus without complications  |
| E1300               | Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC) |
| E139                | Other specified diabetes mellitus without complications   |
| E208                | Other hypoparathyroidism  |
| E221                | Hyperprolactinemia  |
| E229                | Hyperfunction of pituitary gland, unspecified   |
| E230                | Hypopituitarism   |
| E236                | Other disorders of pituitary gland  |
| E272                | Addisonian crisis   |
| E2740               | Unspecified adrenocortical insufficiency  |
| E291                | Testicular hypofunction   |
| E319                | Polyglandular dysfunction, unspecified  |
| E440                | Moderate protein-calorie malnutrition   |
| E441                | Mild protein-calorie malnutrition   |
| E7800               | Pure hypercholesterolemia, unspecified  |
| E7801               | Familial hypercholesterolemia   |
| E781                | Pure hyperglyceridemia  |
| E782                | Mixed hyperlipidemia  |
| E7841               | Elevated Lipoprotein(a)   |
| E7849               | Other hyperlipidemia  |
| E785                | Hyperlipidemia, unspecified   |
| E8351               | Hypocalcemia  |
| E8352               | Hypercalcemia   |
| E8359               | Other disorders of calcium metabolism   |
| E871                | Hypo-osmolality and hyponatremia  |
| E890                | Postprocedural hypothyroidism   |
| E892                | Postprocedural hypoparathyroidism   |
| F0390               | Unspecified dementia without behavioral disturbance   |
| F0633               | Mood disorder due to known physiological condition with manic features  |
| F064                | Anxiety disorder due to known physiological condition   |
| F310                | Bipolar disorder, current episode hypomanic   |
| F3110               | Bipolar disorder, current episode manic without psychotic features, unspecified                                   |
| F3112               | Bipolar disorder, current episode manic without psychotic features, moderate                                      |
| F3113               | Bipolar disorder, current episode manic without psychotic features, severe  |
| F312                | Bipolar disorder, current episode manic severe with psychotic features  |
| F3132               | Discley discurder august anisoda degracead, madarata  |
|                     | Bipolar disorder, current episode depressed, moderate   |



| Principal Diagnosis | Principal Diagnosis Description  |
|---------------------|--|
| F315                | Bipolar disorder, current episode depressed, severe, with psychotic features |
| F3160               | Bipolar disorder, current episode mixed, unspecified                         |
| F3161               | Bipolar disorder, current episode mixed, mild                                |
| F3162               | Bipolar disorder, current episode mixed, moderate                            |
| F3163               | Bipolar disorder, current episode mixed, severe, without psychotic features  |
| F3175               | Bipolar disorder, in partial remission, most recent episode depressed        |
| F3181               | Bipolar II disorder  |
| F3189               | Other bipolar disorder   |
| F319                | Bipolar disorder, unspecified  |
| F320                | Major depressive disorder, single episode, mild                              |
| F321                | Major depressive disorder, single episode, moderate                          |
| F322                | Major depressive disorder, single episode, severe without psychotic features |
| F3281               | Premenstrual dysphoric disorder  |
| F3289               | Other specified depressive episodes  |
| F329                | Major depressive disorder, single episode, unspecified                       |
| F330                | Major depressive disorder, recurrent, mild                                   |
| F331                | Major depressive disorder, recurrent, moderate                               |
| F332                | Major depressive disorder, recurrent severe without psychotic features       |
| F333                | Major depressive disorder, recurrent, severe with psychotic symptoms         |
| F338                | Other recurrent depressive disorders   |
| F339                | Major depressive disorder, recurrent, unspecified                            |
| F3481               | Disruptive mood dysregulation disorder                                       |
| F39                 | Unspecified mood [affective] disorder  |
| F410                | Panic disorder [episodic paroxysmal anxiety]                                 |
| F411                | Generalized anxiety disorder   |
| F418                | Other specified anxiety disorders  |
| F419                | Anxiety disorder, unspecified  |
| G250                | Essential tremor   |
| G300                | Alzheimer's disease with early onset   |
| G301                | Alzheimer's disease with late onset  |
| G309                | Alzheimer's disease, unspecified   |
| G3184               | Mild cognitive impairment, so stated   |
| G4700               | Insomnia, unspecified  |
| G4739               | Other sleep apnea  |
| G5601               | Carpal tunnel syndrome, right upper limb                                     |
| G5602               | Carpal tunnel syndrome, left upper limb                                      |
| G5603               | Carpal tunnel syndrome, bilateral upper limbs                                |



| Principal Diagnosis | Principal Diagnosis Description  |
|---------------------|--|
| G609                | Hereditary and idiopathic neuropathy, unspecified  |
| H0520               | Unspecified exophthalmos   |
| H05241              | Constant exophthalmos, right eye   |
| H0589               | Other disorders of orbit   |
| H4920               | Sixth [abducent] nerve palsy, unspecified eye  |
| H4921               | Sixth [abducent] nerve palsy, right eye  |
| H532                | Diplopia   |
| 110                 | Essential (primary) hypertension   |
| 1129                | Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease |
| 1471                | Supraventricular tachycardia   |
| 1480                | Paroxysmal atrial fibrillation   |
| 1481                | Persistent atrial fibrillation   |
| 1482                | Chronic atrial fibrillation  |
| 14891               | Unspecified atrial fibrillation  |
| 1499                | Cardiac arrhythmia, unspecified  |
| 15020               | Unspecified systolic (congestive) heart failure  |
| 15022               | Chronic systolic (congestive) heart failure  |
| 15023               | Acute on chronic systolic (congestive) heart failure   |
| 15030               | Unspecified diastolic (congestive) heart failure   |
| 15032               | Chronic diastolic (congestive) heart failure   |
| 15042               | Chronic combined systolic (congestive) and diastolic (congestive) heart failure  |
| 1509                | Heart failure, unspecified   |
| 1517                | Cardiomegaly   |
| J9601               | Acute respiratory failure with hypoxia   |
| K5900               | Constipation, unspecified  |
| K5901               | Slow transit constipation  |
| K5909               | Other constipation   |
| L299                | Pruritus, unspecified  |
| L630                | Alopecia (capitis) totalis   |
| L638                | Other alopecia areata  |
| L639                | Alopecia areata, unspecified   |
| L648                | Other androgenic alopecia  |
| L649                | Androgenic alopecia, unspecified   |
| L650                | Telogen effluvium  |
| L658                | Other specified nonscarring hair loss  |
| L659                | Nonscarring hair loss, unspecified   |
| M3210               | Systemic lupus erythematosus, organ, or system involvement unspecified   |
|                     |  |



| Principal Diagnosis | Principal Diagnosis Description  |
|---------------------|--|
| M329                | Systemic lupus erythematosus, unspecified  |
| M349                | Systemic sclerosis, unspecified  |
| M3500               | Sicca syndrome, unspecified  |
| M3501               | Sicca syndrome with keratoconjunctivitis   |
| M351                | Other overlap syndromes  |
| M359                | Systemic involvement of connective tissue, unspecified                                       |
| M6080               | Other myositis, unspecified site   |
| M791                | Myalgia  |
| M7910               | Myalgia, unspecified site  |
| M818                | Other osteoporosis without current pathological fracture                                     |
| N910                | Primary amenorrhea   |
| N911                | Secondary amenorrhea   |
| N912                | Amenorrhea, unspecified  |
| N913                | Primary oligomenorrhea   |
| N914                | Secondary oligomenorrhea   |
| N915                | Oligomenorrhea, unspecified  |
| N920                | Excessive and frequent menstruation with regular cycle                                       |
| N921                | Excessive and frequent menstruation with irregular cycle                                     |
| N926                | Irregular menstruation, unspecified  |
| N944                | Primary dysmenorrhea   |
| N946                | Dysmenorrhea, unspecified  |
| 0905                | Postpartum thyroiditis   |
| 099280              | Endocrine, nutritional, and metabolic diseases complicating pregnancy, unspecified trimester |
| 099281              | Endocrine, nutritional, and metabolic diseases complicating pregnancy, first trimester       |
| 099283              | Endocrine, nutritional, and metabolic diseases complicating pregnancy, third trimester       |
| R000                | Tachycardia, unspecified   |
| R001                | Bradycardia, unspecified   |
| R002                | Palpitations   |
| R0600               | Dyspnea, unspecified   |
| R0609               | Other forms of dyspnea   |
| R0683               | Snoring  |
| R0989               | Other specified symptoms and signs involving the circulatory and respiratory systems         |
| R1310               | Dysphagia, unspecified   |
| R1319               | Other dysphagia  |
| R194                | Change in bowel habit  |
| R197                | Diarrhea, unspecified  |
| R200                | Anesthesia of skin   |



|        | Principal Diagnosis Description                    |
|--------|--|
| R201   | Hypoesthesia of skin                               |
| R202   | Paresthesia of skin                                |
| R208   | Other disturbances of skin sensation               |
| R238   | Other skin changes                                 |
| R251   | Tremor, unspecified                                |
| R252   | Cramp and spasm                                    |
| R253   | Fasciculation                                      |
| R259   | Unspecified abnormal involuntary movements         |
| R270   | Ataxia, unspecified                                |
| R292   | Abnormal reflex                                    |
| R400   | Somnolence   |
| R410   | Disorientation, unspecified                        |
| R413   | Other amnesia                                      |
| R4182  | Altered mental status, unspecified                 |
| R450   | Nervousness  |
| R4702  | Dysphasia  |
| R4781  | Slurred speech                                     |
| R4789  | Other speech disturbances                          |
| R509   | Fever, unspecified                                 |
| R530   | Neoplastic (malignant) related fatigue             |
| R531   | Weakness   |
| R5381  | Other malaise                                      |
| R5382  | Chronic fatigue, unspecified                       |
| R5383  | Other fatigue                                      |
| R600   | Localized edema                                    |
| R609   | Edema, unspecified                                 |
| R61    | Generalized hyperhidrosis                          |
| R630   | Anorexia   |
| R632   | Polyphagia   |
| R634   | Abnormal weight loss                               |
| R635   | Abnormal weight gain                               |
| R6889  | Other general symptoms and signs                   |
| R7303  | Prediabetes  |
| R946   | Abnormal results of thyroid function studies       |
| Z7984  | Long term (current) use of oral hypoglycemic drugs |
| Z79899 | Other long term (current) drug therapy             |
| Z85850 | Personal history of malignant neoplasm of thyroid  |
|        |  |



| Z862  | Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism |
|-------|---|
| Z8639 | Personal history of other endocrine, nutritional and metabolic disease  |
| C73   | Malignant neoplasm of thyroid gland   |
| M797  | Fibromyalgia  |
| Z8632 | Personal history of gestational diabetes  |

# History

| March 1, 2020     | Policy reviewed and approved with changes    |
|-------------------|--|
| December 1, 2020  | Policy reviewed and approved with no changes |
| June 1, 2021      | Policy reviewed and approved with changes    |
| September 1, 2021 | Policy reviewed and approved with changes    |
| September 1, 2022 | Policy reviewed and approved with changes    |
| December 1, 2022  | Policy reviewed and approved with changes    |
|                   |  |



# Durable Medical Equipment

Last Reviewed Date: March 1, 2023 Related Policies: Home Infusion Policy

#### DURABLE MEDICAL EQUIPMENT

Policy Repairs to DME Replacement DME Definitions Referral/Notification/Prior Authorizations Requests Delivery Charges Retrospective Audits Billing/Coding Guidelines CPAP and BiPAP DME Equipment Oxygen and Oxygen Equipment Transcutaneous Electrical Nerve Stimulation (TENS) Medical Supplies HCPCS Modifiers Nebulizers External Infusion Supplies Blood Glucose Monitoring Tracheostomy Care Supplies Ostomy Supplies

# Policy

The DME and Orthotics & Prosthetics Coverage and Purchasing Guidelines apply to all MVP participating DME, Orthotics, prosthetics, and specialty providers only. Physicians, podiatrists, physical therapists, and occupational therapists must refer to the utilization management section of the Provider Resource Manual for DMEPOS information and guidelines.

# Durable Medical Equipment (DME) Rental vs. Purchase

MVP reimburses providers for durable medical equipment (DME) for a limited time period when all required medical necessity guidelines are met. Claims for DME rental must be for the time period the equipment is actually used by the Member, but not to exceed the maximum allowed rental period for the equipment. For authorized items that have a rental price, MVP will calculate the purchase price on either 10- or 13-months rental according to Medicare payment categories. Monthly rentals cannot exceed capped rental period of 10 or 13-months of continuous use. At that time (end of 10 or 13-month rental) ownership of the equipment passes to the member.

Equipment may be purchased or rented at MVP's discretion. Purchase or rental would be specified in the prior authorization approval if the item requires prior authorization. MVP does not authorize used equipment for purchase.

DME rental fees will cover the cost of maintenance, repairs, replacement, supplies and accessories during the rental. Equipment delivery services and set-up, education and training for patient and family, and nursing visits, are not eligible for separate reimbursement.

MVP will only pay for the remainder of the capped consecutive rental period when the rental started under a previous insurer and the item is medically necessary. The DME provider would need to indicate the start date and how many months were rented under the previous insurer when requesting prior authorization for the continued rental through MVP.

Providers are responsible to honor all manufacturers' warranties. MVP will reimburse for one (1) month's rental fee for temporary equipment while patient-owned equipment is being repaired if the repair is going to take longer than one day. Temporary equipment rentals should use HCPCS code K0462. Labor and parts will be reimbursed based on a provider's contracted rate with MVP.

Providers may NOT expect Members to pay "up front" for items or services except for the Members copay, coinsurance, deductibles, or items that are not covered under the Member's benefits.



MVP follows Medicare Payment Guidelines related to Durable Medical Equipment. MVP has implemented exceptions:

- Medicare Payment Guidelines for some DME as indicated in this document.
- MVP follows the Pricing, Data, Analysis and Coding (PDAC) Contractor for assignment of HCPCS codes and product classification: https://www4.palmettogba.com/pdac\_dmecs/
- MVP does not cover spare or back-up equipment. Claims for backup equipment will be denied as not medically necessary.
- This policy relates to the payment of DME items and equipment only; please refer to MVP Medical Policy to review the medical necessity criteria.

Note: Providers looking for MVP's payment policy on Enteral Nutrition Therapy should refer to MVP's Home Infusion Policy.

# Definitions

Durable medical equipment (DME) is defined as:

- An item for external use that can withstand repeated use
- An item that can be used in the home
- · Is reasonable and necessary to sustain a minimum threshold of independent daily living
- Is made primarily to serve a medical purpose
- Is not useful in the absence of illness or injury
- DME includes, but is not limited to, medical supplies, orthotics & prosthetics, custom braces, respiratory equipment, and other qualifying items when acquired from a contracted DME provider

#### Home

For purposes of rental and purchase of DME, a Member's home may be his/her own dwelling, an apartment, a relative's home, a home for the aged, or some other type of institution (such as assisted living facility, or an intermediate care facility for the mentally disabled).

However, an institution may not be considered a Member's home if it:

- Meets at least the basic requirement in the definition of a hospital
- Meets at least the basic requirement in the definition of a skilled nursing facility, i.e., it is primarily engaged in providing to inpatients skilled nursing care and related services for patients who require medical or nursing care, or rehabilitation services.

Thus, if an individual is a patient in an institution or distinct part of an institution which provides the services described above, the individual is not entitled to have separate payment made for rental or purchase of DME. This is because such an institution may not be considered the individual's home.

DMEPOS: Durable Medical Equipment Prosthetic Orthotic Services

**HCPCS Modifiers:** MVP requires the use of the following Medicare modifiers:

#### MVP requires the use of the following Medicare modifiers:

| Code | Description             | Rule  |
|------|-------------------------|---|
| NU   | Purchased/new equipment | Submit with HCPCS DME code to indicate a purchase |
| RR   | Rental use              | Submit with HCPCS DME code to indicate a rental   |



| Code | Description  | Rule   |
|------|--|--|
| RT   | Right Side   | Submit with HCPCS DME procedure code to indicate item ordered for right  |
| LT   | Left Side  | Submit with HCPCS DME procedure code to indicate item ordered for left side.   |
| UE   | Used Equipment   | • MVP does not generally reimburse for used equipment; this may require specific prior approval according to the Prior Authorization List.   |
| AU   | Item furnished in<br>conjunction with a<br>urological, ostomy, or<br>tracheostomy supply | Submit with HCPCS DME procedure codes  |
| AV   | Item furnished in<br>conjunction with a<br>prosthetic device, prosthetic<br>or orthotic  | • Submit with HCPCS DME procedure codes  |
| AW   | Item furnished in<br>conjunction with a surgical<br>dressing                             | Submit with HCPCS DME procedure codes  |
| RA   | Replacement of a DME, orthotic or prosthetic item  | <ul> <li>Use when an item is furnished as a replacement for the same item which has been<br/>lost, stolen or irreparably damaged.</li> </ul> |
| RB   | Replacement of a part of<br>DME furnished as part of a<br>repair                         | • Use to denote the replacement of a part of a DMEPOS item furnished as part of the service of repairing the item.                           |

# **Referral/Notification/Prior Authorization Requests**

Depending on the Member's individual plan and coverage, some items and/or services may or may not be covered. It is imperative that providers verify Member eligibility and benefits before requesting or providing services. To determine if a Member has coverage for specific DME equipment, please call the MVP Customer Care Center.

Please refer to the "DME Prior Authorization Code List" to determine if an authorization is required. Only DMEPOS items and services requiring prior authorization are listed on the "DME Prior Authorization Code List." Note: The "DME Prior Authorization Code List" does not guarantee payment. Log onto mvphealthcare.com or call the MVP Customer Care Center to review the list.

The list is updated periodically and is located on the MVP website in the Provider section, under Reference Library. You can access the document by clicking here.

#### Items and/or services requiring prior authorization:

- Complete the Prior Authorization Request Form (PARF)
- Can be submitted online or faxed to 1-888-452-5947 unless otherwise noted below
- Be sure to include all appropriate and pertinent medical documentation (e.g., office notes, lab and radiology reports) with the completed PARF
- Phone requests will only be taken for urgent care determinations and hospital discharges. Call **1-800-684-9286**
- If MVP is the secondary plan, all medical necessity rules still apply to DME items/services for all MVP products



• If prior authorization is not obtained for the required medically necessary items/services, the Member may not be billed by the provider. MVP does not "backdate" authorizations for items where prior authorization was not obtained.

# **Repairs to DME**

Repairs are covered for medically necessary equipment regardless of who is performing the repair. The repair does not have to be completed by the original provider.

Repair claims must include narrative information itemizing:

- The nature for which the repair was required;
- The actual / anticipated time each repair will take;
- Date of purchase (month/year);
- Product name;
- Make/model;
- Manufacturer's suggested retail price (MSRP) is kept on file and you would bill according to your contract with MVP; and
- For common repairs, MVP follows the allowed units of service published by Medicare. Code K0739 should be billed with one unit of service for each 15 minutes. Suppliers are not paid for travel time, equipment pickup and/or delivery, or postage.

If the repair is urgent and can be completed on site, submit a prior authorization request with the actual number of repair units required within three calendar days and we will approve this for the date that the work was completed. Please make sure you state the actual date the work was completed.

If the repair cannot be completed on site and/or parts are needed, submit a prior authorization request with the anticipated number of repair units and parts and we will review this request.

Code E1399 may be used for any replacement parts without a specific HCPCS code.

### **Replacement DME**

Replacement requests and claims for DME must include the following:

- The description of the owned equipment that is being replaced;
- The HCPCS code of the original piece of equipment;
- The date of purchase of the original piece of equipment;
- Reason for replacement, and;
- New order from physician.

Repair or replacement of durable medical equipment which becomes unusable or nonfunctioning because of individual misuse, abuse, or neglect is not covered under MVP contracts.

Replacement of DME due to manufacturer recall are the responsibility of the manufacturer. Replacement DME only due to changes in technology without improved outcomes are not medically necessary and will result in claims denials.

### **Delivery Charges**

Delivery charges, including shipping and handling, are considered part of the purchase or rental costs. Provider may not bill MVP or the Member for these charges. Provider may not bill MVP or the Member if a wrong item is delivered and needs to be exchanged or returned.



# **Retrospective Audits**

MVP conducts random audits retrospectively to ensure MVP guidelines are being met for medical necessity and claims are processed according to the MVP contract.

# **Billing/Coding Guidelines**

## **CPAP and BiPAP**

| Code                    | Description  | Rule  |
|-------------------------|--|---|
| E0601<br>E0562          | CPAP machine Heated<br>humidifier Includes<br>Auto PAP machines                                  | No prior authorization is required. The initial CPAP rental is for up to three months.<br>In order to continue rental, DME providers must contact Members and confirm<br>compliance via objective reporting from the device and maintain copies of member<br>compliance records per CMS's document retention requirements. Adherence to PAP<br>therapy is defined as use of PAP >4 hours per night on 70% of the nights during a<br>consecutive thirty (30) day period anytime during the first three (3) months of initial<br>usage. Member compliance and DME provider record retention may be subject to<br>retrospective review.  |
|                         |  | Please refer to MVP's Medical Policy to determine medical necessity and rules regarding CPAP machine compliance.  |
|                         |  | • All CPAP machines are a 13-month rental.  |
|                         |  | • All heated humidifiers are a 10-month rental.   |
| E0470<br>E0471<br>E0562 | Respiratory Assist device<br>BiPAP machine Heated<br>humidifier Includes<br>Auto BiPAP machines. | No prior authorization is required. The initial BiPAP rental is for up to three months.<br>In order to continue rental, DME providers must contact Members and confirm<br>compliance via objective reporting from the device and maintain copies of member<br>compliance records per CMS's document retention requirements. Adherence to PAP<br>therapy is defined as use of PAP >4 hours per night on 70% of the nights during a<br>consecutive thirty (30) day period anytime during the first three (3) months of initial<br>usage. Member compliance and DME provider record retention may be subject to<br>retrospective review. |
|                         |  | Please refer to MVP's Medical Policy to determine medical necessity and rules regarding BiPAP machine compliance.   |
|                         |  | • All BiPAP machines are a 13-month rental.   |
|                         |  | • All heated humidifiers are a 10-month rental.   |
| A4604                   | Tubing with integrated heating element   | • 1 per three months  |
| A7027                   | Combo oral/nasal mask  | • 1 per three months  |
| A7028                   | Oral cushion for combo oral nasal mask   | • 2 per one month   |
| A7029                   | Nasal pillows  | • 2 per one month   |
| A7030                   | Full Face Masks  | • 1 per three months  |
| A7031                   | Face mask interface  | • 1 per month   |
| A7032                   | Replacement Cushions   | • 2 per one month   |
| A7033                   | Replacement Pillows  | • 2 per one month   |
|                         |  |   |

#### Durable Equipment Contents Main Contents



| Code  | Description                                       | Rule   |
|-------|---|--|
| A7034 | CPAP Masks  | • 1 per three months                               |
| A7035 | CPAP Headgears                                    | • 1 per six months                                 |
| A7036 | CPAP Chin Straps                                  | • 1 per six months                                 |
| A7037 | CPAP Tubing                                       | • 1 per three months                               |
| A7038 | CPAP Filters                                      | • 2 per one month                                  |
| A7039 | CPAP non-disposable filters                       | • 1 per six months                                 |
| A7046 | Water chamber                                     | • 1 per six months                                 |
| A7047 | Oral interface used with respiratory suction pump | Not covered for Commercial, ASO and Medicaid Plans |

# **DME Equipment**

| Code             | Description                            | Rule   |
|------------------|--|--|
|                  | Continuous<br>Passive Motion<br>Device | • One unit equals one day of rental.   |
| E0935            |  | <ul> <li>Coverage is limited to 21 days following surgery.</li> </ul>  |
|                  |  | • Please refer to MVP Medical Policy for additional information.   |
|                  |  | • MVP will not reimburse for diabetic shoes when billed for more than 2 units (1 pair) within a calendar year (A5500).   |
|                  |  | <ul> <li>MVP will not reimburse for custom molded diabetic shoes with inserts when billed<br/>for more.</li> </ul>   |
| A5500-A5501      | Diabetic Shoes                         | <ul> <li>If bilateral items are provided on the same date of service, bill for both items on<br/>separate claim lines using the RT and LT modifiers i.e. A5500- RT x 1; A5500-LT x1 for<br/>one pair.</li> </ul>   |
|                  |  | <ul> <li>Medicaid Managed Care Plans: allow one pair per year when medical policy criteria<br/>are met.</li> </ul>   |
| A5512-A5513      | Diabetic Shoe Inserts                  | • MVP will not reimburse for diabetic shoe inserts/modifications when billed more than 6 units (3 pair) within a calendar year.  |
|                  |  | <ul> <li>If bilateral items are provided on the same date of service, bill for both items on<br/>separate claim lines using the RT and LT modifiers i.e. A5513- RT x 3; A5513-LT x3 for<br/>three pair.</li> </ul> |
|                  |  | <ul> <li>Medicaid Managed Care Plans: allowed one pair per year when medical policy<br/>criteria are met.</li> </ul>   |
| A5508<br>& A5510 | Diabetic Shoes                         | • MVP does not cover these codes.  |



| Code                          | Description    | Rule   |
|-------------------------------|----------------|--|
| L3000-L3214<br>L3224<br>L3649 | Foot Orthotics | <ul> <li>Foot orthotics are not covered unless the contract specifically states they are<br/>covered. Refer to the specific plan benefit for foot orthotics coverage.</li> </ul>                               |
|                               |                | <ul> <li>If bilateral items are provided on the same date of service, bill for both items on<br/>separate claim lines using the RT and LT modifiers i.e. L3000RT x 1; L3000LT x 1 for<br/>one pair.</li> </ul> |
|                               |                | <ul> <li>Medicaid Managed Care Plans: Follows the New York State Medicaid Program<br/>Durable Medical Equipment, Prosthetics, Orthotics and Supplies Procedures Codes<br/>and Coverage Guidelines</li> </ul>   |
|                               |                | <ul> <li>Foot orthotics are not covered for Medicare Advantage plans.</li> </ul>   |

The right (RT) and/or left (LT) modifiers must be used when billing shoes, inserts, orthotics, or modifications. Claims billed without modifiers RT and/or LT will be rejected as incorrect coding.

| Code  | Description                       | Rule  |
|---|-----------------------------------|---|
| E0424, E0431,<br>E0433, E0434,<br>E0439, E0441,<br>E0442, E0443,<br>E0444, E1390,<br>E1391,<br>E1392,E1405,<br>E1406, K0738 | Oxygen Equipment<br>and Supplies. | <ul> <li>MVP does not follow the Medicare 36 month cap for oxygen.<br/>This applies to all lines of business.</li> <li>MVP allows monthly payment for oxygen equipment as long as medically necessary.</li> </ul>   |
| E0425, E0430,<br>E0435, E0440,<br>E1353, E1355  | Oxygen Equipment<br>and Supplies. | • MVP does not purchase Oxygen or Oxygen Equipment.   |
| E0445   | Oximeters                         | • MVP allows monthly payment. Probes are inclusive during the rental period.  |
| A4606   | Oximeter Replacement<br>Probe     | <ul> <li>Commercial Plans: Covered if contract allows disposable medical supplies and oximeter is owned by Member.</li> <li>Medicaid Managed Care Plans: Included in rental of oximeter device</li> </ul>   |
|   | Ventilators for home use          | • The monthly rental payment for items in this pricing category is all-inclusive meaning there is no separate payment by MVP for any options, accessories or supplies used with a ventilator  |
| E0465, E0466,   |                                   | <ul> <li>All necessary maintenance, servicing, repairs, and replacement are also included<br/>in the monthly rental</li> </ul>  |
| E0403, E0400,<br>E0467  |                                   | <ul> <li>Backup equipment must be distinguished from multiple medically necessary<br/>items which are defined as identical or similar devices, each of which meets a<br/>different medical need for the beneficiary. Although MVP does not pay separately<br/>for backup equipment, MVP will make a separate payment for a second piece of<br/>equipment if it is required to serve a different medical purpose that is determined<br/>by the beneficiary's medical needs.</li> </ul> |

# **Oxygen and Respiratory Equipment**



### **Transcutaneous Electrical Nerve Stimulation (TENS)**

| Code                               | Description   | Rule   |
|------------------------------------|---|--|
| E0720, E0730                       | Transcutaneous electrical<br>nerve stimulation (TENS)<br>Device.    | <ul> <li>MVP allows for the purchase of TENS units.</li> <li>These cannot be prescribed by Chiropractors or therapists; they must be prescribed by a physician.</li> <li>Medicaid Managed Care Plans are not covered for E0720.</li> </ul>   |
| A4556,A4557,<br>A4595 and<br>A4630 | Transcutaneous electrical<br>nerve stimulations (TENS)<br>Supplies. | <ul> <li>Supplies are not covered as a DME benefit. MVP does cover these items if the<br/>Member has the disposable coverage for commercial and ASO products. Please<br/>refer to the Member's benefits to determine if these are covered.</li> <li>Medicaid Managed Care Plans are covered if supplies are medically necessary</li> </ul> |

### **Medical Supplies**

#### **Medicaid Managed Care and HARP plans**

Effective April 1, 2023, providers are no longer able to bill MVP Medicaid Managed Care Plan or HARP members for pharmacy and pharmacy related durable medical equipment and supplies. This includes certain DME, enteral and parenteral nutrition, family planning supplies, medical/surgical supplies, miscellaneous supplies, and hearing aid batteries as designated by the New York State Department of Health. The full list of codes that must be billed to Medicaid Fee-For-Service is located at here (refer to the **OTC and Supply Fee Schedule**).

Providers should bill these codes directly to New York State Medicaid Fee-For-Service using the Medicaid member client identification number (CIN) beginning April 1, 2023. Claims submitted directly to MVP for items that are carved out to Fee-For-Service will be denied as not a Covered Benefit.

#### **Commercial, Medicare and ASO plans**

Required medical/dressing supplies can be obtained by the Member from an MVP-contracted DME provider with a physician's prescription. MVP will not reimburse for disposable medical and surgical supplies unless Member's contract covers disposable medical supplies. Providers should check the Member's benefits to determine if these are covered under their plan. MVP Medicare products have disposable medical supply benefits and do not require a rider for coverage. DME providers need to call MVP to determine if item is considered a disposable medical supply.

| Code                   | Description  | Rule  |
|------------------------|--|---|
| Various<br>HCPCS codes | Disposable Supplies;<br>Medical and Surgical<br>Supplies | <ul> <li>Commercial Products: MVP will not reimburse for these supplies unless the contract<br/>allows disposable medical supplies coverage.</li> </ul> |
|                        |  | <ul> <li>Providers should check the Member's benefits to determine if this is covered under<br/>their plan.</li> </ul>                                  |
|                        |  | • MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service   |
|                        |  | <ul> <li>To determine if an item is considered disposable medical and surgical supplies,<br/>please call the MVP Customer Care Center.</li> </ul>       |



# Nebulizers

| Code  | Description | Rule   |
|---|-------------|--|
|   | Nebulizers  | • MVP allows purchase or rental of a Nebulizer.  |
|   |             | • One will be covered (either 1 standard or 1 portable, but not both).   |
| E0570-E0572,<br>E0574-E0575,<br>E0580, and<br>E0585 |             | <ul> <li>The nebulizer and supplies may also be obtained from an MVP<br/>participating pharmacy.</li> </ul>  |
|   |             | <ul> <li>Nebulizer Kits (disposable tubing, mouthpiece and cup) will be covered to a<br/>maximum of 2 per year (1 every 6 months).</li> </ul>        |
|   |             | <ul> <li>Nebulizer solutions, when used in conjunction with a covered nebulizer must be<br/>billed through the pharmacy benefits manager.</li> </ul> |

# **External Infusion Supplies**

| Code          | Description                           | Rule   |
|---------------|---------------------------------------|--|
| E0784         | Insulin Pump                          | • MVP covers the purchase of this item according to the provider's contract.   |
|               |                                       | <ul> <li>Providers should check the Member's benefits to determine how these are covered<br/>under their individual plan.</li> </ul>   |
|               |                                       | Refer to MVP's Medical Policies for additional information.  |
|               | External Ambulatory                   | • MVP covers the purchase of this item according to the provider's contract.   |
|               |                                       | <ul> <li>Providers should check the Member's benefits to determine how these are covered<br/>under their individual plan.</li> </ul>   |
| A9274         | Delivery System (Disposable           | • Allowed up to 30 per month; up to 90 units once every 90 days.   |
|               | Insulin Pump)                         | • There is a 5 day grace period allowed for shipping/billing on the 85th day.  |
|               |                                       | <ul> <li>This item is not covered under Medicare Part B, coverage may be available under<br/>Medicare Part D pharmacy benefits.</li> </ul>   |
| A4230         | Infusion Set – Cannula Type           | • Covered as diabetic management supplies and can be billed to MVP.  |
|               |                                       | • These supplies may also be obtained from an MVP participating pharmacy.  |
| A4231         | Infusion Set – Needle Type            | • Allowed up to 20 per month; up to 60 units once every 90 days  |
|               | Syringe/reservoirs                    | • There is a 5 day grace period allowed for shipping/billing on the 85th day.  |
| A4232         |                                       | <ul> <li>Vermont Exchange (on and off) Products: Diabetic Supplies are covered under the<br/>member pharmacy benefit and must be submitted through an MVP pharmacy<br/>carrier.</li> </ul> |
|               |                                       | MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service  |
| A4224, A4225  | Supplies for insulin pump             | • Covered as diabetic management supplies but all inclusive and includes cannula and all supplies for insulin pump.  |
| K0552, A4221, | Supplies for External<br>Infusion Pum | Invalid for submission for all MVP plans.  |
| A4222         |                                       | MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service  |



# **Blood Glucose Monitoring**

| Review rules to determine if billed through MVP Medical or Pharma  | ncy Ronotite |
|--|--------------|
| Review fulles to determine if bitted through Myr Medical of Fhamme | acy Denenit. |

| Code               | Description   | Rule   |
|--------------------|---|--|
| E0607              | Blood Glucose Monitor   | <ul> <li>MVP will not reimburse DME providers for Blood Glucose Monitoring machines</li> <li>Blood Glucose Monitors must be obtained from an MVP participating pharmacy or<br/>through one of the preferred monitor free access program</li> </ul>   |
| A4259 and<br>A4253 | Blood Glucose testing supplies.   | <ul> <li>Blood Glucose Supplies must be obtained from an MVP participating pharmacy for<br/>all lines of business.</li> <li>Prior authorization is required for non- preferred test strips</li> </ul>  |
| A4238              | Sensor; for use with<br>Continuous Glucose<br>Monitoring System   | <ul> <li>1 unit = 1 month supply</li> <li>3 month supply = 3 unit of service</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> <li>Covered benefit for Commercial, ASO Products, and Medicare plans</li> </ul>   |
| E2102              | Receiver (monitor) for use<br>with adjunctive Continuous<br>Glucose Monitoring System                     | <ul> <li>Only one (1) Receiver allowed at one time; no duplicates or back-up allowed</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> <li>Commercial, Medicare, ASO covered under the Member diabetic benefit and can be billed to MVP through the medical benefit. Refer to MVP Medical Policy for coverage information</li> </ul> |
| A4239              | Supply allowance for<br>non-adjunctive glucose<br>monitor (CGM), includes all<br>supplies and accessories | <ul> <li>1 unit = 1 month supply</li> <li>3 month supply = 3 unit of service</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> <li>Covered benefit for Commercial, ASO Products, and Medicare plans</li> </ul>   |
| E2103              | Receiver (monitor) for<br>use with non-adjunctive<br>continuous glucose monitor<br>system                 | <ul> <li>Only one (1) Receiver allowed at one time; no duplicates or back-up allowed</li> <li>Covered benefit for Commercial, ASO Products, and Medicare plans</li> <li>Must meet FDA approval as Therapeutic CGMS. See MVP Medical Policy for details</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> </ul>                       |

# Tracheostomy Care Supplies

| Code   | Description                              | Rule  |
|--|--|---|
| A7520-A7522  | Tracheostomy/<br>Laryngectomy Tube       | • MVP does cover this code under the Member's DME benefit   |
| L8501  | Tracheostomy Speaking<br>Valve           | • MVP does cover this code under the Member's DME benefit   |
| A4625 and<br>A4629Tracheostomy Care Kit• MVP does cover this code if the Member's contract covers disposable<br>supplies |  | • MVP does cover this code if the Member's contract covers disposable medical supplies  |
| A4623  | Tracheostomy disposable<br>inner cannula | <ul> <li>MVP does cover this item if the Member's contract covers disposable<br/>medical supplies</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> </ul> |



| Code  | Description                               | Rule  |
|-------|---|---|
| A4626 | Tracheostomy cleaning<br>brush            | <ul> <li>MVP does cover this item if the Member's contract covers disposable<br/>medical supplies; cannot be billed at the same time as A4625 and A4629.</li> </ul>                             |
| A4625 | Tracheal Suction Catheter<br>(not closed) | <ul> <li>MVP does cover this item if the Member's contract covers disposable<br/>medical supplies</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> </ul> |
| A7523 | Tracheostomy Shower<br>Protector          | <ul> <li>MVP does cover this item if the Member's contract covers disposable<br/>medical supplies</li> <li>MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service</li> </ul> |
| A7524 | Tracheostomy Plug/ Button                 | <ul> <li>MVP does cover this item if the Member's contract covers disposable<br/>medical supplies</li> </ul>  |

### **Ostomy Supplies**

| Code                                      | Description   | Rule   |
|---|---------------|--|
| A4361-A4435<br>A5051-A5093<br>A5119-A5200 | Ostomy codes. | <ul> <li>MVP does reimburse for these items under the Member's DME benefits.</li> <li>These items do not require the disposable coverage or rider</li> </ul> |
|   |               | <ul> <li>MVP follows the Medicare guidelines for quantity limits</li> </ul>  |
|   |               | <ul> <li>May be provided from either MVP participating DME or pharmacy providers</li> </ul>  |
|   |               | MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service  |

Over-limits note: If physician prescription is for more quantity than Medicare guidelines allow for supplies, coverage is allowed if the physician prescription indicates the amount required per month. There is no prior authorization for when Medicare quantity limits are exceeded

Medicare Ostomy LCD link: https://med.noridianmedicare.com/documents/2230703/7218263/Ostomy+Supplies+LCD+and+PA/

### **Incontinence Supplies**

• MMC and HARP: Providers must bill New York State Medicaid Fee-for-Service

The following Incontinence supplies are not reimbursed/not covered for Commercial, ASO and Medicare plans: A4335, A4554, T4521, T4522, T4523, T4524, T4529, T4530, T4533, T4535, T4537, T4539, T4540, T4543.

### **Prosthetics**

The following items are included in the reimbursement for a prosthesis and, therefore, are not separately billable to MVP Health Care under the prosthetic benefit: evaluation of the residual limb and gait, fitting of the prosthesis, cost of base component parts and labor contained in HCPCS base codes, repairs due to normal wear or tear within 90 days of delivery, adjustments of the prosthesis or the prosthetic component made when fitting the prosthesis or component and for 90 days from the date of delivery when the adjustments are not necessitated by changes in the residual limb or the Member's functional abilities.

Repairs to a prosthesis are covered when necessary to make the prosthesis functional.

Code L7510 is used to bill for any "minor" materials (i.e., those without specific HCPCS codes) used to achieve the adjustment and/or repair.



Code L7520 is used to bill for labor associated with adjustments and repairs that either do not involve replacement parts or that involve replacement parts billed with code L7510. Code L7520 must not be billed for labor time involved in the replacement of parts that are billed with a specific HCPCS code. Labor is included in the allowance for those codes.

Except for items described by specific HCPCS codes, there should be no separate billing and there is no separate payment for a component or feature of a microprocessor-controlled knee or foot, including but not limited to real time gait analysis, continuous gait assessment, or electronically controlled static stance regulator.

Payment for a prosthesis is included in the payment to a hospital if:

- The prosthesis is provided to a Member during an inpatient hospital stay prior to the day of discharge
- The Member uses the prosthesis for reasonable and necessary inpatient treatment or rehabilitation

# **Orthotic and Scoliosis Bracing**

There is no separate payment if CAD-CAM or 3-D printing technology is used to fabricate an orthosis. Reimbursement is included in the allowance of the codes for custom fabricated orthoses. Fabrication of an orthosis using CAD/CAM or similar technology without the creation of a positive model with minimal self-adjustment at delivery is considered as off-the-shelf (OTS).

There is no separate allowance for the following (included in orthosis):

- Additional fabrication time of an orthosis
- Consult and evaluation
- Digital scanning and casting
- Fabricating an orthosis
- Fitting of orthosis
- Follow up appointments
- Model modification
- Use of CAD-CAM technology
- X-Ray evaluation

The use of HCPCS code L0999 (addition to spinal orthosis, not otherwise specified) or L1499 (spinal orthosis, not otherwise specified) must not be used to bill for any features or functions included in the base code nor should it be used when a specific L-code exists. Use of these two codes in these circumstances is considered incorrect coding (unbundling).

HCPCS codes L1499 and L0999 should not be used as base codes for a scoliosis orthosis.

There are 5 base Healthcare Common Procedure Codes (HCPCS) available to fully describe scoliosis braces. The Rigo Cheneau (WCR) (NYRC) brace, the custom Boston scoliosis brace, the Charleston brace, and the Providence brace are properly described by Healthcare Common Procedure Code System (HCPCS) code L1300.

Three HCPCS codes: L1005, L1300, and L1310 are all inclusive and are not billed with addition codes. The use of addition codes with these three codes will be considered incorrect coding (unbundling).

### **History**

| April 1, 2019     | Policy approved                           |
|-------------------|---|
| March 1, 2021     | Policy reviewed and approved with changes |
| June 1, 2022      | Policy reviewed and approved with changes |
| September 1, 2022 | Policy reviewed and approved with changes |
| March 1, 2023     | Policy reviewed and approved with changes |



# Elective Delivery for Providers and Facilities

Last Reviewed Date: June 1, 2022

# ELECTIVE DELIVERY FOR PROVIDERS AND FACILITIES Policy Notification/Prior Authorization Requests Billing/Coding Guidelines For Provider Claims Fee-for-Service Procedure Codes Requiring a Modifier For Facility Claims Fee-For-Service ICD-10 Procedure Codes Requiring a Condition Code when a C-Section or Induction of Labor Occurs

References

History

# Policy

MVP will reduce payment for elective C-Section deliveries and induction of labor under 39 weeks gestation without a documented acceptable medical indication. MVP reimburses 100% for C-sections or inductions performed at less than 39 weeks gestation for medical necessity. MVP reimburses 25% for C-sections or inductions performed at less than 39 weeks gestation electively.

All obstetric deliveries will require the use of a modifier or condition code to identify the gestational age of the fetus as of the date of delivery. Failure to provide a modifier/condition code with the obstetric delivery procedure codes will result in the claim being denied.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

### **For Provider Claims**

All obstetrical deliveries require the use of a modifier (U7, U8, or U9). Failure to include a U7, U8, or U9 modifier, as appropriate, on a claim will result in denial of the claim.

| U7 – Delivery less than 39 weeks for medical necessity | Full payment           |
|--|------------------------|
| U8 – Delivery less than 39 weeks electively            | <b>Reduced payment</b> |
| U9 – Delivery 39 weeks or greater                      | Full payment           |

### Fee-for-Service Procedure Codes Requiring a Modifier

| <b>CPT Procedure Codes</b> | Description  |
|----------------------------|--|
| 59400                      | Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy, and/or forceps), and postpartum care |
| 59409                      | Vaginal delivery only (with or without episiotomy and/or forceps)  |
| 59410                      | Vaginal delivery (with or without episiotomy and/or forceps); including postpartum care  |



| CPT Procedure Codes | Description  |
|---------------------|--|
| 59510               | Routine obstetric care including antepartum care, cesarean delivery, and postpartum care   |
| 59514               | Cesarean delivery only   |
| 59515               | Cesarean delivery; including postpartum care   |
| 59610               | Routine obstetric care including antepartum care, vaginal delivery (with or without episiotomy and/or forceps) and postpartum care, after previous cesarean delivery |
| 59612               | Vaginal delivery, after previous cesarean delivery (with or without episiotomy and/or forceps)   |
| 59614               | Vaginal delivery, after previous cesarean delivery (with or without episiotomy and/or forceps); including postpartum care  |
| 59618               | Routine obstetric care including antepartum care, cesarean delivery, and postpartum care, following attempted vaginal delivery after previous cesarean delivery      |
| 59620               | Cesarean delivery only, following attempted vaginal delivery after previous cesarean delivery  |
| 59622               | Cesarean delivery, following attempted vaginal delivery after previous cesarean delivery   |

#### CPT Procedure Codes Description

#### **For Facility Claims**

**All C-Sections and inductions of labor** require the use of a condition code (81, 82, or 83). For all spontaneous labor under 39 weeks gestation resulting in a C-Section delivery, please report condition code 81.

| Condition code 81 – C-sections or inductions performed at less than 39<br>weeks gestation for medical necessity. | Full payment    |
|--|-----------------|
| Condition code 82 – C-sections or inductions performed at less than 39<br>weeks gestation electively.            | Reduced payment |
| Condition code 83 – C-sections or inductions performed at 39 weeks gestation or greater.                         | Full payment    |

**Note:** For those facilities submitting a Graduate Medical Education (GME) claim to fee-for-service Medicaid, please follow the billing instructions stated under fee-for-service inpatient facility billing guidelines

# Fee-For-Service ICD-10 Procedure Codes Requiring a Condition Code when a C-Section or Induction of Labor Occurs

Note: Augmentation of labor does not require a condition code.

| <b>CPT Procedure Codes</b> | Description  |
|----------------------------|--|
| 10900ZC                    | Drainage of amniotic fluid, therapeutic from products of conception, open approach |
| 10903ZC                    | Drainage of amniotic fluid, therapeutic from products of conception, open approach |



| <b>CPT Procedure Codes</b> | Description   |  |
|----------------------------|---|--|
| 10904ZC                    | Drainage of amniotic fluid, therapeutic from products of conception, open approach                                |  |
| 10907ZC                    | Drainage of amniotic fluid, therapeutic, from products of conception, via natural or artificial opening           |  |
| 10908ZC                    | Drainage of amniotic fluid, therapeutic from products of conception, via natural or artificial opening endoscopic |  |
| 0U7C7ZZ                    | Dilation of cervix, via natural or artificial opening   |  |
| 3E030VJ                    | Introduction of other hormone into peripheral vein, open approach   |  |
| 3E033VJ                    | Introduction of other hormone into peripheral vein, percutaneous approach   |  |
| 3E0P7VZ                    | Introduction of hormone into female reproductive, via natural or artificial opening                               |  |
| 3E0P7GC                    | Introduction of other therapeutic substance into female reproductive, via natural or artificial opening           |  |
| 10D00Z0                    | Extraction of products of conception, classical open approach   |  |
| 10D00Z1                    | Extraction of products of conception, low cervical, open approach   |  |
| 10D00Z2                    | Extraction of products of conception, extraperitoneal, open approach  |  |

Practitioners and facilities are responsible for ensuring that the codes (and modifiers when applicable) submitted for reimbursement accurately reflect the diagnosis and procedure(s) that were reported.

#### References

New York State Medical Updates: health.ny.gov/health\_care/medicaid/program/update/2015/2015-04.htm health.ny.gov/health\_care/medicaid/program/update/2016/2016-05.htm health.ny.gov/health\_care/medicaid/program/update/2017/2017-06.htm#delivery New York State Medicaid Obstetrical Deliveries Prior to 39 Weeks Gestation https://www.emedny.org/ProviderManuals/communications/OBSTETRICAL\_DELIVERIES\_PRIOR\_TO\_39\_WEEKS\_ GESTATION.pdf

ICD-10 Coding Changes

https://www.emedny.org/ProviderManuals/Physician/PDFS/ICD-10\_Medicaid\_Update\_2.pdf

American College of Obstetrics & Gynecology- Committee Opinion: Non-Medical Indicated Early-Term Deliveries. VOL. 121, NO. 4, APRIL 2013

### History

| December 1, 2018 | Policy approved                              |
|------------------|--|
| December 1, 2019 | Policy approved with no changes              |
| March 1, 2021    | Policy reviewed and approved with no changes |
| June 1, 2022     | Policy reviewed and approved with no changes |



## Emergency Department -Physician

Last Reviewed Date: December 1, 2022

## EMERGENCY DEPARTMENT - PHYSICIAN Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Resources

Policy

All Emergency Department (ED) services must be coded to the appropriate level of service which supports the extent of review required to adequately evaluate and treat patient problem(s) upon presentation to the ED. Physicians should follow the CPT code book to determine complexity requirements for services provided in the Emergency Room. The following billing guidelines are used as a guide for physicians seeing MVP members in the emergency room. These guidelines do not apply to the ER facility charges or to physicians who are employed by the emergency room. MVP requires all professional charges be submitted on a CMS1500 claims form.

History

### Definitions

**In New York**, a medical emergency is defined as a medical or behavioral condition, when onset is sudden, that manifests itself by symptoms of sufficient severity, including severe pain, that a prudent layperson, possessing an average knowledge of medicine and health, could reasonably expect the absence of immediate medical attention to result in:

- A. Placing the health of the afflicted person in serious jeopardy, or in the case of a behavioral condition, placing the health of the person or others in serious jeopardy;
- B. Serious impairment to the person's bodily functions;
- C. Serious dysfunction of any bodily organ or part of the person; or
- D. Serious disfigurement of the person.

**In Vermont**, emergency care is defined as medically necessary covered services to evaluate and treat an emergency medical condition. Further, an "emergency medical condition" means the sudden and, at the time, unexpected onset of an illness or medical condition that manifests itself by symptoms of sufficient severity, including severe pain, that the absence of immediate medical attention could reasonably be expected by the prudent layperson, who possesses an average knowledge of health and medicine, to result in:

- A. Placing the member's physical or mental health in serious jeopardy; or
- B. Serious impairment to bodily functions; or
- C. Serious dysfunction of any bodily organ or part.

#### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.



## Billing/Coding Guidelines

## **Evaluation and Management**

| Code  | Description                             | Rule   |
|-------|---|--|
| 99281 |   | Emergency department visit for the evaluation and management of a patient, which requires these three key components:  |
|       |   | <ul> <li>a problem-focused history;</li> </ul>   |
|       | Evaluation and<br>Management within     | <ul> <li>a problem-focused examination; and</li> </ul>   |
|       | the Emergency Room                      | <ul> <li>straightforward medical decision making.</li> </ul>   |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are self-limited or minor.   |
|       |   | Emergency department visit for the evaluation and management of a patient, which requires these three key components:  |
|       |   | <ul> <li>an expanded problem focused history;</li> </ul>   |
| 00202 | Evaluation and                          | <ul> <li>an expanded problem focused examination; and</li> </ul>   |
| 99282 | Management within<br>the Emergency Room | <ul> <li>medical decision making of low complexity.</li> </ul>   |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity.   |
|       |   | Emergency department visit for the evaluation and management of a patient, which requires these three key components:  |
|       |   | <ul> <li>an expanded problem focused history;</li> </ul>   |
| 99283 | Evaluation and                          | <ul> <li>an expanded problem focused examination; and</li> </ul>   |
| 99283 | Management within<br>the Emergency Room | <ul> <li>medical decision making of moderate complexity.</li> </ul>  |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate severity.  |
|       |   | Emergency department visit for the evaluation and management of a patient, which requires these three key components:  |
|       |   | a detailed history;  |
|       | Evolution and                           | <ul> <li>a detailed examination; and</li> </ul>  |
| 99284 | Evaluation and<br>Management within     | <ul> <li>medical decision making of moderate complexity.</li> </ul>  |
| 33204 | the Emergency Room                      | Counseling and/or coordination of care with other providers or agencies are<br>provided consistent with the nature of the problem(s) and the patient's and/or<br>family's needs. Usually, the presenting problem(s) are of high severity and require<br>urgent evaluation by the physician but do not pose an immediate significant threat<br>to life or physiologic function. |
| 99285 |   | Emergency department visit for the evaluation and management of a patient, which requires these three key components within the constraints imposed by the urgency of the patient's clinical condition and/or mental status:   |
|       |   | <ul> <li>a comprehensive history;</li> </ul>   |
|       | Evaluation and<br>Management within     | <ul> <li>a comprehensive examination; and</li> </ul>   |
|       | the Emergency Room                      | <ul> <li>medical decision making of high complexity.</li> </ul>  |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of high severity and pose an immediate significant threat to life or physiologic function.   |



#### **Documentation of 99285 ED Services**

All patient presenting problems must medically necessitate the extent of the history, exam and/or discussion noted.

The overall medical decision making will be the overarching criterion in determining if a visit is coded appropriately.

The volume of documentation alone will not be the sole determinant of whether a level of service is warranted.

**Note:** In the event of an urgent visit whereby you are unable to secure the required elements of documentation to support a complete, comprehensive HPI and Exam as required by the CMS 1995/1997 documentation guidelines, MVP recommends that a statement be provided as follows:

"Because of [insert reason] I was unable to secure a comprehensive HPI and/or perform a comprehensive examination today."

Possible conditions could be, but are not limited to: dementia, pt is unconscious, pt is poor historian. Language barriers are NOT considered a reason for not meeting documentation requirements.

#### **E&M and Critical Care CPT Codes**

When critical care and ED services are provided on the same date, if there is no break in services and a patient's condition changes, bill the critical care service. If the documentation shows a break in services and a change in the patient's condition, both the initial hospital visit, and the critical care services may be billed.

When billing an E&M visit and Critical Care service on the same claim please review MVP's Modifier Payment Policies regarding rules around Modifier 25.

#### **Observation Codes**

Patients who stay longer than 6 hours in the ED for observation and/or monitoring will be considered observation patients and should be billed using the observation CPT codes NOT the ED CPT codes.

| Code  | Description   | Rule  |
|-------|---|---|
| 99217 | Observation care discharge<br>day management  | This code is to be utilized by the physician to report all services provided to a patient on discharge from "observation status" if the discharge is on other than the initial date of "observation status." To report services to a patient designated as "observation status" or "inpatient status" and discharged on the same date, use the codes for Observation or Inpatient Care Services [including Admission and Discharge Services, 99234-99236 as appropriate]. |
|       |   | This code requires these three key components:  |
|       |   | <ul> <li>detailed or comprehensive history;</li> </ul>  |
|       | Initial observation care per  | <ul> <li>a detailed or comprehensive examination; and</li> </ul>  |
| 99218 | day for the evaluation and management of a patient                                      | <ul> <li>medical decision making that is straightforward or of low complexity.</li> </ul>   |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to "observation status" are of low severity.   |
|       | Initial observation care, per<br>day, for the evaluation and<br>management of a patient | This code requires these three key components:  |
|       |   | <ul> <li>a comprehensive history;</li> </ul>  |
|       |   | <ul> <li>a comprehensive examination; and</li> </ul>  |
| 99219 |   | <ul> <li>medical decision making of moderate complexity.</li> </ul>   |
|       |   | Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to "observation status" are of moderate severity.  |



| Code  | Description  | Rule   |
|-------|--|--|
| 99220 | Initial observation care, per<br>day, for the evaluation and<br>management of a patient  | <ul> <li>This code requires these three key components: <ul> <li>a comprehensive history;</li> <li>a comprehensive examination; and</li> <li>medical decision making of high complexity.</li> </ul> </li> <li>Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the problem(s) requiring admission to "observation status" are of high severity.</li> </ul>                                    |
| 99234 | Observation or inpatient<br>hospital care, for the<br>evaluation and management<br>of a patient including<br>admission and discharge on<br>the same date | <ul> <li>This code requires these three key components: <ul> <li>a detailed or comprehensive history;</li> <li>a detailed or comprehensive examination; and</li> <li>medical decision making that is straightforward or of low complexity.</li> </ul> </li> <li>Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually the presenting problem(s) requiring admission are of low severity.</li> </ul> |
| 99235 | Observation or inpatient<br>hospital care, for the<br>evaluation and management<br>of a patient including<br>admission and discharge on<br>the same date | <ul> <li>This code requires these three key components: <ul> <li>comprehensive history;</li> <li>a comprehensive examination; and</li> <li>medical decision making of moderate complexity.</li> </ul> </li> <li>Counseling and/or coordination of care with other providers or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs.</li> </ul>  |

## Infusion/Injection Services

| Code        | Description   | Rule   |
|-------------|---|--|
| 96360       | Hydration Injections  | MVP does not reimburse for these services when administered in the emergency room. This code will deny as global to the emergency room E&M code. |
| 96365-96379 | Therapeutic, Prophylactic,<br>and Diagnostic Injections/<br>Infusions | MVP does not reimburse for these services when administered in the emergency room. This code will deny as global to the emergency room E&M code. |

### EKGs

| Code  | Description   | Rule   |
|-------|---|--|
| 93040 | Rhythm ECG, 1-3 leads; with interpretation and report                       | Emergency Room physicians will not be reimbursed for EKG interpretation. |
| 93041 | Rhythm ECG, 1-3 leads;<br>tracing only without<br>interpretation and report | Emergency Room physicians will not be reimbursed for EKG interpretation. |
| 93042 | Rhythm ECG, 1-3 leads;<br>interpretation and report<br>only                 | Emergency Room physicians will not be reimbursed for EKG interpretation. |



## Resources

CMS IOM Publication 100-04, Chapter 12, Section 30.6.11 and 30.6.12.H

## History

| June 1, 2019      | Policy approved                              |
|-------------------|--|
| June 1, 2020      | Policy reviewed and approved with no changes |
| September 1, 2021 | Policy reviewed and approved with changes    |
| December 1, 2022  | Policy reviewed and approved with no changes |



# EyeMed Payment Policy

Last Reviewed Date - December 1, 2022

#### EYEMED PAYMENT POLICY

Policy Notifications/Prior Authorization Request Billing/Coding Guidelines History

## Policy

MVP partner's with EyeMed to cover routine eye care for specific MVP Members. MVP will continue to cover claims for medical eye care. To determine what is covered by EyeMed or MVP, please review the CPT codes and Diagnosis codes that will be billed to each. To determine if a Members' plan utilizes the EyeMed network for routine vision care, review the Member's ID card for the EyeMed emblem, or review the Members benefits on the MVP online benefits display.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required, and the Benefit Interpretation Manual for MVP's clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## **Billing/Coding Guidelines**

#### **Routine Only Eye Care**

When the following CPT codes are billed, claims should be sent to EyeMed:

| Vision CPT/HCPCS<br>Codes | Description  |
|---------------------------|--|
| 92310                     | Fitting contact lens   |
| 92352                     | Fitting of spectacle prosthesis for aphakia                                    |
| 92353                     | Fitting of spectacle prosthesis for multifocal                                 |
| 92354                     | Fitting of spectacle mounted low vision aid                                    |
| 92355                     | Fitting of spectacle mounted low vision aid                                    |
| S0500                     | Disposable contact lens, per lens  |
| S0504                     | Single vision prescription lens (safety, athletic, or sunglass), per lens      |
| S0506                     | Bifocal Cal vision prescription lens (safety, athletic, or sunglass), per lens |
| S0508                     | Trifocal vision prescription lens (safety, athletic, or sunglass), per lens    |
| S0510                     | Non-prescription lens (safety, athletic, or sunglass), per lens                |
| S0512                     | Daily wear specialty contact lens, per lens                                    |
| S0514                     | Color contact lens, per lens   |



| Vision CPT/HCPCS<br>Codes | Description  |
|---------------------------|--|
| S0580                     | Polycarbonate lens (list this code in addition to the basic code for the lens)   |
| S0581                     | Nonstandard lens (list this code in addition to the basic code for the lens)     |
| V2025                     | Eyeglasses deluxe frames   |
| V2702                     | Deluxe lens feature  |
| V2710                     | Glass/plastic slab off prism   |
| V2715                     | Prism lens   |
| V2718                     | Fresnell prism press-on lens   |
| V2730                     | Special base curve   |
| V2756                     | Eye glass case   |
| V2760                     | Scratch resistant coating  |
| V2761                     | Mirror coating, any type, solid, gradient, or equal, any lens material, per lens |
| V2770                     | Occluder lens  |
| V2781                     | Progressive lens per lens  |
| V2786                     | Specialty occupational multifocal lens, per lens                                 |
| V2797                     | Vision supply, accessory and/or service component of another HCPCS vision code   |
| V2799                     | Miscellaneous vision service   |

### Medical Only Eye Care

When the following CPT codes are billed for medical eye care, claims would be sent directly to MVP:

| Vision CPT/HCPCS<br>Codes | Description   |
|---------------------------|---|
| 92018                     | Eye exam/evaluation, under general anesthesia; complete   |
| 92019                     | Eye exam/ evaluation, under general anesthesia; limited   |
| 92020                     | Gonioscopy w/medical dx evaluation  |
| 92025                     | Corneal topography  |
| 92060                     | Sensorimotor examination with multiple measurements of ocular deviation (eg, restrictive or paretic muscle with diplopia) with interpretation and report (separate procedure) |
| 92065                     | Orthoptic and/or preoptic training  |
| 92071                     | Fitting of contact lens for treatment of ocular surface disease   |



## Vision CPT/HCPCS Codes

| Vision CPT/HCPCS<br>Codes | Description  |
|---------------------------|--|
| 92081                     | Visual field/medical exam; limited; unilateral or bilateral  |
| 92082                     | Exam visual field intermediate   |
| 92083                     | Visual field/medical exam; extended  |
| 92100                     | Serial tonometry/medical exam; Multiple measurements   |
| 92132                     | Scanning computerized ophthalmic diagnostic imaging, anterior segment, with unilateral, or bilateral, with interpretation and report   |
| 92133                     | Scanning computerized ophthalmic diagnostic imaging, posterior segment, with unilateral, or bilateral, with interpretation and report  |
| 92134                     | Scanning computerized ophthalmic diagnostic imaging, posterior segment, with unilateral, or bilateral, with interpretation and report  |
| 92136                     | Ophthalmic biometry by partial coherence interferometry with intraocular lens power calculation  |
| 92145                     | Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report  |
| 92201                     | Ophthalmoscopy, extended; with retinal drawing and scleral depression of peripheral retinal disease (eg, for retinal tear, retinal detachment, retinal tumor) with interpretation  |
| 92202                     | Ophthalmoscopy, extended; with drawing of optic nerve or macula (eg, for glaucoma, macular pathology, tumor) with unilateral, or bilateral, with interpretation and report lateral |
| 92227                     | Imaging of retina for detection or monitoring of disease   |
| 92228                     | Remote imaging for monitoring and management of active retinal disease (eg, diabetic retinopathy) with physician review  |
| 92230                     | Ophthalmoscopy; fluorescein angioscopy   |
| 92235                     | Ophthalmoscopy, with DX eval; with multiframe procedures   |
| 92240                     | Indocyanine-green angiography with interpretation and report   |
| 92242                     | Fluorescein angiography and indocyanine-green angiography (includes multiframe imaging) performed at the same patient encounter with interpretation and report                     |
| 92250                     | Ophthalmoscopy; with fundus photography  |
| 92260                     | Ophthalmoscpy; with ophthalmodynamometer   |
| 92265                     | Oculoelectromyogrphy,1/mre musc/eye  |
| 92270                     | Electroretinography (ERG) with DX evaluation   |
| 92273                     | Electroretinography (ERG), with interpretation and report; full field -ie, fferg, flash erg, ganzfeld erg  |
| 92274                     | Electroretinography (ERG) with interpretation and report; multifocal -mferg  |
| 92283                     | Color vision exam, extended  |



| Vision CPT/HCPCS<br>Codes | Description   |  |
|---------------------------|---|--|
| 92284                     | Dark adaptation exam w/medical DX evaluation  |  |
| 92285                     | External Ocular photography, with DX evaluation   |  |
| 92286                     | Anterior seg. Photography; with DX evaluation; spec. Endo   |  |
| 92287                     | Anterior seg. Photography; fluorscn angio   |  |
| 92313                     | Prescribe/fit contact lens; corneoscleral   |  |
| 92314                     | Prescribe/fit contact lens, tech; cor, 2 eyes   |  |
| 92315                     | Prescribe/fit con. lens, tech; aphak,1eye   |  |
| 92316                     | Prescribe/fit con. lens, tech; corneal-apha   |  |
| 92317                     | Prescribe/fit contact lens, tech; corneoscl   |  |
| 92325                     | Modification of contact lens  |  |
| 92358                     | Prosth.service for aphakia, temporary   |  |
| 92371                     | Repr/refit spect; prosth. for aphakia   |  |
| 92499                     | Unlisted ophthalmological service or pro  |  |
| C1841                     | Retinal prosthesis, includes all internal and external components   |  |
| V2623                     | Plastic eye prosth custom   |  |
| V2624                     | Polishing artificial eye  |  |
| V2625                     | Enlargement of eye prosthesis   |  |
| V2626                     | Reduction of eye prosthesis   |  |
| V2627                     | Scleral cover shell   |  |
| V2628                     | Fabrication & fitting   |  |
| V2629                     | Prosthetic eye other type   |  |
| V2785                     | Corneal tissue processing   |  |
| V2787                     | Astigmatism correcting function of intraocular lens   |  |
| V2788                     | Presbyopia correcting function of intraocular lens  |  |
| 0329T                     | Monitoring of intraocular pressure for 24 hours or longer, unilateral, or bilateral, with interpretation and report |  |
| 0330T                     | Tear film imaging, unilateral or bilateral, with interpretation and report  |  |
| 0341T                     | Quantitative pupillometry with unilateral, or bilateral, with interpretation and report lateral                     |  |



#### **Vision CPT/HCPCS**

| Codes | Description  |  |
|-------|--|--|
| 0378T | Visual field assessment, with concurrent real time data analysis and accessible data storage with patient-<br>initiated data transmitted to a remote surveillance center for up to |  |
| 0469T | Retinal polarization scan, ocular screening with on-site automated results, bilateral  |  |
| 0506T | Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report   |  |
| 2023F | Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (dm)                                    |  |
| 2025F | 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed: without evidence of retinopathy (dm)                |  |
| 2033F | Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed: without evidence of retinopathy (DM)                   |  |

#### **Routine and Medical Care with Diagnosis Specific Requirements**

#### Bill to EyeMed

When billing the CPT/HCPCS codes below with one of the following routine ICD-10 codes claims should be billed to EyeMed:

| CPT/HCPCS Codes | Claims                                   |
|-----------------|--|
| H5200           | Hypermetropia, unspecified eye           |
| H5201           | Hypermetropia, right eye                 |
| H5202           | Hypermetropia, left eye                  |
| H5203           | Hypermetropia, bilateral                 |
| H5210           | Myopia, unspecified eye                  |
| H5211           | Myopia, right eye                        |
| H5212           | Myopia, left eye                         |
| H5213           | Myopia, bilateral                        |
| H52201          | Unspecified astigmatism, right eye       |
| H52202          | Unspecified astigmatism, left eye        |
| H52203          | Unspecified astigmatism, bilateral       |
| H52209          | Unspecified astigmatism, unspecified eye |
| H52211          | Irregular astigmatism, right eye         |
| H52212          | Irregular astigmatism, left eye          |



| CPT/HCPCS Codes | Claims   |
|-----------------|--|
| H52213          | Irregular astigmatism, bilateral                             |
| H52219          | Irregular astigmatism, unspecified eye                       |
| H52221          | Regular astigmatism, right eye                               |
| H52222          | Regular astigmatism, left eye                                |
| H52223          | Regular astigmatism, bilateral                               |
| H52229          | Regular astigmatism, unspecified eye                         |
| H5231           | Anisometropia  |
| H524            | Presbyopia   |
| H52521          | Paresis of accommodation, right eye                          |
| H52522          | Paresis of accommodation, left eye                           |
| H52523          | Paresis of accommodation, bilateral                          |
| H52529          | Paresis of accommodation, unspecified eye                    |
| H526            | Other disorders of refraction                                |
| H527            | Unspecified disorder of refraction                           |
| H53041          | Amblyopia Suspect right eye                                  |
| H53042          | Amblyopia Suspect left eye                                   |
| H53043          | Amblyopia Suspect Bilateral                                  |
| H53049          | Amblyopia Suspect Unspecified eye                            |
| Z0100           | Encounter for exam of eyes and vision w/o abnormal findings  |
| Z0101           | Encounter for exam of eyes and vision w abnormal findings    |
| H52511          | Internal ophthalmoplegia (complete) (total), right eye       |
| H52512          | Internal ophthalmoplegia (complete) (total), left eye        |
| H52513          | Internal ophthalmoplegia (complete) (total), bilateral       |
| H52519          | Internal ophthalmoplegia (complete) (total), unspecified eye |
| H52531          | Spasm of accommodation, right eye                            |
| H52532          | Spasm of accommodation, left eye                             |
| H52533          | Spasm of accommodation, bilateral                            |



| CPT/HCPCS Codes | Claims                                  |
|-----------------|---|
| H52539          | Spasm of accommodation, unspecified eye |
| H53001          | Unspecified amblyopia, right eye        |
| H53002          | Unspecified amblyopia, left eye         |
| H53003          | Unspecified amblyopia, bilateral        |
| H53009          | Unspecified amblyopia, unspecified eye  |
| H53011          | Deprivation amblyopia, right eye        |
| H53012          | Deprivation amblyopia, left eye         |
| H53013          | Deprivation amblyopia, bilateral        |
| H53019          | Deprivation amblyopia, unspecified eye  |
| H53021          | Refractive amblyopia, right eye         |
| H53022          | Refractive amblyopia, left eye          |
| H53023          | Refractive amblyopia, bilateral         |
| H53029          | Refractive amblyopia, unspecified eye   |
| H53031          | Strabismic amblyopia, right eye         |
| H53032          | Strabismic amblyopia, left eye          |
| H53033          | Strabismic amblyopia, bilateral         |
| H53039          | Strabismic amblyopia, unspecified eye   |
| H53141          | Visual discomfort, right eye            |
| H53142          | Visual discomfort, left eye             |
| H53143          | Visual discomfort, bilateral            |
| H53149          | Visual discomfort, unspecified          |

## Bill to MVP

When billing the CPT/HCPCS codes below with the ICD-10 Code of H5232, Aniseikonia, the claim should be billed to MVP:

#### Vision CPT/HCPCS

| Codes | Description                              |
|-------|--|
| 92002 | Ophthalmologic. Serv; intermediate       |
| 92004 | Eye exam, comprehansive,1or more session |
| 92012 | Eye exam; intermediate, estab. Pt        |



| Vision CPT/HCPCS<br>Codes | Description  |
|---------------------------|--|
| 92014                     | Comprehensive, established patient                                     |
| 92015                     | Determination of refractive state                                      |
| 92072                     | Fitting of contact lens for management of keratoconus, initial fitting |
| 92311                     | Prescribe/fit contact lens, aphakia,1 eye                              |
| 92312                     | Prescribe/fit contact lens, aphakia,2 eyes                             |
| 92326                     | Replacement of contact lens  |
| 92340                     | Fit spectacle, not aphakia; monofocal                                  |
| 92341                     | Fit spectacles, not aphakia; bifocal                                   |
| 92342                     | Fit spectacles, not aphak; multifocal                                  |
| 92370                     | Repair/refit spectacles; except aphakia                                |
| S0590                     | Integral lens service, miscellaneous services reported separately      |
| S0592                     | Comprehensive contact lens evaluation                                  |
| S0620                     | Routine ophthalmological exam  |
| S0621                     | Routine ophthalmological exam  |
| V2020                     | Vision svcs frames purchases   |
| V2100                     | Lens spherocylindrical single plano 4.00                               |
| V2101                     | Single vision spherocylindrical 4.12-7.00                              |
| V2102                     | Single vision spherocylindrical 7.12-20.00                             |
| V2103                     | Spherocylindrical 4.00d/12-2.00d                                       |
| V2104                     | Spherocylinder4.00d/2.12-4d  |
| V2105                     | Spherocylindrical 4.00d/4.25-6d  |
| V2106                     | Spherocylindrical 4.00d/>6.00d   |
| V2107                     | Spherocylindrical 4.25d/12-2d  |
| V2108                     | Spherocylindrical 4.25d/2.12-4d  |
| V2109                     | Spherocylindrical 4.25d/4.25-6d  |
| V2110                     | Spherocylindrical 4.25d/over 6d  |
| V2111                     | Spherocylinder7.25d/.25-2.25   |



| Vision CPT/HCPCS<br>Codes | Description                                 |
|---------------------------|---|
| V2112                     | Spherocylinder7.25d/2.25-4d                 |
| V2113                     | Spherocylinder7.25d/4.25-6d                 |
| V2114                     | spherocylindrical over 12.00d               |
| V2115                     | Lens lenticular bifocal                     |
| V2118                     | Lens aniseikonia single                     |
| V2121                     | Lenticular Lens, per Lens, single           |
| V2199                     | Lens single vision                          |
| V2200                     | Lens spherocylindrical bifocal plano 4.00d  |
| V2201                     | Lens spherocylindrical bifocal 4.12-7.0     |
| V2202                     | Lens spherocylindrical bifocal 7.12-20.     |
| V2203                     | Lens spherocylindrical bifocal 4.00d/.1     |
| V2204                     | Lens spherocylindrical c 4.00d/2.1          |
| V2205                     | Lens spherocylindrical bifocal 4.00d/4.2    |
| V2206                     | Lens spherocylindrical bifocal 4.00d/Ove    |
| V2207                     | Lens spherocylindrical bifocal 4.25-7d/.    |
| V2208                     | Lens spherocylindrical bifocal 4.25-7/2.    |
| V2209                     | Lens spherocylindrical bifocal 4.25-7/4.    |
| V2210                     | Lens spherocylindrical bifocal 4.25-7/ova   |
| V2211                     | Lens spherocylindrical bifocal 7.25-12/.25- |
| V2212                     | Lens spherocylindrical bifocal 7.25-12/2.2  |
| V2213                     | Lens spherocylindrical bifocal 7.25-12/4.2  |
| V2214                     | Lens spherocylindrical bifocal over 12.     |
| V2215                     | Lens lenticular bifocal Cal                 |
| V2218                     | Lens aniseikonia bifocal                    |
| V2219                     | Lens bifocal Cal seg width over             |
| V2220                     | Lens bifocal Cals add over 3.25d            |
| V2221                     | Lenticular lens, per lens, bifocal Cal      |



| Vision CPT/HCPCS<br>Codes | Description                                  |
|---------------------------|--|
| V2299                     | Lens bifocal Cal specialty                   |
| V2300                     | Lens spherocylindrical trifocal 4.00d        |
| V2301                     | Lens supercollider trifocal 4.12-7.          |
| V2302                     | Lens spherocylindrical trifocal 7.12-20      |
| V2303                     | Lens supercollider trifocal 4.0/.12-         |
| V2304                     | Lens spherocylindrical trifocal 4.0/2.25     |
| V2305                     | Lens supercollider trifocal 4.0/4.25         |
| V2306                     | Lens spherocylindrical trifocal 4.00/>6      |
| V2307                     | Lens spherocylindrical trifocal 4.25-7/.     |
| V2308                     | Lens spherocylindrical trifocal 4.25-7/2.    |
| V2309                     | Lens spherocylindrical trifocal 4.25-7/4.    |
| V2310                     | Lens spherocylindrical trifocal 4.25-7/>6    |
| V2311                     | Lens spherocylindrical trifocal 7.25-12/.25- |
| V2312                     | Lens spherocylindrical trifocal 7.25-12/2.25 |
| V2313                     | Lens spherocylindrical trifocal 7.25-12/4.25 |
| V2314                     | Lens spherocylindrical trifocal over 12      |
| V2315                     | Lens lenticular trifocal                     |
| V2318                     | Lens aniseikonia trifocal                    |
| V2319                     | Lens trifocal seg width > 28                 |
| V2320                     | Lens trifocals add over 3.25d                |
| V2321                     | Lenticular lens, per lens, trifocal          |
| V2399                     | Lens trifocal specialty                      |
| V2410                     | Lens variable a sphericity sing              |
| V2430                     | Lens variable sphericity bi                  |
| V2499                     | Variable a sphericity lens                   |
| V2500                     | Contact lens pmma spherical                  |
| V2501                     | Contact lens pmma-toric/prism                |



| Vision CPT/HCPCS<br>Codes | Description  |
|---------------------------|--|
| V2502                     | Contact lens pmma bifocal  |
| V2503                     | Contact lens pmma color vision   |
| V2510                     | Contact gas permeable spherical  |
| V2511                     | Contact toric prism ballast  |
| V2512                     | Contact lens gas perm bifocal  |
| V2513                     | Contact lens extended wear   |
| V2520                     | Contact lens hydrophilic   |
| V2521                     | Contact lens hydrophilic toric   |
| V2522                     | Contact lens hydrophile bifocal call   |
| V2523                     | Contact lens hydrophile extend   |
| V2530                     | Contact lens gas impermeable   |
| V2531                     | Contact lens gas permeable   |
| V2599                     | Contact lens/es other type   |
| V2700                     | Balance lens   |
| V2745                     | Addition to lens, tint, any color, solid, gradient, or equal, excludes photochromatic, any lens material, per lens |
| V2750                     | Anti-reflective coating  |
| V2755                     | UV lens/es   |
| V2762                     | Polarization, any lens material, per lens  |
| V2780                     | Oversize lens/es   |
| V2782                     | Lens, index 1.54 to 1.65 plastic or 1.60 to 1.79 glass, excludes polycarbonate, per lens                           |
| V2783                     | Lens, index greater than/equal to 1.66 plastic or greater than/equal to 1.80, excludes polycarbonate, per lens     |
| V2784                     | Lens, polycarbonate or equal, qny index, per lens  |
| V2744                     | Tint photochromatic lens/es  |
| V2744U1                   | Tint photochromatic lens/es  |
| V2744U2                   | Tint photochromatic lens/es  |
| V2744U5                   | Tint photochromatic lens/es  |
| V2744U6                   | Tint photochromatic lens/es  |



#### Vision CPT/HCPCS

| Codes   | Description                 |
|---------|-----------------------------|
| V2744U7 | Tint photochromatic lens/es |
| V2744U8 | Tint photochromatic lens/es |

## History

December 1, 2021 – New policy, approved

December 1, 2022 Policy reviewed and approved with no changes



# Eye Wear Coverage

MVP Health Care Medicaid Managed Care, Child Health Plus, HARP, and New York State Essential Plans 3 & 4 Only

Last Reviewed Date: September 1, 2022

#### EYE WEAR COVERAGE

Policy Benefits Notification / Prior Authorization Requests Billing / Coding Guidelines References History

## Policy

MVP provides coverage for lenses, frames, and contact lenses for Members when it is deemed medically necessary and have the eye wear benefit. Participating opticians/dispensers have a variety of quality eyewear product lines that can be offered to the Member; these products represent the frames and lenses available for this benefit. A prescription from an optometrist or ophthalmologist is required. Provider must check the Member's specific benefits as it relates to eyewear before dispensing any pairs of lenses, frames, or contact lenses.

## **Benefits**

Eye wear coverage will be reimbursed based on the Members' benefits. Member benefits vary based on the type of product and may change from year to year. All Member benefits can be found online at myphealthcare.com. Providers will need to obtain a secure username and password to log in and utilize the MVP Provider portal. Once Providers have logged into the secure MVP Provider portal, they may access the benefit detail under the Member eligibility section.

## **Notification / Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## **Billing / Coding Guidelines**

Eyeglasses do not require changing more frequently than once every twenty-four (24) months for individuals over the age of 19 and every twelve (12) months for individuals age 19 and under unless medically indicated, such as a change in correction greater than ½ diopter, or unless the glasses are lost, damaged, or destroyed. The replacement of a complete pair must duplicate the original prescription of the lenses and frames. Coverage also includes the repair or replacement of parts in situations where the damage is the result of causes other than defective workmanship. Replacement parts must duplicate the original prescription and frames. Repairs to, and replacements of, frames and/or lenses must be rendered as needed.

When using the eye wear benefit, Members who choose the approved frames and lenses cannot be billed for the difference between what the program allows and the market cost of either the frames or the lenses. For example, if a Member chooses to purchase a more expensive frame or lenses (i.e. no-line bifocal, photo-gray lenses) than the approved frames, then the Member has to agree at the time the glasses are being ordered that she/he will pay the entire cost of the more expensive frame. In this scenario, the Member's Medicaid, CHP, HARP, or Essential Plan benefit cannot be used. Providers should refer to their contractual agreement with MVP and the Member's benefits to determine the reimbursement for the approved "Standard" frames and lenses for the Member's product.



## References

eMedNY: Vision Care Policy Guidelines: emedny.org/ProviderManuals/VisionCare/PDFS/VisionCare\_Policy\_Guidelines.pdf

Medicaid Model Contract:

health.ny.gov/health\_care/managed\_care/docs/medicaid\_managed\_care\_fhp\_hiv-snp\_model\_contract.pdf

March 1, 2019 Policy approved

March 1, 2020 Policy reviewed and approved with no changes

March 1, 2021 Policy reviewed and approved with no changes

September 1, 2022 Policy reviewed and approved with no changes

#### **MVP Health Care Payment Policy**



# Home Infusion

Last Reviewed Date: March 1, 2022 Related Policies: MVP Enteral Therapy NDC Payment Policy Benefit Interpretation Manual

#### HOME INFUSION

Policy Definitions Types of Therapy Per Diem Definition Notification/Prior Authorization Requests Billing/Coding Guidelines Wastage Policy TPN and Peripheral Parenteral Nutrition (PPN) Per Diem Medicare Variation References

## Policy

All Emergency Department (ED) services must be coded to the appropriate level of service which supports the extent of review required to adequately evaluate and treat patient problem(s) upon presentation to the ED. Physicians should follow the CPT code book to determine complexity requirements for services provided in the Emergency Room. The following billing guidelines are used as a guide for physicians seeing MVP members in the emergency room. These guidelines do not apply to the ER facility charges or to physicians who are employed by the emergency room. MVP requires all professional charges be submitted on a CMS1500 claims form.

## Definitions

#### **Infusion Therapy**

Infusion therapy is the continuous, controlled administration of a drug, nutrient, antibiotic, or other fluid into a vein or other tissue on a continuous or intermittent basis, depending on the condition being treated and type of therapy.

Infusion therapy may be performed in the home setting for medication infused or injected through a catheter and may include care and maintenance of the catheter site.

#### **Medical Necessity for Infusion Therapy**

Medical necessity is the overarching criterion for payment in addition to the individual documentation requirements of a CPT code. It would not be medically necessary or appropriate to bill a higher level of evaluation and management service when a lower level of service is warranted. The volume of documentation should not be the primary influence upon which a specific level of service is billed. Documentation should support the level of service being reported.

Infusion must be prescribed by an appropriately licensed prescriber as part of a treatment plan for a covered medical condition.

Administration of the drug via infusion therapy is medically necessary. Infusion therapy is prescribed only when the member's condition cannot be appropriately treated with alternative dosage forms of medication (e.g. oral, topical, or SQ) or the therapy is not available in alternative dosage forms and achieve the same or equivalent therapeutic effect.

All components of the infusion must meet medical necessity criteria and be medically necessary to treat the member's medical condition for the infusion to be covered.

Treatments can be safely administered in the home.

Services must be provided by a network/preferred home infusion therapy provider.



Peripherally Inserted Central Catheter (PICC) line placement does not guarantee approval or payment of the medication to be infused if the medication does not meet medical necessity criteria or requires prior authorization.

## **Types of Therapy**

- Therapeutic (hydration or medication therapy e.g. chemotherapy, IVIG)
- Prophylactic (Injections/infusions to prevent "side effects" e.g. ondansetron)
- Nutritional (Parenteral / Enteral)

#### **Total Parenteral Nutrition (TPN)**

TPN is a form of nutrition that is delivered through a vein which may contain lipids, electrolytes, amino acids, trace elements, and vitamins.

#### **Enteral Nutrition**

Enteral nutrition is a form of nutrition that is delivered into the digestive system as a liquid. Enteral nutrition may be provided orally or through a feeding tube. Enteral products may be liquids or powders that are reconstituted to a liquid form. Refer to the MVP Enteral Policy for coverage criteria.

### **Per Diem Definition**

Per Diem represents each day that a given patient is provided access to a prescribed therapy and is valid for per diem therapies of up to and including every 72 hours. Therapies provided beyond this range (weekly, monthly, etc.) fall outside of the per diem structure, and will receive one (1) per diem unit for the day the infusion was provided. Supplies are included in the rate for those therapies provided on a less frequent basis. Diluents/solutions for the preparation and administration of the medication, and flushing solutions including heparin, saline, and routinely included supplies (e.g. gauze, tape, cleansing solutions, splints), are included in the per diem rates.

The expected course and duration of the treatment shall be determined by the plan of care as prescribed by the ordering physician.

Per Diem includes the following services/items:

#### **1. Professional Pharmacy Services**

- Continuing education to professional pharmacy staff
- Removal, storage, and disposal of infectious waste
- Maintaining accreditation

#### 2. Dispensing

- Medication profile setup and drug utilization review
- Monitoring for potential drug interactions
- Sterile procedures including intravenous admixtures, clean room upkeep, vertical and horizontal laminar flow hood certification, and all other biomedical procedures necessary for a safe environment
- USP797 compliant sterile compounding of medications
- Patient counseling as required under OBRA 1990

#### 3. Clinical Monitoring

- Development and implementation of pharmaceutical care plans
- Pharmacokinetic dosing
- Review and interpretation of patient test results



- Recommending dosage or medication changes based on clinical findings
- · Initial and ongoing pharmacy patient assessment and clinical monitoring
- · Measurement of field nursing competency with subsequent education and training
- Other professional and cognitive services as needed to clinically manage the patient pharmacy care

#### 4. Care Coordination

- Patient admittance services, including communication with other medical professionals, patient assessment, and opening of the medical record
- Patient/caregiver educational activities, including providing training and patient education materials
- Clinical coordination of infusion services care with physicians, nurses, patients, patient's family, other providers, caregivers, and case managers
- · Clinical coordination of non-infusion related services
- Patient discharge services, including communication with other medical professionals and closing of the medical record
- 24 hours/day, 7 days/week availability for questions and/or problems of a dedicated infusion team consisting of pharmacist(s), nurse(s), and all other medical professionals responsible for clinical response, problem solving, trouble shooting, question answering, and other professional duties from pharmacy staff that do not require a patient visit
- Development and monitoring of nursing care plans
- Coordination, education, training and management of field nursing staff (or subcontracted agencies)
- Delivery of medication, supplies, and equipment to patient's home

#### 5. Supplies and Equipment

- Line maintenance supplies including non-therapeutic anti-coagulants and saline.
- DME (pumps, poles and accessories) for drug and nutrition administration\*
- Equipment maintenance and repair (excluding patient owned equipment)
- Short peripheral vascular access devices
- Needles, gauze, non-implanted sterile tubing, catheters, dressing kits, and other necessary supplies for the sale and effective administration of infusion, specialty drug and nutrition therapies\*

\*Enteral supplies (including but not limited to enteral feeding kits, pumps, and poles) and/or nursing and home services when the formula is determined to be not medically necessary are not covered. MVP shall review all claims retrospectively for services and supplies, including but not limited to nursing services, per diem charges, pumps, poles, and feeding bags, associated with enteral formulas.

#### 6. Administrative Services

- · Administering coordination of benefits with other insurers
- Determining insurance coverage, including coverage for compliance with all state and federal regulations
- Verification of insurance eligibility and extent of coverage
- Obtaining certificate of medical necessity and other medical necessity documentation
- Obtaining prior authorizations
- Performing billing functions
- Performing account collection activities



- Internal and external auditing and other regulatory compliance activities
- Postage and shipping
- Design and production of patient education materials

## **Notification/Prior Authorization Requests**

Medications and enteral formula administered in the home may require prior authorization; refer to the <u>MVP Formulary</u> or *Benefit Interpretation Manual* to determine if authorization is required.

## **Billing/Coding Guidelines**

| Anti-infective Therapy (antibio | otics/antifungals/antivirals) |
|---------------------------------|-------------------------------|
|---------------------------------|-------------------------------|

| Code  | Description   | Rule  |
|-------|---|---|
|       | Home infusion therapy, antibiotic, antiviral,<br>or antifungal therapy; once every 3 hours;   | <ul> <li>Members receiving concurrent therapies on the same day, this<br/>will not pay.</li> </ul>                |
| S9497 | administrative services, professional pharmacy services, care coordination, and all necessary   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       | supplies and equipment (drugs and nursing visits coded separately), per diem  | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs.</li> </ul>     |
|       | Home infusion therapy, antibiotic, antiviral, or<br>antifungal; once every 4 hours; administrative  | <ul> <li>Members receiving concurrent therapies on the same day, this<br/>will not pay.</li> </ul>                |
| S9504 | services, professional pharmacy services, care coordination, and all necessary supplies and   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       | equipment (drugs and nursing visits coded separately), per diem   | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs.</li> </ul>     |
| S9503 | Home infusion therapy, antibiotic, antiviral, or<br>antifungal; once every 6 hours; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem          | • Members receiving concurrent therapies on the same day, this will not pay.                                      |
|       |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       |   | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs</li> </ul>      |
|       | Home infusion therapy, antibiotic, antiviral,<br>or antifungal therapy; once every 8 hours,<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem  | • Members receiving concurrent therapies on the same day, this will not pay.                                      |
| S9502 |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       |   | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs.</li> </ul>     |
| S9501 | Home infusion therapy, antibiotic, antiviral,<br>or antifungal therapy; once every 12 hours;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem | <ul> <li>Members receiving concurrent therapies on the same day, this<br/>will not pay.</li> </ul>                |
|       |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       |   | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs.</li> </ul>     |



| Code  | Description   | Rule  |
|-------|---|---|
|       | Home infusion therapy, antibiotic, antiviral,<br>or antifungal therapy; once every 24 hours;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem | <ul> <li>Members receiving concurrent therapies on the same day, this<br/>will not pay.</li> </ul>                |
| S9500 |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul> |
|       |   | <ul> <li>These services are considered global to the per diem except<br/>nursing visits and drugs.</li> </ul>     |

#### Chemotherapy

| Code  | Description   | Rule  |
|-------|---|---|
| S9330 | Home infusion therapy, continuous (24 hours or<br>more) chemotherapy infusion; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem     | These services are considered global to the per diem except nursing visits and drugs. |
| S9331 | Home infusion therapy, intermittent (less than<br>24 hours) chemotherapy infusion; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem | These services are considered global to the per diem except nursing visits and drugs. |

#### **Enteral Nutrition Therapy**

Enteral formula is limited to a 30-day supply per dispensing or as specified in the member's contract, rider, or specific benefit design. The following codes do not apply to nutritional formulas taken orally. Refer to the MVP Enteral Therapy policies for coverage criteria.

| Code  | Description   | Rule   |
|-------|---|--|
|       |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul>  |
| S9343 | Home therapy; enteral nutrition via bolus;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (enteral formula and<br>nursing visits coded separately), per diem   | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services<br>when the formula is determined to be not medically necessary<br>are not covered. MVP shall review all claims retrospectively<br>for services and supplies, including but not limited to nursing<br>services, per diem charges, pumps, poles, and feeding bags,<br>associated with enteral formulas. See MVP Enteral Therapy<br>Benefit Interpretations for additional information. |
| S9341 |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul>  |
|       | Home therapy; enteral nutrition via gravity;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (enteral formula and<br>nursing visits coded separately), per diem | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services,<br>per diem charges, pumps, poles, and feeding bags, associated<br>with enteral formulas. See MVP Enteral Therapy Benefit<br>Interpretations for additional information. |



| Code  | Description   | Rule   |
|-------|---|--|
|       |   | <ul> <li>See above definition for per diem definition. Including or not<br/>limited to the HCPCS Code.</li> </ul>  |
| S9342 | Home therapy; enteral nutrition via pump;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (enteral formula and<br>nursing visits coded separately), per diem  | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services,<br>per diem charges, pumps, poles, and feeding bags, associated<br>with enteral formulas. See MVP Enteral Therapy Benefit<br>Interpretations for additional information. |
|       |   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>   |
|       | Enteral formula, for adults, used to replace  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>   |
|       | fluids and electrolytes (e.g., clear liquids),<br>500 ml = 1 unit*  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>   |
| B4102 | *Enteral supplies (including but not limited to enteral<br>feeding kits, pumps, and poles) and/or nursing and<br>home services when the formula is determined to<br>be not medically necessary are not covered. MVP<br>shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing<br>services, per diem charges, pumps, poles, and<br>feeding bags, associated with enteral formulas. | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.  |
|       |   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>   |
|       | Enteral formula, for pediatrics, used to<br>replace fluids and electrolytes (e.g., clear liquids),<br>500 ml = 1 unit   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>   |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>   |
| B4103 |   | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.  |



| Code  | Description   | Rule  |
|-------|---|---|
|       |   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       | Additive for enteral formula (e.g., fiber)*   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4104 | *Enteral supplies (including but not limited to enteral<br>feeding kits, pumps, and poles) and/or nursing and<br>home services when the formula is determined to<br>be not medically necessary are not covered. MVP<br>shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing<br>services, per diem charges, pumps, poles, and<br>feeding bags, associated with enteral formulas. | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • Exception - Not covered for Medicare members.   |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |
|       | Enteral formula, manufactured blenderized natural<br>foods with intact nutrients, includes proteins, fats,<br>carbohydrates, vitamins and minerals, may include<br>fiber, administered through an enteral feeding<br>tube, 100 calories = 1 unit  | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4149 |   | • Enteral supplies (including but not limited to enteral feeding kits, pumps, and poles) and/or nursing and home services when the formula is determined to be not medically necessary are not covered. MVP shall review all claims retrospectively for services and supplies, including but not limited to nursing services, per diem charges, pumps, poles, and feeding bags, associated with enteral formulas.                   |
|       |   | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |



| Code  | Description  | Rule  |
|-------|--|---|
|       |  | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4150 | Enteral formula, nutritionally complete with intact<br>nutrients, includes proteins, fats, carbohydrates,<br>vitamins, and minerals, may include fiber,<br>administered through an enteral feeding tube, 100<br>calories = 1 unit  | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |  | • <b>Exception</b> - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.   |
|       |  | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |
|       | Enteral formula, nutritionally complete, calorically<br>dense (equal to or greater than 1.5 kcal/ml)<br>with intact nutrients, includes proteins, fats,<br>carbohydrates, vitamins, and minerals, may<br>include fiber, administered through an enteral<br>feeding tube, 100 calories = 1 unit | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4152 |  | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |  | <ul> <li>Exception - Medicare members have these services covered<br/>under the prosthetic benefit if sole source nutrition. Enteral<br/>therapy may be obtained through a participating DME vendor,<br/>Home Infusion vendor, or PBM.</li> </ul>   |
|       |  | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |



| Code  | Description   | Rule  |
|-------|---|---|
|       |   | <ul> <li>The enteral formula must be obtained from an MVP<br/>participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4153 | Enteral formula, nutritionally complete, hydrolyzed<br>proteins (amino acids and peptide chain), includes<br>fats, carbohydrates, vitamins, and minerals, may<br>include fiber, administered through an enteral<br>feeding tube, 100 calories = 1 unit  | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • <b>Exception</b> - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.   |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |
|       | Enteral formula, nutritionally complete, for special<br>metabolic needs, excludes inherited disease of<br>metabolism, includes altered composition of<br>proteins, fats, carbohydrates, vitamins, and/or<br>minerals, may include fiber, administered through<br>an enteral feeding tube, 100 calories = 1 unit | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4154 |   | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |



| Code  | Description   | Rule  |
|-------|---|---|
|       |   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4155 | Enteral formula, nutritionally incomplete/<br>modular nutrients, includes specific nutrients,<br>carbohydrates (e.g., glucose polymers), proteins/<br>amino acids (e.g., glutamine, arginine), fat (e.g.,<br>medium chain triglycerides), or combination,<br>administered through an enteral feeding tube, 100<br>calories = 1 unit | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • <b>Exception</b> - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.   |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |
|       | Enteral formula, nutritionally complete, for<br>special metabolic needs for inherited disease of<br>metabolism, includes proteins, fats, carbohydrates,<br>vitamins, and minerals, may include fiber,<br>administered through an enteral feeding tube, 100<br>calories = 1 unit   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4157 |   | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |   | • Exception - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.  |



| Code  | Description  | Rule  |
|-------|--|---|
|       |  | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4158 | Enteral formula, for pediatrics, nutritionally<br>complete with intact nutrients, includes proteins,<br>fats, carbohydrates, vitamins, and minerals, may<br>include fiber and/or iron, administered through an<br>enteral feeding tube, 100 calories = 1 unit              | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |  | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |  | • Exception - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.  |
|       | Enteral formula, for pediatrics, nutritionally<br>complete soy based with intact nutrients,<br>includes proteins, fats, carbohydrates, vitamins,<br>and minerals, may include fiber and/or iron,<br>administered through an enteral feeding tube, 100<br>calories = 1 unit | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4159 |  | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |  | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |  | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |



| Code  | Description   | Rule  |
|-------|---|---|
|       |   | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4160 | Enteral formula, for pediatrics, nutritionally<br>complete calorically dense (equal to or greater<br>than 0.7 kcal/ml) with intact nutrients, includes<br>proteins, fats, carbohydrates, vitamins, and<br>minerals, may include fiber, administered through<br>an enteral feeding tube, 100 calories = 1 unit | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |
|       | Enteral formula, for pediatrics, hydrolyzed/amino<br>acids and peptide chain proteins, includes fats,<br>carbohydrates, vitamins, and minerals, may<br>include fiber, administered through an enteral<br>feeding tube, 100 calories = 1 unit  | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |   | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |   | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4161 |   | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |   | • Exception - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.  |
|       |   | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |



| Code  | Description  | Rule  |
|-------|--|---|
|       |  | <ul> <li>The enteral formula must be obtained from an MVP participating pharmacy.</li> </ul>  |
|       |  | <ul> <li>Home Infusion Agencies can also provide enteral formula<br/>but they must be billed through the MVP Pharmacy Benefits<br/>Manager (PBM). See exceptions below.</li> </ul>  |
|       |  | <ul> <li>Refer to MVP's Benefit Interpretation Manual to determine if the<br/>enteral formula requires authorization.</li> </ul>  |
| B4162 | Enteral formula, for pediatrics, special metabolic<br>needs for inherited disease of metabolism, includes<br>proteins, fats, carbohydrates, vitamins, and<br>minerals, may include fiber, administered through<br>an enteral feeding tube, 100 calories = 1 unit | • Enteral supplies (including but not limited to enteral feeding<br>kits, pumps, and poles) and/or nursing and home services when<br>the formula is determined to be not medically necessary are not<br>covered. MVP shall review all claims retrospectively for services<br>and supplies, including but not limited to nursing services, per<br>diem charges, pumps, poles, and feeding bags, associated with<br>enteral formulas. |
|       |  | • <b>Exception</b> - Medicare members have these services covered<br>under the prosthetic benefit if sole source nutrition. Enteral<br>therapy may be obtained through a participating DME vendor,<br>Home Infusion vendor, or PBM.   |
|       |  | • <b>Exception</b> - Certain ASO plans have these services covered<br>under the member's medical benefit and must obtain enteral<br>nutrition items from a participating vendor. Providers should<br>review the member benefits to determine if these codes are<br>billable through the member's pharmacy or medical benefit.   |

## Hydration Therapy

| Code  | Description   | Rule |
|-------|---|------|
| S9374 | Home infusion therapy, hydration therapy; 1 liter<br>per day, administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem   |      |
| S9375 | Home infusion therapy, hydration therapy; more<br>than 1 liter but no more than 2 liters per day,<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem  |      |
| S9376 | Home infusion therapy, hydration therapy; more<br>than 2 liters but no more than 3 liters per day,<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem |      |
| S9377 | Home infusion therapy, hydration therapy; more<br>than 3 liters per day, administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies (drugs and nursing visits<br>coded separately), per diem  |      |



## **Pain Management Infusion**

| Code  | Description  | Rule |
|-------|--|------|
| S9326 | Home infusion therapy, continuous (24 hours or<br>more) pain management infusion; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem     |      |
| S9327 | Home infusion therapy, intermittent (less than 24<br>hours) pain management infusion; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem |      |
| S9338 | Home infusion therapy, immunotherapy,<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem   |      |
| S9377 | Home infusion therapy, hydration therapy; more<br>than 3 liters per day, administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies (drugs and nursing visits<br>coded separately), per diem                               |      |

## **Total Parenteral Nutrition**

| Code  | Description  | Rule |
|-------|--|------|
| S9365 | Home infusion therapy, total parenteral nutrition<br>(TPN); 1 liter per day, administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies and equipment including<br>standard TPN formula (lipids, specialty amino acid<br>formulas, drugs, other than in standard formula and<br>nursing visits coded separately), per diem   |      |
| S9366 | Home infusion therapy, total parenteral nutrition<br>(TPN); more than 1 liter but no more than 2 liters<br>per day, administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment including<br>standard TPN formula (lipids, specialty amino acid<br>formulas, drugs other than in standard formula,<br>and nursing visits coded separately), per diem  |      |
| S9367 | Home infusion therapy, total parenteral nutrition<br>(TPN); more than 2 liters but no more than 3 liters<br>per day, administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment including<br>standard TPN formula (lipids, specialty amino acid<br>formulas, drugs other than in standard formula,<br>and nursing visits coded separately), per diem |      |



| Code  | Description  | Rule |
|-------|--|------|
| S9368 | Home infusion therapy, total parenteral nutrition<br>(TPN); more than 3 liters per day, administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment including standard TPN formula (lipids,<br>specialty amino acid formulas, drugs other than<br>in standard formula, and nursing visits coded<br>separately), per diem |      |
| B4185 | Parenteral nutrition solution, per 10 grams lipids   |      |

## Specialty Therapy

| Code  | Description   | Rule |
|-------|---|------|
| S9061 | Home administration of aerosolized drug therapy<br>(e.g., Pentamidine); administrative services,<br>professional pharmacy services, care coordination,<br>all necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem                     |      |
| S9346 | Home infusion therapy, alpha-1-proteinase<br>inhibitor (e.g., Prolastin); administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies and equipment (drugs<br>and nursing visits coded separately), per diem               |      |
| S9372 | Home therapy; intermittent anticoagulant injection<br>therapy (e.g., Heparin); administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies and equipment (drugs<br>and nursing visits coded separately), per diem          |      |
| S9351 | Home infusion therapy, continuous or intermittent<br>antiemetic infusion therapy; administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and visits coded separately), per<br>diem            |      |
| S9370 | Home therapy, intermittent antiemetic injection<br>therapy; administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem                             |      |
| S9345 | Home infusion therapy, antihemophilic agent<br>infusion therapy (e.g., factor VIII); administrative<br>services, professional pharmacy services, care<br>coordination, and all necessary supplies and<br>equipment (drugs and nursing visits coded<br>separately), per diem |      |



| Code   | Description   | ule |
|--------|---|-----|
| S9359  | Home infusion therapy, antitumor necrosis<br>factor intravenous therapy; (e.g., Infliximab);<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem     |     |
| S9355  | Home infusion therapy, chelation therapy;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem  |     |
| S9490  | Home infusion therapy, corticosteroid infusion;<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem  |     |
| \$9361 | Home infusion therapy, diuretic intravenous<br>therapy; administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem   |     |
| S9558  | Home injectable therapy; growth hormone,<br>including administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem   |     |
| S9537  | Home therapy; hematopoietic hormone injection<br>therapy (e.g., erythropoietin, G-CSF, GM- CSF);<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem |     |
| S9348  | Home infusion therapy, sympathomimetic/<br>inotropic agent infusion therapy (e.g.,<br>Dobutamine); administrative services, professional<br>pharmacy services, care coordination, all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem      |     |
| \$5521 | Home infusion therapy, all supplies (including catheter) necessary for a midline catheter insertion   |     |
| S5520  | Home infusion therapy, all supplies (including catheter) necessary for a peripherally inserted central venous catheter (PICC) line insertion  |     |



| Code   | Description  | Rule   |
|--------|--|--|
| S9357  | Home infusion therapy, enzyme replacement<br>intravenous therapy; (e.g., Imiglucerase);<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing visits<br>coded separately), per diem |  |
| \$5517 | Home infusion therapy, all supplies necessary for restoration of catheter patency or declotting  |  |
| \$5518 | Home infusion therapy, all supplies necessary for catheter repair  |  |
| S9379  | Home infusion therapy, infusion therapy, not<br>otherwise classified; administrative services,<br>professional pharmacy services, care coordination,<br>and all necessary supplies and equipment (drugs<br>and nursing visits coded separately), per diem                      | Documentation must be available for retrospective review.<br>Should only be billed for a service or procedure that does not<br>have a valid specific therapy code available. |

# J0640 (Leucovorin) and J0641 (Fusilev)

These medications are classified as therapeutic. The following administration codes will be allowed when billing for these two codes:

## J0640 (Leucovorin)

| 96372         | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug);<br>subcutaneous or intramuscular.   |
|---------------|---|
| 96374         | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug);<br>intravenous push, single or initial substance/drug.  |
| J0641 (Fusile | ev) (requires prior authorization)  |
| 96365         | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.  |
| 96366         | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance<br>or drug); each additional hour (List separately in addition to code for primary<br>procedure). |

Catheter Care – not in conjunction with any other per diem, only when a standalone service

| Code  | Description   | Rule |
|-------|---|------|
| S5498 | Home infusion therapy, catheter care/<br>maintenance, simple (single lumen), includes<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment, (drugs and nursing visits<br>coded separately), per diem |      |



| Code   | Description  | Rule |
|--------|--|------|
| \$5501 | Home infusion therapy, catheter care/<br>maintenance, complex (more than one lumen),<br>includes administrative services, professional<br>pharmacy services, care coordination, and all<br>necessary supplies and equipment (drugs and<br>nursing visits coded separately), per diem   |      |
| S5502  | Home infusion therapy, catheter care/<br>maintenance, implanted access device, includes<br>administrative services, professional pharmacy<br>services, care coordination, and all necessary<br>supplies and equipment (drugs and nursing<br>visits coded separately), per diem (use this code<br>for interim maintenance of vascular access not<br>currently in use) |      |

# **Home Nursing**

| Code  | Description   | Rule |
|-------|---|------|
| 99601 | Home infusion/specialty drug administration, per visit (up to 2 hours);   |      |
| 99602 | Home infusion/specialty drug administration,<br>per visit (up to 2 hours); each additional hour<br>(List separately in addition to code for primary<br>procedure) |      |

# **Per Diem Code Modifiers**

| Code | Description  | Rule                        |
|------|--|-----------------------------|
| SH   | Second concurrently administered infusion therapy                                | Payable at 50%              |
| SJ   | Third or more concurrently administered infusion therapy                         | Payable at 50%              |
| SS   | Home infusion services provided in the infusion suite of the IV therapy provider | For Reporting Purposes Only |

# **Nursing Services**

Services are provided by an RN with special education, training, and expertise in home administration of drugs via infusion and home administration of specialty drugs.

Nursing services may be provided directly by infusion pharmacy nursing staff or by a qualified home health agency.

Home infusion vendors may subcontract with another agency for all or part of the nursing services. In these instances, the home infusion vendor:

- Assumes responsibility and oversight of care provided;
- Bills MVP for their services; and
- Is responsible to pay for all subcontracted services.



## Drugs

Contracted network pharmacies must be able to:

- Deliver home infused drugs in a form that can be easily administered in a clinically appropriate fashion;
- Provide infusible drugs for both short-term acute care and long-term chronic care therapies;
- Ensure that the professional services and ancillary supplies necessary for the provision of home infusion therapy are in place before dispensing home infusion drugs, consistent with the quality assurance requirement for Part D sponsors described in 42 CFR 423.153(c); and
- Provide covered home infusion drugs within 24 hours of discharge from an acute setting, unless the next required dose, as prescribed, is required to be administered later than 24 hours after discharge.

The drug HCPC code set is to be used for claim submission. NDC numbers should be submitted on the claim in the appropriate "additional information" locations on paper and electronic submissions. Refer to the <u>NDC Payment Policy</u> for additional billing information.

Prior authorization is required to receive reimbursement for the administration of a drug that is not on the fee schedule. Reimbursement will be based on the drug pricing process below. Refer to your vendor fee schedule for a list of billable drug codes and to MVP's *Benefit Interpretation Manual* or <u>Prescription Drug Formulary</u> to determine if a specific medication requires prior authorization.

Medications that are self-administered are not reimbursable under Home Infusion. MVP will cover one home infusion nurse visit for the initial self-administration teaching and one follow up visit if determined to be medically necessary. Charges for self-administered drugs are a pharmacy benefit and must be billed online to the pharmacy benefits manager. Supplies required for the administration of the drug during the teaching visit are global to the service and are not reimbursable separately.

MVP offers a Medicare Advantage Plan with and without Part D. Pharmaceuticals which are not covered under mandated medical benefits may be covered under the Part D Prescription Drug benefit if the member has that benefit. Ancillary Provider acknowledges that Ancillary Provider will be required to participate with MVP's or the member's Employer's Pharmacy Benefit Manager for MVP Part D.

# **Billable Units**

Billable Units represent the number of units in a product based on strength of the product per vial/ampule/syringe, etc., as it relates to the HCPCS or CPT Drug Code description. For example:

| Code J0290 - Injection, | , ampicillin sodium | , 500 mg |
|-------------------------|---------------------|----------|
|-------------------------|---------------------|----------|

| Injection, ampicillin sodium <b>500 mg/vial</b> = 1.0 billable unit   | Injection, ampicillin sodium <b>1 gm/vial</b> = 2.0 billable units  |
|---|---|
| Injection, ampicillin sodium <b>250 mg/vial</b> = 0.50 billable unit  | Injection, ampicillin sodium <b>2 gm /vial</b> = 4.0 billable units |
| Injection, ampicillin sodium <b>125 mg/via</b> l = 0.25 billable unit | Injection, ampicillin sodium <b>10gm/vial</b> = 20.0 billable units |

Billable Units per package are the number of units in the entire package as it relates to the HCPCS or CPT<sup>®</sup> drug code.

# **Wastage Policy**

In cases where therapy is terminated or interrupted, MVP will reimburse Ancillary Provider for drugs and supplies (per diem) which are dispensed to the Member and which are non-returnable, up to a seven-day supply. Drugs will be reimbursed at the contracted rate and the supplies (per diem) will be reimbursed at 50% of the contracted rate beginning on the first day of the termination or interruption. MVP will resume full reimbursement of drugs and supplies (per diem) on the first day services have resumed. Documentation must be available regarding interruption/ discontinuation of therapy and resumption of therapy services.



# **TPN and Peripheral Parenteral Nutrition (PPN) Per Diem**

Standard TPN formula includes the following components: non-specialty amino acids, concentrated dextrose, sterile water, electrolytes, standard trace elements, standard multivitamins, and home additives including but not limited to insulin and heparin.

Components not included in standard TPN formula are specialty amino acids, lipids, Tagamet, and antibiotics. Such components are billed on claims with HCPCS medication codes, NDC number of covered medications, description of product, dosage, and units administered.

# **Medicare Variation**

All claims for enteral and parenteral products must meet the current NCD and/or LCD policies for coverage. All claims may be subject to retrospective review to determine coverage. Enteral nutrition which does not meet the coverage criteria identified in the NDC and/LCD and supplemental nutrition are not covered benefits under either Part B or Part D. Parenteral nutrition which does not meet the coverage criteria identified in the NCD and/or LCD may be covered under the Part D benefit.

Intradialytic Parenteral Nutrition (IDPN) is considered a Part D compound and must be billed to the pharmacy vendor. Intraperitoneal Nutrition (IPN) is considered a Part B benefit, even when a pharmacy or home infusion vendor adds amino acids or other ingredients to the dialysate. Non-covered drugs such as sterile water are considered to be part of the per diem and should not be billed independently.

Refer to the Medicare Part D formulary for drugs that may be covered under the Part D benefit.

# References

Centers for Medicare and Medicaid Services memo. IPDN/IPN Coverage under Medicare Part D. distributed 10/5/12

| June 1, 2019  | New policy, approved                          |
|---------------|---|
| June 1, 2020  | Policy reviewed and approved with no changes  |
| March 1, 2022 | Policy reviewed and apprroved with no changes |



# Incident to Guidelines

Last Reviewed Date: December 1, 2022

# INCIDENT TO GUIDELINES

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Reimbursement Guidelines History

# Policy

Reimbursement of services and supplies incident to the professional services of a physician in private practice is limited to situations in which there is direct physician supervision of auxiliary personnel.

# Definitions

**Incident to a physician's professional services** means that the services or supplies are furnished as an integral, although incidental, part of the physician's personal professional services in the course of diagnosis or treatment of an injury or illness.

**Auxiliary personnel** means any individual who is acting under the supervision of a physician, regardless of whether the individual is an employee, leased employee, or independent contractor of the physician, or of the legal entity that employs or contracts with the physician. Likewise, the supervising physician may be an employee, leased employee, or independent contractor of the legal entity billing and receiving payment for the services or supplies.

**Direct supervision in the office** setting does not mean that the physician must be present in the same room with his or her aide. However, the physician must be present in the office suite and immediately available to provide assistance and direction throughout the time the aide is performing services.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

## **General Guidelines**

When a physician supervises auxiliary personnel to assist him/her in rendering services to patients and includes the charges for their services in his/her own bills, the services of such personnel are considered incident to the physician's service if there is a physician's service rendered to which the services of such personnel are an incidental part and there is direct supervision by the physician.

## Services may be provided incident to when:

- The physician has performed an initial service.
- The patient is an established patient with an established diagnosis.
- They are part of a continuing plan of care in which the physician will be an ongoing and active participant. The physician does not need to see the patient every visit, but must prescribe the plan of care and actively manage it.



- There is a physician's service to which the rendering providers' services relate.
- They involve a face-to-face encounter.
- The physician is physically present in the same office suite to provide supervision.

#### **Documentation requirements:**

- A clearly stated reason for the visit
- A means of relating this visit to the initial service and/or ongoing service provided by the physician
- Patient's progress, response to, and changes/revisions in the plan of care
- Date the service was provided
- Signature of person providing the service
- While co-signature of the supervising physician is not required, documentation should contain evidence that he or she was actively involved in the care of the patient, and was present and available during the visit.

# **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

| December 2, 2018  | Policy approves                              |
|-------------------|--|
| December 1, 2019  | Policy reviewed and approved with no changes |
| September 1, 2021 | Policy reviewed and approved with no changes |
| December 1, 2022  | Policy reviewed and approved with no changes |



# Infusion Policy

Last Reviewed Date: March 1, 2022

#### INFUSION POLICY

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines References History

# Policy

MVP reimburses providers for the following infusion services when provided in a contracted office, or outpatient setting, only on the days members receives IV therapy services:

- Administration of the medication
- Medication (not self-administered)

# Definitions

## **Infusion Therapy**

Infusion therapy is the continuous, controlled administration of a drug, nutrient, antibiotic, or other fluid into a vein or other tissue on a daily, weekly, or monthly basis, depending on the condition being treated and the type of therapy.

## **Medical Necessity for Infusion Therapy**

Infused drug is determined to meet medical necessity criteria for infusion in office or outpatient facility site when home infusion is the preferred site of care. Refer to MVP Pharmacy policies for drugs subject to this requirement.

## **Types of Infusion**

Push Technique: When medication is injected through a catheter placed in a vein or artery.

Intrathecal: When medication is injected into the spinal cord through a catheter placed through the space between the lower back bones (via lumbar puncture).

## **Medical Necessity for Infusion Therapy**

Therapeutic (hydration or medication therapy - e.g. chemotherapy, IVIG)

Prophylactic (Injections/infusions to prevent "side effects" - e.g. ondansetron)

Diagnostic (evocative/provocative testing; cortisol stimulation testing)

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

# **Drugs/Medications**

MVP requires all providers to bill using the standard HCPCS and also the 11-digit National Drug Code (NDC) which represents the drug and drug strength, manufacturer and package size used/administered.



Some medications require prior authorization. Refer to the <u>MVP Formulary</u> for specific drugs that require prior authorization.

MVP will provide coverage for drugs that meet medical necessity criteria and meet the site of care requirements noted in this policy.

Administration of the drug via injection/infusion is medically necessary when the member's condition cannot be appropriately treated with alternative dosage forms of medication (e.g. oral, topical or SQ) or the therapy is not available in alternative dosage forms and achieve the same or equivalent therapeutic effect.

All components of the infusion/injection must meet medical necessity criteria and be medically necessary for the member's condition for the infusion/injection to be covered.

## J0640 (Leucovorin) and J0641 (Fusilev)

These medications are classified as therapeutic. The following administration codes will be allowed when billing for these two codes:

#### J0640 (Leucovorin)

| 96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular.                      |
|-------|---|
| 96374 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug. |

#### J0641 (Fusilev) (requires prior authorization)

| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour.  |
|-------|---|
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance<br>or drug); each additional hour (List separately in addition to code for primary<br>procedure). |

## **Miscellaneous Drug Codes**

| Code                           | Description              | Rule  |
|--------------------------------|--------------------------|---|
|                                |                          | Drugs over \$50 must be reviewed by MVP and 1 of the following pieces of information must be submitted: |
| A9699, J3490,<br>J3590, J7199, |                          | <ul> <li>An invoice for the drug must be submitted with the claim.</li> </ul>                           |
|                                | Miscellaneous drug codes | OR  |
|                                |                          | • A valid NDC number for the drug is required to be submitted on the claim.                             |
|                                |                          | • An invoice for the drug must be submitted with the claim. <b>OR</b>                                   |

Items excluded and are non-reimbursable, include but are not limited to:

- Diluents/solution for administration of medication
- Flushing solution including heparin and saline

Refer to the <u>MVP Formulary</u> for medications that must be obtained from MVP's specialty pharmacy vendor. Diagnosis and quantity edits apply only when drugs are billed directly to MVP using the applicable J-code.



Peripherally Inserted Central Catheter (PICC) Line placement does not guarantee approval or payment of the medication to be infused if medication does not meet medical necessity criteria or requires prior authorization.

Drugs determined to be self-administrable and eligible for coverage under the Prescription Drug benefit.

## **Medicare Variation**

All claims for enteral and parenteral products must meet the current NCD and/or LCD policies for coverage. All claims may be subject to retrospective review to determine coverage. Enteral nutrition which does not meet the coverage criteria identified in the NDC and/LCD and supplemental nutrition are not covered benefits under either Part B or Part D.

Parenteral nutrition, which does not meet the coverage criteria identified in the NCD and/or LCD, may be covered under the Part D benefit.

Intradialytic Parenteral Nutrition (IDPN) is considered a Part D compound and must be billed to the pharmacy vendor. Intraperitoneal Nutrition (IPN) is considered a Part B benefit, even when a pharmacy or home infusion vendor adds amino acids or other ingredients to the dialysate. Non- covered drugs such as sterile water are considered to be part of the per diem and should not be billed independently

# References

Remicade (infliximab) Injection. Prescribing Information. Horsham, PA: Janssen Biotech, Inc.; October 2011.

Avastin (bevacizumab) Injection. Prescribing Information. South San Francisco, CA: Genentech, Inc.; 21 December 2011.

Neulasta (pegfilgrastim) Injection. Prescribing Information. Thousand Oaks, California: Amgen Manufacturing, Limited; 2/2010.

Rituxan (rituximab) Injection. Prescribing Information. South San Francisco, Ca: Genentech Inc.; February 2012.

HERCEPTIN® [trastuzumab] Injection. Prescribing Information. South San Francisco, Ca: Genentech Inc.; October 2010.

Zometa<sup>®</sup> (zoledronic acid) Injection. Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2011.

ALOXI<sup>®</sup> (palonosetron hydrochloride) Injection. Prescribing Information. Albuquerque, NM: OSO Biopharmaceuticals, LLC; 06/09.

Velcade (bortezomib) Injection. Prescribing Information. Cambridge, MA: Millennium Pharm, Inc; 2012.

Tysabri (natalizumab) for Injection. Prescribing Information. Cambridge, MA: Biogen Idec Inc. 9/2011.

Sandostatin LAR<sup>®</sup> Depot (octreotide acetate) Injection. East Hanover, NJ: Novartis Pharmaceuticals Corporation 2011.

Luent is (ranibizumab) Injection. Prescribing Information. South San Francisco, CA: Genentech, Inc.; June 2010.

Orencia (abatacept) Injection. Prescribing Information. Princeton, NJ: Bristol-Myers Squibb; December 2011.

Reclast (zoledronic acid Injection). Prescribing Information. East Hanover, NJ: Novartis Pharmaceutical Corporation; August 2011.

ZOFRAN<sup>®</sup> (ondansetron hydrochloride) Injection. Prescribing Information. Research Triangle Park, NC. GlaxoSmithKline; September 2011.

TAXOTERE® (docetaxel) Injection. Prescribing Information. Bridgewater, NJ: sanofi-aventis U.S. LLC. 2010.

National Government Services, Article for zoledronic acid (e.g. Zometa, Reclast) – related to LCD L25820 (A46096). Accessed 3/08/2012: <u>cms.hhs.gov/mcd/results.asp?show=all&t=2009105112826</u>.

Centers for Medicare and Medicaid Services memo. IPDN/IPN Coverage under Medicare Part D. distributed 10/5/12.



- March 1, 2019 New policy, approved
- March 1, 2022 Policy reviewed and approved with no changes



# Interpreter Services Medicaid Products

Last Reviewed Date: March 1, 2023

# INTERPRETER SERVICES

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Reimbursement Guidelines References History

# Policy

The need for medical language interpreter services must be documented in the medical record and must be provided during a medical visit by a third-party interpreter, who is either employed by or contracts with the Medicaid provider.

# Definitions

These services may be provided either face-to-face or by telephone. The interpreter must demonstrate competency and skills in medical interpretation techniques, ethics, and terminology. It is recommended, but not required, that such individuals be recognized by the National Board of Certification for Medical Interpreters (NBCMI).

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Reimbursement of medical language interpreter services is payable with HCPCS procedure code T1013- sign language and oral interpretation services and is billable during a medical visit. Medical language interpreter services are included in the prospective payment system rate for those FQHCs that do not participate in APG reimbursement.

# **Reimbursement for units is as follows:**

**T1013** Includes a minimum of 8 and up to 22 minutes of medical language interpreter services.

**T1013** Includes a minimum of 23 or more minutes of medical language interpreter services.

Code T1013 must be billed in units of 2 in order to be reimbursed at the appropriate rate.

Reimbursement is limited to Medicaid products only. All other MVP products will deny, as these services are not reimbursable.

# **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

# References

NYS Medicaid Update: health.ny.gov/health\_care/medicaid/program/update/2012/2012-10.htm

| December 1, 2018 | New policy, approved                         |
|------------------|--|
| December 1, 2019 | Policy reviewed and approved with no changes |
| March 1, 2022    | Policy reviewed and approved with no changes |
| March 1, 2023    | Policy reviewed and approved with no changes |



# JW and JZ Modifiers

Last Reviewed Date: March 1, 2023

# JW AND JZ MODIFIERS

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines References History

# Policy

MVP encourages physicians, hospitals, and other providers and suppliers to schedule patients in such a way that they can administer drugs or biologicals efficiently and in a clinically appropriate manner and minimize the amount of drug wastage.

# Definitions

When a physician, hospital, or other supplier must discard the remainder of a **single use vial** or **other single use package** after administering a dose/quantity of the drug or biological, payment will be made for the amount of the drug or biological discarded as well as the dose administered, up to the amount of the drug or biological as indicated on the vial or package label.

# **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must also confirm Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into the Provider's account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

JW modifier must be used to identify unused drugs or biologicals from single use vials or single use packages that are appropriately discarded. The use of this modifier is not appropriate for drugs that are from multiple-dose containers. This program provides payment for the amount of drug or biological (hereafter "drug") discarded along with the amount administered up to the amount of the drug or biological indicated on the vial or package label. The smallest vial or package size needed to administer the appropriate dose should be used.

This JW modifier must be billed on a separate line and will provide payment for the amount of the discarded drug or biological. Drug wastage must be documented in the patient's medical record with the date, time, amount wasted, and reason for wastage. Upon review, any discrepancy between amount administered to the patient and amount billed may be denied as non-rendered unless the wastage is clearly and accurately documented. The amount billed as "wasted" must not be administered to another patient or billed to either MVP or another carrier. Drug wastage cannot be billed if none of the drug was administered (e.g. missed appointment).

Under Medicare Part B only, the JZ modifier must be reported on a claim to attest that no amount of drug was discarded and eligible for payment. The JZ modifier is required when there are no discarded amounts of a single-dose container drug for which the JW modifier would be required if there were discarded amounts. The JZ modifier will be required on claims for single-dose container drugs to attest when there are no discarded amounts no later than July 1, 2023.

Example of when JW Modifier IS required:

A single use vial that is labeled to contain 100 units of a drug has 95 units administered to the patient and five units discarded. The 95-unit dose is billed on one line, while the discarded five units may be billed on another line by using the JW modifier. Both line items would process for payment.



Example of when JW Modifier IS NOT required and JZ Modifier IS required if under Medicare Part B:

A billing unit for a single drug is equal to 10mg. A 7mg dose is administered to a patient and 3mg is discarded. The 7mg dose is billed as 10mg on a single line item because the billing unit for this drug is already established at 10mg regardless of how much was administered. The claim would be processed as a single line item for 10mg, which includes the 7mg administered and the 3mg discarded. Billing another unit on a separate line item with the JW modifier for the discarded 3mg of the drug is not permitted because it has already been accounted for. In this example, the actual dose of the drug or biological being administered is less than the billing unit so the JW modifier would not apply. To attest that there was no waste, a JZ Modifier must be submitted.

# References

Medicare Claims Processing Manual: cms.gov/manuals/downloads/clm104c17.pdf

Article - Billing and Coding: JW Modifier Billing Guidelines (A53024) (cms.gov)

Medicare Program Discarded Drugs and Biologicals – JW Modifier and JZ Modifier Policy Frequently Asked Questions: <u>https://www.cms.gov/medicare/medicare-fee-for-service-payment/hospitaloutpatientpps/downloads/jw-modifier-faqs.pdf</u>

| New policy, approved                         |
|--|
| Policy reviewed and approved with no changes |
| Policy reviewed and approved with no changes |
| Policy reviewed and approved with chaanges   |
| Policy reviewed and approved with changes    |
|  |



# Laboratory Services

Last Reviewed Date: March 1, 2023

#### LABORATORY SERVICES

- Policy Notification/Prior Authorization Requests Documentation Guidelines Billing/Coding Guidelines Place of Service Date of Service Date of Services Reference Laboratory Modifier 90 Laboratory Services Performed In a Facility Setting
- Drug Testing Specimen Validity Test Incomplete Laboratory Panels Medicare Medically Unlikely Edits Vitamin D Testing Vitamin B Testing Use of Non-Contracted Labs Non-Covered Services Reimbursement Guidelines History

# Policy

This policy describes the reimbursement methodology for outpatient laboratory tests.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Documentation Guidelines**

According to CMS, the physician or other qualified health care professional who is treating the patient must order all diagnostic laboratory tests, using these results in the management of the patient's condition. Tests not ordered by the physician or other qualified health care professional are not reasonable and necessary.

The physician's or other qualified health care professional's documentation should clearly indicate all tests to be performed. The documentation must include the following:

- Progress notes or office notes signed by the physician or other qualified health care professional
- Physician or other qualified health care professional order/intent to order Laboratory results

# **Billing/Coding Guidelines**

MVP follows Medicare coding and requires providers to submit the correct codes per Medicare guidelines.

# **Place of Service**

The place of service (POS) designation identifies the location where the laboratory service was provided, except in the case of an Independent or a Reference Laboratory.

An Independent or Reference Laboratory must show the place where the sample was taken. If drawn in an Independent Lab or a Reference Lab, report POS 81.



If an independent laboratory bills for a test on a sample drawn on an inpatient or outpatient of a hospital, it reports the code for the inpatient (POS code 21) or outpatient hospital (POS code 22), respectively.

# **Date of Service**

In general, the date of service (DOS) for clinical diagnostic laboratory tests is the date of specimen collection unless the physician orders the test at least 14 days following the patient's discharge from the hospital. When the "14-day rule" applies, the DOS is the date the test is performed, instead of the date of specimen collection.

In the CY 2018 Hospital Outpatient Prospective Payment System (OPPS)/Ambulatory Surgical Center (ASC) final rule published Dec. 14, 2017, CMS established another exception to laboratory DOS policy for Advanced Diagnostic Laboratory Tests (ADLTs) and molecular pathology tests excluded from OPPS packaging policy so that the DOS is the date the test was performed, if certain conditions are met. Specifically, in the case of a molecular pathology test or an ADLT that meets the criteria of section 1834A(d)(5)(A) of the Social Security Act, the date of service must be the date the test was performed only if the following conditions are met:

- 1. The test is performed following a hospital outpatient's discharge from the hospital outpatient department;
- 2. The specimen was collected from a hospital outpatient during an encounter (as both are defined 42 CFR 410.2);
- 3. It was medically appropriate to have collected the sample from the hospital outpatient during the hospital outpatient encounter;
- 4. The results of the test do not guide treatment provided during the hospital outpatient encounter; and
- 5. The test was reasonable and medically necessary for the treatment of an illness.

# **Duplicate Services**

Separate consideration will be given to repeat procedures (i.e., two laboratory procedures performed the same day) by the Same Group Physician or Other Health Care Professional when reported with modifier 91. Modifier 91 is appropriate when the repeat laboratory service is performed by a different individual in the same group with the same Federal Tax Identification number.

According to CMS and CPT guidelines, Modifier 91 is appropriate when, during the course of treatment, it is necessary to repeat the same laboratory test for the same patient on the same day to obtain subsequent test results, such as when repeated blood tests are required at different intervals during the same day.

# **Reference Laboratory**

## **Reference Laboratory and Non-Reference Laboratory Providers**

If a reference laboratory and a non-reference laboratory provider both submit identical or equivalent bundled laboratory codes (excluding 82947 and 82948) for the same patient on the same date of service (plus or minus one business day), only the reference laboratory service is reimbursable, unless the 77 modifier is appended to codes from the non-reference laboratory provider.

## **Pathologist and Physician Laboratory Providers**

If a pathologist and another physician or other qualified health care professional's offices submit identical laboratory codes for the same patient on the same date of service, only the pathologist's service is reimbursable.



#### **Reference Laboratory and Unrelated Reference Laboratory Provider**

If a reference laboratory and an unrelated reference laboratory provider submit identical codes for the same patient on the same date of service, both reference laboratories are reimbursable if one laboratory appends an appropriate modifier (Modifier 77 or 90) to the codes submitted.

# **Modifier 90**

MVP reimburses physicians or other qualified health care professionals submitting claims with modifier 90 when tests are being performed by outside reference laboratories. The reference laboratory service supersedes services billed by a non-reference laboratory. for example, in the event a non-reference laboratory provider reports a laboratory service with modifier 90 and a reference laboratory reports the same service on the same day, the non-reference laboratory provider's service reported with modifier 90 will be denied. Otherwise, if no reference laboratory service is reported, the non-reference laboratory service will modifier 90 will be allowed.

# Laboratory Services Performed In a Facility Setting

Manual and automated laboratory services submitted by a reference or non-reference Laboratory Provider with a CMS facility POS 19, 21, 22, 23, 26, 34, 51, 52, 56, or 61 will not be reimbursable. These services are reimbursable to the facility. When facilities obtain manual or automated laboratory tests

for patients under arrangements with a Reference Laboratory or pathology group, only the facility may be reimbursed for the services.

# **Drug Testing**

IUrine drug testing is performed to detect the use of prescription medications and illegal substances of concern for the purpose of medical treatment. Confirmatory testing is an additional test completed to verify the results of the urine drug test. Urine drug testing should not routinely include a panel of all drugs of abuse. The test should be focused on the detection of specific drugs/drug metabolites. The frequency of testing should be at the lowest level to detect the presence of drugs.

If the provider of the service is other than the ordering/referring physician, that provider must maintain printed copy documentation of the lab results, along with printed copies of the ordering/referring physician's order for the qualitative drug test. The physician must include the clinical indication/medical necessity in the order for the qualitative drug test.

All urine drug testing should be performed at an appropriate frequency based on clinical needs. Substance abuse treatment adherence is often best measured through random testing rather than frequent scheduled testing.

MVP does not cover urine drug testing in any of the following circumstances:

- Testing ordered by third parties, such as school, courts, or employers, or requested by a provider for the sole purpose of meeting the requirements of a third party.
- Testing for residential monitoring.
- Routine urinalysis for confirmation of specimen integrity.

#### **Definitive Drug Testing**

MVP has set a maximum of 18 units of definitive drug testing for codes G0480-G0483 per year.

## **Qualitative Drug Testing**

MVP has set a qualitative (presumptive) drug screening annual limit of 18 for CPT codes 80305-80307



# **Specimen Validity Test**

MVP does not reimburse for specimen validity testing. The following codes will deny the same day as drug testing unless modifier 59 is submitted to indicate that the testing is not being performed for specimen validity. The records must also support that the urinalysis performed was not for specimen validity testing and the modifier was appropriately reported

Codes denied- 81000-81003, 81005, 81099, 82570, 83986, 84311

# **Incomplete Laboratory Panels**

MVP does not routinely compensate for the following, as additional laboratory components of a panel are included in the price of the laboratory panel code itself.

#### **Basic metabolic panel**

- More than two basic metabolic panel procedure codes when submitted on the same date of service.
- More than one of the following procedure codes (82040, 82247, 84075, 84460, 84450, 84155) when billed with a basic metabolic panel procedure code on the same date of service.

#### **Comprehensive metabolic panel**

 More than three comprehensive metabolic panel procedure codes when submitted on the same date of service

#### **Electrolyte panel**

More than two electrolyte panel procedure codes when submitted on the same date of service

#### Hepatic function panel

More than two hepatic function panel procedure codes when submitted on the same date of service

#### **Renal function panel**

• More than three renal function panel procedure codes when submitted on the same date of service

# **Medicare Medically Unlikely Edits**

MVP follows the recommendation from Medicare regarding the Medically Unlikely Edits (MUE). An MUE for an HCPCS/ CPT code is the maximum units of service that a provider would report under most circumstances for a single member on a single date of service.

# **Vitamin D Testing**

MVP will only reimburse for vitamin D testing when there is a known diagnosis or condition associated with Vitamin D deficiency. Vitamin D testing for any other indication including screening is not considered reimbursable. Please see MVP Diagnosis Matching Edits for approved diagnoses.

Code 82306 is only reimbursable up to three times per year. Code 82652 up to two times per year.

# **Vitamin B Testing**

MVP will only reimburse for vitamin B testing when there is a known diagnosis or condition associated with Vitamin B deficiency. Vitamin B testing for any other indication including screening is not considered reimbursable. Please see MVP Diagnosis Matching Edits for approved diagnoses.

CPT code 82607 will only be reimbursed up to 3 times per calendar year. Code 84425 will only be reimbursed once per calendar year.



# **Diagnosis Matching Edits**

MVP will adopt laboratory to diagnosis matching edits and laboratory testing coverage changes as outlined below, based on specific evidence-based guidelines targeting reduction of low value care. Please see MVP Diagnosis Matching Edits for approved diagnoses.

| CPT Code | CPT Code Description for Diagnosis Matching Edits |
|----------|---|
| 82746    | Assay of Folic Acid Serum                         |
| 82785    | Assay of Gammaglobulin Ige                        |
| 83001    | Gonadotropin Follicle Stimulating Hormone         |
| 84480    | Assay of Triiodothyronine T3 Total Tt3            |
| 84481    | Assay of Triiodothyronine T3 Free                 |
| 85652    | Sedimentation Rate RBC Automated                  |
| 86003    | Allergen Spec IGE Crude Allergen Extract Each     |
| 86008    | Allergen Spec IGE Recombinant/Purified Compnt Ea  |
| 86695    | Antibody Herpes SMPLX Type 1                      |
| 86696    | Antibody Herpes SMPLX Type 2                      |

# **Use of Non-Contracted Labs**

MVP participating providers must use participating labs. Use of non-participating labs must be approved by MVP when no participating lab is available. Non-contracted labs may have the unintended consequence of subjecting the Member to unnecessary services not ordered by the treating provider or other unreasonable financial exposure. In such circumstances, MVP may hold the ordering physician accountable for any inappropriate behavior on the part of the non-participating lab that is selected.

Before usage of a non-par lab, you must:

- 1. Discuss options and costs with the member:
  - Review this policy and have the member sign a specific consent form regarding the usage of a non-par lab
  - Provide participating care provider alternatives and explain the reason for using the non-participating care provider
  - Discuss the cost of using a non-participating care provider
    - If the member has out-of-network benefits, they can use those benefits to see a non-participating care provider. However, they may pay more when using them.
    - Members who do not have out-of-network benefits may have to high costs or pay all the costs for the non-participating care provider.

# **Non-Covered Services**

- Laboratory and pathology services that are rendered in conjunction with an inpatient stay or an observation stay. (They are included in the respective global payment; for example, DRG, per diem, etc.)
- Handling charges



- Specimen collection
- Routine venipuncture charges made in conjunction with blood or related laboratory services or evaluation and management services
- Paternity blood tests
- NAbFeron (IFNb) antibody test
- Mandated drug testing (e.g., court-ordered, residential monitoring, non-medically necessary testing)
- Laboratory and pathology services submitted with unlisted CPT codes when an appropriate specific code is available
- Laboratory and pathology services provided at no charge by state agencies, including but not limited to pertussis and rubella
- Drugs, devices, treatments, procedures, laboratory and pathology tests that are experimental, unproven, or investigational and not supported by evidence-based medicine and established peer reviewed scientific data
- Employment drug screening
- NAB (neutralizing antibody testing) in multiple sclerosis patients
- · Lipoprotein subclass testing in the evaluation of cardiovascular disease
- Quantitative urine drug testing where there has been no underlying qualitative test or where the qualitative test is negative

| CPT Code | CPT Code Description                                | Laboratory Services Policy Updates  | Reference   |
|----------|---|---|---|
| 82150    | ASSAY OF AMYLASE                                    | Do not test for amylase in cases of suspected acute<br>pancreatitis. Instead, test for lipase. MVP will deny<br>the code below if billed on the same day as Lipase<br>(83690).  | Per the American Society<br>for Clinical Pathology (see<br><u>website</u> for more details)       |
| 89300    | SEMEN ALYS PRESENCE&/<br>MOTILITY SPRM HUHNER       | Do not perform a postcoital test (PCT) for the  | Per the American Society<br>of Reproductive Medicine<br>(see <u>website</u> for more<br>details). |
| 89310    | SEMEN ALYS MOTILITY&CNT X<br>W/HUHNER TST           | evaluation of infertility. MVP will no longer cover the code listed below going forward.  |   |
| 86001    | ALLERGEN SPECIFIC IGG QUAN/<br>SEMIQUAN EA ALLERGEN | The American Society of Clinical Pathology does not   | Per the American Society<br>for Clinical Pathology (see<br><u>website</u> for more details)       |
| 86005    | ALLERGEN SPEC IGE QUAL<br>MULTIALLERGEN SCREEN      | support the following codes when performing IgG lab testing   |   |
| 85652    | SEDIMENTATION RATE RBC<br>AUTOMATED                 | Do not order an erythrocyte sedimentation rate<br>(ESR) to look for inflammation in patients with<br>undiagnosed conditions. Order a C-reactive protein<br>(CRP) to detect acute phase inflammation. MVP will<br>deny the code below if billed on the same day as<br>CRP (86140). | Per the American Society<br>for Clinical Pathology (see<br><u>website</u> for more details).      |
| 82747    | ASSAY OF FOLIC ACID RBC                             | The American Society of Clinical Pathology does not<br>support the following codes when performing Folic<br>Acid lab testing  | Per the American Society<br>for Clinical Pathology (see<br><u>website</u> for more details)       |
| 86677    | ANTIBODY HELICOBACTER<br>PYLORI                     | Do not request serology for H. pylori. Use the stool<br>antigen or breath tests instead. MVP will no longer<br>cover the code listed below going forward.   | Per the American Society for Clinical Pathology (see <u>website</u> for more details).            |



# **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

| December 1, 2018 | New policy, approved                         |
|------------------|--|
| December 1, 2019 | Policy reviewed and approved with changes    |
| October 1, 2020  | Policy reviewed and approved with changes    |
| March 1, 2022    | Policy reviewed and approved with no changes |
| March 1, 2023    | Policy reviewed and approved with no changes |



# Locum Tenens

Last Reviewed Date: June 1, 2022

#### LOCUM TENENS

| Policy   |
|--|
| Definitions  |
| Notification/Prior Authorization Requests  |
| Billing/Coding Guidelines  |
| Medical Group Claims   |
| Billing/Coding Guidelines for Locum Tenens for Physician Who has Left the Practice |
| References   |
| History  |
|  |

# Policy

## Locum Tenens for a physician under leave of absence:

Participating Provider Physicians may retain substitute physicians to take over their professional practices when the Participating Provider physicians are absent for reasons such as illness, pregnancy, vacation, deployment in armed forces, or continuing medical education. The Participating Provider physician can bill and receive payment for the substitute physician's Covered Services as though they performed the Covered Services themselves. The Locum Tenens cannot be an employee of the regular Participating Provider and should be paid for their services on a per diem or similar fee-for-time basis. Locum Tenens may only substitute for a Participating Provider physician for a maximum of 60 days. Locum Tenens can also cover for Participating Provider Physical Therapists.

## Locum Tenens for a physician that has left the practice:

MVP does not allow Participating Provider practices to retain a substitute physician when a Participating Provider physician has left the Participating Provider practice and will not return. The Locum Tenens, if substituting for a Participating Provider who left a practice, must be contracted and Credentialed with MVP and bill under their own provider NPI, and will be reimbursed per the terms of the Provider Agreement with MVP. At MVPs sole discretion and any applicable Medicare Requirements, Participating Provider practice in a health professional shortage area, medically under-served area, or rural area may request an exception to this policy. If approved by MVP, the Locum Tenens provider is limited to the 60 days and is required to meet all MVP Registration requirements (in lieu of full Credentialing).

# Definitions

## **Locum Tenens or Substitute Physician**

A substitute physician who works in place of a Regular Physician when the Regular Physician has taken a leave of absence

# **Regular Physician**

Includes a Participating Provider physician (or Physical Therapist) who is absent for reasons such as illness, pregnancy, vacation, deployment in armed forces, or continuing medical education.

# **MVP Policies/Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Participating Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Participating Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. Locum Tenens are required to abide by all MVP P Protocols including the Benefits Interpretation Manual, Provider Resource Manual, and Payment Policies. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.



# **Billing/Coding Guidelines for Locum Tenens**

All claims for Covered Services should be submitted under the Member's Regular Physician if performance deficiencies and corrective actions related to performance issues. In addition, MVP reports any serious or significant health and safety concerns to OMH and OASAS immediately upon discovery.

performed by a Locum Tenens provider. The Covered Services performed by a Locum Tenens are not restricted to the Regular Physician's office if the following guidelines are met:

- The Member had arranged or seeks to receive the Covered Services from the Regular Physician.
- The Regular Physician pays the Locum Tenens for their services on a per diem or similar fee-for-time basis.
- The Locum Tenens does not provide Covered Services to Members over a continuous period of more than sixty (60) days. If there is a break after the initial 60 days of Locum Tenens service, the same Locum Tenens may be used to provide services again.

The Regular Physician must bill using their NPI and enter the HCPCS Q6 modifier (services furnished by a Locum Tenens physician) after the procedure code. If the only Covered Services performed by a Locum Tenens are postoperative Covered Services furnished during the post-operative period covered, such Covered Services, HCPCS Q6 modifier is not required.

# **Participating Provider Group Claims**

Participating Provider groups submitting claims for Covered Services provided to Members by a Locum Tenens physician for a Regular Physician must meet the requirements set forth in this Policy. For purposes of these requirements, per diem or similar fee-for-time compensation that the Participating Provider group pays the Locum Tenens physician is considered paid by the Regular Physician.

Participating Provider Group must keep accurate files of Covered Services provided by the Locum Tenens physician associated with the Locum Tenens physician's NPI and make this record available upon request.

# Billing/Coding Guidelines for Locum Tenens for Physician Who has Left the Practice

Except as outline in this policy, Locum Tenens may not be used on a per-diem or similar fee-for-time basis to provide Covered Services on a temporary basis when a Participating Provider has left the practice. Providers filling in for a Participating Provider who has left the practice must follow all applicable MVP Credentialing or Registrations requirements based on their specialty and location of practice.

# References

MVP Credentialing and Recredentialing of Practitioners

CMS Guidelines: cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/Downloads/MM10090.pdf

| March 1, 2019 | Policy approved   |
|---------------|---|
| March 1, 2020 | Changes to policy regarding health professional shortage area |
| March 1, 2021 | Policy reviewed and approved with no changes                  |
| June 1, 2022  | Policy reviewed and approved with no changes                  |



# Mental Health and Substance Use Disorder

Last Reviewed Date: March 1, 2023 Related Policies–MVP Behavioral Health <u>Policy</u> MVP Claims <u>Section</u> Policy Definitions Billing/Coding Guidelines Reimbursement Guidelines Notifications/ Prior Authorization Request References History

# Policy

This policy applies to the Medicaid Managed Care Plans (including Health and Recovery Plans ("HARP"), Essential Health Plans, Exchange Plans, Child Health Plus (CHP) Plans, Commercial Plans, Medicare Advantage Plans, and Dual Eligible Special Needs Plans (D-SNP). Requirements for each are set forth below.

MVP reimburses Participating Providers for Medically Necessary Behavioral Health and Substance Use Disorders Covered Services. This policy documents administrative rules and requirements needed for behavioral health claim payment. Covered Services and payments are based on the Member's Benefit Plan terms in Provider Agreement. In addition to the guidelines in this policy, MVP uses claims payment rules supported by the American Medical Association, National Correct Coding Initiative, ClaimsXten, and other MVP administrative guidelines. For specific NYS Medicaid Managed Care CPT codes and rate codes by services, MVP follows the applicable State and Federal guidance.

# **Mental Health Parity**

In accordance with federal and state laws and regulations, MVP has conducted non-quantitative treatment limitation ("NQTL") comparability and stringency analyses. MVP maintains these NQTL and other parity standards as operational policies that align with the Mental Health Parity and Addiction Equity Act of 2008 ("MHPAEA"), the Consolidated Appropriations Act of 2021, and various guidance issued by the NYS Department of Financial Services (DFS), NYS Department of Health (DOH), NYS Office of Mental Health (OMH), and the U.S. Department of Labor.

# **Billing/Coding Guidelines**

All Behavioral Health Participating Providers must submit claims using the correct forms and CPT and HCPCS codes and billing guidelines.

For those benefits covered by Commercial plans, MVP follows Medicare Advantage payment rules unless otherwise specified in the Provider Contract, State or Federal Regulations, should be listed or as outlined below. Medicaid, HARP and CHP reimbursement follows all relevant State-specific guidance and requirements and can be found below.

# **Electroconvulsive Therapy (ECT)**

MVP will reimburse for electroconvulsive therapy when performed by a psychiatrist.

# Transcranial Magnetic Stimulation (TMS)

MVP will reimburse psychiatrists for Transcranial Magnetic Stimulation.

## **Psychological and Neuropsychological Therapy**

MVP will reimburse licensed physicians, doctorate-level psychologists, and qualified technicians for psychological and neuropsychological testing.



#### **Evaluation and Management Codes**

MVP will reimburse psychiatrists and psychiatric nurse practitioners according to the terms of their agreements with MVP. We expect claims to be submitted with the appropriate outpatient E&M CPT code selected from the E&M code range.

#### **Inpatient Treatment**

Medically necessary inpatient care is covered.

#### **Residential Treatment Centers (RTC)**

Medically necessary treatment provided in RTCs is covered, determined by line of business for which the Member is covered. Mental Health Residential is not covered for CHP, Medicaid Managed Care Plans, or Medicare Advantage Plans (including D-SNP). Substance Use Residential is not covered for Medicare Advantage Plans (including D-SNP).

Accepted Bill Types and Revenue codes for Managed Medicaid, CHP and HARP Members for Part 820 Residential Substance Use programs:

Bill Types: 731,762,763,861,086,891

Revenue Codes: 0900.0902.0911.0914.0944.0945.1002

#### **Partial Hospitalization**

Partial hospitalization services must be provided under the direct supervision of a physician pursuant to an individualized treatment plan, and the services must be essential for treatment of the patient's condition.

#### **Outpatient Treatment**

Medically necessary diagnostic and treatment services provided by Mental Health Outpatient Treatment and Rehabilitative Services (MHOTRS) and OASAS clinics, physicians, including psychiatrists, as well as clinical psychologists, social workers, psychiatric nurse specialists, nurse practitioners, licensed professional counselor physicians' assistants are covered.

## Managed Medicaid, CHP and HARP Variations:

All billing for Behavioral Health Services for Managed Medicaid, CHP and HARP Members must follow the New York State OMH 14 NYCRR Part 599 Clinic Treatment Programs Interpretive/Implementation Guidance, OASAS APG Clinical and Medicaid Billing Guidance, HARP/Mainstream Behavioral Health Billing and Coding Manual, CORE Benefit and Billing Guidance, the Children's Health and Behavioral Health Services Billing and Coding Manual and/or 29 I Health Facility Billing Guidance as applicable to the service being rendered.

Billing requirements are specific to service and facility type. Billing guidelines include, but are not limited to:

#### Ambulatory Behavioral Health Services.

Ambulatory Behavioral Health Services including, but not limited to Assertive Community Treatment (ACT), OMH licensed and OASAS Certified clinics, Continuing Day Treatment (CDT), Comprehensive Psychiatric Emergency Program (CPEP), Intensive Psychiatric Rehabilitation Treatment (IPRT), Partial Hospitalization (PHP) and Personalized Recovered Oriented Services (PROS), shall be reimbursed using APG rate-setting methodology or other government rates established and published by OMH. The lesser of billed charges or the rates set forth in the Provider Services Agreement or fee schedules, is not applicable to claims reimbursed using the APG methodology.

#### Adult Behavioral Health Home and Community Based Services (BH HCBS)

Services may only be billed for HARP Members meeting eligibility requirements as defined by NYS. Specific billing and coding requirements are attributable to all HCBS services and must follow NYS billing guidelines, including transportation requirements. <u>Home and Community Based Services (HCBS) Overview</u>.



## Artical 29-I Health Facility (VFCA) Services

Article 29-I Health Facility services are available to Managed Medicaid under the age of 21 (effective July 1, 2021) and CHP Members (effective 1/1/2023). Specific billing and coding requirements are attributable to 29-I Health facilities. 29-I Health facilities must follow <u>New York States 29-I Health Facility Billing guidelines</u>.

#### Assertive Community Treatment (ACT), Young Adult and Youth Assertive Community Treatment

ACT, Young Adult ACT and Youth ACT services must be billed in accordance with NYS Billing guidelines. Effective 1/1/2023, ACT, Youth ACT and Young Adult ACT services are available to CHP Members and must be billed in accordance with NYS Billing guidelines.

#### **Children's HCBS**

Children's HCBS Services may only be billed for Members under the age of 21 that are eligible for waiver services. Specific billing and coding requirements are attributable to all Children's HCBS services and must follow NYS Children's Health and Behavioral Health Billing and Coding Manual. Allowable Service combinations can be found in the <u>Billing guidance. Children's HCBS Billing Guidance</u>

#### Children's Family Treatment and Support Services (CFTSS)

CFTSS Services may only be billed for Managed Medicaid Members under the age of 21 that meet applicable medical necessity criteria. CFTSS services must follow the specific billing and coding requirements indicated within the NYS Children's Health and Behavioral Health Billing and Coding Manual. Effective 1/1/2023, CFTSS services are available to CHP Members and must be billed in accordance with the same billing guidance. Children's HCBS Billing Guidance

#### **Crisis Residence**

Both Children's and Adult Crisis Residence services must be billed in accordance with the applicable Crisis Residence Program guidance.Crisis Residence services for youth ages 18-20 <u>follow the Children's Crisis</u> <u>Residence billing guidance</u>. Medicaid Managed Care

## Comprehensive Psychiatric Emergency Program (CPEP)

All CPEP services must be billed in accordance with NYS billing guidance.

## Community Oriented Recovery and Empowerment Services (CORE)

Services may only be billed for HARP Members. Specific billing and coding requirements are attributable to all CORE services and must follow NYS billing guidelines. CORE and BH HCBS Allowable Service Combinations and the CORE and other OASAS/OMH Service Allowable combinations can be found in the NYS CORE Billing guide. Community Oriented Recovery and Empowerment (CORE) <u>Overview</u>

#### **Personalized Recovery Oriented Services (PROS)**

PROS may be billed for Managed Medicaid or HARP Members that are 18 or over which meet applicable medical necessity criteria. PROS services must be billed in accordance with NYS billing guidelines to be reimbursable. Guidance can be found <u>here</u>.

#### **Gambling Disorder Treatment**

In accordance with NYS guidance, Providers must have the OASAS Gambling Designation in order to be eligible for reimbursement when providing problem gambling only services for Government program Members.

#### Claims

Electronic claims for the mental health or substance use programs outlined above will be submitted using the 837i (institutional) claim form. This will allow for use of rate codes which will inform the Plans as to the type of behavioral health program submitting the claim and the service(s) being provided. Rate code will be a required input to MEDS (the Medicaid Encounter Data System) for all outpatient MH/SUD services. Therefore, the Plan must accept rate code on all behavioral health outpatient claims and pass that rate code to MEDS. All other services will be reported to MEDS using the definitions in the MEDS manual.



Providers will enter the rate code in the header of the claim as a value code. This is done in the value code field by first typing in "24" and following that immediately with the appropriate four-digit rate code. This is the standard mechanism historically and currently used in Medicaid FFS billing.

Billing requirements depend on the type of service provided; however, every electronic claim submitted will require at least the following:

- Use of the 837i claim form;
- Medicaid fee-for-service rate code;
- Valid procedure code(s);
- Procedure code modifiers (as needed); and
- Units of service.

For additional information on claims, please review the Claims section of MVPs Provider Resource Manual by clicking <u>here</u>.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# References

https://omh.ny.gov/omhweb/bho/billing-services.html https://www.health.ny.gov/health\_care/medicaid/redesign/behavioral\_health/children/billing.htm https://www.health.ny.gov/health\_care/medicaid/redesign/behavioral\_health/children/vol\_foster\_trans.htm https://omh.ny.gov/omhweb/bho/hcbs.html https://omh.ny.gov/omhweb/bho/core/ https://omh.ny.gov/omhweb/bho/crisis-intervention.html

| December 1, 2019 | New Policy, approved                      |
|------------------|---|
| December 1, 2021 | Policy reviewed and approved with changes |
| March 1, 2022    | Policy reviewed and approved with changes |
| March 1, 2023    | Policy reviewed and approved with changes |



# Mid-Level Payment Policy

Last Reviewed Date: March 1, 2023 Related Policies: Incident to Guidelines NP/PA/CNS Billing in a Skilled Nursing Facility Anesthesia Payment Policy: Credentialing

#### MID-LEVEL PAYMENT POLICY

Policy Definitions Notification/Prior Authorization Requests Payment Guidelines History

# Policy

Reimbursement for services provided by mid-level providers.

# Definitions

Mid-Level providers are Physician Assistants (PA), Nurse Practitioners (NP), Registered Nurse First Assistants (RNFA), Certified Registered Nurse Anesthetists (CRNA), and Certified Nurse Midwife (CNM) practicing independently or within a physician office or facility.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Payment Guidelines**

## **General Guidelines**

**PA, NP, RNFA, CRNA, CNM Payment Policy:** Payment for services rendered by these provider types, subject to the Incident. To see policy, please refer to your provider Fee Schedule or IPA contract for specific reimbursement guidelines.

Notwithstanding this provision, no payment for RNFA services shall be issued for:

- Medicare Advantage Members
- RNFA services billed for services rendered in a Teaching Hospital

| December 1, 2018 | New policy, approved                         |
|------------------|--|
| December 1, 2019 | Policy reviewed and approved with no changes |
| June 1, 2020     | Policy reviewed and approved with no changes |
| March 1, 2022    | Policy reviewed and approved with no changes |
| March 1, 2023    | Policy reviewed and approved with no changes |



# Modifier Policy for Physician

Last Reviewed Date: September 1, 2022

# MODIFIER POLICY FOR PHYSICIAN Policy Definitions Process for Documentation Submission Notification/Prior Authorization Requests Billing/Coding Guidelines References History

# Policy

MVP reimburses for modifiers when billed per the MVP payment guidelines. MVP reserves the right to deny additional payment if the appropriate guidelines are not followed. MVP follows standard CPT correct billing guidelines and has implemented custom edits for modifiers as listed below. In certain circumstances MVP will recognize the use of modifiers in order to provide additional clarification regarding services provided. See Billing/Coding Guidelines below for Modifier Guidance. Modifiers should not be used to bypass an edit. For modifiers that require documentation, the documentation should always support the definition.

# Definitions

A modifier provides the means to report or indicate that a service or procedure that has been performed has been altered by some specific circumstance but not changed in its definition or code. Modifiers also enable health care professionals to effectively respond to payment policy requirements.

# **Process for Documentation Submission**

Paper claim submission is preferable to electronic submission at the present time, as documentation can be submitted along with the paper claim. If a claim is submitted without documentation and gets denied, the MVP Claim Adjustment Request Form (CARF) should be used for the appeal and to direct the reviewers as to the specific diagnosis(es) to link to the claim.

All documentation is scanned into the MVP system; it would be helpful if the specific portion of the documentation that supports the request is underlined, starred, or bracketed. Highlighting may result in those sections being blacked out when they go through the scanner.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

# Modifier 22 Description

When the work required to provide a service is substantially greater than typically required, it may be identified by adding modifier 22 to the usual procedure code. Documentation must support the substantial additional work and the reason for the additional work (i.e., increased intensity, time, technical difficulty of procedure, severity of patient's condition, and physical and mental effort required). Note: This modifier should not be appended to an E&M service.



#### Rule

MVP cannot accept documentation electronically to support Modifier 22 at this time. Additional reimbursement will be considered when the operative report accompanies the paper claim.

Absent documentation to support the claim, Modifier 22 will be removed, and the claim will pay at the physician contracted rate with a payment code and description of WZ- Cl - XTEN - CPT modifier disallowed - Medical documentation required.

When documentation does not accompany the claim and the provider desires the additional 20 percent reimbursement beyond the normal fee schedule as outlined above, additional reimbursement will be considered when the following documentation is provided:

- Claim Adjustment Review Form;
- Operative report

MVP may request additional information when the operative report does not clearly demonstrate the additional work performed. This may include:

- Documentation that clearly illustrates the increased complexity of the services provided;
- Rationale for why the use of Modifier 22 is warranted, including the degree of difficulty above and beyond (0-100 percent)

If upon review of the documentation, Modifier 22 is deemed inappropriate, the modifier will be removed from the claim and provider will remain paid at their contracted rate.

#### Reimbursement

If supporting documentation is not attached, claim will be paid 100 percent of allowed amount.

With documentation to support the use of Modifier 22, the claim will be paid an additional 20 percent.

#### Modifier 25 Description

This modifier is used when a procedure or service identified by a CPT code was performed due to the fact that the patient's condition required a significant, separate, identifiable Evaluation and Management Service by the same physician above and beyond the other service provided or beyond the usual preoperative and postoperative care associated with the procedure that was performed.

#### Rule

#### **Preventive and E&M**

Documentation that satisfies the relevant criteria for both evaluation and management services and procedures to be reported will be required in the patient's medical record. Documentation is not required up front but may be requested on audit.

#### **E&M and Office Procedure**

Documentation that satisfies the relevant criteria for the respective E&M service and procedure to be reported will be required in the patient's chart. Documentation is not required up front but may be requested on audit.

#### Reimbursement

Claims that are determined to meet the clinical criteria as a separate identifiable procedure will be paid at the physician contracted fee schedule.

#### Primary considerations for modifier 25 usages are:

- Why is the physician seeing the patient?
- Could the complaint or problem stand alone as a billable service; and did you perform and document the key components of a problem-oriented E/M service for the complaint or problem?



If the patient exhibits symptoms from which the physician diagnoses the condition and begins treatment by performing a minor procedure or an endoscopy on that same day, modifier 25 should be added to the correct level of E/M service.

If the patient is present for the minor procedure or endoscopy only, modifier 25 does not apply.

If the E/M service was to familiarize the patient with the minor procedure or endoscopy immediately before the procedure, modifier 25 does not apply.

If the E/M service is related to the decision to perform a major procedure (90-day global), modifier 25 is not appropriate. The correct modifier is modifier 57, decision for surgery.

When determining the level of visit to bill when modifier 25 is used, physicians should consider only the content and time associated with the separate E/M service, not the content or time of the procedure.

If during a well/preventive care visit, the provider discovers a new problem or abnormality with a pre-existing problem that is significant enough to require additional work to perform the key components of a problem-oriented E&M, then the appropriate office/outpatient code may be billed with modifier 25.

#### **Examples of Appropriate Use of Modifier 25**

#### Example 1:

A patient has a nosebleed. The physician performs packing of the nose in the office, which stops the bleeding. At the same visit, the physician then evaluates the patient for moderate hypertension that was not well controlled and adjusts the antihypertensive medications.

The 25 modifier may be reported with the appropriate level of E/M code in addition to the minor procedure. The hypertension E/M was medically necessary, significant, and a separately identifiable service performed on the same day as control of the nosebleed. The hypertension was exacerbating the nosebleed and was actually related to the nosebleed, but management of the hypertension was a separate service from actually packing the nose.

#### Example 2:

A patient presents to the physician with symptoms of urinary retention. The physician performs a thorough E/M service and decides to perform a cystourethroscopy. Cystourethroscopy is performed the same day as the E/M code.

The 25 modifier may be reported with the appropriate level of E/M code in addition to the cystourethroscopy. The physician had to evaluate the patient based on the symptoms and decides on the procedure to be performed. The procedure was then performed on the same day as the E/M.

#### Example 3:

A patient presents to a Dermatologist with a concern about a small skin lesion on his back that has not healed. The Dermatologist examines the patient and documents a detailed history, detailed exam (including the skin of the patient's back, neck, arms, and legs; and cervical and axillary lymph nodes), and moderate medical decision making (including the decision to excise the lesion at this visit). Excision, malignant lesion, trunk, 0.5 cm or less (11600 – 10 global days) is performed with intermediate repair (layered closure) of wounds of trunk, 5.0 cm (12032 – 10 global days). Use modifier 25 on the E/M service.

The 25 modifier may be reported with the appropriate level of E/M code in addition to the lesion removal. The physician had to evaluate the patient based on the symptoms and decides on the procedure to be performed. The procedure was then performed on the same day as the E/M.

#### Example 4:

A 52-year-old established patient presents for an annual exam. When you ask about his current complaints, he mentions that he has had mild chest pain and a productive cough over the past week and that the pain is worse on deep inspiration. You take additional history related to his symptoms, perform a detailed respiratory and CV exam, and order an electrocardiogram and chest X-ray. You make a diagnosis of acute bronchitis with chest pain and prescribe



medication and bed rest along with instructions to stop smoking. You document both the problem-oriented and the preventive components of the encounter in detail.

You should submit 99396, "Periodic comprehensive preventive medicine, established patient; 40-64 years" and ICD-9 code V70.0, and the problem-oriented code that describes the additional work associated with the evaluation of the respiratory complaints with modifier 25 attached, ICD-9 codes 466.0, "Acute bronchitis" and 786.50, "Chest pain" and the appropriate code for the electrocardiogram.

\*Note that the work associated with performing the history, examination, and medical decision making for the problemoriented E/M service will likely overlap those performed as part of the comprehensive preventive service to a certain extent. Therefore, the E/M code reported for the problem-oriented service should be based on the additional work performed by the physician to evaluate that problem. An insignificant or trivial problem or abnormality that does not require performance of these key components should not be reported separately from the preventive medicine service.

## Example 5:

An established 42-year-old patient reports to the outpatient office for her yearly gynecological exam, including breast exam and Pap smear. During the same encounter the patient complains of irregular menstrual cycles and has noticeable ovarian pain and tenderness during the pelvic exam, requiring the physician to order additional tests such as an ultrasound or CT scan and schedule a follow-up visit.

An additional Office/Outpatient code may be applied with a Modifier 25 Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure or service. The service would be reported as: 99396, 99213-25

## **Examples of Inappropriate Use of Modifier 25**

Example 1:

A patient has a small skin cancer of the forearm removed in the physician's office. This is a routine procedure and no other conditions are treated.

The office visit is considered part of the surgery service and, therefore, not separately reimbursable. The use of modifier 25 is inappropriate. Only the surgical procedure should be reported.

## Example 2:

A patient visits the physician on Monday with symptoms of GI bleeding. The physician evaluates the patient and bills and E/M service. The physician tells the patient to return on Wednesday for a sigmoidoscopy. On Wednesday, a sigmoidoscopy is performed in a routine manner.

An E/M service (no modifier applied) may be billed for the service provided on Monday. However, a separate E/M service should not be reported for Wednesday when the patient returned for the sigmoidoscopy.

Example 3:

A Gastroenterologist has been asked to place an NG tube. A brief evaluation of the patient's oropharynx and airway is performed. The Gastroenterologist documents an EPF history, PF exam, and low decision making. The NG tube is placed.

The office visit is considered part of the surgery service and, therefore, not separately reimbursable. The use of the 25 modifier is inappropriate. Only the surgical procedure should be reported.

## Example 4:

A patient presented to her physician's office complaining of a painful abscess on her back. The physician took a problem-focused history and performed a problem-focused exam. He decided to incise and drain the abscess while the patient was still in the office. The office visit is considered part of the surgery service and, therefore, not separately reimbursable. The use of modifier 25 is inappropriate. Only the surgical procedure should be reported.



#### Example 5:

A 44-year-old established patient presents for her annual well-woman exam. A complete review of systems is obtained, and an interval past, family, and social history is reviewed and updated. A neck-to-groin exam is performed, including a pelvic exam, and a Pap smear is taken. Counseling is given on diet and exercise. Appropriate labs are ordered. The patient also complains of vaginal dryness, and her prescriptions for oral contraception and chronic allergy medication are renewed.

This additional work would be considered part of the preventive service, and the prescription renewal would not be considered significant.

#### Example 6:

A 44-year-old established patient presents for her annual well-woman exam. A complete review of systems is obtained, and an interval past, family, and social history is reviewed and updated. A neck-to-groin exam is performed, including a pelvic exam, and a Pap smear is taken. Counseling is given on diet and exercise. Appropriate labs are ordered. The patient also complains of vaginal dryness, and her prescriptions for oral contraception and chronic allergy medication are renewed. The patient also requests advice on hormone replacement therapy. She is anticipating menopause but is currently asymptomatic.

This would not be considered significant because the patient is asymptomatic and preventive medicine services include counseling or guidance on issues common to the patient's age group.

#### Example 7:

An E/M service is submitted with CPT code 99213 and CPT modifier 25. During the same patient encounter, the physician also debrides the skin and subcutaneous tissues (CPT code 11042, 0 global days). CPT 99213 was submitted to reflect the physician's time, examination, and decision making related to determining the need for skin debridement. The physician's time was not significant and separately identifiable from the usual work associated with the surgery, and no other conditions were addressed during the encounter.

\*See <u>Reference section</u> at the end of this document for source of examples.

| Modifier 26 | Description   |
|-------------|---|
|             | This modifier is used to report the physician component in procedures were there are a combination of a physician and technical component.  |
|             | Rule  |
|             | When the physician component is reported separately, the service may be identified by adding modifier 26 to the usual procedure number.   |
|             | Reimbursement   |
|             | Providers will be paid at the contracted rate for the professional component.   |
| Modifier TC | Description   |
|             | This modifier is used to report the technical component alone in procedures were there are a combination of a physician and technical component.  |
|             | Rule  |
|             | Technical component charges are institutional charges and not billed separately by physicians. However, portable x-ray suppliers only bill for technical component and should utilize modifier TC. The charge data from portable x-ray suppliers will then be used to build customary and prevailing profile. |



#### Reimbursement

Providers will be paid at the contracted rate for the technical component.

## Modifier 50 Description

Used to report bilateral procedures (CPT codes 10040-69990) performed in the same operative session and radiology procedures performed bilaterally. Bilateral procedures that are performed at the same session should be identified by adding Modifier 50 to the appropriate 5-digit code.

#### Rule

Identify that a second (bilateral) procedure has been performed by adding modifier 50 to the procedure code.

Do not report two line items to indicate a bilateral procedure.

Do not use modifier with surgical procedures identified by their terminology as "bilateral" (e.g., 27395, lengthening of hamstring tendon, multiple, bilateral), or as "unilateral or bilateral" (e.g., 52290, cystourethroscopy, with meatotomy, unilateral or bilateral).

Report only one unit of service when modifier 50 is reported.

Modifier 50 should not be appended to a claim when appending the LT/RT modifiers.

#### Reimbursement

150 percent of the provider's contracted rate.

#### Modifier 51 Description

When multiple procedures, other than E/M services, Physical Medicine, and Rehabilitation services, or provision of supplies (e.g., vaccines), are performed at the same session by the same provider, the primary procedure or service may be reported as listed. The additional procedure(s) or service(s) may be identified by appending modifier 51 to the additional procedure or service code(s).

#### Rule

MVP complies with the Medicare Guidelines for billing with a modifier 51. The primary procedure is identified by the higher priced allowed amount.

Note: This modifier should not be appended to designated "add-on" codes (see Appendix D).

#### Reimbursement

When a procedure is reported on the same day as another procedure with an indicator of 1, 2, or 3, the appropriate reduction is applied to the codes (i.e. 100 percent, 50 percent, 50 percent, 50 percent, 50 percent, 50 percent etc.).

#### Modifier 52 Description

Used when a service or procedure is partially reduced or eliminated at the provider's discretion. Note: For hospital outpatient reporting of a previously scheduled procedure/service that is partially reduced or cancelled as a result of extenuating circumstances or those that threaten the well-being of the patient prior to or after administration of anesthesia, see modifiers 73 and 74.

#### Rule

Report this modifier when the procedure was discontinued after the patient was prepared and brought to the room where the procedure was to be performed.



Modifier is valid for reporting reduced radiology procedures.

Procedures with bilateral surgery indicator "2" must be billed with the appropriate two (2) units of service with modifier 52: RT or LT for indicator "2".

When a radiology procedure is reduced, the correct reporting is to assign the CPT code to the extent of the procedure performed. This modifier is used only to report a radiology procedure that has been reduced when no other code exists to report what has been done. Report the intended code with Modifier 52.

#### Reimbursement

Modifier 52 is reimbursed at the lesser of 50 percent of charges or contracted rate.

## Modifier 53 Description

Used when the provider elects to terminate a surgical or diagnostic procedure due to extenuating circumstances or those that threatens the well being of the patient. In certain circumstances it may be necessary to indicate that a surgical or diagnostic procedure was started but discontinued.

Note: For outpatient hospital/ambulatory surgery center (ASC) reporting of a previously scheduled procedure/service that is partially reduced or cancelled as a result of extenuating circumstances or those that threaten the well-being of the patient prior to or after administration of anesthesia, see modifiers 73 and 74.

#### Rule

This modifier is not used to report the elective cancellation of a procedure prior to the patient's anesthesia induction and/or surgical preparation in the operating suite.

#### Reimbursement

Modifier 53 is reimbursed at the lesser of 50 percent of charges or contracted rate.

#### Modifier 54 Description

Used when one physician performs preoperative and/or postoperative management and another physician performs a surgical procedure.

#### Rule

This should only be added to the claim with the surgical code.

#### Reimbursement

Modifier 54 is reimbursed at the lesser of 80 percent of charges or contracted rate.

## Modifier 55 Description

Used when one physician performs postoperative management and another physician performs a surgical procedure.

#### Rule

This modifier should only be used by the physician billing for the postoperative management.

#### Reimbursement

Modifier 55 is reimbursed the lesser of 10 percent of charges or contracted rate.

Description

Modifier 56



| Modifier 56                     | Description   |     |  |
|---------------------------------|---|-----|--|
|                                 | Used when one physician performs preoperative care and evaluation and another physician performs a surgical procedure.  | а   |  |
|                                 | Rule  |     |  |
|                                 | This modifier should only be used by the physician billing for the preoperative care and evaluation.  |     |  |
|                                 | Reimbursement   |     |  |
|                                 | Modifier 56 is reimbursed at the lesser of 10 percent of charges or contracted rate.  |     |  |
| Modifiers 59,<br>XE, XS, XP, XU | Description   |     |  |
|                                 | These modifiers are used to identify procedures/ services, other than E&M services, that are not normal reported together, but are appropriate under the circumstances. | lly |  |
|                                 | Modifier 59 Distinct Procedural Service   |     |  |
|                                 | Modifier XE Separate Encounter, A Service That Is Distinct Because It Occurred During A Separate Encounter  |     |  |
|                                 | Modifier XS Separate Structure, A Service That Is Distinct Because It Was Performed On A Separate<br>Organ/Structure  |     |  |
|                                 | Modifier XP Separate Practitioner, A Service That Is Distinct Because It Was Performed By A Different Practitioner  |     |  |
|                                 | Modifier XU Unusual Non-Overlapping Service, The Use Of A Service That Is Distinct Because It Does<br>Not Overlap Usual Components Of The Main Service                  |     |  |
|                                 |   |     |  |

#### Rule

MVP cannot accept documentation electronically to support modifiers 59, XE, XS, XP, XU at this time. Additional reimbursement will be considered when the operative report accompanies the paper claim.

MVP may request additional information when the operative report does not clearly demonstrate that the procedures should be unbundled. This may include documentation that demonstrates why a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual was done; rationale for why the use of modifiers 59, XE, XS, XP, XU is warranted.

When another already established modifier is appropriate it should be used rather than modifier 59. Only if another descriptive modifier is unavailable, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. Note: Modifier 59 should not be appended to an E&M service. To report a separate and distinct E&M service with a non-E&M service performed on the same date, see modifier 25.

#### Reimbursement

Claims that are determined to meet the clinical criteria as a separate identifiable procedure will be paid at the physician contracted rate.



## Modifier 62 Description

Used when two surgeons work together as primary surgeons performing distinct part(s) of a procedure.

#### Rule

Each surgeon should report his/her distinct operative work by adding modifier 62 to the procedure code and any associated add-on code(s) for that procedure as long as both surgeons continue to work together as primary surgeons.

Each surgeon should report the co-surgery once using the same procedure code. If additional procedure(s) (including add-on procedure(s)) are performed during the same surgical session, separate code(s) may also be reported with modifier 62 added.

If a co-surgeon acts as an assistant in the performance of additional procedure(s) during the same surgical session, modifier 80 or modifier 82 should be used as appropriate.

#### Reimbursement

Modifier 62 is reimbursed at 62.5 percent of the providers contracted rate.

#### Modifier 63 Description

Used when procedures are performed on neonates and infants up to a present body weight of 4kg which may involve significant increase in complexity for physicians and other health care professionals whose work is commonly associated with these patients

#### Rule

This circumstance may be reported by adding modifier 63 to the procedure number. Note: Unless otherwise designated, this modifier may only be appended to procedures/services listed in the 20100-69990 code series and 92920, 92928, 92953, 92960, 92986, 92987, 92990, 92997, 92998, 93312, 93313, 93314, 93315, 93316, 93317, 93318, 93452, 93505, 93530, 93531, 93532, 93533, 93561, 93562, 93563, 93564, 93568, 93580, 93582, 93590, 93591, 93592, 93615, 93616 from the Medicine/Cardiovascular section. Modifier 63 should not be appended to any CPT codes listed in the Evaluation and Management Services, Anesthesia, Radiology, Pathology/Laboratory, or Medicine sections (other than those identified above from the Medicine/Cardiovascular section).

#### Reimbursement

Modifier 63 is reimbursed at 120% of the contracted rate

#### Modifier 73

#### For Facility Use Only Description

Due to extenuating circumstances or those that threaten the well-being of the patient, the physician may cancel a surgical or diagnostic procedure subsequent to the patient's surgical preparation (including sedation when provided, and being taken to the room where the procedure is to be performed), but prior to the administration of anesthesia (local, regional block(s), or general).

#### Rule

This code is to be used by the Hospital/Ambulatory Surgery Center when the procedure is discontinued.

This modifier is not used to indicate discontinued radiology procedures.

This modifier applies in extenuating circumstances and when the well-being of the patient is threatened. The patient must be taken to the room where the procedure is to be performed in order to report this modifier.



When one or more of the planned procedures is completed, report the completed procedure as usual. Any others that were planned and not started are not reported.

When none of the procedures that were planned are completed, the first procedure that was planned to be done is reported with this modifier.

#### Reimbursement

Modifier 73 is reimbursed at 50 percent of the facilities contracted rate.

# Modifier 74For Facility Use OnlyDescription

Due to extenuating circumstances or those that threaten the well-being of the patient, the physician may terminate a surgical or diagnostic procedure after the administration of anesthesia (local, regional block(s), general) or after the procedure was started (incision made, intubation started, scope inserted, etc.).

#### Rule

This code is to be used by the Outpatient Hospital/Ambulatory Surgery Center (ASC) when the procedures is discontinued after the administration of anesthesia.

This modifier is not used to indicate discontinued radiology procedures.

This modifier applies in extenuating circumstances and when the well-being of the patient is threatened. The patient must be taken to the room where the procedure is to be performed in order to report this modifier.

When one or more of the planned procedures is completed, report the completed procedure as usual. Any others that were planned and not started are not reported.

When none of the procedures that were planned are completed, the first procedure that was planned to be done is reported with this modifier.

#### Reimbursement

Modifier 74 is reimbursed at 100 percent of the facilities contracted rate.

#### Modifier 76 Description

Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional

(This modifier is allowable for radiology services. It may also be used with surgical or medical codes in appropriate circumstances).

#### Rule

It may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. This circumstance may be reported by adding modifier 76 to the repeated procedure/service.

This modifier should not be appended to an E/M service.

Documentation is required.

#### Reimbursement

Will be reimbursed at the lesser of 100 percent of charges or contracted rate.

#### Modifier 78 Description

Unplanned Return to the Operating/Procedure Room by the Same Physician or Other Qualified Health Care Professional Following Initial Procedure for a Related Procedure During the Postoperative Period.



#### Rule

It may be necessary to indicate that another procedure was performed during the postoperative period of the initial procedure (unplanned procedure following initial procedure). When this procedure is related to the first, and requires the use of an operating/procedure room, it may be reported by adding modifier 78 to the related procedure.

For repeat procedures, see modifier 76

Documentation is required.

#### Reimbursement

Will be reimbursed at the lesser of 80 percent of charges or contracted rate.

| Modifier AS,<br>80, 81, 82 | Description  |  |  |  |  |  |
|----------------------------|--|--|--|--|--|--|
|                            | Modifier AS Physician assistant, nurse practitioner for assistant at surgery   |  |  |  |  |  |
|                            | Modifier 80 Assistant Surgeon. Surgical assistant services may be identified by adding Modifier 80 to the usual procedure number(s).   |  |  |  |  |  |
|                            | Modifier 81 Minimum Assistant Surgeon. Minimum surgical assistant services are identified by adding modifier 81 to the usual procedure number.   |  |  |  |  |  |
|                            | Modifier 82 Assistant Surgeon (when qualified resident surgeon not available). The unavailability of a qualified resident surgeon is a prerequisite for use of modifier 82 appended to the usual procedure code number(s). |  |  |  |  |  |
|                            | Rule   |  |  |  |  |  |
|                            | Modifier 80 by itself should be added by the assistant surgeon.  |  |  |  |  |  |
|                            | Modifier AS is used to clarify if the assistant was a Physician Assistant or Nurse Practitioner vs. an MD.   |  |  |  |  |  |
|                            | The assistant at surgery must report the same CPT codes as the primary surgeon.  |  |  |  |  |  |
|                            | Refer to the <u>Assistant Surgeon List</u> at <u>mvphealthcare.com</u> to determine which codes MVP will reimburse.  |  |  |  |  |  |
|                            | Reimbursement  |  |  |  |  |  |
|                            | Modifier AS is reimbursed at 16 percent of the assistant surgeon's contracted fee schedule.  |  |  |  |  |  |
|                            | Modifiers 80-82 are reimbursed at 16 percent of the assistant surgeon's contracted fee schedule.   |  |  |  |  |  |
| Modifier CG                | Description  |  |  |  |  |  |
|                            | Policy criteria applies.   |  |  |  |  |  |
|                            | Rule   |  |  |  |  |  |
|                            | When submitting a venipuncture claim when laboratory work is sent to an external lab, modifier CG is require   |  |  |  |  |  |
|                            | Reimbursement  |  |  |  |  |  |
|                            | Claims submitted without the modifier will be denied as global.  |  |  |  |  |  |



#### Modifier CH-CN Description

Functional G-codes and corresponding severity modifiers are used in the required reporting on specified therapy claims.

#### Rule

At the outset of a therapy episode of care, i.e., on the DOS for the initial therapy service;

At least once every 10 treatment days -- which is the same as the newly revised progress reporting period – the functional reporting is required on the claim for services on same DOS that the services related to the progress report are furnished;

The same DOS that an evaluative procedure, including a re-evaluative one, is submitted on the claim (see below for applicable HCPCS/CPT codes);

At the time of discharge from the therapy episode of care, if data is available; and,

On the same DOS the reporting of a particular functional limitation is ended, in cases where the need for further therapy is necessary.

#### Reimbursement

Claims submitted without the severity modifiers will be denied.

#### Modifier CO-CQ Description

Therapy modifier indicating a Physical Therapy Assistant or Occupational Therapy assistant performed a service in whole or in part.

#### Rule

• Services wholly furnished by PTAs and OTAs.

- In cases where one final 15-minute unit (of a multi-unit scenario) remains to be billed, the de minimis standard is applied to: Services where the PTA/OTA furnishes 8 or more minutes of a 15-minute unit of service and the PT/OT furnishes less than 8 minutes bill with the CQ/CO modifier as the de minimis standard is exceeded.
- Services where both the PTA/OTA and the PT/OT each provide less than 8 minutes of a service bill with the CQ/CO modifier if the minutes furnished by the PTA/OTA exceed the de minimis standard.

#### Reimbursement

Claims submitted with these modifiers will be reimburses at 85% of charges or contracted rate.

#### Modifier GN-GP Description

Therapy modifier indicating the discipline of the plan of care.

#### Rule

The provider should use GP, GO, or GN for PT, OT, and SLP services, respectively.

#### Reimbursement

Claims submitted without the therapy modifier will be denied.



#### Modifier KX Description

Therapy modifier indicating that the services over the CMS therapy cap were medically necessary. Please refer to <u>CMS.Gov</u> for annual KX therapy caps.

#### Rule

The provider should use the KX modifier to the therapy procedure code (physical/speech and/or occupational) that is subject to CMS cap limits only when a beneficiary qualifies for a therapy cap exception. The KX modifier should not be used prior to the member meeting their therapy cap. Submission of medical records will be required to support the use of modifier KX. By attaching the KX modifier, the provider is attesting that the services billed:

- Qualified for the cap exception;
- Are reasonable and necessary services that require the skills of a therapist; and
- Are justified by appropriate documentation in the medical record.

#### Modifier PT Description

This modifier should be used when a CRC screening test has been converted to diagnostic test or other procedure.

#### Rule

MVP will pay the diagnostic procedure code that is reported instead of the screening colonoscopy or screening flexible sigmoidoscopy HCPCS code, or screening barium enema when the screening test becomes a diagnostic service.

#### Reimbursement

The claims processing system would respond to the modifier by waiving the deductible for all surgical services on the same date as the diagnostic test.

Coinsurance for Medicare beneficiaries would continue to apply to the diagnostic test and to other services furnished in connection with, as a result of, and in the same clinical encounter as the screening test.

#### Modifier Q6 Description

Services furnished by a Locum Tenens physician.

#### Rule

The patient's regular physician may submit the claim and receive payment for covered-visit services (including emergency visits and related services) of a Locum Tenens physician who is not an employee of the regular physician and whose services for the regular physician's patients are not restricted to the regular physician's office.

#### Reimbursement

Reimbursement would be made at the regular physician's fee schedule.



| Modifier QK,<br>QY, QX | Description – QK   |  |  |  |  |  |
|------------------------|--|--|--|--|--|--|
|                        | Modifier QK – Medical direction of 2, 3, or 4 concurrent anesthesia procedures involving qualified individuals |  |  |  |  |  |
|                        | Reimbursement – QK   |  |  |  |  |  |
|                        | Modifier QK will be reimbursed at the lesser of 50 percent of charges or the contracted rate.                  |  |  |  |  |  |
|                        | Description – QY   |  |  |  |  |  |
|                        | Modifier QY – Medical direction of one certified registered nurse anesthetist (CRNA) by an anesthesiologist    |  |  |  |  |  |
|                        | Reimbursement – QY   |  |  |  |  |  |
|                        | Modifier QY will be reimbursed at the lesser of 50 percent of charges or the contracted rate                   |  |  |  |  |  |
|                        | Description – QX   |  |  |  |  |  |
|                        | Modifier QX – CRNA service: with medical direction by a physician  |  |  |  |  |  |
|                        | Reimbursement – QX   |  |  |  |  |  |
|                        | Modifier QX will be reimbursed at the lesser of 50 percent of charges or the contracted rate                   |  |  |  |  |  |
| Modifier<br>U8, U9, UB | Description – U8   |  |  |  |  |  |
|                        | Modifier U8 – Delivery prior to 39 weeks gestation   |  |  |  |  |  |
|                        | Reimbursement – U8   |  |  |  |  |  |
|                        | A 75 percent reduction will apply when modifier U8 is billed and an acceptable diagnosis is not documented     |  |  |  |  |  |
|                        | Description – U9   |  |  |  |  |  |
|                        | Modifier U9 – Delivery at 39 weeks gestation or later  |  |  |  |  |  |
|                        | Reimbursement – U9   |  |  |  |  |  |
|                        | Full payment will be made when modifier U9 is submitted  |  |  |  |  |  |
|                        | Description – UB   |  |  |  |  |  |
|                        | Modifier UB- Spontaneous obstetrical deliveries occurring between 37-39 weeks gestation                        |  |  |  |  |  |
|                        | Reimbursement – UB   |  |  |  |  |  |
|                        | Full payment will be made when modifier UB and U8 are billed   |  |  |  |  |  |
| Modifier CT            | Description  |  |  |  |  |  |
|                        | Modifier CT  |  |  |  |  |  |
|                        |  |  |  |  |  |  |

#### Reimbursement

For a global procedure billed with CT, global fee schedule will be reduced by 15% of the amount for TC only code. For codes with both TC and CT, fee schedule amount is decreased by 15 percent



# Modifiers

| GA, GY, GZ      | Description   |  |  |  |  |  |
|-----------------|---|--|--|--|--|--|
|                 | Modifier GA, GY, GZ   |  |  |  |  |  |
|                 | Reimbursement   |  |  |  |  |  |
|                 | Only applicable with a valid pre-authorization denial. ABN is not applicable.                                   |  |  |  |  |  |
|                 | Providers are to use GA, GY, GZ modifiers only if the service is not an MVP benefit; use will result in denial. |  |  |  |  |  |
| References      |   |  |  |  |  |  |
| MVP Provider Re | esource Manual Policy-Elective Delivery (For Providers and Facilities)  |  |  |  |  |  |
| CMS Pub. 100-0  | 04, chapter 12, section 40.2-40.5, and chapter 23, section 30.2   |  |  |  |  |  |

CPT 2019 Preventive Medicine Services Section

CPT 2019 Professional Edition, American Medical Association

Grider, Deborah, Coding with Modifiers, 5th Edition. American Medical Association. 2013

Medicare Claims Processing Manual Chapter 12 §§ 30.3.7, 40.2(A)(4)

| June 1, 2019      | Policy Approved                           |
|-------------------|---|
| March 1, 2020     | Policy reviewed with changes              |
| June 1,2020       | Policy reviewed and approved with changes |
| December 1, 2020  | Policy reviewed and approved with changes |
| September 1, 2022 | Policy reviewed and approved with changes |



# Multiple Surgery – VT Facilities Only

# MULTIPLE SURGERY - VT FACILITIES ONLY Policy Notification/Prior Authorization Requests Billing/Coding Guidelines History

Last Reviewed Date: March 1, 2023

# Policy

For surgical procedures that occur in the outpatient or inpatient facility setting, MVP follows the basic multiple surgery rules and will reduce reimbursement for the second procedure when done at the same time as the first procedure.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Participating Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Participating Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **Multiple Surgery Rule**

| Code        | Description   | Rule  |
|-------------|---|---|
| 10021-69990 | Surgical Procedural Codes   | • The primary procedure is identified by the higher priced allowed amount   |
|             |   | <ul> <li>The primary procedure performed in the operating room will be<br/>reimbursed at 100 percent of the contractual rate</li> </ul>                           |
|             |   | <ul> <li>Any subsequent surgical procedures performed in the operating room at<br/>the same time will be reduced to 50 percent of the contractual rate</li> </ul> |
|             |   | <ul> <li>Exemptions: Appendix D and E of the current year AMA Current<br/>Procedural Terminology (CPT) manual</li> </ul>  |
|             |   | <ul> <li>Existing Clinical Edits will still apply to these claims</li> </ul>  |
| 51798       | Measurement of post-voiding residual<br>urine and/or bladder capacity by<br>ultrasound, non-imaging | • This code will be exempt from the multiple surgery rule   |

| September 1, 2018 | New policy, approved                         |
|-------------------|--|
| September 1, 2020 | Policy reviewed and approved with no changes |
| March 1, 2022     | Policy reviewed and approved with no changes |
| March 1, 2023     | Policy reviewed and approved with no changes |



# NDC Policy

Last Reviewed Date: March 1, 2023

#### NDC POLICY

Policy Definitions Notification/Prior Authorization Requests **Billing/Coding Guidelines** NDC Formatting References History

# **Policy**

Only valid National Drug Code (NCD) numbers may be submitted. MVP requires the valid NDC and quantity to be included on all claims where a medication is administered for outpatient or professional setting with a procedure code beginning with J, or for codes that have an O1E or O1D BETOS designation. The BETOS designation can be referenced here.

When an NDC is submitted on any claim or; for any procedure, that NDC will be verified for accuracy, and the unit quantity will be reviewed to ensure it is not a value of zero.

# **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must confirm Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into the Providers account at myphealthcare.com.

# **Billing/Coding Guidelines**

#### Instructions for filling out the Health Insurance Claim Form (CMS 1500)

Vailid NDC numbers should be entered in the respective fields 24A – 24G for the corresponding CPT codes.

The following should be included in order:

- Report the N4 qualifier (left justified)
- Followed immediately by 11 digit NDC (no hyphens)
- One space
- Followed immediately by Unit or Basis for Measurement Code:
  - F2 International Unit ML – Milliliter GR – Gram
    - UN Unit
- Followed immediately by:
  - Unit Quantity is limited to eight digits before the decimal and three digits after the decimal. If entering a whole number, do not use a decimal.
  - Must be > 0 and <= 9,999,999.999.
  - Examples: 1234.56 9,999,999.999 2
- Example: N412345678901 UN1234.567



#### **NDC Number**

| 24. A.<br>MM | From | DATE(S) | OF SEF | To<br>DD | YY | B.<br>PLACE OF<br>SERVICE | C.<br>EMG | D. PROCEDURI<br>(Explain Un<br>CPT/HCPCS |  | E.<br>DIAGNOSIS<br>POINTER | F.<br>\$ CHARGE | S  | G.<br>DAYS<br>OR<br>UNITS | H.<br>EPSOT<br>Family<br>Plan | I.<br>ID.<br>QUAL | J.<br>RENDERING<br>PROVIDER ID. # |
|--------------|------|---------|--------|----------|----|---------------------------|-----------|--|--|----------------------------|-----------------|----|---------------------------|-------------------------------|-------------------|-----------------------------------|
| N459         | 1480 | 01665   | UN1    |          |    |                           | 1         |  |  |                            |                 |    |                           | N                             | G2                | 12345678901                       |
| 10           | 01   | 05      | 10     | 01       | 05 | 11                        |           | J0400                                    |  | A                          | 500             | 00 | 1                         | N                             | NPI               | 0123456789                        |

#### Instructions for filling out UB 04 claim form

NDC should be entered into field 43 - Revenue Code Description.

The following should be included in order:

- Report the N4 qualifier (left justified) followed immediately by:
- 11 digit NDC (no hyphens) followed immediately by:
- Unit or Basis for Measurement Code:

| F2 – International Unit | ML – Milliliter |
|-------------------------|-----------------|
| GR – Gram               | UN - Unit       |

- followed immediately by:
  - Quantity is limited to eight digits before the decimal and three digits after the decimal. If entering a whole number, do not use a decimal.
  - Must be > 0 and <= 9,999,999.999.
  - Examples: 1234.56 2 9,999,999.999

#### **Instructions for Electronic Claim Format**

If you bill electronically, complete the drug identification and drug pricing segments in Loop 2410 following the instructions below:

| Loop | Segment | Element Name                          | Information   |
|------|---------|---------------------------------------|---|
| 2410 | LIN 02  | Product or Service ID<br>Qualifier    | Use qualifier N4 to indicate that entry of the 11 digit NDC in 5-4-2 format in LIN03  |
| 2410 | LIN 03  | Product or Service ID<br>Qualifier    | Include the 11-digit NDC (No hyphens)   |
| 2410 | CTP 04  | Quantity                              | <ul> <li>Include the quantity for the NDC billed in LIN03</li> <li>Quantity is limited to eight digits before the decimal and three digits after the decimal. If entering a whole number, do not use a decimal</li> <li>Must be &gt; 0 and &lt;= 9,999,999.999</li> <li>Examples: 123456 2 9,999,999.999</li> </ul> |
| 2410 | CTP 05  | Unit or Basis for<br>Measurement Code | For the NDC billed in LIN03, include the unit or basis for measurement code<br>using the appropriate code qualifier:FR – International UnitML – MillimeterGR – GramUN – Unit  |



## **NDC Formatting**

A valid NDC is submitted as an 11-digit code without any hyphens.

However, you will rarely see 11 digits when referring to an NDC on a medication package. This is because the 11 digits of an NDC are separated into three (3) sections.

- The first 5 digits identify the drug manufacturer.
- The next 4 digits identify the specific drug and its strength.
- The last 2 digits indicate the package size.

In some cases, you may see a 5 digit-4 digit-2 digit code (for example 12345-1234-12). In this situation, you should remove hyphens, and submit the 11 numbers.

But in most cases, you will see other formats as many manufacturers omit leading zeros in one or more of the three NDC sections.

In order for MVP to process a claim for reimbursement, the leading zeros must be added back into the appropriate place within the NDC to create an 11 digit NDC number that matches the Medispan and/or First Data Bank databases.

The following table provides illustrative examples on how to convert sample NDC numbers into the acceptable 5-4-2 format and how to enter them appropriately into a claim form by adding the N4 qualifier:

| Packaging<br>NDC Format | Add leading zero(s) to the:                                       | Conversion Examples                               | and is keyed as |
|-------------------------|---|---|-----------------|
| 4-4-2                   | First segment to make it 5-4-2                                    | 4-4-2=1234-1234-12<br>becomes 5-4-2=01234-1234-12 | N401234123412   |
| 5-3-2                   | Second segment to make it 5-4-2                                   | 5-3-2=12345-123-12<br>becomes 5-4-2=12345-0123-12 | N401234123412   |
| 5-4-1                   | Third segment to make it 5-4-2                                    | 5-4-1=12345-1234-1<br>becomes 5-4-2=12345-1234-01 | N401234123412   |
| 3-2-1                   | <u>First, second</u> , and <u>third</u> segments to make it 5-4-2 | 3-2-1=333-22-1<br>becomes 5-4-2=00333-0022-       | N400333002201   |

#### **Choosing the Applicable NDC**

If a drug has two (2) NDC numbers - one on the package and one on the vial, submit the NDC on the package rather than the number on the vial.

If the drug is a compound drug and does not have a single Federal NDC, individual components and their respective Federal NDC's numbers must be billed on separate lines with appropriate numbers of units.

If the drug is available in both medical and cosmetic packaging (e.g. Botox and Botox Cosmetic), use the appropriate NDC for the medical packaging. Submission of an NDC associated with the cosmetic product will result in a claim denial regardless of authorization status and diagnosis being treated.

#### References

NYSDOH Memo Update: Encounter Intake System (EIS) NDC Edit Logic EIS Edit 00237 Logic Change\_09032021.pdf

| February 1, 2018 | New policy, approved                         |
|------------------|--|
| June 1, 2020     | Policy reviewed and approved with no changes |
| March 1, 2022    | Policy reviewed and approved with no changes |
| March 1, 2023    | Policy reviewed and approved with changes    |
|                  | _  |



Nurse Practitioner (NP)/Physician Assistant (PA)/ Clinical Nurse Specialists (CNS) Billing in a Skilled Nursing Facility, Nursing Facility, Inpatient Setting

NURSE PRACTITIONER (NP)/PHYSICIAN ASSISTANT (PA)/ CLINICAL NURSE SPECIALISTS (CNS) BILLING IN A SKILLED NURSING FACILITY, NURSING FACILITY, INPATIENT SETTING Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines in a Skilled Nursing Facility Billing/Coding Guidelines in a Nursing Facility Reimbursement Guidelines Sources History

Last Reviewed Date: March 1, 2023

# Policy

MVP recognizes nurse practitioner, physician assistant and clinical nurse specialist billing guidelines as outlined below.

MVP Commercial/ASO Members are not eligible for nurse practitioner or physician assistant services in a skilled nursing facility.

# Definitions

#### **Consolidated Billing**

Consolidated billing, which is similar in concept to hospital bundling, requires the SNF or NF to include on its Part A bill all Medicare-covered services that a resident has received during a covered Part A stay, other than a small list of excluded services that are billed separately under Part B by an outside entity. CB also places with the SNF itself the Medicare billing responsibility for all of its residents' physical therapy (PT), occupational therapy (OT), and speech-language pathology (SLP) services, regardless of whether the resident who receives the services is in a covered Part A stay. There are a number of services that are excluded from SNF CB. Services that are categorically excluded from SNF CB include physicians' services furnished to SNF residents. Physician assistants working under a physician's supervision and nurse practitioners and clinical nurse specialists working in collaboration with a physician are also excluded.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines in a Skilled Nursing Facility**

MVP Commercial/ASO Members are not eligible for nurse practitioner or physician assistant services in a skilled nursing facility.

Except for the therapy services (PT,OT,SLP), the professional component of physician services and services of the following non-physician providers are excluded from Part A PPS payment and the requirement for consolidated billing, and may be billed separately:

- Physician assistants, working under a physician's supervision
- Nurse practitioners and clinical nurse specialists working in collaboration with a physician

Providers should use appropriate place of service according to Medicare guidelines.



A physician may not delegate a task when the regulations specify that the physician must perform it personally, or when the delegation is prohibited under State law or by the facility's own policies.

The initial comprehensive visit in an SNF is the initial visit during which the physician completes a thorough assessment, develops a plan of care, and writes or verifies admitting orders for the resident. Under the regulations at 42 C.F.R. 483.40(c)(1), the initial comprehensive visit must occur no later

than 30 days after admission. Further, under 42 C.F.R. 483.40(c)(4) and (e), the physician may not delegate the initial comprehensive visit in an SNF. Non-physician practitioners may perform other medically necessary visits prior to and after the physician initial comprehensive visit.

Once the physician has completed the initial comprehensive visit in the SNF, the physician may then delegate alternate visits to a Physician Assistant (PA), Nurse Practitioner (NP), or Clinical Nurse Specialist (CNS) who is licensed as such by the State and performing within the scope of practice in that State, as required under 42 C.F.R. 483.40(c)(4).

MVP only pays for medically necessary face-to-face visits by the physician or NP/PA with the resident. If the NP/PA is performing the medically necessary visit, the NP/PA would bill for the visit.

Payment may be made for the services of Nurse Practitioners (NPs) and Clinical Nurse Specialists (CNSs) who are employed by a SNF or NF when their services are rendered to facility residents. If NPs and CNSs employed by a facility opt to reassign payment for their professional services to the facility, the facility can bill the appropriate Medicare Part B carrier under the NPs' or CNSs' PINs for their professional services. Otherwise, the NPs or CNSs who are employed by an SNF or NF bill the carrier directly for their services to facility residents.

Physician Assistants (PAs) who are employed by an SNF or NF cannot reassign payment for their professional services to the facility because Medicare law requires the employer of a PA to bill for the PA's services. The facility must always bill the Part B carrier under the PA's PIN for the PA's professional services to facility residents.

The regulation at 42 CFR, § 483.40(b)(3) states the physician must "Sign and date all orders with the exception of influenza and pneumococcal polysaccharide vaccines, which may be administered per physician-approved facility policy after an assessment for contraindications." In accordance with 42 CFR, Section 483.40(f), required physician tasks, such as verifying and signing orders in an NF, can be delegated under certain circumstances to a physician assistant, nurse practitioner, or clinical nurse specialist who is not an employee of the facility but who is working in collaboration with a physician. Therefore, in order to comply with survey and certification requirements, the physician must sign all orders written by an NP who is employed by the NF.

# **Billing/Coding Guidelines in a Nursing Facility**

The initial comprehensive visit in an NF is the same as in an SNF. That is, the initial comprehensive visit is the initial visit during which the physician completes a thorough assessment, develops a plan of care, and writes or verifies admitting orders for the resident, which must take place no later than 30 days after admission. The regulations at 42 C.F.R. 483.40(f) state that "At the option of the State, any required physician task in an NF (including tasks which the regulations specify must be performed personally by the physician) may also be satisfied when performed by a nurse practitioner, clinical nurse specialist, or physician assistant who is not an employee of the facility but who is working in collaboration with a physician." In other words, non-physician practitioners that have a direct relationship with a physician and who are not employed by the facility may perform the initial comprehensive visit, any other required physician visit and other medically necessary visits for a resident of an NF as the State allows. Non-physician practitioners may also perform other medically necessary visits prior to and after the physician initial comprehensive visit.

At the option of the State, NPs, PAs, and CNSs who are employees of the facility, while not permitted to perform visits required under the schedule prescribed at 42 C.F.R. 483.40(c)(1), are permitted to perform other medically necessary visits and write orders based on these visits. The physician must verify and sign any orders written by non-physician practitioners who are employed by the facility. For example, if a resident complains of a headache, the NP, CNS, or PA employed by the facility may assess the resident and write orders to address the condition. The physician must then verify and sign the orders. However, these medically necessary visits performed by NPs, CNSs, and PAs employed by the



facility may not take the place of the physician required visits, nor may the visit count towards meeting the required physician visit schedule prescribed at 42 C.F.R. 483.40(c)(1).

# **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

#### Sources

<u>cms.gov/manuals/downloads/clm104c06.pdf</u> <u>cms.gov/SurveyCertificationGenInfo/downloads/SCLetter04-08.pdf</u> <u>www.cms.gov/MLNProducts/downloads/snfprospaymtfctsht.pdf</u> <u>cms.gov/SNFPPS/05\_ConsolidatedBilling.asp www.cms.gov/MLNMattersArticles/downloads/SE0418.pdf</u>

# **History**

June 1, 2019New policy, approvedSeptember 1, 2020Policy reviewed, and approved with no changesMarch 1, 2023Policy reviewed, and approved with no changes



# Observation Status for Facility and Provider

Last Reviewed Date: September 1, 2022

# OBSERVATION STATUS FOR FACILITY AND PROVIDER Policy Definitions Notification/Prior Authorization Requests

**Billing/Coding Guidelines** 

References History

Policy

MVP does not require a preauthorization for observation services. However, any observation services that are converted to an inpatient stay will require an authorization. Any observation greater than 48 hours may have medical records requested to perform a medical necessity review to verify if there is clinical justification for additional hours to be billed.

# Definitions

Observation care is a well-defined set of specific, clinically appropriate services, which include ongoing short-term treatment, assessment, and reassessment before a decision can be made regarding whether patients will require further treatment as hospital inpatients or if they are able to be discharged from the hospital. Observation services are commonly ordered for patients who present to the emergency department and who then require a significant period of treatment or monitoring in order to make a decision concerning their admission or discharge.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Observation services are covered only when provided by the order of a physician or another individual authorized by State licensure law and hospital staff bylaws to admit patients to the hospital or to order outpatient tests. In the majority of cases, the decision whether to discharge a patient from the hospital following resolution of the reason for the observation care or to admit the patient as an inpatient can be made in less than 48 hours, usually in less than 24 hours.

When a physician orders that a patient receive observation care, the patient's status is that of an outpatient. The purpose of observation is to determine the need for further treatment or for inpatient admission. Thus, a patient receiving observation services may improve and be released or be admitted as an inpatient.

The chart must document that the physician explicitly assessed patient risk to determine that the member would benefit from observation care. The physician's clinical documentation must support the requirement for an observation level of care or for full admission; in addition, the physician's order must clearly identify the date and time of the member's admission or placement into observation status. The attending physician is responsible for evaluating the member at least each 24-hour interval.

MVP may retrospectively review observation services either pre-claim payment or post claim payment to ensure compliance with medical necessity criteria/regulatory as well as Administrative and Medical policies.

MVP does not reimburse observation services for the following:

- Preparation for, or recover from, diagnostic tests
- The routine recovery period following an ambulatory surgical procedure or an outpatient procedure



- Services routinely performed in the emergency department or outpatient department; observation services should not be billed concurrently with diagnostic or therapeutic services for which active monitoring is a part of the service
- Observation services submitted with routine pregnancy diagnosis
- Retaining a member for socioeconomic factors
- Custodial care

## References

Medicare Claims Processing Manual Chapter 4 - Part B Hospital (Including Inpatient Hospital Part B and OPPS)

cms.gov/Regulations-and-Guidance/Guidance/Manuals/Downloads/clm104c04.pdf

| March 1, 2019     | Policy approved                              |
|-------------------|--|
| June 1, 2021      | Policy reviewed and approved with changes    |
| September 1, 2022 | Policy reviewed and approved with no changes |



# Occupational Therapy (OT)

Last Reviewed Date: June 1, 2022

# OCCUPATIONAL THERAPY (OT)

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Non-Reimbursable OT Services Medicare Therapy Cap History

# Policy

Occupational therapy is reimbursed only when provided for the purpose of enabling the Member to perform the activities of daily living.

# Definitions

Occupational therapy (OT) is the use of purposeful activity or interventions designed to achieve functional outcomes which promote health or prevent injury or disability. It includes assessment by means of skilled observation or evaluation through the administration and interpretation of tests and measurements. OT may be appropriate for clinical findings such as changes in fine motor abilities, decreased strength or range of motion in small muscle groups, presence of pain, difficulty with activities of daily living (ADLs), and circulatory problems.

The American Medical Association (AMA) Current Procedural Terminology (CPT) manual defines a modality as, "any physical agent applied to produce therapeutic changes to biologic tissue; includes but is not limited to thermal, acoustic, light, mechanical, or electric energy." Modalities may be supervised, not requiring direct patient contact by the provider, or modalities may require constant attendance by a health care professional. Examples of supervised modalities may include application of hot or cold packs, vasopneumatic devices, whirlpool, diathermy, and infrared. Modalities that require constant attendance include ultrasound, electrical stimulation, and iontophoresis.

The AMA CPT manual defines therapeutic procedures as, "A manner of effecting change through the application of clinical skills and/or services that attempt to improve function." Examples of therapeutic procedures include therapeutic exercise to develop strength and endurance, range of motion and flexibility; neuromuscular re-education of movement, balance and coordination; and manual therapy techniques.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

The following CPT codes are covered for Occupational Therapy providers:

| CPT Code | Description                               |
|----------|---|
| 97165    | Occupation therapy: low complexity        |
| 97166    | Occupational therapy: moderate complexity |
| 97167    | Occupational therapy: high complexity     |

#### OT Contents Main Contents



| CPT Code | Description   |
|----------|---|
| 97168    | Re-evaluation of occupational therapy standard plan of care   |
| 97010    | Application of a modality to one or more areas; hot or cold packs   |
| 97012    | Application of a modality to one or more areas; traction, mechanical  |
| 97014    | Application of a modality to one or more areas; electrical stimulation (unattended)   |
| 97016    | Application of a modality to one or more areas; vasopneumatic devices   |
| 97018    | Application of a modality to one or more areas; paraffin bath   |
| 97022    | Application of a modality to one or more areas; whirlpool   |
| 97024    | Application of a modality to one or more areas; diathermy (eg. microwave)   |
| 97026    | Application of a modality to one or more areas; infrared  |
| 97028    | Application of a modality to one or more areas; ultraviolet   |
| 97032    | Application of a modality to one or more areas; electrical stimulation (manual), each 15 minutes  |
| 97033    | Application of a modality to one or more areas; iontophoresis, each 15 minutes  |
| 97034    | Application of a modality to one or more areas; contrast baths, each 15 minutes   |
| 97035    | Application of a modality to one or more areas; ultrasound, each 15 minutes   |
| 97036    | Application of a modality to one or more areas; Hubbard tank, each 15 minutes   |
| 97110    | Therapeutic procedure, one or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility   |
| 97112    | Therapeutic procedure, one or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities |
| 97113    | Therapeutic procedure, one or more areas, each 15 minutes; aquatic therapy with therapeutic exercises   |
| 97116    | Therapeutic procedure, one or more areas, each 15 minutes; gait training<br>(includes stair climbing)   |
| 97140    | Manual therapy techniques (eg, mobilization/ manipulation, manual<br>lymphatic drainage, manual traction), one or more regions, each 15 minutes   |
| 97530    | Therapeutic activities, direct (one-on-one) patient contact by the provider<br>(use of dynamic activities to improve functional performance), each 15<br>minutes  |
| 97535    | Self-care/home management training (eg, activities of daily living (ADL)<br>and compensatory training, meal preparation, safety procedures, and<br>instructions in  |
| 97542    | Wheelchair management (eg, assessment, fitting, training), each 15 minutes  |



| CPT Code | Description  |
|----------|--|
| 97760    | Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes |
| 97761    | Prosthetic training, upper and/or lower extremity(s), each 15 minutes  |
| 97762    | Checkout for orthotic/prosthetic use, established patient, each 15 minutes   |

For reimbursement of DME supplies, please see the Utilization Management policy in the PRM for dispensing guidelines and code coverage.

# **Non-Reimbursable OT Services**

Duplicate therapy–if patients receive both occupational and physical or speech therapy, the therapies should provide different treatments and not duplicate the same treatment.

Non-Skilled Services-treatments that do not require the skills of a qualified provider of OT services, such as services which maintain function by using routine, repetitive, and reinforced procedures such as daily feeding programs, once adaptive procedures are in place.

Work-hardening program-programs which attempt to recreate the work environment to rebuild self- esteem. These programs are designed to recondition a patient for their unique job situation, not to treat a specific medical condition; therefore, they are not covered. However, work-hardening therapies that improve mobility and function would be medically necessary. In those instances, work-hardening therapy would be reimbursable.

# **Medicare Therapy Cap**

There is a combined annual per-beneficiary therapy cap amount for physical therapy and speech language pathology services combined and a separate amount allotted for occupational therapy services. The amount of the cap is determined by CMS and may change periodically.

The therapy cap with an exceptions process applies to services furnished in the following outpatient therapy settings: physical therapists in private practice, physician offices, skilled nursing facilities (Part B), rehabilitation agencies (or ORFs), comprehensive outpatient rehabilitation facilities (CORFs), and outpatient hospital departments.

The provider should use the KX modifier to the therapy procedure code that is subject to the cap limits only when a beneficiary qualifies for a therapy cap exception. The KX modifier should not be used prior to the Member meeting their therapy cap. By attaching the KX modifier, the provider is attesting that the services billed:

- Qualified for the cap exception
- Are reasonable and necessary services that require the skills of a therapist and
- Are justified by appropriate documentation in the medical record.

Claims for patients who meet or exceed the Medicare annual stated therapy service threshold in therapy expenditures will be subject to a manual medical review.

| March 1, 2021 | Policy approved                              |
|---------------|--|
| March 1, 2021 | Policy reviewed and approved with no changes |
| June 1, 2022  | Policy reviewed and approved with no changes |

#### **MVP Health Care Payment Policy**



Personal Care/ Consumer Directed Personal Assistance Services - Service Units Billing

# PERSONAL CARE/CONSUMER DIRECTED PERSONAL ASSISTANCE SERVICES - SERVICE UNITS BILLING

Policy Definitions Notifications/Prior Authorization Request Billing/Coding Guidelines References History

Last Reviewed Date - September 1, 2022

# Policy

MVP requires Providers billing claims for reimbursement of Personal Care Services (PCS) or Consumer Directed Personal Assistance Services (CDPAS) units of service for a date of service on a single line. Units of service provided for each date of service should not be split to separate lines on claim submissions.

This policy applies to Medicaid and HARP Members.

# **Definitions**

Activities of Daily Living (ADL) include bathing, dressing, grooming, eating, transferring, ambulating, and toileting.

**Consumer Directed Personal Assistance Service (CDPAS)** is the New York State Medicaid program for chronically ill or disabled individuals who have a medical need for help with activities of daily living (ADLs), instrumental activities of daily living (IADLs), or skilled nursing services provided by a personal care aide (home attendant), home health aide, or nurse under the supervision of the consumer.

**Consumer** is the medical assistance recipient who a social services district has determined eligible to participate in the consumer directed personal assistance program.

**Instrumental Activities of Daily Living (IADL)** include housekeeping, laundry, meal planning and preparation, use of a telephone, managing finances, and shopping or errands.

**Personal Care Assistance (PCA)** assist an individual with day-to-day activities in their home and community. PCA's assist with ADLs, health-related procedures and tasks, observation and redirection of behaviors, and IADLs.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required, and the *Benefit Interpretation Manual* for MVP's clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Billing with the appropriate procedure and diagnosis codes expedites processing for payment of services. It is important to code to the highest specificity based on the diagnoses of the Member. MVP will deny claims if a non-specific diagnosis code is utilized as outlined below.



# Non-Specific Diagnosis Codes:

| Diagnosis Code | Description   |
|----------------|---|
| R69            | Illness, unspecified  |
| R5381          | Other malaise   |
| R6889          | Other general symptoms and signs  |
| R52            | Pain, unspecified   |
| 16990          | Unspecified sequelae of unspecified cerebrovascular disease                 |
| R5383          | Other fatigue   |
| R54            | Age related physical debility   |
| Q8789          | Other specified congenital malformation syndromes, not elsewhere classified |

Sign In to your MVP Provider online account to review the Personal Care & Consumer Directed Services for MVP Medicaid Managed Care Medical Policy.

| Service Type           | Procedure Code | Unit of<br>Measurement   | Billing<br>Instructions | Code Description  |
|------------------------|----------------|--------------------------|-------------------------|---|
| PCS – Level I          | S5130          | 1 unit per 15<br>minutes | Use Modifier U1         | Homemaker service, NOS; per 15  |
| Nursing<br>Supervision | T1001          | Per visit                | n/a                     | Nursing Assessment Evaluation   |
| PCS – Level II Basic   | T1019          | 1 unit per 15<br>minutes | Use Modifier U1         | PCS, per 15 minutes, not for an inpatient or<br>resident of a hospital, nursing facility, ICF/MR or<br>IMD, part of the individualized plan of treatment<br>(code cannot be used to identify services<br>provided by home health aide or certified nurse<br>assistant). |
| CDPAS Basic            | T1019          | 1 unit per 15<br>minutes | Use Modifier U6         | PCS, per 15 minutes, not for an inpatient or<br>resident of a hospital, nursing facility, ICF/MR or<br>IMD, part of the individualized plan of treatment<br>(code cannot be used to identify services<br>provided by home health aide or certified nurse<br>assistant). |
| PCS Level II Live In   | T1020          | Per Diem (13<br>Hours)   | n/a                     | PCS, per diem, not for an inpatient or resident of<br>a hospital, nursing facility, ICF/MR or IMD, part of<br>the individualized plan of treatment (code cannot<br>be used to identify services provided by home<br>health aide or certified nurse assistant.)          |
| CDPAS Live In          | T1020          | Per Diem (13<br>Hours)   | Use Modifier U6         | PCS, per diem, not for an inpatient or resident of<br>a hospital, nursing facility, ICF/MR or IMD, part of<br>the individualized plan of treatment (code cannot<br>be used to identify services provided by home<br>health aide or certified nurse assistant.)          |



| Service Type     | Procedure Code | Unit of<br>Measurement | Billing<br>Instructions | Code Description                            |
|------------------|----------------|------------------------|-------------------------|---|
| UAS Assessment   | T2024          | Per Visit              | n/a                     | Service Assessment/plan of care development |
| UAS Reassessment | T2024          | Per Visit              | n/a                     | Service Assessment/plan or care development |

# References

NYS Department of Health: <u>https://www.health.ny.gov/health\_care/medicaid/program/longterm/cdpap.htm</u> <u>https://www.health.ny.gov/health\_care/medicaid/program/longterm/pcs.htm</u>

| December 1, 202   | Policy approved                           |
|-------------------|---|
| September 1, 2021 | Policy reviewed and approved with changes |
| September 1, 2022 | Policy reviewed and approved with changes |



# Physical Therapy (PT)

Last Reviewed Date: September 1, 2022

#### PHYSICAL THERAPY (PT)

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Non-Reimbursable PT Services Medicare Therapy Cap Reimbursement Guidelines References History

# Policy

Medically necessary physical therapy, including rehabilitation after various surgeries, injuries, and illness is considered reimbursable.

# Definitions

Physical therapy (PT) is a prescribed program of treatment generally provided to improve or restore lost or impaired physical function resulting from illness, injury, congenital defect, or surgery. The physical therapist enhances rehabilitation and recovery by clarifying a Member's impairments and functional limitations and by identifying interventions, treatment goals, and precautions.

The American Medical Association (AMA) Current Procedural Terminology (CPT) manual defines a modality as, "any physical agent applied to produce therapeutic changes to biologic tissue; includes but is not limited to thermal, acoustic, light, mechanical, or electric energy." Modalities may be supervised, not requiring direct Member contact by the provider, or modalities may require constant attendance by a healthcare professional. Examples of supervised modalities may include application of hot or cold packs, vasopneumatic devices, whirlpool, diathermy, and infrared. Modalities that require constant attendance include ultrasound, electrical stimulation, and iontophoresis.

The AMA CPT manual defines therapeutic procedures as, "A manner of effecting change through the application of clinical skills and/or services that attempt to improve function." Examples of therapeutic procedures include therapeutic exercise to develop strength and endurance, range of motion, and flexibility; neuromuscular re-education of movement, balance, and coordination; gait training; and manual therapy techniques (e.g., manual traction).

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

The following CPT codes are covered for Physical Therapy providers:

| CPT Code | Description  |
|----------|--|
| 95992    | Canalith repositioning procedure(s) (eg, Epley maneuver, Semont maneuver), per day |
| 97161    | Physical therapy evaluation: low complexity  |
| 97162    | Physical therapy evaluation: moderate complexity                                   |



| CPT Code | Description   |  |  |
|----------|---|--|--|
| 97163    | Physical therapy evaluation: high complexity  |  |  |
| 97164    | Re-evaluation of physical therapy established plan of care  |  |  |
| 97010    | Application of a modality to one or more areas; hot or cold packs   |  |  |
| 97012    | Application of a modality to one or more areas; traction, mechanical  |  |  |
| 97014    | Application of a modality to one or more areas; electrical stimulation (unattended)   |  |  |
| 97016    | Application of a modality to one or more areas; vasopneumatic devices   |  |  |
| 97018    | Application of a modality to one or more areas; paraffin bath   |  |  |
| 97022    | Application of a modality to one or more areas; whirlpool   |  |  |
| 97024    | Application of a modality to one or more areas; diathermy (eg, microwave)   |  |  |
| 97026    | Application of a modality to one or more areas; infrared  |  |  |
| 97028    | Application of a modality to one or more areas; ultraviolet   |  |  |
| 97032    | Application of a modality to one or more areas; electrical stimulation (manual), each 15 minutes  |  |  |
| 97033    | Application of a modality to one or more areas; iontophoresis, each 15 minutes  |  |  |
| 97034    | Application of a modality to one or more areas; contrast baths, each 15 minutes   |  |  |
| 97035    | Application of a modality to one or more areas; ultrasound, each 15 minutes   |  |  |
| 97036    | Application of a modality to one or more areas; Hubbard tank, each 15 minutes   |  |  |
| 97110    | Therapeutic procedure, one or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility   |  |  |
| 97112    | Therapeutic procedure, one or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities |  |  |
| 97113    | Therapeutic procedure, one or more areas, each 15 minutes; aquatic therapy with therapeutic exercises   |  |  |
| 97116    | Therapeutic procedure, one or more areas, each 15 minutes; gait training<br>(includes stair climbing)   |  |  |
| 97124    | Therapeutic procedure, one or more areas, each 15 minutes; massage, including effleurage, petrissage and/or tapotement  |  |  |
| 97140    | Manual therapy techniques (e.g., mobilization/manipulation, manual lymphatic drainage, manual traction), one or more regions, each 15 minutes   |  |  |
| 97530    | Therapeutic activities, direct (one-on-one) patient contact by the provider (use of dynamic activities to improve functional performance), each 15 minutes  |  |  |



| CPT Code | Description  |
|----------|--|
| 97535    | Self-care/home management training (eg, activities of daily living (ADL)<br>and compensatory training, meal preparation, safety procedures, and<br>instructions in use of assistive technology devices/adaptive equipment)<br>direct one-on-one contact by provider, each 15 minutes |
| 97542    | Wheelchair management (eg, assessment, fitting, training), each 15 minutes   |
| 97760    | Orthotic(s) management and training (including assessment and fitting when not otherwise reported), upper extremity(s), lower extremity(s) and/or trunk, each 15 minutes   |
| 97761    | Prosthetic training, upper and/or lower extremity(s), each 15 minutes  |
| 97762    | Checkout for orthotic/prosthetic use, established patient, each 15 minutes   |

For coverage of DME supplies please see the Utilization Management policy in the PRM for dispensing guidelines and code coverage.

# **Non-Reimbursable PT Services**

Non-skilled services—treatments that do not require the skills of a qualified PT provider, such as passive range of motion (PROM) treatment that is not related to restoration of a specific loss of function.

Duplicate therapy—if Members receive both physical and occupational therapy, the therapies should provide different treatments and not duplicate the same treatment. They must also have separate treatment plans and goals.

Maintenance programs—activities that preserve the Member's present level of function and prevent regression of that function. Maintenance begins when the therapeutic goals of a treatment plan have been achieved, or when no additional functional progress is apparent or expected to occur.

Physical Therapy for Acute Low Back Pain (<3 months)—MVP follows the National Institute of Health (NIH) guidelines for treatment of low back pain. The following physical therapy treatments are considered to be not medically necessary, unproven, or ineffective for patients with acute low back pain:

- Traction has not been proven effective
- Ultrasound, massage, ice, heat, diathermy, lasers, electrical stimulation to relieve symptoms of low back pain have not been proven effective
- TENS units
- Biofeedback has not been proven effective for acute low back pain
- · Acupuncture is not recommended for acute back pain
- Back (lumbar) corsets to treat acute low back pain have not been proven effective
- "Back School," a type of educational program for low back pain, has not been proven to be more effective than other treatments, and is not reimbursable

# **Medicare Therapy Cap**

There is a combined annual per-beneficiary therapy cap amount for physical therapy and speech language pathology services combined and a separate amount allotted for occupational therapy services. The amount of the cap is determined by CMS and may change periodically.

The therapy cap with an exceptions process applies to services furnished in the following outpatient therapy settings: physical therapists in private practice, physician offices, skilled nursing facilities (Part B), rehabilitation agencies (or ORFs), comprehensive outpatient rehabilitation facilities (CORFs), and outpatient hospital departments.



The Provider should use the KX modifier to the therapy procedure code that is subject to the cap limits only when a Member qualifies for a therapy cap exception. The KX modifier should not be used prior to the Member meeting their therapy cap. By attaching the KX modifier, the provider is attesting that the services billed:

- Qualified for the cap exception;
- Are reasonable and necessary services that require the skills of a therapist; and
- Are justified by appropriate documentation in the medical record.

Claims for patients who meet or exceed the Medicare annual stated therapy service threshold in therapy expenditures will be subject to a manual medical review.

## **Reimbursement Guidelines**

Please see your provider fee schedule or your Provider agreement for specific reimbursement guidelines.

# References

MVP Utilization Management Policy, Provider Resource Manual

| March 1, 2019     | Policy approved                              |
|-------------------|--|
| March 1, 2021     | Policy reviewed and approved with no changes |
| June 1, 2022      | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with changes    |



# Preoperative Lab Testing

Last Reviewed Date: September 1, 2022

# PREOPERATIVE LAB TESTING Policy Definitions Notification/Prior Authorization Requests

Billing/Coding Guidelines ICD-10 Codes that DO NOT Support Reimbursement Reimbursement Guidelines

History

# Policy

Routine preoperative testing is not reimbursable for up to 30 days prior to any inpatient or outpatient surgery. Routine preoperative testing will be denied as global to the surgery for all products. This policy applies to all physicians, free standing facilities, labs, and hospitals.

# Definitions

Preoperative diagnostic tests are those that are performed to determine a patient's perioperative risk and optimize perioperative care.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **General Guidelines**

The use of diagnostic testing as part of a pre-operative examination, where there is an absence of signs or symptoms indicating a need for the test, is not reimbursed. These services will be denied as global.

Examples of diagnostic tests which are often performed routinely prior to surgical procedures include:

- Electrocardiograms performed pre-operatively, when there are no indications for this test
- Radiologic examination of the chest performed pre-operatively, when there are no indications for this test
- Partial thromboplastin time (PTT) performed prior to medical intervention when there are no signs or symptoms of bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis conditions associated with coagulopathy
- Prothrombin Time (PT) performed prior to medical intervention when there are no signs or symptoms of bleeding or thrombotic abnormality or a personal history of bleeding, thrombosis conditions associated with coagulopathy
- Serum iron studies performed as a pre-operative test when there is no indication of anemia or recent autologous blood collections prior to surgery

Claims submitted for these tests performed solely as part of a preoperative examination, without additional diagnoses, will be denied as global. This is not an all-inclusive list of tests or laboratory services; any test done for pre-operative purposes without signs or symptoms will be denied.



Hospital/clinic-specific policies, protocols, etc., in and of themselves cannot alone justify coverage. Assign the ICD-10 codes describing the signs, symptoms, or conditions that justify the need for the test. If no underlying signs, symptoms, or conditions are present, a screening code must be used.

# **ICD-10 Codes that DO NOT Support Reimbursement**

For pre-operative testing (Chest X-ray, EKG, Partial Thromboplastin, Prothrombin Time, Serum Iron):

| ICD-10 Code  | Description   |  |
|--|---|--|
| Z01.810  | Encounter for preprocedural cardiovascular examination                |  |
| Z01.811  | Encounter for preprocedural respiratory examination                   |  |
| Z01.818  | Encounter for other preprocedural examination                         |  |
| Z01.812  | Encounter for preprocedural laboratory examination                    |  |
| Z01.818  | Encounter for other preprocedural examination                         |  |
| Z01.30   | Encounter for examination of blood pressure without abnormal findings |  |
| Z01.31   | Encounter for examination of blood pressure with abnormal findings    |  |
| Z01.89   | Z01.89         Encounter for other specified special examinations     |  |
| <b>Z00.00</b> Encounter for general adult medical examination without abnormal finding |   |  |
| Z01.89   | .89 Encounter for other specified special examinations                |  |

# **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

| June 1, 2017      | Policy approved                              |
|-------------------|--|
| June 1, 2020      | Policy reviewed and approved with no changes |
| June 1, 2021      | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



# Preventive Health Care

Last Reviewed Date: March 1, 2023

# PREVENTIVE HEALTH CAREPolicyDefinitionsNotification/Prior Authorization RequestsBilling/Coding GuidelinesUnited States Preventive Service Task Force RecommendationsNon-USPSTF Preventative Services CoverageHistory

# Policy

MVP covers the full cost of Preventive Services outlined below with no co-pays, deductibles, or co-insurance for Members in accordance with state and federal regulations when these services are the primary reason for a visit. Providers should still bill MVP for these services as appropriate; however, no co-pay/co-insurance/cost share should be taken at the time of service. Claims will still be subject to clinical edits and bundling. Some products (including but not limited to MVP Medicare) may have exclusions or variations to the Federal Healthcare Reform; providers should check the Member's benefits to determine if preventive services apply to their plan.

Payment of preventive services by MVP is dependent on correct claim submission using diagnosis and procedure codes which identify the services as preventive. All standard coding practices should be observed. When billing the primary reason for the visit, the diagnosis codes identified should be billed on the claim line level in the principal diagnosis position. The following pages provide guidance related to designated preventive services and the associated ICD-10, CPT, and HCPCS codes.

# Definitions

#### **Adolescents and Children**

Affordable Care Act (ACA)-covered preventive services are provided to Members from birth through attainment of age 19.

#### Adults

ACA covered preventive services are provided to Members 19 and older.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

#### **General Guidelines**

No co-payment, deductible, or co-insurance will be applied when billed in accordance with standard code billing practices.

The following code sets, (99401-99404), (99381-99387), and (99391-99397), are used repeatedly throughout sections of the policy entitled "United States Preventive Services Task Force Recommendations."

Preventive medicine-Individual Counseling-Risk factor reduction for persons without specific illness (E&M Codes)



CPT codes **99401–99404** are used to report services that promote health and prevent illness or injury in persons without a specific illness for which the counseling might otherwise be used as part of treatment.

Face to Face preventive counseling and risk factor reduction interventions will vary with age.

These codes are not to be used to report counseling and risk factor reduction interventions provided to patients with symptoms or established illness. For counseling individual patients with symptoms or established illness, use the appropriate office, hospital, consultation or other evaluation and management (E&M) codes.

These codes will be referred to as: **Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness** throughout this policy

| CPT Codes | Description   |  |
|-----------|---|--|
| 99401     | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes    |  |
| 99402     | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate<br>procedure); approximately 30 minutes |  |
| 99403     | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separat procedure); approximately 45 minutes     |  |
| 99404     | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (sep procedure); approximately 60 minutes         |  |

#### New Patient comprehensive preventive medicine evaluation and management

CPT codes 99381-99387-Preventive initial E&M (new patient):

These preventive evaluation and management (E&M) services are represented by distinct CPT codes from those that represent problem-oriented evaluation and management (E&M) services. They are inherently Preventive and, therefore, modifier 33 would not be used with them.

Note that codes 99381–99387 are age-delimited and include counseling, anticipatory guidance, and risk factor reduction interventions that are provided at the time of the **initial** preventive medicine examination.

These codes will be referred to as: **New Patient comprehensive preventive medicine evaluation and management** throughout this policy.

| CPT Codes  | Description  |  |
|--|--|--|
| 99381  | Initial comprehensive preventive medicine evaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; infant (age younger than 1 year)        |  |
| 99382  | Initial comprehensive preventive medicine evaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; early childhood (age 1 through 4 years) |  |
| 99383  | Initial comprehensive preventive medicine evaluation and management of an individual including an age- an gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventior and the ordering of laboratory/diagnostic procedures, new patient; late childhood (age 5 through 11 years)    |  |
| 99384 Initial comprehensive preventive medicine evaluation and management of an individual including a gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction int and the ordering of laboratory/diagnostic procedures, new patient; adolescent (age 12 through 17 ye |  |  |



|   | CPT Codes  | Description   |
|---|--|---|
| 99385 gender-appropriate history, examination, counseling/anticipatory guidance/r |  | Initial comprehensive preventive medicine evaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 18-39 years        |
|   | 99386 Initial comprehensive preventive medicine evaluation and management of an individual includir gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction and the ordering of laboratory/diagnostic procedures, new patient; 40-64 years |   |
| 99387 gender-appropriate history, examination, counseling/anticipatory guidance   |  | Initial comprehensive preventive medicine evaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, new patient; 65 years and older |

#### Established Patient comprehensive preventive medicine evaluation and management

#### CPT codes 99391-99397:

These preventive evaluation and management (E&M) services are represented by distinct CPT codes from those that represent problem-oriented evaluation and management (E&M) services. They are inherently Preventive and, therefore, modifier 33 would not be used with them.

• Preventive periodic E&M (established patient)(CPT codes 99391-99397)

Note that codes 99391–99397 are age delimited and include counseling, anticipatory guidance, and risk factor reduction interventions that are provided at the time of the **periodic** comprehensive preventive medicine examination.

# These codes will be referred to as: **Established Patient comprehensive preventive medicine evaluation and management** throughout this policy.

| CPT Codes | Description   |  |
|-----------|---|--|
| 99391     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; infant (age younger than 1 year)        |  |
| 99392     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) |  |
| 99393     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) |  |
| 99394     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years)    |  |
| 99395     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years                             |  |
| 99396     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 40-64 years                             |  |
| 99397     | Periodic comprehensive preventive medicine reevaluation and management of an individual including an age- and gender-appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 65 years and older                      |  |



The following table indicates how preventive services should be billed for the MVP's claims system to recognize that a co-pay, co-insurance, or deductible should not be taken. Typically, the procedure code that is billed needs to have an appropriate diagnosis or modifier on the claim to alert MVP the service is preventable. There are some procedures codes that do not apply co-payment, co-insurance, or deductible regardless of the diagnosis or modifier billed. This billing rules may also apply to state regulation that vary from US Preventive Services Task Force guidelines. For example, a 55-year-old man has a colonoscopy for colorectal cancer screening. The procedure for colonoscopy is billed using CPT procedure code 45378. The claim will not take a co-pay if either a modifier 33 is appended to the procedure or one of the diagnosis codes in the table, such as z12.10 (Encounter for screening for malignant neoplasm of the intestinal tract, unspecified), is put in the first position on the claim. Associated services such as anesthesia will not be subject to co-pay, co-insurance, or deductible if a diagnosis code such as z12.10 is the first diagnosis on the claim. For another example, a 40-year-old woman has her first mammogram for breast cancer screening. The procedure for bilateral screening mammography is billed using CPT procedure code 77067. There are no other billing requirements. The claim will not take a co-pay for screening mammography for women, with or without clinical breast examination, every 1 to 2 years for women age 40 years and older.

# **United States Preventive Service Task Force Recommendations**

#### **Abdominal Aortic Aneurysm Screening: Men**

(June 2014) Rating B

#### "Task Force" Recommendation

**Medical** – The USPSTF recommends one-time screening for abdominal aortic aneurysm (AAA) by ultrasonography in men aged 65 to 75 years who have ever smoked.

**Facility** – No cost share for one (1)-time screening in men aged 65 to 75 who have ever smoked when billed with appropriate code and one of the following revenue codes: 0320-0329, 0400,0402, 0409.

| Code  | <b>Billing Instruction</b> | Code Description   |
|-------|----------------------------|--|
| 76706 |                            | Ultrasound B-scan and/or real-time with image documentation; for abdominal aortic aneurysm (AAA) screening |

#### Unhealthy Alcohol Use in Adolescents and Adults: Screening and Behavioral Counseling Interventions (November 2018) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for unhealthy alcohol use in primary care settings in adults 18 years or older, including pregnant persons, and providing persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce unhealthy alcohol use.

| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| G0442 |                            | Annual alcohol misuse screening, 15 minutes   |
| G0443 |                            | Brief face-to-face behavioral   |
| 99408 |                            | Alcohol and/or substance (other than tobacco) abuse structured screening (eg, AUDIT, DAST), and brief intervention (SBI) services |
| 99409 |                            | Brief interventions greater than 30 minutes   |



#### **Unhealthy Drug Use: Screening**

(July 2020) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening by asking questions about the unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment and appropriate care can be offered or referred.

(Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)

| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| 99408 |                            | Alcohol and/or substance (other than tobacco) abuse structured screening<br>(eg, AUDIT, DAST), and brief intervention (SBI) services; 15 to 30 minutes        |
| 99409 |                            | Alcohol and/or substance (other than tobacco) abuse structured screening<br>(eg, AUDIT, DAST), and brief intervention (SBI) services; greater than 30 minutes |

#### **Bacteriuria Screening: Pregnant Persons**

(July 2008) Rating A

#### "Task Force" Recommendation

The USPSTF recommends screening for asymptomatic bacteriuria with urine culture in pregnant persons at 12 to16 weeks' gestation or at the first prenatal visit, if later.

| Code  | <b>Billing Instruction</b>   | Code Description   |
|-------|--|--|
| 87086 | Bill with pregnancy related<br>diagnosis code. See<br>Pregnancy related diagnosis<br>code set at the end of Policy | Culture, bacterial; quantitative colony count, urine                                     |
| 87088 | Bill with pregnancy related<br>diagnosis code. See<br>Pregnancy related diagnosis<br>code set at the end of policy | Culture, bacterial; with isolation and presumptive identification of each isolate, urine |

#### BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing

(August 2019) Rating B

#### "Task Force" Recommendation

**Medical** – The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA 1/2) gene mutations with an appropriate brief familial risk assessment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.

Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.

**Facility** – No cost share for women to discuss positive BRCA testing when billed with appropriate code Modifier 33 must be appended to the code (96040, S0265) to consider it preventative. These services must also be billed with the following revenue codes: 0500, 0510.

| Code            | <b>Billing Instruction</b> | Code Description   |
|-----------------|----------------------------|--|
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |



| Code           | <b>Billing Instruction</b> | Code Description   |
|----------------|----------------------------|--|
| 96040          | Bill with Modifier 33      | Covers genetic counseling (GC) visits provided by counselors only  |
| S0265          | Bill with Modifier 33      | Genetic counseling, under physician supervision, each 15 minutes   |
| 81163<br>81164 |                            | BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated)<br>(e.g., hereditary breast and ovarian   |
| 81165          |                            | BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full sequence analysis  |
| 81166          |                            | BRCA1 (BRCA1, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements) |
| 81167          |                            | BRCA2 (BRCA2, DNA repair associated) (e.g., hereditary breast and ovarian cancer) gene analysis; full duplication/deletion analysis (ie, detection of large gene rearrangements) |
| 81212          |                            | BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary breast and ovarian cancer) gene analysis; 185delAG, 5385insC, 6174delT variants   |
| 81215          |                            | BRCA1 (breast cancer 1) (e.g., hereditary breast and ovarian cancer) gene analysis;<br>known familial variant  |
| 81216          |                            | BRCA2 (breast cancer 2) (e.g., hereditary breast and ovarian cancer) gene analysis;<br>full sequence analysis  |
| 81217          |                            | BRCA2 (breast cancer 2) (e.g.,hereditary breast and ovarian cancer) gene analysis;<br>known familial variant   |
| 81162          |                            | BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary BRCA1, BRCA2 (breast cancer 1 and 2) (e.g., hereditary)   |

#### **Breast Cancer: Medication Used to Reduce Risk**

(Sept 2019) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that clinicians offer to prescribe risk-reducing medications, such as tamoxifen, raloxifene, or aromatase inhibitors, to women who are at increased risk for breast cancer and at low risk for adverse medication effects.

| Code            | <b>Billing Instruction</b> | Code Description  |
|-----------------|----------------------------|---|
| 99385-<br>99397 |                            | Established Patient comprehensive preventive medicine evaluation and management |



#### **Breast Cancer Screening**

| lanuar | v 2016) | Rating <b>B</b> |  |  |
|--------|---------|-----------------|--|--|
| Junuar | y 2010) | Rating D        |  |  |

#### "Task Force" Recommendation

The USPSTF recommends screening mammography for women, with or without clinical breast examination, every 1 to 2 years for women age 40 years and older.

| Code            | <b>Billing Instruction</b>                      | Code Description  |
|-----------------|---|---|
| 99401-<br>99404 | Medical &Facility codes                         | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. |
| 99386-<br>99387 |   | New Patient comprehensive preventive medicine evaluation and management   |
| 99396-<br>99397 |   | Established Patient comprehensive preventive medicine evaluation and management   |
| 77063           | Add on code, only use in conjunction with 77067 | Screening digital breast Tomosynthesis, bilateral   |
| 77067           |   | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed         |
| G0202           |   | Screening mammography, producing direct digital image, bilateral, all views   |

#### **Breastfeeding Interventions**

(2016) Rating B

#### "Task Force" Recommendation

The USPSTF recommends interventions during pregnancy and after birth to promote and support breastfeeding.

| Code            | <b>Billing Instruction</b> | Code Description   |  |
|-----------------|----------------------------|--|--|
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |  |

#### **Cervical Cancer Screening**

(August 2018) Rating A

#### **"Task Force" Recommendation**

The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women ages 21 to 29 years. For women ages 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (co-testing).

| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| 88141 |                            | Cytopathology, cervical, or vaginal (any reporting system), requiring interpretation by physician   |
| 88142 |                            | Cytopathology, cervical, or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision |



| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| 88143 |                            | Cytopathology, cervical, or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision                                    |
| 88147 |                            | Cytopathology smears, cervical, or vaginal; screening by automated system under physician supervision   |
| 88148 |                            | Cytopathology smears, cervical, or vaginal; screening by automated system with manual rescreening under physician supervision   |
| 88150 |                            | Cytopathology, slides, cervical, or vaginal; manual screening under physician supervision   |
| 88152 |                            | Cytopathology, slides, cervical or vaginal; with manual screening and computer-<br>assisted rescreening under physician supervision   |
| 88153 |                            | Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision   |
| 88154 |                            | Cytopathology, slides, cervical or vaginal; with manual screening and computer-<br>assisted rescreening using cell selection and review under physician supervision   |
| 88155 |                            | Cytopathology, slides, cervical or vaginal definitive hormonal evaluation (e.g.<br>maturation index, karyopyknotic index, estrogenic index). List separately in addition<br>to code(s) or other technical and interpretive services |
| 88164 |                            | Cytopathology, slides, cervical or vaginal (the Bethesda System); manual screening under physician supervision  |
| 88165 |                            | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and rescreening under physician supervision   |
| 88166 |                            | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening under physician supervision   |
| 88167 |                            | Cytopathology, slides, cervical or vaginal (the Bethesda System); with manual screening and computer-assisted rescreening using cell selection and review under physician supervision   |
| 88174 |                            | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; screening by automated system, under physician supervision  |
| 88175 |                            | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision      |
| G0101 |                            | Cervical or vaginal cancer screening; pelvic and clinical breast examination  |
| G0123 |                            | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision                                   |
| G0124 |                            | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician   |



| Code  | <b>Billing Instruction</b> | Code Description   |
|-------|----------------------------|--|
| G0141 |                            | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician   |
| G0143 |                            | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision                  |
| G0144 |                            | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision  |
| G0145 |                            | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision                  |
| G0147 |                            | Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision   |
| G0148 |                            | Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening   |
| G0476 |                            | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv),<br>high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer<br>screening, must be performed in addition to pap test |
| P3000 |                            | Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, by technician under physician supervision   |
| P3001 |                            | Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, requiring interpretation by physician   |
| Q0091 |                            | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory   |

#### Screening for Chlamydia and Gonorrhea

(Sept 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection.

The USPSTF recommends screening for gonorrhea in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection.

This recommendation applies to asymptomatic, sexually active adolescents and adults, including pregnant persons.

| Code           | <b>Billing Instruction</b> | Code Description  |
|----------------|----------------------------|---|
| 87270<br>87320 |                            | Infectious agent antigen detection by immunofluorescent technique; Chlamydia trachomatis                  |
| 87490          |                            | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, direct probe technique    |
| 87491          |                            | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique |



| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| 87492 |                            | Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, quantification            |
| 87590 |                            | Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, direct probe technique    |
| 87591 |                            | Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique |
| 87592 |                            | Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, quantification            |
| 87110 |                            | Culture, chlamydia, any source  |
| 86631 |                            | Antibody: Chlamydia   |
| 86632 |                            | Antibody; Chlamydia, IgM  |

## **Colorectal Cancer Screening**

(May 2021) Rating A and Rating B

# "Task Force" Recommendation

Rating A - The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.

Rating B - The USPSTF recommends screening for colorectal cancer starting at age 45 years and continuing until age 49 years.

ALL Services associated with a screening colonoscopy including anesthesia, medically necessary office visits, and associated laboratory tests are covered with no co-pay/deductible /co-insurance.

# **Colorectal Cancer Screening - NY and VT**

| Code                       | <b>Billing Instruction</b>  | Code Description   |
|----------------------------|---|--|
| Medical<br>and<br>Facility | No cost share for Medical or Facility<br>services when one billed with a modifier<br>PT or 33 |  |
| 44388                      | No cost share when billed with Modifier<br>33 or PT   | Colonoscopy Stomal Diagnostic  |
| 44390                      | No cost share when billed with Modifier<br>33 or PT   | Colonoscopy Stomal W Removal of foreign body   |
| 44391                      | No cost share when billed with Modifier<br>33 or PT   | Fiberoptic Colonoscopy; Hemorrhage Control   |
| 44402                      | No cost share when billed with Modifier<br>33 or PT   | Colonoscopy through stoma; with endoscopic stent placement (including pre- and post-dilation and guide wire passage, when performed) |
| 44403                      | No cost share when billed with Modifier<br>33 or PT   | Colonoscopy through stoma; with endoscopic mucosal resection   |
| 44404                      | No cost share when billed with Modifier<br>33 or PT   | Colonoscopy through stoma; with directed submucosal injection(s), any substance  |



| Code  | <b>Billing Instruction</b>  | Code Description  |
|-------|---|---|
| 44405 | No cost share when billed with Modifier 33 or PT  | Colonoscopy through stoma; with transendoscopic balloon dilation  |
| 44406 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy through stoma; with endoscopic ultrasound examination,<br>limited to the sigmoid, descending, transverse, or ascending colon and<br>cecum and adjacent structures         |
| 44407 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy through stoma; with transendoscopic ultrasound guided<br>intramural or transmural fine needle aspiration/biopsy(s), includes<br>endoscopic ultrasound examination limited |
| 44408 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy through stoma; with decompression (for pathologic distention) (eg, volvulus, megacolon), including placement of decompression tube, when performed                        |
| 45300 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; diagnostic, with or without collection of specimen(s) by brushing or washing (separate procedure)   |
| 45303 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with dilation (e.g., balloon, guide wire, bougie)   |
| 45305 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with biopsy, single or multiple   |
| 45307 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with removal of foreign body  |
| 45309 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with removal of single tumor, polyp, or other lesion by snare technique   |
| 45315 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with removal of multiple tumors, polyps, or other lesions by hot biopsy forceps, bipolar cautery or snare technique                                       |
| 45317 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with control of bleeding (e.g., injection, bipolar cautery, unipolar cautery, laser, heater probe, stapler, plasma coagulator)                            |
| 45320 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snar technique (e.g., laser)    |
| 45327 | No cost share when billed with Modifier<br>33 or PT                                       | Proctosigmoidoscopy, rigid; with transendoscopic stent placement (includes predilation)   |
| 45330 | No cost share when billed with Modifier<br>33 or PT                                       | Sigmoidoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)  |
| 45332 | No cost share when billed with Modifier<br>33 or PT                                       | Sigmoidoscopy, flexible; with removal of foreign body   |
| 45334 | No cost share for Medical or Facility<br>services when billed with a modifier<br>PT or 33 | Sigmoidoscopy with Control Hemorrhage   |
| 45337 | No cost share when billed with Modifier<br>33 or PT                                       | Sigmoidoscopy, flexible; with decompression (for Pathologic distention)<br>(e.g., volvulus, megacolon), including placement of decompression tube,<br>when performed                  |



| Code  | <b>Billing Instruction</b>  | Code Description   |
|-------|---|--|
| 45341 | No cost share when billed with Modifier<br>33 or PT                                       | Sigmoidoscopy, flexible; with endoscopic ultrasound examination  |
| 45342 | No cost share for Medical or Facility<br>services when billed with a modifier<br>PT or 33 | Under Endoscopy Procedures on the Rectum. Code is active   |
| 45347 | No cost share when billed with Modifier<br>33 or PT                                       | Sigmoidoscopy, flexible; with placement of endoscopic stent (includes pre- and post-dilation and guide wire passage, when performed)   |
| 45378 | No cost share when billed with a modifier PT or 33.                                       | Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or<br>without collection of specimen(s) by brushing or washing, with or without<br>colon decompression (separate procedure)   |
| 45379 | No cost share when billed with a modifier PT or 33  | Colonoscopy, flexible, proximal to splenic flexure; with removal of foreign body   |
| 45381 | No cost share when billed with a modifier PT or 33  | Colonoscope, submucous injection   |
| 45382 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy, flexible, proximal to splenic flexure; with directed submucosal injection(s), any substance   |
| 45386 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy, flexible; with transendoscopic balloon dilation   |
| 45389 | No cost share when billed with Modifier<br>33 or PT                                       | Colonoscopy, flexible; with endoscopic stent placement (includes pre-<br>and post-dilation and guide wire passage, when performed)   |
| 81528 | No modifier or diagnosis code are required to be covered in full                          | Oncology (colorectal) screening, quantitative real-time target and signal<br>amplification of 10 DNA markers (KRAS mutations, promoter methylation<br>of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm<br>reported as a positive or negative result |
| G0104 | No modifier or diagnosis code is required to be covered in full                           | Colorectal cancer screening; flexible sigmoidoscopy  |
| 82274 | No modifier or diagnosis code are required to be covered in full                          | Blood, occult, by fecal hemoglobin determination by immunoassay, qualitative, feces, 1-3 simultaneous determinations   |
| 82270 | No modifier or diagnosis code are required to be covered in full                          | Blood, occult, by peroxidase activity (e.g., guaiac), qualitative;   |
| G0105 | No modifier or diagnosis code is required to be covered in full                           | Colorectal cancer screening; colonoscopy on individual at high risk  |
| G0106 | No modifier or diagnosis code are required to be covered in full                          | Colorectal cancer screening; alternative to G0104, screening sigmoidoscopy, barium enema   |
| G0120 | No modifier or diagnosis code is required to be covered in full                           | Colorectal cancer screening; alternative to G0105, screening colonoscopy, barium enema   |
| G0121 | No modifier or diagnosis code is required to be covered in full                           | Colorectal cancer screening; colonoscopy on individual not meeting criteria for  |
| G0122 | No modifier or diagnosis code is required to be covered in full                           | Colorectal cancer screening; barium enema  |



| Code          | <b>Billing Instruction</b>   | Code Description   |
|---------------|--|--|
| G0328         | No modifier or diagnosis code are required to be covered in full   | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous determinations |
| <b>S</b> 0285 | No modifier or diagnosis code is<br>required to be covered in full<br>Reimbursement will be set to Provider's<br>contracted rate for 99212<br><b>Exception:</b> Consistent with Medicare<br>guidelines, code S0285 will not be<br>reimbursed separately for Medicare<br>product lines. | Colonoscopy consultation performed prior to a screening colonoscopy procedure                      |

# Colorectal Cancer Screening - NY only

| Code                       | Billing Instruction   | Code Description   |
|----------------------------|---|--|
| Medical<br>and<br>Facility | No cost share for Medical or Facility<br>services when one billed with a modifier<br>PT or 33 or one of the following ICD-10<br>codes are billed at the line level in the<br>principal diagnosis position: Z12.10,<br>Z12.11, Z12.12, Z80.0, Z83.71, Z83.79 |  |
| 44389                      | No cost share when billed with Modifier<br>33, PT, or above ICD-10 code billed in<br>principal position   | Fiberoptic Colonoscopy; W Biopsy Collect S   |
| 44392                      | No cost share when billed with Modifier<br>33, PT, or above ICD-10 code billed in<br>principal position   | Colonoscopy Stomal W Rem Polyp Les   |
| 44394                      | No cost share when billed with Modifier<br>33, PT, or above ICD-10 code billed in<br>principal position   | Colonoscopy Through Stoma; W Removal of<br>Tumor/Polyp/Lesions By Snare  |
| 44401                      | No cost share when billed with Modifier<br>33, PT, or above ICD-10 code billed in<br>principal position   | Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) (includes pre-and post-dilation and guide wire passage, when performed) |
| 45305                      | No cost share when billed with Modifier<br>33, PT, or above ICD-10 code billed in<br>principal position   | Proctosigmoidoscopy W Biopsy   |
| 45309                      | No cost share when billed with Modifier<br>33, PT, or one of the following ICD-10<br>codes are billed at the line level in the<br>principal diagnosis position: Z12.10,<br>Z12.11, Z12.12, Z80.0, Z83.71, Z83.79  | Proctosigmoidoscop y, Rigid; W Removal Single Tumor/Polyp/Lesion By<br>Snare   |
| 45315                      | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position   | Proctosigmoidoscop y; Multiple Removals  |



| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| 45331 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Sigmoidoscopy, flexible; with biopsy, single or multiple  |
| 45333 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Sigmoidoscopy, flexible; with removal of tumor(s) polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery   |
| 45338 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique  |
| 45346 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other<br>lesion(s) (includes pre- and post- dilation and guide wire passage, when<br>performed)  |
| 45378 | No cost share when billed with Modifier<br>33, PT, or one of the following ICD-10<br>codes are billed at the line level in the<br>principal diagnosis position: Z12.10,<br>Z12.11, Z12.12, Z80.0, Z83.71, Z83.79 | Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or<br>without collection of specimen(s) by brushing or washing, with or without<br>colon decompression (separate procedure)  |
| 45380 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple   |
| 45384 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery   |
| 45385 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique   |
| 45388 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other<br>lesion(s) (includes pre- and post-dilation and guide wire passage, when<br>performed)   |
| 74263 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Computed Tomographic (CT) colonography, screening, including image post processing  |
| 88305 | No cost share when billed with Modifier<br>33, PT, or one of the following ICD-10<br>codes are billed at the line level in the<br>principal diagnosis position: Z12.10,<br>Z12.11, Z12.12, Z80.0, Z83.71, Z83.79 | Surg Pathology; Level 4 Gross & Microscopic examination   |
| 99152 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Moderate sedation services provided by the same physician or other<br>qualified health care professional performing the diagnostic or<br>therapeutic service that the sedation support. Initial 15 minutes of<br>intraservice time, age 5 and older |
| 99153 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Moderate sedation services provided by the same physician or other<br>qualified health care professional performing the diagnostic or<br>therapeutic service that the sedation support, each additional 15 minutes<br>intra service time.           |



| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| 99156 | No cost share when billed with Modifier<br>33, PT, or one of the following ICD-10<br>codes are billed at the line level in the<br>principal diagnosis position: Z12.10,<br>Z12.11, Z12.12, Z80.0, Z83.71, Z83.79 | Moderate sedation services provided by a physician or other qualified<br>health care professional other than the physician or other qualified<br>health care professional performing the diagnostic or therapeutic<br>services that the sedation supports. Initial 15 minutes of intraservice<br>time, patient age 5 and older. |
| 99157 | No cost share when billed with Modifier<br>33, PT, or ICD 10 code above billed in<br>principal position  | Moderate sedation services provided by a physician or other qualified<br>health care professional other than the physician or other qualified<br>health care professional performing the diagnostic or therapeutic<br>services that the sedation supports. Each additional 15 minutes<br>intraservice time.                     |
| 00811 | Bill with Modifier PT or 33 or with one<br>of the following ICD 10 Codes in the first<br>Position. Z12.10, Z12.11, Z12.12, Z80.0,<br>Z83.71, Z83.79  | Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; not otherwise specified   |
| 00812 | No cost share when billed with Modifier<br>33, PT, or ICD-10 code above billed in<br>principal position  | Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy   |

# Colorectal Cancer Screening-NYS Circular Letter No. 4 (2022) (NY only)

(December 2021)

MVP covers Colorectal Cancer in adults beginning at the age of 45 years.

In addition, MVP covers follow-up Colonoscopies for New York Members when based on the following requirements:

• If an abnormal or positive non-invasive stool-based screening test or direct visualization screening test as recommended by the USPSTF and clarified in federal guidance is obtained, a follow-up Colonoscopy will be covered as Preventive

Covered recommended positive non-invasive stool-based screening tests or direct visualization screening tests:

45330, 45331, 45332, 45333, 45334, 45337, 45338, 45341, 45342, 45346, 45347, 82270, 82274, 81528

If one of the above screening tests results in an abnormal or positive test outcome, bill the follow-up Colonoscopy as outlined below.

| Code  | <b>Billing Instruction</b>                                   | Code Description  |
|-------|--|---|
| 45378 | No cost share when billed with<br>Modifier 33 or PT          | Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or without collection of specimens(s) by brushing or washing, with or without colon decompression (separate procedure) |
| 45379 | No cost share when billed with<br>Modifier 33 or PT          | Colonoscopy, flexible, proximal to splenic flexure; with removal of foreign body  |
| 45380 | No cost share when billed with<br>Modifier 33 or PT          | Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple   |
| 45381 | No cost share when billed with<br>Modifier 33 or PT          | Colonoscopy, submucous injection  |
| 45382 | No cost share when billed with a modifier PT or thirty-three | Colonoscopy, flexible, proximal to splenic flexure; with directed submucosal injection(s), any substance  |
| 45384 | No cost share when billed with<br>Modifier 33 or PT          | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery   |



| Code  | <b>Billing Instruction</b>                          | Code Description   |
|-------|---|--|
| 45385 | No cost share when billed with<br>Modifier 33 or PT | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique                              |
| 45386 | No cost share when billed with<br>Modifier 33 or PT | Colonoscopy, flexible; with transendoscopic balloon dilation   |
| 45388 | No cost share when billed with<br>Modifier 33 or PT | Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s)<br>(includes pre- and post-dilation and guide wire passage, when performed) |
| 45389 | No cost share when billed with<br>Modifier 33 or PT | Colonoscopy, flexible; with endoscopic stent placement (includes pre- and post-dilation and guide wire passage, when performed)                            |

# **Colorectal Cancer Screening – Vermont Variation**

MVP covers colorectal cancer screening for Vermont Members as follows:

- Member is 50 years of age or older with the option of:
  - Annual fecal occult blood testing plus one flexible sigmoidoscopy every five years; or
  - One colonoscopy every 10 years.
- Member is at high risk for colorectal cancer<sup>\*</sup>, colorectal cancer screening examinations and laboratory tests as recommended by the treating physician.

\*An individual is at high risk for colorectal cancer if the individual has:

- A family medical history of colorectal cancer or a genetic syndrome predisposing the individual to colorectal cancer;
- A prior occurrence of colorectal cancer or precursor polyps;
- A prior occurrence of a chronic digestive disease condition such as inflammatory bowel disease, Crohn's disease, or ulcerative colitis; or
- Other predisposing factors as determined by the individual's treating physician.

Colorectal cancer screening services are not subject to any co-pay, deductible, co-insurance, or other cost-sharing requirement. In addition, there is no additional charge for any services associated with a procedure or test for colorectal cancer screening, which may include one or more of the following:

- removal of tissue or other matter;
- laboratory services;
- physician services;
- facility use; and
- anesthesia.

| Code                  | <b>Billing Instruction</b>  | Code Description                           |
|-----------------------|---|--|
| Medical &<br>Facility | No cost share for Medical or Facility<br>services when one billed with a<br>modifier PT or 33 or one of the<br>following ICD-10 codes: D12.0,<br>D12.2, D12.3, D12.4, D12.5, D12.6,<br>D12.7, D12.8, D12.9, D50.9, K63.5,<br>Z00.00, Z00.01, Z12.10, Z12.11,<br>Z12.12, Z12.13, Z13.811, Z80.0,<br>Z80.9, Z83.71, Z85.030, Z85.038,<br>Z85.040, Z85.048, Z85.060, Z85.068,<br>Z86.010, Z86.018, Z87.19. |  |
| 44389                 | No cost share when billed with<br>Modifier 33, PT, or above ICD-10 code.  | Fiberoptic Colonoscopy; W Biopsy Collect S |



| Code  | <b>Billing Instruction</b>   | Code Description   |
|-------|--|--|
| 44392 | No cost share when billed with<br>Modifier 33, PT, or above ICD-10 code.   | Colonoscopy Stomal W Rem Polyp Les   |
| 44394 | No cost share when billed with<br>Modifier 33, PT, or above ICD-10 code.   | Colonoscopy Through Stoma; W Removal of Tumor/Polyp/Lesions By Snare   |
| 44401 | No cost share when billed with<br>Modifier 33, PT, or above ICD-10 code.   | Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other<br>lesion(s) (includes pre- and post-dilation and guide wire passage, when<br>performed)                                |
| 45305 | No cost share when billed with<br>Modifier 33, PT, or above ICD-10 code.   | Proctosigmoidoscopy W Biopsy   |
| 45309 | No cost share for services when<br>billed with a modifier PT or 33 or<br>one of the following ICD-10 codes:<br>D12.0, D12.2, D12.3, D12.4, D12.5,<br>D12.6, D12.7, D12.8, D12.9, K63.5,<br>Z12.10, Z12.11, Z12.12, Z80.0, Z80.9,<br>Z83.71, Z85.030, Z85.038, Z85.040,<br>Z85.048, Z86.010, Z86.018  | Proctosigmoidoscopy, Rigid; W Removal Single Tumor/ Polyp/Lesion By<br>Snare   |
| 45315 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Proctosigmoidoscopy; Multiple Removals   |
| 45331 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Sigmoidoscopy, flexible; with biopsy, single or multiple   |
| 45333 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s by hot biopsy forceps or bipolar cautery  |
| 45338 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Sigmoidoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique   |
| 45346 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other<br>lesion(s) (includes pre- and post-dilation and guide wire passage, when<br>performed)                                  |
| 45378 | No cost share for services when<br>billed with a modifier PT or 33 or<br>one of the following ICD-10 codes:<br>D12.0, D12.2, D12.3, D12.4, D12.5,<br>D12.6, D12.7, D12.8, D12.9, D50.9,<br>K63.5, Z00.00, Z00.01, Z12.10,<br>Z12.11, Z12.12, Z12.13, Z13.811,<br>Z80.0, Z80.9, Z83.71, Z85.030,<br>Z85.038, Z85.040, Z85.048, Z85.060,<br>Z85.068, Z86.010, Z86.018, Z87.19. | Colonoscopy, flexible, proximal to splenic flexure; diagnostic, with or<br>without collection of specimen(s) by brushing or washing, with or without<br>colon decompression (separate procedure) |
| 45380 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Colonoscopy, flexible, proximal to splenic flexure; with biopsy, single or multiple  |
| 45384 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by hot biopsy forceps or bipolar cautery  |
| 45385 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above  | Colonoscopy, flexible, proximal to splenic flexure; with removal of tumor(s), polyp(s), or other lesion(s) by snare technique  |



| Code  | <b>Billing Instruction</b>  | Code Description  |
|-------|---|---|
| 45388 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above   | Colonoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesion(s)<br>(includes pre- and post- dilation and guide wire passage, when performed)   |
| 74263 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code above   | Computed Tomographic (CT) colonography, screening, including image post processing  |
| 88305 | No cost share for services when<br>billed with a modifier PT or 33 or<br>one of the following ICD-10 codes:<br>D12.0, D12.2, D12.3, D12.4, D12.5,<br>D12.6, D12.7, D12.8, D12.9, K63.5,<br>Z12.10, Z12.11, Z12.12, Z80.0, Z80.9,<br>Z83.71, Z85.030, Z85.038, Z85.040,<br>Z85.048, Z86.010, Z86.018 | Surg Pathology; Level 4 Gross & Microscopic examination   |
| 99152 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code<br>above  | Moderate sedation services provided by the same physician or other<br>qualified health care professional performing the diagnostic or therapeutic<br>service that the sedation support. Initial 15 minutes of intraservice time, age<br>5 and older   |
| 99153 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code<br>above  | Moderate sedation services provided by the same physician or other<br>qualified health care professional performing the diagnostic or therapeutic<br>service that the sedation supports, each additional 15 minutes intraservice<br>time.   |
| 99156 | No cost share for services when<br>billed with a modifier PT or 33 or<br>one of the following ICD-10 codes:<br>D12.0, D12.2, D12.3, D12.4, D12.5,<br>D12.6, D12.7, D12.8, D12.9, K63.5,<br>Z12.10, Z12.11, Z12.12, Z80.0, Z80.9,<br>Z83.71, Z85.030, Z85.038, Z85.040,<br>Z85.048, Z86.010, Z86.018 | Moderate sedation services provided by a physician or other qualified health<br>care professional other than the physician or other qualified health care<br>professional performing the diagnostic or therapeutic services that the<br>sedation supports. Initial 15 minutes of intraservice time, patient age 5 and<br>older. |
| 99157 | No cost share when billed with<br>Modifier 33, PT, or ICD 10 code<br>above  | Moderate sedation services provided by a physician or other qualified health<br>care professional other than the physician or other qualified health care<br>professional performing the diagnostic or therapeutic services that the<br>sedation supports. Each additional 15 minutes intraservice time.                        |
| 00811 | No cost share for services when<br>billed with a modifier PT or 33 or<br>one of the following ICD-10 codes:<br>D12.0, D12.2, D12.3, D12.4, D12.5,<br>D12.6, D12.7, D12.8, D12.9, K63.5,<br>Z12.10, Z12.11, Z12.12, Z80.0, Z80.9,<br>Z83.71, Z85.030, Z85.038, Z85.040,<br>Z85.048, Z86.010, Z86.018 | Anesthesia for lower intestinal endoscopic procedures, endoscope<br>introduced distal to duodenum; not otherwise specified  |
| 00812 | No cost share when billed with<br>Modifier 33, PT, or ICD-10 code<br>above  | Anesthesia for lower intestinal endoscopic procedures, endoscope introduced distal to duodenum; screening colonoscopy   |



# Dental Caries prevention - Screening and Interventions to Prevent Dental Caries in Children Younger Than 5 Years

(December 2021) Rating B

## "Task Force" Recommendation

The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.

The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.

| Code            | <b>Billing Instruction</b> | Code Description   |
|-----------------|----------------------------|--|
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |
| 99188           |                            | Application of topical fluoride varnish by a physician or other qualified health care professional                             |

\*Codes D1206 and D1208 are not reimbursable under the medical benefit.

## **Depression Screening - Adolescents**

(Feb 2016) Rating B

## "Task Force" Recommendation

The USPSTF recommends screening for major depressive disorder (MDD) in adolescents ages 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up).

| Code  | <b>Billing Instruction</b>  | Code Description   |
|-------|---|--|
| 96160 | <b>Medical &amp; Facility</b><br>Applies to children and adolescents<br>– 2 years of<br>age and older | Administration of patient-focused health risk assessment instrument (e.g., health hazard appraisal) with scoring and documentation, per standardized instrument.                                       |
| 96161 | <b>Medical &amp; Facility</b><br>Applies to children and adolescents<br>– 2 years of<br>age and older | Administration of caregiver- focused health risk assessment instrument<br>(e.g., depression inventory) for the benefit of the patient, with scoring and<br>documentation, per standardized instrument. |

# **Depression Screening – Adults, including Pregnant and Postpartum Women**

(Jan 2016) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up (when staff-assisted depression care supports are in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up).

| Code            | <b>Billing Instruction</b> | Code Description   |
|-----------------|----------------------------|--|
| 99401-<br>99404 | Medical & Facility         | Medical & Facility Annual wellness Visit Preventive medicine counseling and/<br>or risk factor reduction intervention(s) provided to an individual without<br>specific illness |



| Code  | <b>Billing Instruction</b> | Code Description   |
|-------|----------------------------|--|
| 96127 | Medical & Facility         | Brief emotional/behavioral assessment (e.g., depression inventory, attention- deficit/hyperactivity disorder [ADHD] scale), with scoring and documentation, per standardized instrument                |
| 96160 | Medical & Facility         | Administration of patient-focused health risk assessment instrument (e.g.,<br>health hazard appraisal) with scoring and documentation, per standardized<br>instrument                                  |
| 96161 |                            | Administration of caregiver- focused health risk assessment instrument<br>(e.g., depression inventory) for the benefit of the patient, with scoring and<br>documentation, per standardized instrument. |
| G0439 |                            | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit  |
| G0444 |                            | Annual Depression Screening 15 minutes   |
| G0447 |                            | Face-to-face behavioral counseling for obesity, 15 minutes   |
| G0473 |                            | Face-to-face behavioral counseling for obesity, group (2-10), 30 minutes   |

# **Screening for Prediabetes and Type 2 Diabetes**

(August 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who are have who have overweight or obeseity. Clinicians should offer, or refer patients with prediabetes to effective preventive interventions. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity. See Women's Preventive Health section on *Screening for Gestational Diabetes Mellitus and Screening for Diabetes Mellitus after Pregnancy*.

| Code  | Billing Instruction  | Code Description  |
|-------|--|---|
|       | <ul> <li>Bill with one of the following ICD 10 Codes:<br/>Z00.00, Z00.01, Z13.1, Z86.32</li> </ul>                               | Medical & Facility Annual wellness Visit Preventive<br>medicine counseling and/or risk factor reduction |
|       | <ul> <li>And at least one of the following Additional Diagnosis<br/>Codes as follows:</li> </ul>                                 | intervention(s) provided to an individual without specific illness                                      |
|       | <b>OVERWEIGHT:</b><br>ICD-10: E66.3, Z68.25, Z68.26, Z68.27, Z68.28, Z68.29  |   |
| 82947 | <b>OBESITY:</b><br>ICD-10: E66.01, E66.09, E66.1, E66.8, E66.9, Z68.41,<br>Z68.42, Z68.43, Z68.44, Z68.45                        | Glucose; quantitative, blood (except reagent strip).  |
|       | BODY MASS INDEX 25.0 – 29.9:   |   |
|       | ICD-10: Z68.25, Z68.26, Z68.27, Z68.28, Z68.29   |   |
|       | <b>BODY MASS INDEX 30.0 – 39.9:</b><br>ICD-10: Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35,<br>Z68.36, Z68.37, Z68.38, Z68.39 |   |
|       | <b>BODY MASS INDEX 40.0 AND OVER:</b><br>ICD-10: Z68.41, Z68.42, Z68.43, Z68.44, Z68.45  |   |
| 82950 | Bill with one of the ICD – 10 codes listed above.  | Glucose; post-glucose dose<br>(includes glucose)  |



| Code  | Billing Instruction                               | Code Description  |
|-------|---|---|
| 82951 | Bill with one of the ICD – 10 codes listed above. | Glucose: tolerance test (GTT),<br>3 specimens (includes glucose)  |
| 82952 | Bill with one of the ICD – 10 codes listed above. | Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure) |
| 82948 | Bill with one of the ICD – 10 codes listed above. | Glucose; blood, reagent strip   |
| 83036 | Bill with one of the ICD – 10 codes listed above. | Hemoglobin; glycosylated (A1c)  |

#### **Falls Prevention in Older Adults**

(April 2018) Rating B

#### "Task Force" Recommendation

The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.

# Folic Acid: Supplementation

(Feb 2016) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800  $\mu$ g) of folic acid.

| Code            | <b>Billing Instruction</b> | Code Description   |
|-----------------|----------------------------|--|
| 99401-<br>99404 | Medical & Facility         | <b>Medical &amp; Facility</b> – Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |

# **Screening for Gestational Diabetes**

(August 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for gestational diabetes in asymptomatic pregnant persons at or after 24 weeks of gestation. For additional diabetes screening benefits, see the Women's Preventive Health section for Screening for Gestational Diabetes Mellitus and Screening for Diabetes Mellitus after Pregnancy.

| Code  | <b>Billing Instruction</b>   | Code Description                                     |
|-------|--|--|
| 82947 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Glucose; quantitative, blood (except reagent strip). |
| 82950 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Glucose; post-glucose dose (includes glucose)        |



| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| 82951 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Glucose: tolerance test (GTT),3 specimens (includes glucose)  |
| 82952 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Glucose; tolerance test, each additional beyond 3 specimens (List separately in addition to code for primary procedure) |
| 82948 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Glucose; blood, reagent strip   |
| 83036 | Bill with appropriate code and<br>appropriate Pregnancy related<br>ICD 10 diagnosis code billed in the<br>principal diagnosis position | Hemoglobin; glycosylated (A1c)  |

# Healthy Weight and Weight Gain During Pregnancy: Behavioral Counseling Interventions

(May 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and preventing excess gestational weight gain in pregnancy.

| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| 99401 | Preventive medicine counseling<br>and/or risk factor reduction<br>intervention(s) provided to an<br>individual (separate procedure);<br>approximately 15 minutes | No cost share when billed for healthy weight and weight gain during pregnancy |
| 99402 | Preventive medicine counseling<br>and/or risk factor reduction<br>intervention(s) provided to an<br>individual (separate procedure);<br>approximately 30 minutes | No cost share when billed for healthy weight and weight gain during pregnancy |
| 99403 | Preventive medicine counseling<br>and/or risk factor reduction<br>intervention(s) provided to an<br>individual (separate procedure);<br>approximately 45 minutes | No cost share when billed for healthy weight and weight gain during pregnancy |
| 99404 | Preventive medicine counseling<br>and/or risk factor reduction<br>intervention(s) provided to an<br>individual (separate procedure);<br>approximately 60 minutes | No cost share when billed for healthy weight and weight gain during pregnancy |



| Code  | <b>Billing Instruction</b>  | Code Description  |
|-------|---|---|
| 97802 | Medical nutrition therapy; initial<br>assessment and intervention,<br>individual, face-to-face with the<br>patient, each 15 minutes | No cost share for women when billed with appropriate pregnancy related ICD<br>10 Diagnosis code |
| 97803 | Medical nutrition therapy; re-<br>assessment and intervention,<br>individual, face-to-face with the<br>patient, each 15 minutes     | No cost share for women when billed with appropriate pregnancy related ICD<br>10 Diagnosis code |
| 97804 | Medical nutrition therapy; group<br>(2 or more individual(s)), each 30<br>minutes   | No cost share for women when billed with appropriate pregnancy related ICD 10 Diagnosis code    |
| S9470 | Nutritional counseling, dietitian<br>visit  | No cost share for women when billed with appropriate pregnancy related ICD 10 Diagnosis code    |

# Preventive Medications Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum

(Jan 2019) Rating A

#### "Task Force" Recommendation

The USPSTF recommends prophylactic ocular topical medication for all newborns for the prevention of gonococcal ophthalmic neonatorum.

| Code                  | <b>Billing Instruction</b>                        | Code Description                                       |
|-----------------------|---|--|
| Medical<br>& Facility | Global to infant nursery care inpatient admission | Would be included in Hospital bill or well-baby codes. |

# Healthy Diet, Physical Activity and Behavioral Health Counseling Interventions for Adults with Cardiovascular Risk Factors.

(November 2020) Rating B

#### "Task Force" Recommendation

The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.

## "Task Force" Recommendation

The USPSTF recommends offering or referring adults with cardiovascular disease risk factors to behavioral counseling interventions to promote a healthy diet and physical activity.

| Code                                     | <b>Billing Instruction</b> | Code Description   |
|--|----------------------------|--|
| Medical<br>& Facility<br>99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |
| G0446                                    |                            | Intensive behavioral counseling for cardiovascular disease for 15 minutes.   |



# **Hearing Loss Screening: Newborns**

(July 2008) Rating B

#### "Task Force" Recommendation

**Medical** – The USPSTF recommends screening for hearing loss in all newborn infants. When billed with appropriate code (left) along with ICD 10 codes billed in the principal diagnosis position

Facility – No co-pay for screening hearing loss in newborns when billed with appropriate code.

| Code                           | <b>Billing Instruction</b>  | Code Description  |
|--------------------------------|---|---|
| Medical<br>& Facility<br>92551 | Diagnosis Code set for Hearing loss<br>screening in newborns Z00.110,<br>Z00.111, Z00.121, Z00.129. No<br>diagnosis code required for Facility. | Definition needed- No results Screening test, pure tone, air only.  |
| 92560                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Bekesy audiometry; screening  |
| 92552                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Pure tone audiometry (threshold); air only  |
| 92585                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; comprehensive   |
| 92586                          | Diagnosis Code set for Hearing loss<br>screening in newborns Z00.110,<br>Z00.111, Z00.121, Z00.129. No<br>diagnosis code required for Facility. | Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; limited   |
| 92587                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Evoked otoacoustic emissions; limited (single stimulus level, either transient or distortion products)  |
| 92588                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Distortion product evoked otoacoustic emissions; comprehensive diagnostic<br>evaluation (quantitative analysis of outer hair cell function by cochlear<br>mapping, minimum of 12 frequencies), with interpretation and report |
| V5008                          | Bill with one of the ICD – 10<br>diagnosis codes listed above   | Hearing screening   |

# **Hemoglobinopathies Screening: Newborns**

(Sept 2017) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for sickle cell disease in newborns. No co-pay for screening of sickle cell disease in newborns under 2 months old when submitted with appropriate code (below).

# Code Billing Instruction Code Description

85660

Sickle Cell Disease screening



# Hepatitis B Screening: Virus Infection in Adolescents and Adults at increased risk

(December 2020) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. See the Practice Considerations section for a description of adolescents and adults at increased risk for infection.

| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| G0499 | Bill with one of the ICD-10<br>screening diagnosis codes<br>Z00.00, Z00.01, Z11.59,<br>Z57.8, Z11.3, Z11.4, Z20.2,<br>Z20.6, Z72.51, Z72.52,<br>Z72.53 | Hepatitis B screening in nonpregnant, high-risk individual  |
| 86704 | Bill with one of the ICD-10<br>screening diagnosis codes<br>Z00.00, Z00.01, Z11.59,<br>Z57.8, Z11.3, Z11.4, Z20.2,<br>Z20.6, Z72.51, Z72.52,<br>Z72.53 | Hepatitis B core antibody (HBcAb); total                    |
| 86705 | Bill with one of the ICD-10<br>screening diagnosis codes<br>Z00.00, Z00.01, Z11.59,<br>Z57.8, Z11.3, Z11.4, Z20.2,<br>Z20.6, Z72.51, Z72.52,<br>Z72.53 | Hepatitis B core antibody (HBcAb); IgM antibody             |
| 86706 | Bill with one of the ICD-10<br>screening diagnosis codes<br>Z00.00, Z00.01, Z11.59,<br>Z57.8, Z11.3, Z11.4, Z20.2,<br>Z20.6, Z72.51, Z72.52,<br>Z72.53 | Hepatitis B surface antibody (HBsAb)                        |
| 87340 | Bill with one of the ICD-10<br>screening diagnosis codes<br>Z00.00, Z00.01, Z11.59,<br>Z57.8, Z11.3, Z11.4, Z20.2,<br>Z20.6, Z72.51, Z72.52,<br>Z72.53 | Infectious agent antigen detection by immunoassay technique |

## **Hepatitis B Virus Infection Screening: Pregnant Persons**

(June 2019) Rating A

#### "Task Force" Recommendation

The USPSTF recommends screening for hepatitis B virus infection in pregnant persons at their first prenatal visit.

| Code  | <b>Billing Instruction</b>           | Code Description                         |
|-------|--------------------------------------|--|
| 87340 | Medical & Facility                   | Hepatitis B surface antigen (HbsAg)      |
| 86704 | Bill with a pregnancy diagnosis code | Hepatitis B core antibody (HBcAb); total |



| Code  | <b>Billing Instruction</b>           | Code Description  |
|-------|--------------------------------------|---|
| 86705 | Bill with a pregnancy diagnosis code | Hepatitis B core antibody (HBcAb); IgM antibody             |
| 86706 | Bill with a pregnancy diagnosis code | Hepatitis B surface antibody (HBsAb)                        |
| 87340 | Bill with a pregnancy diagnosis code | Infectious agent antigen detection by immunoassay technique |

# **Hepatitis C Virus Infection Screening: Adults**

(March 2020) Rating B

## "Task Force" Recommendation

The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18–79 years.

| Code   | <b>Billing Instruction</b> | Code Description  |
|--------|----------------------------|---|
| 86803  |                            | Hepatitis C antibody; confirmatory test (e.g., immunoblot)  |
| 86804  |                            | Hepatitis C antibody; confirmatory test (e.g., immunoblot)  |
| G0472  |                            | Hepatitis C antibody screening for individual at high risk and other covered indication(s)  |
| 87390  |                            | Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi quantitative, multiple-step method; HIV-1 |
| G0432  |                            | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening                          |
| G0433  |                            | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa)<br>technique, hiv-1 and/or hiv-2, screening      |
| G0435  |                            | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening or just "Oral hiv-1/hiv-2 screen"       |
| G0475  |                            | HIV antigen/antibody, combination assay, screening  |
| \$3645 |                            | Hiv-1 antibody testing of oral mucosal transudate mucosal transudate  |

## **Screening for Hypertension in Adults**

(April 2021) Rating A

#### "Task Force" Recommendation

The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement (OBPM). The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.

| Code            | <b>Billing Instruction</b> | Code Description   |
|-----------------|----------------------------|--|
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness |



# Human Immunodeficiency Virus (HIV) Infections: Screening for Pregnant Persons, Adolescents, and Adults 15–65)

(June 2019) Rating A

#### "Task Force" Recommendation

The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk of infection should also be screened. The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown.

**Medical & Facility** – No cost share for screening HIV infection in pregnant women, including those who present in labor who are untested and whose HIV status is unknown. Submit bill with appropriate code.

| Code   | <b>Billing Instruction</b> | Code Description  |
|--------|----------------------------|---|
| G0432  |                            | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening                          |
| G0433  |                            | Infectious agent antibody detection by enzyme immunoassay (elisa) technique, hiv-1 and/or hiv-2, screening                        |
| G0435  |                            | Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening or just "Oral hiv-1/hiv-2 screen"       |
| G0475  |                            | HIV antigen/antibody, combination assay, screening  |
| 86701  |                            | Antibody; HIV-1   |
| 86702  |                            | Antibody; HIV-2   |
| 86703  |                            | Antibody; HIV-1 and HIV-2, single assay   |
| 87390  |                            | Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semi quantitative, multiple-step method; HIV-1 |
| \$3645 |                            | Hiv-1 antibody testing of oral mucosal transudate   |
| 87389  |                            | Microbiology procedures   |

# Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis

(June 2019) Rating A

## "Task Force" Recommendation

The USPSTF recommends that clinicians offer preexposure prophylaxis (PrEP) with effective antiretroviral therapy to persons who are at high risk of HIV acquisition.

Note: This benefit also includes the following services:

- Kidney function testing (creatinine),
- Serologic testing for Hepatitis B and C virus,
- Testing for other STIs,
- Pregnancy testing (when appropriate), and
- Ongoing follow-up and monitoring including HIV testing every 3 months

\*Refer to the plan's pharmacy benefit for details on prescription medications available under plans preventive benefit.



| Code             | <b>Billing Instruction</b>   | Code Description   |
|------------------|--|--|
| 82565            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Creatinine; Blood  |
| 82570            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Creatinine; Urine  |
| 81025            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Urine pregnancy test, by visual color comparison methods   |
| 84702,<br>84703  | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Gonadotropin, Chorionic; Quantitative; Gonadotropin, Chorionic;<br>Qualitative   |
| 99202-<br>99205* | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Office or other outpatient visit for the evaluation and management of a new patient  |
| 99212-<br>99215  | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Established Outpatient Office Visit  |
| 99417            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Prolonged Codes Specific to 99205 and 99215  |
| G0463            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Hospital outpatient clinic visit for assessment and management of a patient  |
| 96372            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Therapeutic, Prophylactic, or Diagnostic Injection (Specify<br>Substance or Drug); Subcutaneous or Intramuscular                     |
| J0739            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Injection, cabotegravir, 1 mg  |
| 87147            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Under Microbiology Culture and Typing Procedures   |
| 36415,<br>36416  | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Collection of venous blood by venipuncture   |
| 86689            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Antibody Htlv/Hiv Antibody Confirm   |
| 87391            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Infectious agent antigen detection   |
| 87806            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Infectious agent antigen detection by immunoassay with direct optical observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies |
| 87801            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Nucleic Acid Detection, Multiple Organisms; Amplified Probe(s)<br>Techniq  |
| 87810            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | Immunoassay With Direct Optical Observation; Chlamydia<br>Trachomatis  |
| 87850            | Bill with the following diagnosis codes: Z11.3,<br>Z11.4, Z20.2, Z20.6, Z72.51, Z72.52, Z72.53 | 87850 - Immunoassay With Direct Optical Observation; Neisseria<br>Gonorrhoeae  |

\*Also see codes in the wellness section

Please refer to supporting policies:

- Sexually Transmitted Infections Counseling
- Screening for Chlamydia and Gonorrhea
- · Hepatitis B Screening: Virus Infection in Adolescents and Adults at increased risk
- Hepatitis B Virus Infection Screening: Pregnant Women
- Hepatitis C Virus Infection Screening: Adults
- · Syphilis Infection in Nonpregnant Adults and Adolescents: Screening
- Syphilis Screening: Pregnant Persons
- Human Immunodeficiency Virus (HIV) Infection: Screening for Pregnant Persons, Adolescents, and Adults 15–65

#### Hypothyroidism Screening (Newborns)

(March 2008) Rating A

#### "Task Force" Recommendation

The USPSTF recommends screening for congenital hypothyroidism in newborns. No cost share for congenital hypothyroidism screening in newborns when billed with appropriate CPT code.

| Code  | <b>Billing Instruction</b> | Code Description                     |
|-------|----------------------------|--------------------------------------|
| 84437 |                            | Hypothyroidism screening in newborns |

#### **Intimate Partner Violence Screening: Women of Childbearing Age**

(Jan 2013) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that clinicians screen women of childbearing age for intimate partner violence, such as domestic violence, and provide or refer women who screen positive to intervention services. This recommendation applies to women who do not have signs or symptoms of abuse.

| Code            | <b>Billing Instruction</b> | Code Description  |
|-----------------|----------------------------|---|
| 99385-<br>99387 | Medical & Facility         | New Patient comprehensive preventive medicine evaluation and management   |
| 99395-<br>99397 |                            | Established Patient comprehensive preventive medicine evaluation and management   |
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. |

#### Lung Cancer Screening

(March 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends annual screening for lung cancer with low-dose computed tomography in adult's ages 50 to 80 years old who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. Counseling to discuss lung cancer screening should be discussed.



| Code  | <b>Billing Instruction</b>                | Code Description   |
|-------|---|--|
| 71271 | Prior authorization is required for 71271 | Computed tomography, thorax, low dose for lung cancer screening, without contrast material is intended to be the replacement code.                                   |
| G0296 |   | Counseling visit to discuss need for lung cancer screening (ldct) using<br>low dose CT scan (service is for eligibility determination and shared<br>decision making) |

# **Maternal Depression Screening**

New York State Department of Financial Services to Title 11 NYCRR 52, Amendment 52 (Insurance Regulation 62) Sections: 52.1(r), 52.17(a)(39), and 52.18(a)(14)

| Description/<br>Recommendation   | Code  | Description             | Business Rule  |
|--|---|-------------------------|--|
| Coverage will be<br>provided for screening<br>and referral for<br>maternal depression. | Medical<br>Screening<br>Services<br>99401-99404<br>96127<br>96160<br>96161<br>G0444 | Depression<br>Screening | Medical Services<br>No cost share for depression screening when performed by a<br>provider of obstetrical, gynecologic, or pediatric services.<br>In the event the mother is covered under a different policy<br>than the infant and the screening and referral are performed<br>by a provider of pediatric services, coverage for the screening<br>and referral shall also be provided under the policy in which<br>the infant is covered.<br>The provider should bill the maternal screening services on<br>the infants claim. |

# **Obesity, Screening and Counseling: Adults**

(September 2018) Rating B

## "Task Force" Recommendation

The USPSTF recommends that clinicians offer or refer adults with a body mass index of 30 or higher (calculated as weight in kilograms divided by height in meters squared) to intensive, multicomponent behavioral interventions.

| Code            | <b>Billing Instruction</b> | Code Description  |
|-----------------|----------------------------|---|
| 99381-<br>99387 |                            | New Patient comprehensive preventive medicine evaluation and management   |
| 99395-<br>99397 |                            | Established Patient comprehensive preventive medicine evaluation and management   |
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. |
| G0447           |                            | Face-to-face behavioral counseling for obesity, 15 minutes  |



# **Obesity Screening and Counseling: Children**

(Jan 2010) Rating B

## "Task Force" Recommendation

The USPSTF recommends that clinicians screen children ages 6 years and older for obesity and offer them or refer them to comprehensive, intensive behavioral interventions to promote improvement in weight status.

| Code                                     | <b>Billing Instruction</b> | Code Description  |
|--|----------------------------|---|
| Medical<br>& Facility<br>99381-<br>99387 |                            | New Patient comprehensive preventive medicine evaluation & management   |
| 99395-<br>99397                          |                            | Established Patient comprehensive preventive medicine evaluation and management   |
| 99401-<br>99404                          |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. |
| G0447                                    |                            | Face-to-face behavioral counseling for obesity, 15 minutes  |

# **Osteoporosis Screening: Women**

(June 2018) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for osteoporosis with bone measurement testing: To prevent osteoporotic fractures in women 65 years and older. In postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.

| Code                           | <b>Billing Instruction</b> | Code Description   |
|--------------------------------|----------------------------|--|
| Medical<br>& Facility<br>77080 |                            | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, & spine)                      |
| 77081                          |                            | Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites;<br>appendicular skeleton (peripheral) (e.g., radius, wrist, heel) |

## **Preeclampsia Screening**

(April 2017) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for preeclampsia in pregnant persons with blood pressure measurements throughout pregnancy.

| Code                    | <b>Billing Instruction</b>                  | Code Description   |
|-------------------------|---|--|
| 99394<br>99395<br>99396 | Medical & Facility<br>Use codes to the left | Established Patient comprehensive preventive medicine evaluation and management. |



# Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication

(September 2021) Rating B

#### "Task Force" Recommendation

The USPSTF recommends the use of low-dose aspirin (81 mg/day) as preventive medication after 12 weeks of gestation in persons who are at high risk for preeclampsia. A written prescription for aspirin is required: Age limit >/= 12 (women) QL of 100 units/fill Generics only Single ingredient OTC dosages 325mg or less.

# **Perinatal Depression, Preventive Interventions**

(Feb 2019) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that clinicians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling intervention.

| Code  | <b>Billing Instruction</b> | Code Description  |
|-------|----------------------------|---|
| 96127 |                            | Brief emotional/behavioral assessment (for example, depression inventory, ADHD scale), with scoring and documentation, per standardized instrument. |
| G0444 |                            | Annual depression screening, 15 minutes   |

## **Rh Incompatibility Screening: 24-28 Weeks Gestation**

(Feb 2004) Rating A

#### "Task Force" Recommendation

The USPSTF recommends repeated Rh (D) antibody testing for all unsensitized Rh (D)- negative women at 24 to 28 weeks' gestation, unless the biological father is known to be Rh (D)- negative.

| Code  | <b>Billing Instruction</b>  | Code Description                     |
|-------|---|--------------------------------------|
| 86901 | Medical & Facility and<br>appropriate Pregnancy<br>related ICD 10 diagnosis<br>code at end of Policy. | Blood typing; Rh (D)antibody testing |

# **Rh Incompatibility Screening: First Pregnancy Visit**

(Feb 2004) Rating B

#### "Task Force" Recommendation

**Medical & Facility** – No cost share for Rh incompatibility screening for all pregnant persons during their first visit for pregnancy-related care when billed with appropriate code and appropriate Pregnancy related ICD 10 diagnosis code set billed in the principal diagnosis position

| Code                  | <b>Billing Instruction</b> | Code Description  |
|-----------------------|----------------------------|---|
| Medical<br>& Facility |                            | Medical & Facility – Blood typing; Rh (D)antibody testing |



# **Sexually Transmitted Infections Counseling**

(August 2020) Rating B

#### "Task Force" Recommendation

The USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections. No co-pay in females with Cervical Dysplasia Sexually Active Females.

| Code            | <b>Billing Instruction</b> | Code Description  |
|-----------------|----------------------------|---|
| 99401-<br>99404 |                            | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness.   |
| G0445           | Limited to 2x a year       | Semi-annual high intensity behavioral counseling to prevent STIs, individual, face-to-<br>face, includes education skills training & guidance on how to change sexual behavior. |

#### **Skin Cancer Behavioral Counseling**

March 2018 (May 2012) Rating B

#### "Task Force" Recommendation

The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons ages 6 months to 24 years with fair skin types to reduce their risk of skin cancer.

| Code            | <b>Billing Instruction</b> | Code Description  |
|-----------------|----------------------------|---|
| 99381-<br>99385 |                            | New Patient comprehensive preventive medicine evaluation and management   |
| 99391-<br>99395 |                            | Established Patient comprehensive preventive medicine evaluation and management   |
| 99401-<br>99404 |                            | Preventive medicine Counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. |

## **Statin Preventive Medication**

adults ages 40–75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater

#### "Task Force" Recommendation (1 of 2)

No cost share for adults without a history of cardiovascular disease (CVD) (i.e., symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all the following criteria are met: 1) they are ages 40 to 75 years; 2) they have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10- year risk of a cardiovascular event of 10% or greater. Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in adults ages 40 to 75 years.

| Code  | <b>Billing Instruction</b>   | Code Description  |
|-------|--|---|
| 80061 | Procedure codes 82465,<br>83718,84478 will not be<br>reimbursed if billed with<br>80061 (lipid panel). | Lipid panel. This panel must include the following: Cholesterol, serum, total (82465),<br>Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718),<br>Triglycerides (84478) |
| 82465 |  | Cholesterol, serum or whole blood, total  |



| Code  | <b>Billing Instruction</b> | Code Description   |
|-------|----------------------------|--|
| 83718 |                            | Lipoprotein, direct measurement; high density cholesterol<br>(HDL cholesterol) |
| 84478 |                            | Triglycerides  |

#### "Task Force" Recommendation (2 0f 2)

Pharmacy Guidelines for men and women – ages 40 through 75 years old:

- No quantity limit
- No prior authorization
- Low to moderate dose statins, generics only (no high dose or brand statins are included)
  - Atorvastatin 10 mg, 20 mg
  - Fluvastatin 20 mg, 40 mg
  - Fluvastatin ER 80 mg o Lovastatin 10 mg, 20 mg, 40 mg
  - Pravastatin 10 mg, 20 mg, 40 mg, 80 mg
  - Rosuvastatin 5 mg, 10 mg
  - Simvastatin 5 mg, 10 mg, 20 mg, 40 mg

As with other ACA- mandated preventive services coverage for non-grandfathered plans, coverage will be provided at zero Member cost share. For statin prescriptions outside of these age ranges and/or strengths, the standard plan benefits will apply.

| Code  | <b>Billing Instruction</b>   | Code Description  |  |
|-------|--|---|--|
| 82465 |  | Cholesterol, serum or whole blood, total  |  |
| 83718 |  | Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)   |  |
| 84478 |  | Triglycerides   |  |
| 80061 | Procedure codes 82465,<br>83718,84478 will not be<br>reimbursed if billed with<br>80061 (lipid panel). | Lipid panel. This panel must include the following: Cholesterol, serum, total (82465),<br>Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718),<br>Triglycerides (84478) |  |

# Syphilis Infection in Nonpregnant Adults and Adolescents: Screening

(June 2016) Rating A

#### "Task Force" Recommendation

The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.

| Code  | <b>Billing Instruction</b> | Code Description   |  |
|-------|----------------------------|--|--|
| 86592 |                            | Syphilis test, non- Treponema antibody; qualitative (e.g., VDRL, RPR, ART) |  |
| 86593 |                            | Syphilis test, non- treponemal antibody; quantitative                      |  |
| 86780 |                            | Antibody; Treponema pallidum   |  |



# **Syphilis Screening: Pregnant Persons**

(May 2009) Rating A

#### "Task Force" Recommendation

The USPSTF recommends early screening for syphilis infection in all pregnant persons.

| Code  | <b>Billing Instruction</b> | Code Description   |  |
|-------|----------------------------|--|--|
| 86592 |                            | Syphilis test, non- Treponema antibody; qualitative (e.g., VDRL, RPR, ART) |  |
| 86593 |                            | Syphilis test, non- treponemal antibody; quantitative                      |  |
| 86780 |                            | Antibody; Treponema pallidum   |  |

# Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons

(January 2021) Rating A

#### "Task Force" Recommendation

The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)– approved pharmacotherapy for cessation to nonpregnant adults who use tobacco.

The USPSTF recommends that clinicians ask all pregnant persons about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant persons who use tobacco.

Reimbursement restricted to the following specialties:

- Primary Care Physicians: Family Practice, Internal Medicine, General Practitioners
- Specialists: OB/GYN, Pediatricians Services (included in Preventative E&M codes)

Note: MVP considers Smoking, Tobacco, Vaping/ E-cigarettes included under this recommendation

| Code  | <b>Billing Instruction</b>                                | Code Description  |
|-------|---|---|
| 99406 | <b>Medical and Facility</b><br>Bill with CPT code to left | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes |
| 99407 | <b>Medical and Facility</b><br>Bill with CPT code to left | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes                    |

# **Tobacco Use Interventions: Children and Adolescents**

(Aug 2020) Rating B

#### "Task Force" Recommendation

The USPSTF recommends that clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use in school-age children and adolescents.

Note: MVP considers Smoking, Tobacco, Vaping/E-cigarettes included under this recommendation

| Code  | <b>Billing Instruction</b>                                | Code Description  |  |
|-------|---|---|--|
| 99406 | <b>Medical and Facility</b><br>Bill with CPT code to left | Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes |  |
| 99407 | <b>Medical and Facility</b><br>Bill with CPT code to left | Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes                    |  |



# **Tuberculosis Screening: Adults**

(Sept 2016) Rating B

#### "Task Force" Recommendation

The USPSTF recommends screening for latent tuberculosis infection in populations at increased risk.

| Code  | <b>Billing Instruction</b>   | Code Description  |
|---|--|---|
| CPT<br>codes<br>86480,<br>86481<br>86580<br>ICD-10<br>codes<br>Z11.1<br>Z20.1 | <b>Medical &amp; Facility</b><br>Use the appropriate<br>CPT code along with the<br>appropriate ICD-10 code<br>to the left. | <ul> <li>86480 Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon</li> <li>86481 Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T- cells in cell suspension</li> <li>86580 Skin test; tuberculosis, intradermal</li> <li>Z11.1 Screening for respiratory tuberculosis</li> <li>Z20.1 Contact with or suspected exposure to tuberculosis</li> </ul> |

# **Visual Acuity Screening in Children**

(Jan 2011) Rating B

#### "Task Force" Recommendation

**Medical & Facility** – The USPSTF recommends vision screening for all children at least once between the ages of 3 and 5 years, to detect the presence of amblyopia or its risk factors.

| Code  | <b>Billing Instruction</b> | Code Description   |
|-------|----------------------------|--|
| 99173 |                            | Medical & Facility – Visual acuity screening in children |

# **Non-USPSTF Preventative Services Coverage**

Women's Preventive Health Policies (HRSA)

Women's Preventive Health-Contraception methods and counseling. *No cost share when billed with the appropriate code.* 



| Code  | Description  | Business Rule   |
|---|--|---|
| Contrace  | ptive Care   | No cost share when billed with appropriate codes.   |
| 99401 -<br>99404                                    | No cost share for contraceptive methods<br>and counseling in females when billed with<br>appropriate CPT codes   | • HRSA Requirement (Jan. 2023): WPSI recommends that<br>adolescent and adult women have access to the full range of<br>contraceptives and contraceptive care to prevent unintended<br>pregnancies and improve birth outcomes. Contraceptive care  |
| 99202,<br>99203,<br>99204,<br>99205                 | No cost share for contraceptive use and counseling<br>for women when billed with appropriate CPT code<br>(left) and appropriate Contraceptive related ICD 10<br>diagnosis code set billed in the principal diagnosis<br>position | includes screening, education, counseling, and provision<br>of contraceptives (including in the immediate postpartum<br>period). Contraceptive care also includes follow-up care (e.g.<br>management, evaluation and changes, including the remova<br>continuation, and discontinuation of contraceptives).   |
| 99211,<br>99212,<br>99213,<br>99214,<br>99215       | No cost share for contraceptive use and counseling<br>for women when billed with appropriate CPT code<br>(left) and appropriate Contraceptive related ICD 10<br>diagnosis code set billed in the principal diagnosis<br>position | <ul> <li>WPSI recommends that the full range of U.S. Food and<br/>Drug Administration (FDA)- approved, -granted, or -cleared<br/>contraceptives, effective family planning practices, and<br/>sterilization procedures be available as part of contraceptive<br/>care.</li> <li>The full range of contraceptives includes those currently</li> </ul>  |
| Please se   | e Policy: Contraceptive Use and Counseling   | <ul> <li>listed in the FDA's Birth Control Guide****: (1) sterilization</li> <li>surgery for women, (2) implantable rods, (3) copper</li> </ul>   |
| Please see Policy: Contraceptive ose and Counseting |  | <ul> <li>intrauterine devices, (4) intrauterine devices with progestin<br/>(all durations and doses), (5) injectable contraceptives, (6)<br/>oral contraceptives (combined pill), 7) oral contraceptives<br/>(progestin only), (8) oral contraceptives (extended or<br/>continuous use), (9) the contraceptive patch, (10) vaginal<br/>contraceptive rings, (11) diaphragms, (12) contraceptive<br/>sponges, (13) cervical caps, (14) condoms, (15) spermicides,<br/>(16) emergency contraception (levonorgestrel), and (17)<br/>emergency contraception (ulipristal acetate), and any<br/>additional contraceptives approved, granted, or cleared by<br/>the FDA.</li> </ul> |

# Contraceptive Use and Counseling

| Code  | Description   | Business Rule   |
|-------|---|---|
| 11976 | Removal Only Implanted Contraceptive Cap  | No cost share for contraceptive use and counseling for women when billed with appropriate CPT codes   |
| 11980 | Subcutaneous hormone pellet implantation<br>(implantation of estradiol and/or testosterone<br>pellets beneath the skin) | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |
| 11981 | Insertion, non-biodegradable drug delivery implant  | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |
| 11982 | Removal, non-biodegradable drug delivery implant  | No cost share for contraceptive use and counseling for women<br>when billed with appropriate code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position     |



| Code  | Description   | Business Rule   |
|-------|---|---|
| 11983 | Removal with reinsertion, non-biodegradable drug delivery implant   | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |
| 96372 | Therapeutic, prophylactic, or diagnostic injection<br>(specify substance or drug); subcutaneous or<br>intramuscular | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |
| S4993 | Contraceptive pills for birth control   | No cost share for contraceptive use and counseling for women when billed with appropriate code (left)   |
| 57170 | Diaphragm or cervical cap fitting with instructions   | No cost share for contraceptive use and counseling for women when billed with appropriate CPT code  |
| 58300 | Insertion of intrauterine device (IUD)  | No cost share for contraceptive use and counseling for women when billed with appropriate CPT code  |
| 58301 | Removal of intrauterine device (IUD)  | No cost share for contraceptive use and counseling for women when billed with appropriate CPT code  |
| A4267 | Mail Condom (obtained thru Pharmacy with prescription   |   |
| S4981 | Insertion of levonorgestrel- releasing intrauterine system  | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| S4989 | Contraceptive intrauterine device (e.g., progestacert iud), including implants and supplies                         | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| S4993 | Contraceptive pills for birth control   | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| A4261 | Cervical cap for contraceptive use  | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| A4264 | Permanent implantable contraceptive intratubal occlusion device(s) and delivery system                              | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| A4266 | Diaphragm for contraceptive use   | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| A4268 | Contraceptive supply, condom, female, each  | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| A4269 | Contraceptive supply, spermicide (e.g., foam, gel), each  | No cost share for contraceptive use and counseling for women when billed with appropriate code  |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg  | No cost share for contraceptive use and counseling for women<br>when billed with appropriate code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position     |
| J7296 | Levonorgestrel-releasing intrauterine<br>contraceptive system, (Kyleena), 19.5 mg                                   | No cost share for contraceptive use and counseling for women when billed with appropriate code  |



| Code  | Description   | Business Rule  |
|-------|---|--|
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg                                 | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg                                  | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7300 | Intrauterine copper contraceptive   | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7301 | Levonorgestrel releasing intrauterine contraceptive system, 13.5 mg   | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7304 | Contraceptive supply, hormone containing patch, each  | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7306 | Levonorgestrel (contraceptive) implant system, including implants and supplies                              | No cost share for contraceptive use and counseling for women when billed with appropriate code   |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies                                 | No cost share for contraceptive use and counseling for women when billed with appropriate CPT code   |
| 00851 | Anes, Intraperitoneal Procedures in Lower<br>Abdomen Including Laparoscopy; Tubal Ligation/<br>Transection. | No cost share for contraceptive use and counseling for women when billed with appropriate CPT code   |
| 00840 | Anesthesia intraperitoneal lower abd w/laps nos   | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position  |
| 00940 | Anesthesia vaginal procedure w/biopsy nos   | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position. |
| 00952 | Anes hysteroscopy&/hysterosalpingography w/bx   | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position  |
| 81025 | Urine pregnancy test, by visual color comparison methods  | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position  |
| 74018 | Radiologic exam abdomen 1 view  | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position  |
| 76857 | Ultrasound pelvic nonobstetric image DCMTN<br>limited/f/u   | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position  |



|   | Code  | Description                        | Business Rule   |
|---|-------|------------------------------------|---|
|   | 76830 | Ultrasound transvaginal            | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |
| 7 | 76998 | Ultrasonic guidance intraoperative | No cost share for contraceptive use and counseling for women<br>when billed with appropriate CPT code (left) and appropriate<br>Contraceptive related ICD-10 diagnosis code set billed in the<br>principal diagnosis position |

# Contraceptive-related ICD 10 diagnosis code set billed in the principal diagnosis position:

T8331XA, T8331XD, T8331XS, T83.32XA, T83.32XD, T83.32XS, T83.39XA, T8339XD, T8339XS, Z30.011, Z30.012, Z30.013, Z30.014, Z30.015, Z30.016, Z30.017, Z30.018, Z30.019, Z30.02, Z30.09, Z30.2, Z30.40, Z30.41, Z30.42, Z30.430, Z30.431, Z30.432, Z30.433, Z30.44, Z30.45, Z30.46, Z30.49, Z30.8, Z30.9, Z97.5, Z98.51

## **Women's Preventive Health-Well-woman Preventive Visits**

| Code            | Description  | Business Rule   |
|-----------------|--|---|
| 99202-<br>99215 | The 1st prenatal visit is global to the total OB<br>Delivery charges with the entire global OB<br>allowable amount reimbursed on the Global<br>delivery claim.<br>* No cost share for contraceptive use and<br>counseling for women when billed with<br>appropriate code (left) and appropriate<br>Contraceptive related ICD 10 diagnosis code set<br>billed in the principal diagnosis position | <ul> <li>No cost share when billed with appropriate code.</li> <li>HRSA Requirement (Jan. 2023): WPSI recommends that<br/>women receive at least one preventive care visit per year<br/>beginning in adolescence and continuing across the lifespan<br/>to ensure the provision of all recommended preventive<br/>services, including preconception and many services<br/>necessary for prenatal and interconception care, are<br/>obtained.</li> </ul> |
| 99401-<br>99404 | E&M Codes Preventive medicine counseling and/<br>or risk factor reduction intervention(s) provided to<br>an individual without specific illness.   | <ul> <li>The primary purpose of these visits should be the delivery<br/>and coordination of recommended preventive services as<br/>determined by age and risk factors. These services may be<br/>completed at a single or as part of a series of visits that take</li> </ul>  |
| 99381-<br>99387 | New Patient comprehensive preventive medicine evaluation and management  | place over time to obtain all necessary services depending<br>on a woman's age, health status, reproductive health needs,<br>pregnancy status, and risk factors.  |
| 99391-<br>99397 | Established Patient comprehensive preventive medicine evaluation and management  | <ul> <li>Well-women visits also include pre-pregnancy, prenatal,<br/>postpartum and interpregnancy visits.</li> </ul>   |
| S0610           | Annual Gynecological Examination   |   |
| S0612           | Annual Gynecological Examination   | See Policies: Pediatric and Adult Preventive Exams  |
| \$0613          | Annual breast exam   |   |
| G0438           | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visi  |   |
| G0439           | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit  |   |



# **Pediatric and Adult Preventive Exams**

| Code            | Description  | Business Rule   |
|-----------------|--|---|
| 99381-<br>99387 | New Patient comprehensive preventive medicine evaluation and management  | No cost share for a routine preventative exam when billed with the appropriate CPT code.        |
| 99391-<br>99397 | Established Patient comprehensive preventive medicine evaluation and management  | No cost share for a routine preventative exam when billed with the appropriate CPT code (left). |
| 99401-<br>99404 | E&M Codes Preventive medicine counseling and/<br>or risk factor reduction intervention(s) provided to<br>an individual without specific illness. | No co-pay for a routine preventative exam.  |
| G0438           | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit   | No co-pay for a routine preventative exam when billed with the appropriate CPT code             |
| G0439           | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit  | No co-pay for a routine preventative exam when billed with the appropriate CPT code             |
| S0610           | Annual Gynecological Examination   | No cost share for a routine preventative exam when billed with the appropriate CPT code         |
| S0612           | Annual Gynecological Examination   | No cost share for a routine preventative exam when billed with the appropriate CPT code         |
| S0613           | Annual breast exam   | No cost share for a routine preventative exam when billed with the appropriate CPT code         |

## **Immunizations for Adults and Children**

The immunizations below were identified using ACIP guidelines.

Business Rule: No co-pay when immunization is provided based on ACIP guidelines.

| Code  | de Description   |  |
|---|--|--|
| 90587   | Dengue vaccine, quadrivalent, live, 3 dose schedule, for subcutaneous use  |  |
| 90611   | Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use |  |
| 90622   | Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use  |  |
| 90671   | Pneumococcal conjugate vaccine, 15 valent (PCV15), for intramuscular use   |  |
| 90677 Pneumococcal conjugate vaccine, 20 valent (PCV20), for intramuscular use  |  |  |
| <b>90620</b> Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB), 2 dose sc intramuscular use Ages 16 – 23 years |  |  |
| 90621   | Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB), 3 dose schedule, for intramuscular use Ages<br>16–23 years                        |  |
| 90630   | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, for intradermal use Ages 2-71 months                                   |  |
| 90632   | Hepatitis A vaccine, adult dosage, for intramuscular use Age 12 months and older   |  |
| 90633 Hepatitis A vaccine, pediatric/adolescent dosage-2 dose schedule, for intramuscular use Age 12 months and                                       |  |  |



| Code  | Description   |  |
|---|---|--|
| 90634   | Hepatitis A vaccine, pediatric/adolescent dosage-3 dose schedule, for intramuscular use Age 12 months and older   |  |
| 90636   | Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use Age 18 years and older   |  |
| <b>90644</b> Meningococcal conjugate vaccine, serogroups C & Y and Haemophilus influenzae type b vaccine (Hib-Mer schedule, when administered to children 6 weeks-18 months of age, for intramuscular use |   |  |
| 90647   | Hemophilus influenza b vaccine (Hib), PRP-OMP conjugate (3 dose schedule), for intramuscular use Age 0 and older  |  |
| 90648   | Hemophilus influenza b vaccine (Hib), PRP-T conjugate (4 dose schedule), for intramuscular use Age 0 and older  |  |
| 90649   | Human Papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use, ages   |  |
| 90650   | Human Papilloma virus (HPV) vaccine, types 16, 18, bivalent, 3 dose schedule, for intramuscular use Male/female ages  |  |
| 90651   | Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 3 dose schedule, for<br>intramuscular use Female age 9 – 45 years           |  |
| 90653   | Influenza vaccine, inactivated (IIV), subunit, adjuvanted, for intramuscular use Age 65 years and older   |  |
| 90654   | Influenza virus vaccine, trivalent (IIV3), split virus, preservative-free, for intradermal use Age 18 – 64 years  |  |
| 90655   | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for intramuscular use All NDCs inactive 7/9/15                             |  |
| 90656   | Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use Age 3 years and older.                                |  |
| 90657   | Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for intramuscular use Afluria age 9 years and older   |  |
| 90658 Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use Age 3 years and older  |   |  |
| 90660   | Influenza virus vaccine, trivalent, live (LAIV3), for intranasal use  |  |
| 90661   | Influenza virus vaccine (ccIIV3), derived from cell cultures, subunit, preservative and antibiotic free, for intramuscular use Age 4 years and older                  |  |
| 90662   | Influenza virus vaccine (IIV), split virus, preservative free, enhanced immunogenicity via increased antigen content, for intramuscular use Age 65 years and older    |  |
| 90664   | Influenza virus vaccine, live (LAIV), pandemic formulation, for intranasal use. Benefit limit:  |  |
| 90666   | Influenza virus vaccine (IIV), pandemic formulation, split virus, preservative free, for intramuscular use  |  |
| 90667   | Influenza virus vaccine (IIV), pandemic formulation, split virus, adjuvanted, for intramuscular use   |  |
| 90668   | Influenza virus vaccine (IIV), pandemic formulation, split virus, for intramuscular use   |  |
| 90670   | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use  |  |
| 90682   | Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use. |  |
| 90686   | Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use.   |  |
| 90687   | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use. Benefit limit: Ages 6-35 months old                                 |  |



| Code   | Description   |  |
|--|---|--|
| 90688  | Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use.  |  |
| 90689  | Influenza virus vaccine quadrivalent (IIV4), inactivated, adjuvanted, preservative free, 0.25mL dosage, for intramuscular use   |  |
| 90694  | Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 ml dosage, for intramuscluar use   |  |
| 90696  | Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use Ages 4 – 6 years.  |  |
| 90696  | Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use |  |
| 90698  | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use.                   |  |
| 90700  | Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than 7 years, for intramuscular use                                     |  |
| 90702  | Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use   |  |
| 90707  | Measles, mumps, and rubella virus vaccine (MMR), live, for subcutaneous use Ages 0 and older  |  |
| 90710  | Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use Ages 12 months -12 years  |  |
| 90713  | Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use  |  |
| 90714  | Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, when administered to individuals 7 years or older, for intramuscular use Ages 7 years and older.                     |  |
| <b>90715</b> Tetanus, diphtheria toxoids, and acellular pertussis vaccine (Tdap), when administered to individuals 7 for intramuscular use |   |  |
| <b>90716</b> Varicella virus vaccine, live, for subcutaneous use Ages 12 months and older  |   |  |
| 90723  | Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B, and poliovirus vaccine, inactivated (DtaP-HepB-<br>IPV), for intramuscular use Ages 6 weeks – 6 years          |  |
| 90732  | Pneumococcal polysaccharide vaccine, 23-valent, adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use    |  |
| 90733  | Meningococcal polysaccharide vaccine (any group(s)), for subcutaneous use Ages 2 years and older  |  |
| 90734  | Meningococcal conjugate vaccine, serogroups A, C, Y and W- 135 (tetravalent), for intramuscular use ages 9 months- 55 years 9 - 23 months 2 doses, 2 -55 years 1 dose                 |  |
| 90736  | Zoster (shingles) vaccine, live, for subcutaneous injection Ages 50 years and older   |  |
| 90739  | Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use.   |  |
| 90740  | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use Ages 18 years and older   |  |
| 90743  | Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use Ages 7 – 18 years  |  |
| 90744  | Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use Ages 0-18 years   |  |
|  |   |  |



| Code  | Description   |  |
|-------|---|--|
| 90746 | Hepatitis B vaccine, adult dosage, for intramuscular use Ages 10 years and older  |  |
| 90747 | Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use Ages 0 and<br>older   |  |
| 90748 | Hepatitis B andHemophilus influenza b vaccine (HepB-Hib), for intramuscular use Ages 6 weeks – 15 months  |  |
| 90750 | Zoster (shingles) vaccine (HZV), recombinant, subunit, adjuvanted, for intramuscular useShingrix® age 50 years & older,<br>Zostavax® age 60 years & older   |  |
| 90756 | Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use   |  |
| 90759 | Hepatitis B vaccine (HepB), 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dosage, 3 dose schedule, for intramuscular use  |  |
| J3530 | Nasal vaccine inhalation ACIP recommendation - do not use product   |  |
| Q2034 | Influenza virus vaccine, split virus, for intramuscular use (Agriflu) Ages 6 months and older. All NDCs Inactive 6/13/12  |  |
| Q2035 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (AFLURIA) Ages 5 years and older   |  |
| Q2036 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (FLULAVAL) age 6 months or older for Flulaval Quadrivalent.>>>All NDCs Inactive as of 6/4/15                           |  |
| Q2037 | , Influenza virus vaccine, split virus, when administered to individuals 4 years of age and older, for intramuscular use (FLUVIRIN) age 4 years & older for Fluvirin  |  |
| Q2038 | Influenza virus vaccine, split virus, for intramuscular use (Fluzone) FDA approved age 6 months of age or older for<br>Fluzone. FDA approved 65 years of age or older for Fluzone High Dose. FDA approved age 18- 64 for Fluzone Intradermal. |  |
| Q2039 | Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (not otherwise specified) Ages 3 years and older)  |  |

# Immunization Administration

| Code  | Description  | Business Rule   |
|-------|--|---|
| 90460 | Immunization administration through 18 years of age via<br>any route of administration, with counseling by physician<br>or other qualified health care professional; first or only<br>component of each vaccine or toxoid administered   | No cost share when submitted with an appropriate CPT code (left) and immunization code (above).     |
| 90461 | Immunization administration through 18 years of age via<br>any route of administration, with counseling by physician<br>or other qualified health care professional; each additional<br>vaccine or toxoid component administered. (List separately<br>in addition to code for primary procedure) | No cost share when submitted with the appropriate<br>CPT code (left) and immunization code (above). |
| 90471 | Immunization administration (includes percutaneous,<br>intradermal, subcutaneous, or intramuscular injections); 1<br>vaccine (single or combination vaccine/toxoid)  | No cost share when submitted with an appropriate immunization code (above).                         |
| 90472 | Immunization administration (includes percutaneous,<br>intradermal, subcutaneous, or intramuscular injections);<br>each additional vaccine (single or combination vaccine/<br>toxoid). (List separately in addition to code for primary<br>procedure)  | No cost share when submitted with an appropriate immunization code (above).                         |



| Code  | Description   | Business Rule   |  |
|-------|---|---|--|
| 90473 | Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)   | No cost share when submitted with an appropriate immunization code (above). |  |
| 90474 | Immunization administration by intranasal or oral route;<br>each additional vaccine (single or combination vaccine/<br>toxoid) (List separately in addition to code for primary<br>procedure) | No cost share when submitted with an appropriate immunization code (above). |  |
| G0008 | Administration of influenza virus vaccine   | No cost share when submitted with an appropriate immunization code (above). |  |
| G0009 | Administration of pneumococcal vaccine  | No cost share when submitted with an appropriate immunization code (above). |  |
| G0010 | Administration of hepatitis B vaccine   | No cost share when submitted with an appropriate immunization code (above). |  |

# Hemoglobin/Hematocrit Testing

| Code  | Description       | Business Rule   |  |
|-------|-------------------|---|--|
| 86762 | Antibody; rubella | No cost share for rubella antibody testing as follows: when performed on children<br>under the age of 13 months as a preventative visit when billed with the appropriate<br>CPT code (left). Children are covered for one (1) test and immunization between 11<br>and 17 years of age as a preventative visit when billed with the appropriate CPT code<br>(left). Adults are covered for one (1) test and immunization between 18 and 49 years of<br>age as a preventative visit when billed with the appropriate CPT code (left). |  |

# **Women's Preventative Health**

| Code  | Description  | Business Rule                             |
|-------|--|---|
| 88141 | Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician   | No co-pay                                 |
| 88142 | Cytopathology, cervical or vaginal (any reporting system),<br>collected in preservative fluid, automated thin layer<br>preparation; manual screening under physician supervision                         | No co-pay                                 |
| 88143 | Cytopathology, cervical or vaginal (any reporting system),<br>collected in preservative fluid, automated thin layer<br>preparation; with manual screening and rescreening under<br>physician supervision | No со-рау                                 |
| 88147 | Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision   | No со-рау                                 |
| 88148 | Cytopathology smears, cervical or vaginal; screening<br>by automated system with manual rescreening under<br>physician supervision   | No co-рау                                 |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision   | No co-pay when modifier attached to code. |



| Code  | Description   | Business Rule |
|-------|---|---------------|
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision   | No co-pay     |
| 88153 | Cytopathology, slides, cervical or vaginal; with manual screening and rescreening under physician supervision   | No co-pay     |
| 88154 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening using cell selection and review under physician supervision   | No co-pay     |
| 88155 | Cytopathology, slides, cervical or vaginal, definitive<br>hormonal evaluation (e.g., maturation index, karyopyknotic<br>index, estrogenic index). (List separately in addition to<br>code[s] for other technical and interpretation services) | No co-pay     |
| 88164 | Cytopathology, slides, cervical or vaginal (the Bethesda<br>System); manual screening under physician supervision   | No co-pay     |
| 88165 | Cytopathology, slides, cervical or vaginal (the Bethesda<br>System); with manual screening and rescreening under<br>physician supervision   | No co-pay     |
| 88166 | Cytopathology, slides, cervical or vaginal (the Bethesda<br>System); with manual screening and computer-assisted<br>rescreening under physician supervision   | No co-pay     |
| 88167 | Cytopathology, slides, cervical or vaginal (the Bethesda<br>System); with manual screening and computer-assisted<br>rescreening using cell selection and review under physician<br>supervision  | No co-pay     |
| 88174 | Cytopathology, cervical or vaginal (any reporting system),<br>collected in preservative fluid, automated thin layer<br>preparation; screening by automated system, under<br>physician supervision   | No co-pay     |
| 88175 | Cytopathology, cervical or vaginal (any reporting system),<br>collected in preservative fluid, automated thin layer<br>preparation; with screening by automated system and<br>manual rescreening or review, under physician supervision       | No co-pay     |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination  | No co-pay     |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting<br>system), collected in preservative fluid, automated thin<br>layer preparation, screening by cytotechnologist under<br>physician supervision                                    | No co-pay     |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician   | No co-pay     |
| G0141 | Screening cytopathology smears, cervical or vaginal,<br>performed by automated system, with manual rescreening,<br>requiring interpretation by physician  | No co-pay     |



| Code  | Description  | Business Rule |
|-------|--|---------------|
| G0143 | Screening cytopathology, cervical or vaginal (any reporting<br>system), collected in preservative fluid, automated thin<br>layer preparation, with manual screening and rescreening<br>by cytotechnologist under physician supervision | No co-pay     |
| G0144 | Screening cytopathology, cervical or vaginal (any reporting<br>system), collected in preservative fluid, automated thin<br>layer preparation, with screening by automated system,<br>under physician supervision                       | No co-pay     |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting<br>system), collected in preservative fluid, automated thin<br>layer preparation, with screening by automated system and<br>manual rescreening under physician supervision | No co-pay     |
| G0147 | Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision   | No co-pay     |
| G0148 | Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening   | No co-pay     |
| P3000 | Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, by technician under physician supervision   | No co-pay     |
| P3001 | Screening Papanicolaou smear, cervical or vaginal, up to 3 smears, requiring interpretation by physician   | No co-pay     |
| Q0091 | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory   | No co-pay     |

# Women's Preventative Health - HPV Testing

| Code  | Description   | Business Rule  |
|-------|---|--|
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA);<br>Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42,<br>43, 44)   | No cost share for HPV testing in females over age 30 when billed with appropriate CPT code |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA);<br>Human Papillomavirus (HPV), high-risk types (e.g., 16, 18,<br>31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68)                             | No cost share for HPV testing in females over age 30 when billed with appropriate CPT code |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA);<br>Human Papillomavirus (HPV), types 16 and 18 only, includes<br>type 45, if performed   | No cost share for HPV testing in females over age 30 when billed with appropriate CPT code |
| 88174 | Cytopathology, cervical or vaginal (any reporting system),<br>collected in preservative fluid, automated thin layer<br>preparation; screening by automated system, under<br>physician supervision | No cost share for HPV testing in females over age 30 when billed with appropriate CPT code |



## Women's Preventative Health - Counseling and screening for human immune-deficiency virus

| Code  | Description  | Business Rule  |
|-------|--|--|
| 86701 | Antibody; HIV-1  | No cost share when billed with appropriate code.   |
| 86702 | Antibody; HIV-2  | HRSA Requirement (Jan. 2023): WPSI recommends<br>all adolescent and adult women, ages 15 and older,  |
| 86703 | Antibody; HIV-1 and HIV-2, single result   | receive a screening test for HIV at least once during<br>their lifetime. Earlier or additional screening should  |
| 86689 | Antibody; HTLV or HIV antibody, confirmatory test (e.g.,<br>Western Blot   | be based on risk, and rescreening annually or more<br>often may be appropriate beginning at age 13 for<br>adolescent and adult women with an increased risk of   |
| G0432 | Infectious agent antibody detection by enzyme<br>immunoassay (EIA) technique, HIV-1 and/or HIV-2, screening                      | HIV infection.<br>WPSI recommends risk assessment and prevention   |
| G0433 | Infectious agent antibody detection by enzyme-linked<br>immunosorbent assay (ELISA) technique, HIV-1 and/or HIV-<br>2, screening | <ul> <li>education for HIV infection beginning at age 13 and<br/>continuing as determined by risk.</li> <li>A screening test for HIV is recommended for all<br/>pregnant persons upon initiation of prenatal care</li> </ul> |
| G0435 | Infectious agent antibody detection by rapid antibody test,<br>HIV-1 and/or HIV-2, screening                                     | with rescreening during pregnancy based on risk<br>factors. Rapid HIV testing is recommended for<br>pregnant persons who present in active labor   |
| G0475 | HIV antigen/antibody, combination assay, screening   | with an undocumented HIV status. Screening during pregnancy enables prevention of vertical   |
| S3645 | HIV-1 antibody testing of oral mucosal transudate  | transmission.  |

# Women's Preventative Health - Sexually Transmitted Infection Counseling

| Code  | Description   | Business Rule  |
|-------|---|--|
| 99401 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 15 minutes                            | <ul> <li>No cost share when billed with appropriate code.</li> <li>HRSA Requirement (Jan. 2023): WPSI recommends directed behavioral counseling by a health care</li> </ul>  |
| 99402 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual (separate procedure); approximately 30 minutes                            | <ul> <li>clinician or other appropriately trained individual<br/>for sexually active adolescent and adult women at<br/>an increased risk for STIs.</li> <li>WPSI recommends that clinicians review a woman's</li> </ul>  |
| 99403 | Preventive medicine counseling and/or risk factor reduction<br>intervention(s) provided to an individual (separate<br>procedure); approximately 45 minutes                      | sexual history and risk factors to help identify those<br>at an increased risk of STIs. Risk factors include,<br>but are not limited to, age younger than 25, a<br>recent history of an STI, a new sex partner, multiple |
| 99404 | Preventive medicine counseling and/or risk factor reduction<br>intervention(s) provided to an individual (separate<br>procedure); approximately 60 minutes                      | partners, a partner with concurrent partners, a<br>partner with an STI, and a lack of or inconsistent<br>condom use. For adolescents and women not<br>identified as high risk, counseling to reduce the                  |
| G0445 | Semiannual high intensity behavioral counseling to prevent<br>STIs, individual, face-to-face, includes education skills<br>training & guidance on how to change sexual behavior | risk of STIs should be considered, as determined by clinical judgment.   |
| 99411 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to individuals in a group setting (separate procedure); approximately 30 minutes           |  |
| 99412 | Preventive medicine counseling and/or risk factor reduction<br>intervention(s) provided to individuals in a group setting<br>(separate procedure); approximately 60 minutes     |  |



## Women's Preventative Health - Obesity Prevention in Midlife Women

| Code             | Description  | Business Rule   |
|------------------|--|---|
| G0447            | Face-to-face behavioral counseling for obesity, 15 minutes   |   |
| G0473            | Face-to-face behavioral counseling for obesity, group (2-10), 30 minutes   | <ul> <li>No cost share when billed with appropriate code.</li> <li>HRSA Requirement (Jan. 2023): WPSI recommends counseling midlife women aged 40 to 60 years with</li> </ul> |
| 99401 -<br>99404 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness | normal or overweight body mass index (BMI) (18.5-<br>29.9 kg/m2) to maintain weight or limit  |
| 99385 -<br>99387 | New Patient comprehensive preventive medicine evaluation and management  | • Bill with appropriate BMI code:<br>Z68.1 = BMI 19.9 or less   |
| 99395 -<br>99397 | Established Patient comprehensive preventive medicine evaluation and management  | Z68.2 = BMI 20 – 29   |

### Women's Preventative Health - Contraceptive Methods and Counseling

Vermont Only

8 V.S.A. § 4099c. Reproductive health equity in health insurance coverage

| Code  | Description                                      | Business Rule   |
|-------|--|---|
| 99202 | Office/outpatient new sf MDM 15-29 minutes       | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99203 | Office/outpatient new low MDM 30-44 minutes      | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99204 | Office/outpatient new moderate MDM 45-59 minutes | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99205 | Office/outpatient new high MDM 60-74 minutes     | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99211 | Office/outpatient established minimal problem(s) | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99212 | Office/outpatient established sf MDM 10-19 min   | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |



| Code  | Description                                      | Business Rule   |
|-------|--|---|
| 99213 | Office/outpatient established low MDM 20-29 min  | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99214 | Office/outpatient established mod MDM 30-39 min  | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 99215 | Office/outpatient established high MDM 40-54 min | No cost share for contraceptive use and counseling for<br>women when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |

# Women's Preventative Health – Sterilization Surgery

| Code  | Description  | Business Rule  |
|-------|--|--|
| 58565 | Hysteroscopy, surgical   | No cost share for contraceptive use and counseling for women when billed with appropriate CPT codes  |
| 58600 | Ligation or transection of fallopian tube(s), abdominal or vaginal approach, unilateral or bilateral   | No cost share for female sterilization surgery for females when billed with the appropriate CPT codes  |
| 58605 | Ligation or transection of fallopian tube(s), abdominal or<br>vaginal approach, postpartum, unilateral or bilateral, during<br>same hospitalization  | No cost share for female sterilization surgery for females when billed with the appropriate CPT codes  |
| 58611 | Ligation or transection of fallopian tube(s) when done at the<br>time of cesarean delivery or intra-abdominal surgery (not a<br>separate procedure) (List separately in addition to code for<br>primary procedure) | No cost share for female sterilization surgery for females when billed with the appropriate CPT codes  |
| 58615 | Occlusion of fallopian tube(s) by device (e.g., band, clip,<br>Falope ring) vaginal or suprapubic approach   | No cost share for female sterilization surgery for females when billed with the appropriate CPT codes  |
| 58661 | Removal of adnexal structures (partial or total oophorectomy and/or salpingectomy)   | No cost share for female sterilization surgery when<br>billed with the appropriate CPT codes (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |
| 58670 | Laparoscopy, surgical; with fulguration of oviducts (with or without transection)  | No cost share for female sterilization surgery for females when billed with the appropriate CPT codes  |
| 58671 | Laparoscopy, surgical; with occlusion of oviducts by device<br>(eg, band, clip, or Falope ring)  | No cost share for contraceptive use and counseling for women when billed with appropriate CPT codes  |
| 58555 | Hysteroscopy diagnostic separate procedure   | No cost share for female sterilization surgery when<br>billed with the appropriate CPT codes (left) and<br>appropriate contraceptive related ICD10 diagnosis<br>code set billed in the principal diagnosis position  |
| 58562 | Hysteroscopy removal impacted foreign body   | No cost share for female sterilization surgery when<br>billed with the appropriate CPT codes (left) and<br>appropriate contraceptive related ICD10 diagnosis<br>code set billed in the principal diagnosis position  |



| Code  | Description   | Business Rule   |
|-------|---|---|
| 58340 | Saline or contrast material / cath & saline/contrast<br>sonohyster/hysterosalpi | No cost share for female sterilization surgery when<br>billed with the appropriate CPT codes (left) and<br>appropriate contraceptive related ICD-10 diagnosis<br>code set billed in the principal diagnosis position          |
| 74740 | Hysterosalpingography   | No cost share for female sterilization surgery when<br>billed with the appropriate cpt codes (left) and<br>appropriate contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position          |
| 88302 | Level II Surgical Pathology Gross & Microscope Exam                             | No cost share for contraceptive use and counseling for<br>women when billed with appropriate CPT code (left)<br>and appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position |

# Women's Preventative Health - Counseling to Detect and Prevent Interpersonal and Domestic Violence

| Code                             | Description   | Business Rule   |
|----------------------------------|---|---|
| 99401<br>99402<br>99403<br>99404 | Preventive medicine counseling and/or risk factor reduction interventions | No co-pay screening and counseling to detect and<br>prevent interpersonal and domestic violence for<br>females when billed with the appropriate CPT codes |

# Women's Preventative Health – Breastfeeding Services and Supplies (Breastfeeding support, supplies, and counseling)

| Code                    | Description   | Business Rule   |
|-------------------------|---|---|
| E0602<br>E0603<br>E0604 | Breast pump, manual, any type of Breast pump, electric (AC<br>and/or DC), any type<br>Breast pump, hospital grade, electric (AC and/or DC), any<br>type | <ul> <li>No cost share when billed with appropriate code.</li> <li>HRSA Requirement (Jan. 2023): Comprehensive lactation support services (including consultation; counseling; education by clinicians and peer expression of the environment.</li> </ul> |
| A4281                   | Tubing for breast pump, replacement   | <ul> <li>support services; and breastfeeding equipment</li> <li>and supplies) during the antenatal, perinatal, and</li> <li>postpartum periods to optimize the successful</li> </ul>  |
| A4282                   | Adapter for breast pump, replacement  | initiation and maintenance of breastfeeding.  |
| A4283                   | Cap for breast pump bottle, replacement   | <ul> <li>Breastfeeding equipment and supplies include,<br/>but are not limited to, double electric breast</li> </ul>  |
| A4284                   | Breast shield and splash protector for use with breast pump, replacement  | pumps (including pump parts and maintenance)<br>and breast milk storage supplies. Access to double<br>electric pumps should be a priority to optimize   |
| A4285                   | Polycarbonate bottle for use with breast pump, replacement  | breastfeeding and should not be predicated on prior failure of a manual pump. Breastfeeding   |
| A4286                   | Locking ring for breast pump, replacement   | equipment may also include equipment and<br>supplies as clinically indicated to support dyads   |
| K1005                   | Disposable collection and storage bag for breast milk, any size, any type, each   | <ul> <li>with breastfeeding difficulties and those who need additional services.</li> <li>Members are allowed reimbursement for 1 breast</li> </ul>   |
| S9443                   | Non-physician conducting a lactation class  | <ul> <li>Members are allowed remoursement for 1 breast<br/>pump per live birth. Members can complete the<br/>Child Care Form to be reimbursed for the purchase<br/>of a breast pump</li> <li>Members must use current vendor</li> </ul>                   |



| Code                                      | Description  | Business Rule  |
|---|--|--|
| 99501                                     | Home visit for postnatal assessment and follow-up care   |  |
| 99502                                     | Home visit for newborn care and assessment   |  |
| 99211<br>99212<br>99213<br>99214<br>99215 | Nurse visit usually under 5 minutes Office or other<br>outpatient visit for the evaluation and management of an<br>established patient | No cost share for supervision of lactation when billed<br>by a physician with the appropriate E&M code and<br>the following diagnosis codes billed in the principal<br>diagnosis position; Z39.1 |

# Women's Preventative Health - Screening for Gestational Diabetes Mellitus

| Code  | Description   | Business Rule  |
|-------|---|--|
| 82947 | Glucose; quantitative, blood (except reagent strip).  | No cost share for women when billed with     appropriate Programmy related ICD 10 Diagnosis  |
| 82950 | Glucose; post-glucose dose  | <ul> <li>appropriate Pregnancy related ICD 10 Diagnosis<br/>code.</li> </ul>   |
| 82951 | Glucose: tolerance test (GTT),3 specimens (includes glucose)  | HRSA Requirement (Dec. 2016): Recommends     screening pregnant persons for gestational diabetes   |
| 82952 | Glucose; tolerance test, each additional beyond 3<br>specimens (List separately in addition to code for primary<br>procedure) | mellitus after 24 weeks of gestation (preferably<br>between 24 and 28 weeks of gestation) in order to<br>prevent adverse birth outcomes. Screening with<br>a 50-g oral glucose challenge test (followed by a   |
| 82948 | Glucose; blood, reagent strip   | 3-hour 100-g oral glucose tolerance test if results on the initial oral glucose challenge test are abnormal)   |
| 83036 | Hemoglobin; glycosylated (A1c)  | <ul> <li>is preferred because of its high sensitivity and<br/>specificity. This recommendation also suggests that<br/>women with risk factors for diabetes mellitus be<br/>screened for preexisting diabetes before 24 weeks<br/>of gestation—ideally at the first prenatal visit, based<br/>on current clinical best practices.</li> <li>Also see Pre-Diabetes Screening and Gestational<br/>Diabetes Screening in the Preventive Healthcare<br/>Payment Policy.</li> </ul> |



### Women's Preventative Health - Screening Diabetes Mellitus after Pregnancy

| Code                  | Description   | Business Rule  |
|-----------------------|---|--|
| 82947                 | Glucose; quantitative, blood (except reagent strip).  | • No cost share for women when billed with a   |
| 82950                 | Glucose; post-glucose dose  | <ul> <li>Pregnancy diagnosis Z86.32 (personal history of gestational diabetes) or Z39.2 (routine postpartum)</li> </ul>  |
| (includes<br>glucose) | Glucose: tolerance test (GTT),3 specimens (includes glucose)  | <ul> <li>HRSA Requirement (Dec. 2017): The Women's<br/>Preventive Services Initiative recommends women<br/>with a history of gestational diabetes mellitus (GDM)</li> </ul>                          |
| 82951                 | Glucose; tolerance test (GTT),3 specimens (includes glucose)  | who are not currently pregnant and who have not previously been diagnosed with type 2 diabetes   |
| 82952                 | Glucose; tolerance test, each additional beyond 3<br>specimens (List separately in addition to code for primary<br>procedure) | mellitus should be screened for diabetes mellitus.<br>Initial testing should ideally occur within the first<br>year postpartum and can be conducted as early as<br>4–6 weeks postpartum.             |
| 82948                 | Glucose; blood, reagent strip   | • Women with a negative initial postpartum screening test result should be rescreened at least every 3   |
| 83036                 | Hemoglobin; glycosylated (A1c)  | <ul> <li>years for a minimum of 10 years after pregnancy</li> <li>Also see Pre-Diabetes Screening and Gestational<br/>Diabetes Screening in the Preventive Healthcare<br/>Payment Policy.</li> </ul> |

### Women's Preventative Health - Screening for Urinary Incontinence

| Code            | Description   | Business Rule  |
|-----------------|---|--|
| 99381-<br>99387 | New Patient comprehensive preventive medicine evaluation and management   | No cost share for screening women for urinary incontinence annually. |
| 99395-<br>99397 | Established Patient comprehensive preventive medicine evaluation and management   | No cost share for screening women for urinary incontinence annually. |
| 99401-<br>99404 | Preventive medicine counseling and/or risk factor reduction intervention(s) provided to an individual without specific illness. | No cost share for screening women for urinary incontinence annually. |

#### Women's Preventative Health - Breast Cancer Screening

**Business Rule**: Call-back mammograms and ultrasounds for patients whose screening mammograms were inconclusive or who have dense breast tissue, or both, will be covered in full when billed with diagnosis code R92.2, R92.8

| Code   | Description  |  |
|--|--|--|
| 76641-76642  | Diagnostic Ultrasound Procedures of the Chest                                |  |
| 77061- 77063   | Under Breast, Mammography  |  |
| 77065-77067  | Under Breast, Mammography  |  |
| <b>G0279</b> Diagnostic digital breast tomosynthesis, unilateral or bilatera       |  |  |
| 99401-99404 Preventive medicine counseling and/or risk factor reduct interventions |  |  |
| 99386, 99387,  | Initial comprehensive preventive medicine evaluation and management code set |  |



| Code         | Description   |
|--------------|---|
| 99396, 99397 | Established patient comprehensive preventive medicine evaluation and management |

USPSTF recommends screening mammography for women, with or without clinical breast examination, every 1 to 2 years for women age 40 years and older.

#### Men's Preventive Health—Contraception Consultation and Voluntary Sterilization

#### (Vermont Only)

#### 8 V.S.A. § 4099c. Reproductive health equity in health insurance coverage

A health insurance plan shall provide coverage for voluntary sterilization procedures for men and women without any deductible, coinsurance, co-payment, or other cost-sharing requirement, except to the extent that such coverage would disqualify a high-deductible health plan from eligibility for a health savings account pursuant to 26 U.S.C. § 223.

This includes consultation services associated with providing the procedures covered under this section.

| Code  | Description   | Business Rule  |
|-------|---|--|
| 99202 | Office/outpatient new sf MDM 15-29<br>minutes       | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.                        |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position. |
| 99203 | Office/outpatient new low MDM 30-44<br>minutes      | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.                        |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position. |
| 99204 | Office/outpatient new moderate MDM<br>45-59 minutes | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.                        |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position. |
| 99205 | Office/outpatient new high MDM 60-74<br>minutes     | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.                        |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position. |
| 99211 | Office/outpatient established minimal<br>problem(s) | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.                        |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position. |



| Code  | Description   | Business Rule   |
|-------|---|---|
| 99212 | Office/outpatient established sf MDM<br>10-19 min   | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.<br><b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate |
|       |   | Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.   |
| 99213 | Office/outpatient established low MDM<br>20-29 min  | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.   |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.  |
| 99214 | Office/outpatient established mod MDM<br>30-39 min  | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.   |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.  |
| 99215 | Office/outpatient established high MDM<br>40-54 min | <b>Non-HDHP Plans:</b> No cost share for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.   |
|       |   | <b>Qualified HDHP Plans:</b> No cost share after Deductible for male counseling when billed with appropriate code (left) and appropriate Contraceptive related ICD 10 diagnosis code set billed in the principal diagnosis position.  |

### Men's Preventive Health-Elective Sterilization Vasectomy Surgery

(Vermont Only)

#### 8 V.S.A. § 4099c. Reproductive Health Equity in Health Insurance Coverage

A health insurance plan shall provide coverage for voluntary sterilization procedures for men and women without any deductible, coinsurance, co-payment, or other cost-sharing requirement, except to the extent that such coverage would disqualify a high-deductible health plan from eligibility for a health savings account pursuant to 26 U.S.C. sec 223.

| Code  | Description          | Business Rule   |
|-------|----------------------|---|
| 55250 | Vasectomy            | <b>Non-HDHP Plans:</b> No cost share for male sterilization surgery when billed with the appropriate CPT codes                              |
|       |                      | <b>Qualified HDHP Plans:</b> No cost share after<br>Deductible for male sterilization surgery when billed<br>with the appropriate CPT codes |
|       |                      | <b>Non-HDHP Plans:</b> No cost share for male sterilization surgery when billed with the appropriate CPT codes                              |
| 00921 | Anesthesia Vasectomy | <b>Qualified HDHP Plans:</b> No cost share after<br>Deductible for male sterilization surgery when billed<br>with the appropriate CPT codes |



| Code  | Description  | Business Rule  |
|-------|--|--|
| 88302 | Level II Surgical Pathology Gross & Microscopic Exam | <ul> <li>Non-HDHP Plans: No cost share for lab when<br/>billed with appropriate code (left) and appropriate<br/>Contraceptive related ICD 10 diagnosis code set billed<br/>in the principal diagnosis position</li> <li>Qualified HDHP Plans: No cost share after Deductible<br/>for lab when billed with appropriate code (left) and<br/>appropriate Contraceptive related ICD 10 diagnosis<br/>code set billed in the principal diagnosis position.</li> </ul> |

## Post-Surgical Lab work

| Code  | Description                                    | Business Rule   |
|-------|--|---|
| 89321 | Semen analysis sperm presence &/motility sperm | <b>Non-HDHP Plans:</b> No cost share for lab when<br>billed with appropriate code (left) and appropriate<br>Contraceptive related ICD 10 diagnosis code set billed<br>in the principal diagnosis position.                        |
|       |  | <b>Qualified HDHP Plans:</b> No cost share after Deductible<br>for lab when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position. |
| 89320 | Semen analysis volume count motility different | <b>Non-HDHP Plans:</b> No cost share for lab when<br>billed with appropriate code (left) and appropriate<br>Contraceptive related ICD 10 diagnosis code set billed<br>in the principal diagnosis position.                        |
|       |  | <b>Qualified HDHP Plans:</b> No cost share after Deductible<br>for lab when billed with appropriate code (left) and<br>appropriate Contraceptive related ICD 10 diagnosis<br>code set billed in the principal diagnosis position. |

# New York State Insurance Law Chapter 74 of the Laws of 2016 Insurance Law §§ 3216(i)(11)(F), 3221(l)(11)(F), and 4303(p)(5)

#### **Diagnostic Mammograms Medical Services**

New York State Insurance Law Chapter 74 of the Laws of 2016 Insurance Law requires no cost share for diagnostic imaging, ultrasounds, and MRI of the breast.

| Code  | Description   | Business Rule  |
|---|---|--|
| Medical Services<br>76641*, 76642*,<br>77053, 77046**,<br>77047**,    |   | Medical Services   |
| 77048**,<br>77049**, 77054,   | Annual wellness visit,<br>includes a personalized     | No cost share for diagnostic imaging, ultrasounds, and MRI of the breast when billed with the appropriate CPT code.              |
| 77061*, 77062*,<br>77063, 77065*,<br>77066*, 77067,<br>G0279*, S8080, | prevention plan of service<br>(pps), subsequent visit | *Codes are covered in full only when billed with diagnosis codes R92.2 and<br>R92.8<br>**Require prior authorization via eviCore |
| C8903, C8905,<br>C8906, C8908   |   |  |



| Code  | Description       | Business Rule  |
|---|-------------------|--|
| Medical Services<br>77046**,<br>77047**,<br>77048**,<br>77049** | MRI of the breast | No cost share for MRI of the breast when billed with the appropriate<br>CPT code.<br>**Require prior authorization via eviCore |

#### VT Diagnostic MRI with Screening (Vermont Diagnostic Mammogram Medical Services)

#### **Medicaid Product Variation**

#### Medicaid and HARP Long-Acting Reversible Contraception (LARC) Provided as an Inpatient Post-Partum Service

Long-Acting Reversible Contraception (LARC) is covered for Medicaid and HARP products only when provided to women during their postpartum inpatient hospital stay.

| Code  | Description   | Business Rule   |
|-------|---|---|
| J7300 | Intrauterine copper contraceptive   | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |
| J7301 | <b>Levonorgestrel</b><br>releasing intrauterine contraceptive system,<br>13.5 mg                | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |
| J7306 | <b>Levonorgestrel</b><br>(contraceptive) implant system, including<br>implants and supplies     | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |
| J7307 | <b>Etonogestrel</b><br>(contraceptive) implant system, including<br>implant and supplies        | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |
| J7297 | <b>Levonorgestrel</b><br>releasing intrauterine contraceptive system,<br>52 mg, 3 year duration | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |
| J7307 | <b>Levonorgestrel</b><br>releasing intrauterine contraceptive<br>system,52 mg, 5 year duration  | Long-Acting Reversible Contraception (LARC) is covered during a postpartum inpatient hospital stay when submitted with Bill type 131, Revenue codes 0250 or 0636, and the appropriate HCPCS code. |

#### **Modifier PT and Modifier 33**

#### **Modifier PT**

Code

#### Description

**Modifier PT** should be used when a CRC screening test has been converted to diagnostic test or other procedure MVP will pay the diagnostic procedure code that is reported instead of the screening colonoscopy or screening flexible sigmoidoscopy HCPCS code, or screening barium enema, when the screening test becomes a diagnostic service.

#### **Business Rule**

The claims processing system would respond to the modifier by waiving the deductible for all surgical services on the same date as the diagnostic test. Co-insurance for Medicare beneficiaries would continue to apply to the diagnostic test and to other services furnished in connection with, as a result of, and in the same clinical encounter as the screening test.



#### **Modifier 33**

\*Each preventive care service will identify the specific billing rules as to when to apply Modifier 33 or when Modifier is not needed to be billed.

| Code                   | Description   | Business Rule   |
|------------------------|---|---|
| Preventive<br>Services | When the primary purpose of the service is the delivery of an<br>evidence based service in accordance with a US Preventive<br>Services Task Force A or B rating in effect and other preventive<br>services identified in preventive services mandates (legislative<br>or regulatory), the service may be identified by adding 33 to<br>the procedure. For separately reported services specifically<br>identified as preventive, the modifier should not be used. | The Member's co-pay/co-insurance/cost share for this service will be waived as appropriate. |

#### **Code Sets**

#### Pregnancy-related ICD 10 diagnosis code set

billed in the principal diagnosis position:

A34.0, E07.81, O00.0, O00.1, O00.101, O00.102, O00.109, O00.111, O00.112, O00.119, O00.201, O00.202, O00.209, O00.211, O00.212, 000.219, 000.80, 000.81, 000.90, 000.91, 002.0, 002.1, 002.81, 002.89, 002.9, 003.0, 003.1, 003.2, 003.30, 003.31, 003.32, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.32, 003.33, 003.31, 003.32, 003.33, 003.31, 003.22, 003.33, 003.31, 003.32, 003.33, 003.31, 003.32, 003.33, 003.31, 003.22, 003.33, 003.31, 003.22, 003.33, 003.31, 003.32, 003.33, 003.31, 003.22, 003.33, 003.31, 003.32, 003.33, 003.31, 003.32, 003.33, 003.33, 003.33, 003.33, 003.32, 003.33, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003.33, 003.32, 003. 003.34, 003.35, 003.36, 003.37, 003.38, 003.39, 003.4, 003.5, 003.6, 003.7, 003.80, 003.81, 003.82, 003.83, 003.84, 003.85, 003.86, 003.87, 003.88, 003.89, 003.9, 004.5, 004.6, 004.7, 004.80, 004.81, 004.82, 004.83, 004.84, 004.85, 004.86, 004.87, 004.88, 004.89, 007.0, 007.1, 007.2, 007.30, 007.31, 007.32, 007.33, 007.34, 007.35, 007.36, 007.37, 007.38, 007.39, 007.4, 008.0, 008.1, 008.2, 008.3, 008.4, 008.5, 008.6, 008.7, 008.81, 008.82, 008.83, 008.89, 008.9, 009.0, 009.1, 009.2, 009.3, 009.10, 009.11, 009.12, 009.13, 009.211, 009.212, 009.213, 009.219, 009.291, 009.292, 009.293, 009.299, 009.30, 009.31, 009.32, 009.33, 009.40, 009.41, 009.42, 009.43, 009.511, 009.512, 009.513, 009.519, 009.521, 009.522, 009.523, 009.529, 009.611, 009.612, 009.613, 009.619, 009.621, 009.622, 009.623, 009.629, 009.70, 009.71, 009.72, 009.73, 009.811, 009.812, 009.813, 009.819, 009.821, 009.822, 009.823, 009.829, 009.891, 009.892, 009.893, 009.899, 009.90, 009.91, 009.92, 009.93, 009.A0, 009.A1, 009.A2, 009.A3, 010.11, 010.12, 010.13, 010.19, 010.2, 010.3, 010.111, 010.112, 010.113, 010.119, 010.12, 010.13, 010.211, 010.212, 010.213, 010.219, 010.22, 010.23, 010.311, 010.312, 010.313, 010.319, 010.32, 010.33, 010.411, 010.412, 010.413, 010.419, 010.42, 010.43, 010.911, 010.912, 010.913, 010.919, 010.92, 010.93, 011.1, 011.2, 011.3, 011.4, 011.5, 011.9, 012.0, 012.1, 012.2, 012.3, 012.4, 012.5, 012.10, 012.11, 012.12, 012.13, 012.14, 012.15, 012.20, 012.21, 012.22, 012.23, 012.24, 012.25, 013.1, 013.2, 013.3, 013.4, 013.5, 013.9, 014.0, 014.2, 014.3, 014.4, 014.5, 014.10, 014.12, 014.13, 014.14, 014.15, 014.20, 014.22, 014.23, 014.24, 014.25, 014.90, 014.92, 014.93, 014.94,014.94, 014.95, 015.0, 015.2, 015.3, 015.1, 015.2, 015.9, 016.1, 016.2, 016.3, 016.4, 016.5, 016.9, 020.0, 020.8, 020.9, 021.0, 021.1, 021.2, 021.8, 021.9, 022.0, 022.1, 022.2, 022.3, 022.10, 022.11, 022.12, 022.13, 022.20, 022.21, 022.22, 022.23, 022.30, 022.31, 022.32, 022.33, 022.40, 022.41, 022.42, 022.43, 022.50, 022.51, 022.52, 022.53, 022.8X1, 022.8X2, 022.8X3, 022.8X9, 022.90, 022.91, 022.92, 022.93, 023.0, 023.1, 023.2, 023.3, 023.10, 023.11, 023.12, 023.13, 023.20, 023.21, 023.22, 023.23, 023.30, 023.31, 023.32, 023.33, 023.40, 023.41, 023.42, 023.43, 023.511, 023.512, 023.513, 023.519, 023.521, 023.522, 023.523, 023.529, 023.591, 023.592, 023.591, 023.592, 023.591, 023.592, 023.591, 023.592, 023.592, 023.593, 023.592, 023.593, 023.599, 023.90, 023.91, 023.92, 023.93, 024.11, 024.12, 024.13, 024.19, 024.2, 024.3, 024.111, 024.112, 024.113, 024.119, 024.12, 024.13, 024.311, 024.312, 024.313, 024.319, 024.32, 024.33, 024.410, 024.414, 024.415, 024.419, 024.420, 024.424, 024.425, 024.429, 024.430, 024.434, 024.435, 024.439, 024.811, 024.812, 024.813, 024.819, 024.82, 024.83, 024.911, 024.912, 024.913, 024.919, 024.92, 024.93, 025.10, 025.11, 025.12, 025.13, 025.2, 025.3, 026.0, 026.1, 026.2, 026.3, 026.10, 026.11, 026.12, 026.13, 026.20, 026.21, 026.22, 026.23, 026.30, 026.31, 026.32, 026.33, 026.40, 026.41, 026.42, 026.43, 026.50, 026.51, 026.52, 026.53, 026.611, 026.612, 026.613, 026.619, 026.62, 026.63, 026.711, 026.712, 026.713, 026.719, 026.72, 026.73, 026.811, 026.812, 026.813, 026.819, 026.821, 026.822, 026.823, 026.829, 026.831, 026.832, 026.833, 026.839, 026.841, 026.842, 026.843, 026.849, 026.851, 026.852, 026.853, 026.859, 026.86, 026.872, 026.873, 026.879, 026.891, 026.892, 026.893, 026.899, 026.90, 026.91, 026.92, 026.93, 029.11, 029.12, 029.13, 029.19, 029.21, 029.22, 029.23, 029.29, 029.91, 029.92, 029.93, 029.99, 029.111, 029.112, 029.113, 029.119, 029.121, 029.122, 029.123, 029.129, 029.191, 029.192, 029.193, 029.199, 029.211, 029.212, 029.213, 029.219, 029.291, 029.292, 029.293, 029.299, 029.3X1, 029.3X2, 029.3X3, 029.3X9, 029.40, 029.41, 029.42, 029.43, 029.5X1, 029.5X2, 029.5X3, 029.5X9, 029.60, 029.61, 029.62, 029.63, 029.8X1, 029.8X2, 029.8X3, 029.8X9, 029.90, 029.91, 029.92, 029.93, 030.1, 030.2, 030.3, 030.9, 030.11, 030.12, 030.13, 030.19, 030.21, 030.22, 030.23, 030.29, 030.31, 030.32, 030.33, 030.39, 030.41, 030.42, 030.43, 030.49, 030.91, 030.92, 030.93, 030.99, 030.101, 030.102, 030.103, 030.109, 030.111, 030.112, 030.113, 030.119, 030.121, 030.122, 030.123, 030.129, 030.131, 030.132, 030.133, 030.139, 030.191, 030.192, 030.193, 030.199, 030.201, 030.202, 030.203, 030.209, 030.211, 030.212, 030.213, 030.219, 030.221, 030.222, 030.223, 030.229, 030.231, 030.232, 030.233, 030.239, 030.291, 030.292, 030.293, 030.299, 030.801, 030.802, 030.803, 030.809, 030.811, 030.812, 030.813, 030.819, 030.821, 030.822, 030.823,



030.829, 030.831, 030.832, 030.833, 030.839, 030.891, 030.892, 030.893, 030.899, 030.90, 030.91, 030.92, 030.93, 031.00X0, O31.00X1, O31.00X2, O31.00X3, O31.00X4, O31.00X5, O31.00X9, O31.01X0, O31.01X1, O31.01X2, O31.01X3, O31.01X4, O31.01X5, 031.01X9, 031.02X0, 031.02X1, 031.02X2, 031.02X3, 031.02X4, 031.02X5, 031.02X9, 031.03X0, 031.03X1, 031.03X2, 031.03X3, O31.03X4, O31.03X5, O31.03X9, O31.10X0, O31.10X1, O31.10X2, O31.10X3, O31.10X4, O31.10X5, O31.10X9, O31.11X0, O31.11X1, 031.11X2, 031.11X3, 031.11X4, 031.11X5, 031.11X9, 031.12X0, 031.12X1, 031.12X2, 031.12X3, 031.12X4, 031.12X5, 031.12X9, 031.13X0, 031.13X1, 031.13X2, 031.13X3, 031.13X4, 031.13X5, 031.13X9, 031.20X0, 031.20X1, 031.20X2, 031.20X3, 031.20X4, 031.20X5, 031.20X9, 031.21X0, 031.21X1, 031.21X2, 031.21X3, 031.21X4, 031.21X5, 031.21X9, 031.22X0, 031.22X1, 031.22X2, 031.22X3, 031.22X4, 031.22X5, 031.22X9, 031.23X0, 031.23X1, 031.23X2, 031.23X3, 031.23X4, 031.23X5, 031.23X9, 031.30X0, 031.30X1, 031.30X2, 031.30X3, 031.30X4, 031.30X5, 031.30X9, 031.31X0, 031.31X1, 031.31X2, 031.31X3, 031.31X4, 031.31X5, 031.31X9, 031.32X0, 031.32X1, 031.32X2, 031.32X3, 031.32X4, 031.32X5, 031.32X9, 031.33X0, 031.33X1, 031.33X2, 031.33X3, 031.33X4, 031.33X5, 031.33X9, 031.8X10, 031.8X11, 031.8X12, 031.8X13, 031.8X14, 031.8X15, 031.8X19, 031.8X20, 031.8X21, 031.8X22, 031.8X23, 031.8X24, 031.8X25, 031.8X29, 031.8X30, 031.8X31, 031.8X32, 031.8X33, 031.8X34, 031.8X35, 031.8X39, O31.8X90, O31.8X91, O31.8X92, O31.8X93, O31.8X94, O31.8X95, O31.8X99, O32.0XX0, O32.0XX1, O32.0XX2, O32.0XX3, O32.0XX4, 032.0XX5, 032.0XX9, 032.1XX0, 032.1XX1, 032.1XX2, 032.1XX3, 032.1XX4, 032.1XX5, 032.1XX9, 032.2XX0, 032.2XX1, 032.2XX2, 032.2XX3, 032.2XX4, 032.2XX5, 032.2XX9, 032.3XX0, 032.3XX1, 032.3XX2, 032.3XX3, 032.3XX4, 032.3XX5, 032.3XX9, 032.4XX0, 032.4XX1, 032.4XX2, 032.4XX3, 032.4XX4, 032.4XX5, 032.4XX9, 032.6XX0, 032.6XX1, 032.6XX2, 032.6XX3, 032.6XX4, 032.6XX5, 032.6XX9, 032.8XX0, 032.8XX1, 032.8XX2, 032.8XX3, 032.8XX4, 032.8XX5, 032.8XX9, 032.9XX0, 032.9XX1, 032.9XX2, 032.9XX3, 032.9XX4, 032.9XX5, 032.9XX9, 033.0, 033.1, 033.2, 033.3XX0, 033.3XX1, 033.3XX2, 033.3XX3, 033.3XX4, 033.3XX5, 033.3XX9, 033.4XX0, 033.4XX1, 033.4XX2, 033.4XX3, 033.4XX4, 033.4XX5, 033.4XX9, 033.5XX0, 033.5XX1, 033.5XX2, 033.5XX3, 033.5XX4, 033.5XX5, 033.5XX9, 033.6XX0, 033.6XX1, 033.6XX2, 033.6XX3, 033.6XX4, 033.6XX5, 033.6XX9, 033.7XX0, 033.7XX1, 033.7XX2, 033.7XX3, 033.7XX4, 033.7XX5, 033.7XX9, 033.8, 033.9, 034.0, 034.1, 034.2, 034.3, 034.10, 034.11, 034.12, 034.13, 034.211, 034.212, 034.218, 034.219, 034.22, 034.29, 034.30, 034.31, 034.32, 034.33, 034.40, 034.41, 034.42, 034.43, 034.511, 034.512, 034.513, 034.519, 034.521, 034.522, 034.523, 034.529, 034.531, 034.532, 034.533, 034.539, 034.591, 034.592, 034.593, 034.599, 034.60, 034.61, 034.62, 034.63, 034.70, 034.71, 034.72, 034.73, 034.80, 034.81, 034.82, 034.83, 034.90, 034.91, 034.92, 034.93, 035.00X0, 035.00X1, 035.00X2, 035.00X3, 035.00X4, 035.00X5, 035.00X9, 035.01X0, 035.01X1, 035.01X2, 035.01X3, 035.01X4, 035.01X5, 035.01X9, 035.02X0, 035.02X1, 035.02X2, 035.02X3, 035.02X4, 035.02X5, 035.02X9, 035.03X0, 035.03X1, 035.03X2, 035.03X3, 035.03X4, 035.03X5, 035.03X9, 035.04X0, 035.04X1, 035.04X2, 035.04X3, 035.04X4, 035.04X5, 035.04X9, 035.05X0, 035.05X1, 035.05X2, 035.05X3, 035.05X4, 035.05X5, 035.05X9, 035.06X0, 035.06X1, 035.06X2, 035.06X3, 035.06X4, 035.06X5, 035.06X9, 035.07X0, 035.07X1, 035.07X2, 035.07X3, 035.07X4, 035.07X5, 035.07X9, 035.08X0, 035.08X1, 035.08X2, 035.08X3, 035.08X4, 035.08X5, 035.08X9, 035.09X0, 035.09X1, 035.09X2, 035.09X3, 035.09X4, 035.09X5, 035.09X9, 035.0XX0, 035.0XX1, O35.0XX2, O35.0XX3, O35.0XX4, O35.0XX5, O35.0XX9, O35.10X0, O35.10X1, O35.10X2, O35.10X3, O35.10X4, O35.10X5, O35.10X9, 035.11X0, 035.11X1, 035.11X2, 035.11X3, 035.11X4, 035.11X5, 035.11X9, 035.12X0, 035.12X1, 035.12X2, 035.12X3, 035.12X4, 035.12X5, 035.12X9, 035.13X0, 035.13X1, 035.13X2, 035.13X3, 035.13X4, 035.13X5, 035.13X9, 035.14X0, 035.14X1, 035.14X2, 035.14X3, 035.14X4, 035.14X5, 035.14X9, 035.15X0, 035.15X1, 035.15X2, 035.15X3, 035.15X4, 035.15X5, 035.15X9, 035.19X0, 035.19X1, 035.19X2, 035.19X3, 035.19X4, 035.19X5, 035.19X9, 035.1XX0, 035.1XX1, 035.1XX2, 035.1XX3, 035.1XX4, 035.1XX5, O35.1XX9, O35.2XX0, O35.2XX1, O35.2XX2, O35.2XX3, O35.2XX4, O35.2XX5, O35.2XX9, O35.3XX0, O35.3XX1, O35.3XX2, O35.3XX3, O35.3XX4, O35.3XX5, O35.3XX9, O35.4XX0, O35.4XX1, O35.4XX2, O35.4XX3, O35.4XX4, O35.4XX5, O35.4XX9, O35.5XX0, O35.5XX1, 035.5XX2, 035.5XX3, 035.5XX4, 035.5XX5, 035.5XX9, 035.6XX0, 035.6XX1, 035.6XX2, 035.6XX3, 035.6XX4, 035.6XX5, 035.6XX9, 035.7XX0, 035.7XX1, 035.7XX2, 035.7XX3, 035.7XX4, 035.7XX5, 035.7XX9, 035.8XX0, 035.8XX1, 035.8XX2, 035.8XX3, 035.8XX4, O35.8XX5, O35.8XX9, O35.9XX0, O35.9XX1, O35.9XX2, O35.9XX3, O35.9XX4, O35.9XX5, O35.9XX9, O35.AXX0, O35.AXX1, O35.AXX2, O35. AXX3, O35.AXX4, O35.AXX5, O35.AXX9, O35.BXX0, O35.BXX1, O35.BXX2, O35.BXX3, O35.BXX4, O35.BXX5, O35.BXX9, O35.CXX0, O35. CXX1, O35.CXX2, O35.CXX3, O35.CXX4, O35.CXX5, O35.CXX9, O35.DXX0, O35.DXX1, O35.DXX2, O35.DXX3, O35.DXX4, O35.DXX5, O35. DXX9, O35.EXX0, O35.EXX1, O35.EXX2, O35.EXX3, O35.EXX4, O35.EXX5, O35.EXX9, O35.FXX0, O35.FXX1, O35.FXX2, O35.FXX3, O35.FXX4, 035.FXX5, 035.FXX9, 035.GXX0, 035.GXX1, 035.GXX2, 035.GXX3, 035.GXX4, 035.GXX5, 035.GXX9, 035.HXX0, 035.HXX1, 035.HXX2, O35.HXX3, O35.HXX4, O35.HXX5, O35.HXX9, O36.110, O36.111, O36.112, O36.113, O36.114, O36.115, O36.119, O36.120, O36.121, 036.122, 036.123, 036.124, 036.125, 036.129, 036.130, 036.131, 036.132, 036.133, 036.134, 036.135, 036.139, 036.190, 036.191, 036.192, 036.193, 036.194, 036.195, 036.199, 036.910, 036.911, 036.912, 036.913, 036.914, 036.915, 036.919, 036.920, 036.921, 036.922, 036.923, 036.924, 036.925, 036.929, 036.930, 036.931, 036.932, 036.933, 036.934, 036.935, 036.939, 036.990, 036.991, 036.992, 036.993, 036.994, 036.995, 036.999, 036.1110, 036.1111, 036.1112, 036.1113, 036.1114, 036.1115, 036.1119, 036.1120, 036.1121, 036.1122, 036.1123, 036.1124, 036.1125, 036.1129, 036.1130, 036.1131, 036.1132, 036.1133, 036.1134, 036.1135, 036.1139, 036.1190, 036.1191, 036.1192, 036.1193, 036.1194, 036.1195, 036.1199, 036.1910, 036.1911, 036.1912, 036.1913, 036.1914, 036.1915, 036.1919, 036.1920, 036.1921, 036.1922, 036.1923, 036.1924, 036.1925, 036.1929, 036.1930, 036.1931, 036.1932, 036.1933, 036.1934, 036.1935, 036.1939, 036.1990, 036.1991, 036.1992, 036.1993, 036.1994, 036.1995, 036.1999, 036.20X0, 036.20X1, 036.20X2, 036.20X3, 036.20X4, 036.20X5, 036.20X9, 036.21X0, 036.21X1, 036.21X2, 036.21X3, 036.21X4,



036.21X5, 036.21X9, 036.22X0, 036.22X1, 036.22X2, 036.22X3, 036.22X4, 036.22X5, 036.22X9, 036.23X0, 036.23X1, 036.23X2, 036.23X3, 036.23X4, 036.23X5, 036.23X9, 036.4XX0, 036.4XX1, 036.4XX2, 036.4XX3, 036.4XX4, 036.4XX5, 036.4XX9, 036.5110, 036.5111, 036.5112, 036.5113, 036.5114, 036.5115, 036.5119, 036.5120, 036.5121, 036.5122, 036.5123, 036.5124, 036.5125, 036.5129, 036.5130, 036.5131, 036.5132, 036.5133, 036.5134, 036.5135, 036.5139, 036.5190, 036.5191, 036.5192, 036.5193, 036.5194, 036.5195, 036.5199, 036.5910, 036.5911, 036.5912, 036.5913, 036.5914, 036.5915, 036.5919, 036.5920, 036.5921, 036.5922, 036.5923, 036.5924, 036.5925, 036.5929, 036.5930, 036.5931, 036.5932, 036.5933, 036.5934, 036.5935, 036.5939, O36.5990, O36.5991, O36.5992, O36.5993, O36.5994, O36.5995, O36.5999, O36.60X0, O36.60X1, O36.60X2, O36.60X3, O36.60X4, 036.60X5, 036.60X9, 036.61X0, 036.61X1, 036.61X2, 036.61X3, 036.61X4, 036.61X5, 036.61X9, 036.62X0, 036.62X1, 036.62X2, 036.62X3, 036.62X4, 036.62X5, 036.62X9, 036.63X0, 036.63X1, 036.63X2, 036.63X3, 036.63X4, 036.63X5, 036.63X9, 036.70X0, 036.70X1, 036.70X2, 036.70X3, 036.70X4, 036.70X5, 036.70X9, 036.71X0, 036.71X1, 036.71X2, 036.71X3, 036.71X4, 036.71X5, 036.71X9, 036.72X0, 036.72X1, 036.72X2, 036.72X3, 036.72X4, 036.72X5, 036.72X9, 036.73X0, 036.73X1, 036.73X2, 036.73X3, 036.73X4, 036.73X5, 036.73X9, 036.80X0, 036.80X1, 036.80X2, 036.80X3, 036.80X4, 036.80X5, 036.80X9, 036.8120, 036.8121, 036.8122, 036.8123, 036.8124, 036.8125, 036.8129, 036.8130, 036.8131, 036.8132, 036.8133, 036.8134, 036.8135, 036.8139, 036.8190, 036.8191, 036.8192, 036.8193, 036.8194, 036.8195, 036.8199, 036.8210, 036.8211, 036.8212, 036.8213, 036.8214, 036.8215, 036.8219, 036.8220, 036.8221, 036.8222, 036.8223, 036.8224, 036.8225, 036.8229, 036.8230, 036.8231, 036.8232, 036.8233, 036.8234, 036.8235, 036.8239, 036.8290, 036.8291, 036.8292, 036.8293, 036.8294, 036.8295, 036.8299, 036.8310, 036.8311, 036.8312, 036.8313, 036.8314, 036.8315, 036.8319, 036.8320, 036.8321, 036.8322, 036.8323, 036.8324, 036.8325, 036.8329, 036.8330, 036.8331, 036.8332, 036.8333, 036.8334, 036.8335, 036.8339, 036.8390, 036.8391, 036.8392, 036.8393, 036.8394, 036.8395, 036.8399, 036.8910, 036.8911, 036.8912, 036.8913, 036.8914, 036.8915, 036.8919, 036.8920, 036.8921, 036.8922, 036.8923, 036.8924, 036.8925, 036.8929, 036.8930, 036.8931, 036.8932, 036.8933, 036.8934, 036.8935, 036.8939, O36.8990, O36.8991, O36.8992, O36.8993, O36.8994, O36.8995, O36.8999, O36.90X0, O36.90X1, O36.90X2, O36.90X3, O36.90X4, 036.90X5, 036.90X9, 036.91X0, 036.91X1, 036.91X2, 036.91X3, 036.91X4, 036.91X5, 036.91X9, 036.92X0, 036.92X1, 036.92X2, 036.92X3, 036.92X4, 036.92X5, 036.92X9, 036.93X0, 036.93X1, 036.93X2, 036.93X3, 036.93X4, 036.93X5, 036.93X9, 040.1XX0, 040.1XX1, 040.1XX2, 040.1XX3, 040.1XX4, 040.1XX5, 040.1XX9, 040.2XX0, 040.2XX1, 040.2XX2, 040.2XX3, 040.2XX4, 040.2XX5, 040.2XX9, 040.3XX0, 040.3XX1, 040.3XX2, 040.3XX3, 040.3XX4, 040.3XX5, 040.3XX9, 040.9XX0, 040.9XX1, 040.9XX2, 040.9XX3, 040.9XX4, 040.9XX5, 040.9XX9, 041.00X0, 041.00X1, 041.00X2, 041.00X3, 041.00X4, 041.00X5, 041.00X9, 041.01X0, 041.01X1, 041.01X2, 041.01X3, 041.01X4, 041.01X5, 041.01X9, 041.02X0, 041.02X1, 041.02X2, 041.02X3, 041.02X4, 041.02X5, 041.02X9, 041.03X0, 041.03X1, 041.03X2, 041.03X3, 041.03X4, 041.03X5, 041.03X9, 041.1010, 041.1011, 041.1012, 041.1013, 041.1014, 041.1015, 041.1019, 041.1020, 041.1021, 041.1022, 041.1023, 041.1024, 041.1025, 041.1029, 041.1030, 041.1031, 041.1032, 041.1032, 041.1031, 041.1032, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1032, 041.1031, 041.1031, 041.1032, 041.1031, 041.103 041.1033, 041.1034, 041.1035, 041.1039, 041.1090, 041.1091, 041.1092, 041.1093, 041.1094, 041.1095, 041.1099, 041.1210, 041.1211, 041.1212, 041.1213, 041.1214, 041.1215, 041.1219, 041.1220, 041.1221, 041.1222, 041.1223, 041.1224, 041.1225, 041.1229, 041.1230, 041.1231, 041.1232, 041.1233, 041.1234, 041.1235, 041.1239, 041.1290, 041.1291, 041.1292, 041.1293, 041.1294, 041.1295, 041.1299, 041.1410, 041.1411, 041.1412, 041.1413, 041.1414, 041.1415, 041.1419, 041.1420, 041.1421, 041.1422, 041.1423, 041.1424, 041.1425, 041.1429, 041.1430, 041.1431, 041.1432, 041.1433, 041.1434, 041.1435, 041.1439, 041.1439, 041.1431, 041.1432, 041.1433, 041.1434, 041.1435, 041.1439, 041.1431, 041.1431, 041.1433, 041.1433, 041.1434, 041.1435, 041.1439, 041.1431, 041.1431, 041.1433, 041.1433, 041.1434, 041.1435, 041.1439, 041.1431, 041.1431, 041.1433, 041.1433, 041.1434, 041.1435, 041.1439, 041.1431, 041.1431, 041.1432, 041.1433, 041.1433, 041.1434, 041.1435, 041.1439, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1435, 041.1434, 041.1444, 041.144 041.1490, 041.1491, 041.1492, 041.1493, 041.1494, 041.1495, 041.1499, 041.8X10, 041.8X11, 041.8X12, 041.8X13, 041.8X14, 041.8X15, 041.8X19, 041.8X20, 041.8X21, 041.8X22, 041.8X23, 041.8X24, 041.8X25, 041.8X29, 041.8X30, 041.8X31, 041.8X32, 041.8X33, 041.8X34, 041.8X35, 041.8X39, 041.8X90, 041.8X91, 041.8X92, 041.8X93, 041.8X94, 041.8X95, 041.8X99, 041.90X0, 041.90X1, 041.90X2, 041.90X3, 041.90X4, 041.90X5, 041.90X9, 041.91X0, 041.91X1, 041.91X2, 041.91X3, 041.91X4, 041.91X5, 041.91X9, 041.92X0, 041.92X1, 041.92X2, 041.92X3, 041.92X4, 041.92X5, 041.92X9, 041.93X0, 041.93X1, 041.93X2, 041.93X3, 041.93X4, 041.93X5, 041.93X9, 042.0, 042.11, 042.12, 042.13, 042.19, 042.2, 042.10, 042.111, 042.112, 042.113, 042.119, 042.12, 042.90, 042.911, 042.912, 042.913, 042.919, 042.92, 043.11, 043.12, 043.13, 043.19, 043.21, 043.22, 043.23, 043.29, 043.101, 043.102, 043.103, 043.109, 043.111, 043.112, 043.113, 043.119, 043.121, 043.122, 043.123, 043.129, 043.191, 043.192, 043.193, 043.199, 043.211, 043.212, 043.213, 043.219, 043.221, 043.222, 043.223, 043.229, 043.231, 043.232, 043.233, 043.239, 043.811, 043.812, 043.813, 043.819, 043.891, 043.892, 043.893, 043.899, 043.90, 043.91, 043.92, 043.93, 044.0, 044.1, 044.2, 044.3, 044.10, 044.11, 044.12, 044.13, 044.20, 044.21, 044.22, 044.23, 044.30, 044.31, 044.32, 044.33, 044.40, 044.41, 044.42, 044.43, 044.50, 044.51, 044.52, 044.53, 045.1, 045.2, 045.3, 045.9, 045.11, 045.12, 045.13, 045.19, 045.21, 045.22, 045.23, 045.29, 045.91, 045.92, 045.93, 045.99, 045.8X1, 045.8X2, 045.8X3, 045.8X9, 045.90, 045.91, 045.92, 045.93, 046.1, 046.2, 046.3, 046.9, 046.11, 046.12, 046.13, 046.19, 046.21, 046.22, 046.23, 046.29, 046.91, 046.92, 046.93, 046.99, 046.8X1, 046.8X2, 046.8X3, 046.8X9, 046.90, 046.91, 046.92, 046.93, 047.0, 047.2, 047.3, 047.1, 047.9, 048.0, 048.1, 060.0, 060.2, 060.3, 060.10X0, 060.10X1, 060.10X2, 060.10X3, 060.10X4, 060.10X5, 060.10X9, 060.12X0, 060.12X1, 060.12X2, 060.12X3, 060.12X4, 060.12X5, 060.12X9, 060.13X0, 060.13X1, 060.13X2, 060.13X3, 060.13X4, 060.13X5, 060.13X9, 060.14X0, 060.14X1, 060.14X2, 060.14X3, 060.14X4, 060.14X5, 060.14X9, 060.20X0, 060.20X1, 060.20X2, 060.20X3, 060.20X4, 060.20X5, 060.20X9, 060.22X0, 060.22X1, 060.22X2, 060.22X3, 060.22X4, 060.22X5, 060.22X9, 060.23X0, 060.23X1, 060.23X2, 060.23X3, 060.23X4, 060.23X5, 060.23X9, 061.0, 061.1, 061.8, 061.9, 062.0, 062.1, 062.2, 062.3, 062.4, 062.8, 062.9, 063.0, 063.1, 063.2, 063.9, 064.0XX0, 064.0XX1, 064.0XX2, 064.0XX3, 064.0XX4, 064.0XX5,



064.0XX9, 064.1XX0, 064.1XX1, 064.1XX2, 064.1XX3, 064.1XX4, 064.1XX5, 064.1XX9, 064.2XX0, 064.2XX1, 064.2XX2, 064.2XX3, 064.2X 064.2XX4, 064.2XX5, 064.2XX9, 064.3XX0, 064.3XX1, 064.3XX2, 064.3XX3, 064.3XX4, 064.3XX5, 064.3XX9, 064.4XX0, 064.4XX1, 064.4XX2, 064.4XX3, 064.4XX4, 064.4XX5, 064.4XX9, 064.5XX0, 064.5XX1, 064.5XX2, 064.5XX3, 064.5XX4, 064.5XX5, 064.5XX9, 064.8XX0, 064.8XX1, 064.8XX2, 064.8XX3, 064.8XX4, 064.8XX5, 064.8XX9, 064.9XX0, 064.9XX1, 064.9XX2, 064.9XX3, 064.9XX4, 064.9XX5, 064.9XX9, 065.0, 065.1, 065.2, 065.3, 065.4, 065.5, 065.8, 065.9, 066.0, 066.1, 066.2, 066.3, 066.40, 066.41, 066.5, 066.6, O66.8, O66.9, O67.0, O67.8, O67.9, O68.0, O69.0XX0, O69.0XX1, O69.0XX2, O69.0XX3, O69.0XX4, O69.0XX5, O69.0XX9, O69.1XX0, 069.1XX1, 069.1XX2, 069.1XX3, 069.1XX4, 069.1XX5, 069.1XX9, 069.2XX0, 069.2XX1, 069.2XX2, 069.2XX3, 069.2XX4, 069.2XX5, 069.2XX9, 069.3XX0, 069.3XX1, 069.3XX2, 069.3XX3, 069.3XX4, 069.3XX5, 069.3XX9, 069.4XX0, 069.4XX1, 069.4XX2, 069.4XX3, 069.4XX4, 069.4XX5, 069.4XX9, 069.5XX0, 069.5XX1, 069.5XX2, 069.5XX3, 069.5XX4, 069.5XX5, 069.5XX9, 069.81X0, 069.81X1, 069.81X2, 069.81X3, 069.81X4, 069.81X5, 069.81X9, 069.82X0, 069.82X1, 069.82X2, 069.82X3, 069.82X4, 069.82X5, 069.82X9, O69.89X0, O69.89X1, O69.89X2, O69.89X3, O69.89X4, O69.89X5, O69.89X9, O69.9XX0, O69.9XX1, O69.9XX2, O69.9XX3, O69.9XX4, 069.9XX5, 069.9XX9, 070.0, 070.1, 070.20, 070.21, 070.22, 070.23, 070.3, 070.4, 070.9, 071.0, 071.2, 071.3, 071.1, 071.2, 071.3, 071.4, 071.4, 071.5, 071.6, 071.7, 071.81, 071.82, 071.89, 071.9, 072.0, 072.1, 072.2, 072.3, 073.0, 073.1, 074.0, 074.1, 074.2, 074.3, 074.4, 074.5, 074.6, 074.7, 074.8, 074.9, 075.0, 075.1, 075.2, 075.3, 075.4, 075.5, 075.81, 075.82, 075.89, 075.9, 076.0, 077.0, 077.1, 077.8, 077.9, 082.0, 085.0, 086.0, 086.1, 086.2, 086.3, 086.4, 086.9, 086.11, 086.12, 086.13, 086.19, 086.20, 086.21, 086.22, 086.29, 086.4, 086.81, 086.89, 087.0, 087.1, 087.2, 087.3, 087.4, 087.8, 087.9, 088.11, 088.12, 088.13, 088.19, 088.2, 088.3, 088.111, 088.112, 088.113, 088.119, 088.12, 088.13, 088.211, 088.212, 088.213, 088.219, 088.22, 088.23, 088.311, 088.312, 088.313, 088.319, 088.32, 088.33, 088.811, 088.812, 088.813, 088.819, 088.82, 088.83, 089.1, 089.9, 089.1, 089.2, 089.3, 089.4, 089.5, 089.6, 089.8, 089.9, 090.0, 090.1, 090.2, 090.3, 090.4, 090.5, 090.6, 090.81, 090.89, 090.9, 091.11, 091.12, 091.13, 091.19, 091.2, 091.3, 091.111, 091.112, 091.113, 091.119, 091.12, 091.13, 091.211, 091.212, 091.213, 091.219, 091.22, 091.23, 092.11, 092.12, 092.13, 092.19, 092.2, 092.3, 092.111, 092.112, 092.113, 092.119, 092.12, 092.13, 092.20, 092.29, 092.3, 092.4, 092.5, 092.6, 092.70, 092.79, 098.11, 098.12, 098.13, 098.19, 098.2, 098.3, 098.111, 098.112, 098.113, 098.119, 098.12, 098.13, 098.211, 098.212, 098.213, 098.219, 098.22, 098.23, 098.311, 098.312, 098.313, 098.319, 098.32, 098.33, 098.411, 098.412, 098.413, 098.419, 098.42, 098.43, 098.511, 098.512, 098.513, 098.519, 098.52, 098.53, 098.611, 098.612, 098.613, 098.619, 098.62, 098.63, 098.711, 098.712, 098.713, 098.719, 098.72, 098.73, 098.811, 098.812, 098.813, 098.819, 098.82, 098.83, 098.911, 098.912, 098.913, 098.919, 098.92, 098.93, 099.11, 099.12, 099.13, 099.19, 099.2, 099.3, 099.111, 099.112, 099.113, 099.119, 099.12, 099.13, 099.210, 099.211, 099.212, 099.213, 099.214, 099.215, 099.280, 099.281, 099.282, 099.283, 099.284, 099.285, 099.310, 099.311, 099.312, 099.313, 099.314, 099.315, 099.320, 099.321, 099.322, 099.323, 099.324, 099.325, 099.330, 099.331, 099.332, 099.333, 099.334, 099.335, 099.340, 099.341, 099.342, 099.343, 099.344, 099.345, 099.350, 099.351, 099.352, 099.353, 099.354, 099.355, 099.411, 099.412, 099.413, 099.419, 099.42, 099.43, 099.511, 099.512, 099.513, 099.519, 099.52, 099.53, 099.611, 099.612, 099.613, 099.619, 099.62, 099.63, 099.711, 099.712, 099.713, 099.719, 099.72, 099.73, 099.810, 099.814, 099.815, 099.820, 099.824, 099.825, 099.830, 099.834, 099.835, 099.840, 099.841, 099.842, 099.843, 099.844, 099.845, 099.891, 099.892, 099.893, 09A.111, 09A.112, 09A.113, 09A.119, 09A.12, 09A.13, 09A.211, 09A.212, 09A.213, 09A.219, 09A.22, 09A.23, 09A.311, 09A.312, O9A.313, O9A.319, O9A.32, O9A.33, O9A.411, O9A.412, O9A.413, O9A.419, O9A.42, O9A.43, O9A.511, O9A.512, O9A.513, O9A.519, 09A.52, 09A.53, Q86.0, Q86.1, Q86.2, Q86.8, Z03.79, Z33.1, Z33.3, Z34.0, Z34.1, Z34.2, Z34.3, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93, Z36.0, Z36.1, Z36.2, Z36.3, Z36.4, Z36.5, Z36.81, Z36.82, Z36.83, Z36.84, Z36.85, Z36.86, Z36.87, Z36.88, Z36.89, Z36.8A, Z36.9, Z37.0, Z37.1, Z37.2, Z37.3, Z37.4, Z37.50, Z37.51, Z37.52, Z37.53, Z37.54, Z37.59, Z37.60, Z37.61, Z37.62, Z37.63, Z37.64, Z37.69, Z37.7, Z37.9, Z39.0, Z39.1, Z39.2, Z3A.0, Z3A.1, Z3A.8, Z3A.9, Z3A.10, Z3A.11, Z3A.12, Z3A.13, Z3A.14, Z3A.15, Z3A.16, Z3A.17, Z3A.18, Z3A.19, Z3A.20, Z3A.21, Z3A.22, Z3A.23, Z3A.24, Z3A.25, Z3A.26, Z3A.27, Z3A.28, Z3A.29, Z3A.30, Z3A.31, Z3A.32, Z3A.33, Z3A.34, Z3A.35, Z3A.36, Z3A.37, Z3A.38, Z3A.39, Z3A.40, Z3A.41, Z3A.42, Z3A.49

#### Initial comprehensive preventive medicine evaluation and management code set:

99381, 99382, 99383, 99384, 99385, 99386, 99387

Periodic comprehensive preventive medicine reevaluation and management code set:

99391, 99392, 99393, 99394, 99395, 99396, 99397

#### Mammography code set:

76641, 77046\*, 77047\*, 77048\*, 77049\*, 77053, 77054, 77061, 77062, 77063, 77065, 77066, 77067, G0279

Preventive medicine counseling and/or risk factor reduction interventions service code set:

99401, 99402, 99403, 99404

\*Mammography codes requiring prior authorization via eviCore.



## History

June 1, 2019 October 1, 2019 January 1, 2020 March 1, 2020 June 1, 2020 September 1, 2020 March 1, 2021 September 1, 2021 December 1, 2021 March 1, 2022 September 1, 2022 December 1, 2022 March 1, 2023

#### New Policy approved

Policy reviewed and approved with changes Policy reviewed and approved with changes



# Radiology

Last Reviewed Date: March 1, 2023

RADIOLOGY Policy Prior Authorization Requests Billing/Coding Guidelines History

# Policy

MVP requires authorizations for select radiology services through eviCore for all Commercial, Essential Plan and select ASO Members. When an authorization is required, this authorization applies to all Technical, Professional, Global and/or Facility claims submitted for the service. If services requiring authorization are provided without prior approval, then all claims associated with those services will be denied administratively.

MVP requires an overread by a Radiologist or a Specialist Physician within the scope of their specialty when diagnostic images are performed and read by a Primary Care Physicians, Physician Assistants and Nurse Practitioners. Physician specialists are required to have the image overread by a Radiologist if the imaging is outside the scope of their practice.

## **Prior Authorization Requests**

To determine prior authorization requirements for radiology, please refer to eviCore at evicore.com.

## **Billing/Coding Guidelines**

### Diagnostic Radiology Reading

MVP reimburses for only one reading of a diagnostic radiology test. Duplicate readings are not eligible for reimbursement.

### **Diagnostic Radiology Prior Authorization**

MVP will not reimburse for Professional, Technical, Global, and/or Facility radiology claims submitted for services that require a prior authorization in the following situations:

- Services provided when an authorization is required but there is not a valid authorization for the services obtained
- Radiology claims that require prior authorization that are submitted with a Modifier 26 for the professional reading will not be reimbursed without a valid authorization

Prior authorization for a Member can be confirmed through eviCore's website by the following steps:

- 1. Go to evicore.com
- 2. Click on Check Status of Existing Prior Authorization
- 3. Choose Search by Member Information and then choose MVP for Healthplan

| Authorization   | Lookup                                   |   |
|-----------------|--|---|
| Search by Memb  | er Information                           |   |
| REQUIRED FIELDS |  |   |
| Healthplan:     |  | • |
|                 | LIFEWISE OREGON<br>LIFEWISE WASHINGTON   | - |
| Print           | MVP                                      |   |
|                 | NEIGHBORHOOD HP OF MA<br>OSCAR<br>OXFORD |   |



4. Enter the Provider's Name and NPI and click Submit.

| Authorization I                | .ookup      |  |
|--------------------------------|-------------|--|
| Search by Member               | Information |  |
| REQUIRED FIELDS<br>Healthplan: | MVP         |  |
| Provider NPI or TIN:           |             |  |
| Office or Physician Nan        | ne:         |  |
|                                | SUBMIT      |  |

5. Enter the Members information, the MVP Member ID and DOB (MM/DD/YYYY) or the Authorization number if you have it. Click *Search*.

| Search by Member Info     | rmation    |   |
|---------------------------|------------|---|
| REQUIRED FIELDS           |            |   |
| Healthplan:               | MVP        | ٣ |
| Provider NPI or TIN:      |            |   |
| Office or Physician Name: |            |   |
| Patient ID:               |            |   |
| Patient Date of Birth:    |            |   |
|                           | MM/DD/YYYY |   |
| OPTIONAL FIELDS           |            |   |
| Case Number:              |            |   |
| or                        |            |   |
| Authorization Number:     |            |   |

Results will be returned for all authorization requests and approvals will be displayed for the Member. The Authorization number, the status (pended, approved, or denied), the approval date, the expiration date of the authorization and the authorized procedures will be displayed. If records are not returned the Member does not have an authorization for the service.

## History

| September 1, 2018                 | New policy, approved  |
|-----------------------------------|---|
| September 1, 2020                 | Policy reviewed and approved with no changes  |
| December 1, 2021                  | Policy reviewed and approved with no changes  |
| March 1, 2022                     | Policy reviewed and approved with changes   |
| March 1, 2023                     | Policy reviewed and approved with no changes  |
| December 1, 2021<br>March 1, 2022 | Policy reviewed and approved with no changes<br>Policy reviewed and approved with changes |



# Radiopharmaceuticals

Last Reviewed Date: September 1, 2022

### RADIOPHARMACEUTICALS

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines For Medicare Claims History

## Policy

Radiopharmaceuticals will be paid by either billed charges or by invoice, depending on the product and the billed charges.

## **Definitions**

Radiopharmaceuticals are used in nuclear medicine and molecular imaging.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## **Billing/Coding Guidelines**

| For Commercial, Exchange, and Medicaid Claims. Codes will be paid up to \$100 without an invoice |   |  |
|--|---|--|
| A9541  | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries          |  |
| A9560  | Technetium tc-99m labeled red blood cells, diagnostic, per study dose, up to 30 millicuries |  |
| The follo  | wing Radiopharmaceutical codes will be paid up to \$160 without an invoice                  |  |
| A9500  | Technetium te-99m sestamibi, diagnostic, per study dose                                     |  |
| The follo  | wing Radiopharmaceutical codes will be paid up to \$160 without an invoice                  |  |
| A9502  | Technetium tc-99m tetrofosmin, diagnostic, per study dose                                   |  |
| A9505  | Thallium tl-201 thallous chloride, diagnostic, per millicurie                               |  |
| A9538  | Technetium tc-99m pyrophosphate, diagnostic, per study dose, up to 25 millicuries           |  |
|  |   |  |
| The follo  | wing Radiopharmaceutical codes will be paid up to \$250 without an invoice                  |  |
| The follo  | Technetium tc-99m mertiatide, diagnostic, per study dose, up to 15 millicuries              |  |

# The following Radiopharmaceutical codes will not be reimbursed as they are considered inclusive of the procedure:

A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries

Any other Radiopharmaceutical code not on the above tiers with a billed charge of over \$50 will require an invoice.



## **For Medicare Claims**

Radiopharmaceutical codes that are billed less than \$50 will be reimbursed at 100 percent of the charges. An invoice is required for any billed charge over \$50. If an invoice is not submitted, we will pay at a reasonable and customary rate as set by MVP. If the reasonable and customary rate does not meet the invoice cost, a CARF can be submitted with the invoice.

## **History**

December 1, 2020Policy reviewed and approved with changesSeptember 1, 2022Policy reviewed and approved with no changes



# Robotic and Computer Assisted Surgery

Last Reviewed Date: September 1, 2021

ROBOTIC AND COMPUTER ASSISTED SURGERY Policy Definitions Notification/Prior Authorization Billing/Coding Guidelines Reimbursement Guidelines Notification/Prior Authorization Requests References History

# Policy

*Robotic and Computer Assisted Surgery* refers to the use of surgical robots, and computer-assisted devices to facilitate manipulation, positioning, and control of instrumentation during a variety of surgical procedures. These devices are used at the discretion of a surgeon.

## Definitions

Computer-assisted navigation devices may be image-based or non-image-based. Imaged-based devices use preoperative computed tomography scans, and operative fluoroscopy to direct implant positioning. Newer non-image-based devices use information obtained in the operating room, typically with infrared probes.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## **Billing/Coding Guidelines**

| CPT Codes | Guidelines  |
|-----------|---|
| 0054T     | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images        |
| 0055T     | Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images              |
| 20985     | Computer-assisted surgical navigational procedure for musculoskeletal procedures, image-less  |
| S2900     | Surgical techniques requiring use of robotic surgical system  |
| 31627     | Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with computer-assisted, image-<br>guided navigation |
| 61781     | Stereotactic computer-assisted (navigational) procedure; cranial, intradural  |
| 61872     | Stereotactic computer-assisted (navigational) procedure; cranial, extradural  |
| 61783     | Stereotactic computer-assisted (navigational) procedure; spinal   |



## **Reimbursement Guidelines**

MVP provides coverage for surgical procedures that are medically necessary and meet the criteria in MVP Medical Policies. The use of specific surgical techniques, instrumentation, and surgical approaches is left to the discretion of the surgeon. MVP does not provide additional professional or technical reimbursement for use of robotic, or computer assisted instrumentation utilizing CPT codes 0054T, 0055T, 20985, 31627, 61781, 61782, 61783 and S2900 because payment is included in the reimbursement for the primary procedure. CPT-4 or HCPC Level II Codes indicating robotic surgical system(s) or computer-assisted navigation will be denied as inclusive or global as they are not eligible for separate payment. This policy applies to both professional and facility providers.

Use of Modifier 22 (increased procedural services) appended to the primary surgical procedure is not appropriate if used exclusively for the purpose of reporting the use of robotic assistance. Modifier 22 may only be used when substantial additional work is performed, (ie, increased intensity, time, technical difficulty of procedure, severity of patient's condition, and physical and mental effort required) that is unrelated to robotic assistance.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## References

- 1. Functional outcomes following total knee arthroplasty: A randomized trial comparing computer-assisted surgery with conventional techniques. Knee. Hoppe S, Mainzer JD, Frauchiger L. March 2014
- 2. More accurate component alignment in navigated total knee arthroplasty has no clinical benefit at 5-year follow-up. Acta Orthop. Hoppe S, Mainzer JD, Frauchiger L. December 2012
- 3. Computer-assisted surgical navigation does not improve the alignment and orientation of the components in total knee arthroplasty. J Bone Joint Surg Am. Kim YH, Kim JS, Choi Y. January 2009
- 4. Computer-navigated versus conventional total knee arthroplasty a prospective randomized trial. J Bone Joint Surg Am. Kim YH, Park JW, Kim JS. November 2012
- 5. Robotic surgery. A current perspective. Annals of Surgery. Lanfranco, AR, Castellanos, AE, Desai, JP, Meyers, WC. January 2004
- 6. No difference between computer-assisted and conventional total knee arthroplasty: five-year results of a prospective randomized study. Knee Surg Sports Traumatol Arthrosc. Lutzner J, Dexel J, Kirschner S. October 2013
- 7. Practice Management. So, you think you want a robot: Analyzing cost and implementation. The Female Patient. Swisher E, MD; Weiss PM, MD; Scribner Jr. July 2011.
- 8. Advantages and limits of robot-assisted laparoscopic surgery: preliminary experience. Surg Endosc. Corcione F, Esposito C, Cuccurullo D, et al. January 2005

### History

| June 1, 2021      | Policy approved                           |
|-------------------|---|
| September 1, 2022 | Policy reviewed and approved with changes |



# Services Not Separately Reimbursed

Last Reviewed Date: December 1, 2022

### SERVICES NOT SEPARATELY REIMBURSED Policy Notification/Prior Authorization Requests

Notification/Prior Authorization Requests Reimbursement Guidelines History

# Policy

MVP follows Claims EXT edits for services that are not reimbursed distinctly and separately. In addition, MVP does not reimburse separately for the services that fall under the categories listed below; these services are inclusive in other payments made by MVP.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

## **Reimbursement Guidelines**

Services and CPT codes that are considered inclusive and are not separately reimbursed include but are not limited to:

| Category  | CPT Codes   |
|---|---|
| Care Management Services (including care planning, care plan<br>oversight, assessment, care management home visits, and<br>medication therapy management)                       | 99366, 99367, 99368, G0076, G0077, G0078, G0079, G0080,<br>G0081, G0082, G0083, G0084, G0085, G0086, G0087, G0088,<br>G0089, G0090, G2215, G2216, 99339, 99340, 99379, 99380, |
| Note: Facilities that have been identified by MVP as a Health<br>Home Health Home will be reimbursed separately for these<br>services as outlined by New York State Guidelines. | S0315, S0316, S0317, S0320, S0280, S0281, 99605, 99606,<br>99607, G0506, G9001, G9005, T2022  |
| Chronic Care Management   | 99424, 99425, 99426, 99427, 99437, 99439, 99487, 99489,   |
| Note: Chronic Care Management will be reimbursed separately for Medicare plans.   | 99490, 99491  |
| Bundled Payments for Care Improvement Advanced  | G9978, G9979, G9980, G9981, G9982, G9983, G9984, G9985,<br>G9986, G9987   |
| Results/Data Collection & Review  | 99090, 93793, G0452   |
| Informational Codes   | 0001F - 9999F, G2173 - G2211, M1146 - M1149   |
| Review of Medical Records   | 99358, 99359, \$9981, \$9982  |
| Miscellaneous Special Services Procedures and Reports   | P9603, P9604, H0048, S3600, S3601, 99000, 99001, 99002,<br>99024, 99070, 99080, S8415, 99091, 99098, 98969, 98961,<br>98962, S2900, Q0511, Q0512, Q0513, S5000, S5001         |
| On Call & Standby Service   | 99026, 99027, 99360   |



# History

| September 1, 2019 | Policy approved                              |
|-------------------|--|
| June 1, 2020      | Policy reviewed and approved with no changes |
| June 1, 2021      | Policy reviewed and approved with changes    |
| December 1, 2022  | Policy reviewed and approved with changes    |



# Speech Therapy (ST)

Last Reviewed Date: June 1, 2022

#### SPEECH THERAPY (ST)

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Non-Reimbursable PT Services Medicare Therapy Cap Reimbursement Guidelines References History

## Policy

Speech therapy is reimbursed when performed by an appropriate health care provider for the treatment of a severe impairment of speech/language and an evaluation has been completed by a certified speech-language pathologist that includes age-appropriate standardized tests that measure the extent of the impairment, performance deviation, and language and pragmatic skills assessment levels.

Speech therapy is also reimbursed when prescribed for a course of voice therapy by an appropriate health care provider for a significant voice disorder that is the result of anatomic abnormality, neurological condition, injury (e.g., vocal nodules or polyps, vocal cord paresis or paralysis, paradoxical vocal cord motion) or provided after vocal cord surgery.

## Definitions

Speech therapy is the treatment of defects and disorders of speech and language disorders. Prior to the initiation of speech therapy, a comprehensive evaluation of the patient and his or her speech and language potential is generally required before a full treatment plan is formulated.

Speech therapy services should be individualized to the specific communication needs of the patients. They should be provided one-to-one by a speech-language pathologist educated in the assessment of speech and language development and the treatment of language and speech disorders. A speech-language pathologist can offer specific strategies, exercises, and activities to regain function communication abilities.

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

The following CPT codes are covered for Speech Therapy providers:

| CPT Code | Description  |
|----------|--|
| 92507    | Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual |
| 92521    | Evaluation of speech fluency (e.g., stuttering, cluttering)  |



| CPT Code | Description   |  |  |  |
|----------|---|--|--|--|
| 92522    | Evaluation of speech sound production (e.g., articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (e.g., receptive and expressive language)   |  |  |  |
| 92523    | Evaluation of speech sound production (e.g., articulation, phonological process, apraxia, dysarthria); with evaluation of language comprehension and expression (e.g., receptive and expressive language)   |  |  |  |
| 92524    | Behavioral and qualitative analysis of voice and resonance  |  |  |  |
| 92526    | Treatment of swallowing dysfunction and/or oral function for feeding  |  |  |  |
| 92609    | Therapeutic services for the use of speech-generating device, including programming and modification  |  |  |  |
| 92610    | Evaluation of oral and pharyngeal swallowing function   |  |  |  |
| 92611    | Motion fluoroscopic evaluation of swallowing function by cine or video recording  |  |  |  |
| 92612    | Flexible endoscopic evaluation of swallowing by cine or video recording;  |  |  |  |
| 92626    | Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour  |  |  |  |
| 92627    | Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); each additional 15 minutes  |  |  |  |
| 92630    | Auditory rehabilitation; prelingual hearing loss  |  |  |  |
| 92633    | Auditory rehabilitation; post lingual hearing loss  |  |  |  |
| 96105    | Assessment of aphasia (includes assessment of expressive and receptive<br>speech and language function, language comprehension, speech production<br>ability, reading, spelling, writing, eg, by Boston Diagnostic Aphasia<br>Examination) with interpretation and report, per hour |  |  |  |
| G0153    | Services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes  |  |  |  |
| S9128    | Speech therapy, in the home, per diem   |  |  |  |
| S9152    | Speech therapy, re-evaluation   |  |  |  |

For reimbursement of DME supplies, please see the Utilization Management policy in the PRM for dispensing guidelines and code coverage.

## Non-Reimbursable Speech Therapy Services

- Any computer-based learning program for speech or voice training purposes
- School speech programs
- Speech or voice therapy that duplicates services already being provided as part of an authorized therapy program through another therapy discipline (e.g., occupational therapy)
- Group speech or voice therapy (because it is not one-on-one, individualized to the specific person's needs, code 92508)



- Maintenance programs of routine, repetitive drills/exercises that do not require the skills of a speechlanguage therapist and that can be reinforced by the individual or caregiver
- Vocational rehabilitation programs and any programs with the primary goal of returning an individual to work
- Therapy or treatment provided to prevent or slow deterioration in function or prevent reoccurrences
- Therapy or treatment intended to improve or maintain general physical condition
- Therapy or treatment provided to improve or enhance job, school or recreational performance
- · Long-term rehabilitative services when significant therapeutic improvement is not expected
- Laryngoscopy, flexible or rigid telescopic, with stroboscopy (CPT 31579) is a diagnostic procedure to be performed by a physician. It may not be performed by a speech-language pathologist.

## **Medicare Therapy Cap**

There is a combined annual per beneficiary therapy cap amount for physical therapy and speech language pathology services combined and a separate amount allotted for occupational therapy services. The amount of the cap is determined by CMS and may change periodically.

The therapy cap with an exceptions process applies to services furnished in the following outpatient therapy settings: physical therapists in private practice, physician offices, skilled nursing facilities (Part B), rehabilitation agencies (or ORFs), comprehensive outpatient rehabilitation facilities (CORFs), and outpatient hospital departments.

The provider should use the KX modifier to the therapy procedure code that is subject to the cap limits only when a beneficiary qualifies for a therapy cap exception. The KX modifier should not be used prior to the Member meeting their therapy cap. By attaching the KX modifier, the provider is attesting that the services billed:

- Qualified for the cap exception
- Are reasonable and necessary services that require the skills of a therapist and
- Are justified by appropriate documentation in the medical record.

Claims for patients who meet or exceed the annual Medicare stated therapy service threshold in therapy expenditures will be subject to a manual medical review.

### **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

### References

MVP Utilization Management Policy, Provider Resource Manual

### History

| March 1, 2019 | Policy approved                              |
|---------------|--|
| March 1, 2021 | Policy reviewed and approved with no changes |
| June 1, 2022  | Policy reviewed and approved with changes    |



# Surgical Supplies

Last Reviewed Date: September 1, 2022

# SURGICAL SUPPLIES

Policy Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines References History

# Policy

MVP follows CMS guidelines and does not reimburse for surgical supplies (except Splinting and Casting) separate from the Evaluation and Management and/or Procedure codes when billed at the professional level. These supplies are bundled into the practice expense RVU and will not be reimbursed when billed with the E&M/procedure code or as a stand-alone service.

# Definitions

The Practice Expense (PE) RVU reflects the costs of maintaining a practice. PE RVU includes but is not limited to:

- Medical and/or Surgical Supplies (i.e. surgical trays, syringes, saline irrigation or flush supplies, dressings, and gloves)
- Staff Costs
- Renting office space and expenses incurred to run the office (i.e. furniture, utilities, office supplies)
- Purchasing and maintaining equipment

## **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

| Code  | Description   | Rule   |
|-------|---|--|
| A4550 | Surgical Trays  | <ul> <li>Surgical Trays are not reimbursable when billed at the professional level.</li> <li>Surgical trays are considered part of the practice expense RVU for E&amp;M and procedure codes.</li> </ul>        |
| A4263 | Permanent, long-term,<br>non-dissolvable lacrimal<br>duct implant | <ul> <li>Lacrimal duct implants are not reimbursable when billed at the professional level.</li> <li>Surgical trays are considered part of the practice expense RVU for E&amp;M and procedure codes</li> </ul> |

## References

CMS Regulations and Guidance: <u>cms.gov/Regulations-and-Guidance/Guidance/Manuals/downloads/clm104c12.pdf</u>

CMS Medicare Physician Fee Schedule Fact Sheet:

cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/ medcrephysfeeschedfctsht.pdf



# AMA – Medicare Physician Payment Schedules:

ama-assn.org/practice-management/medicare-physician-payment-schedules

# History

| September 1, 2019 | Policy approved                              |
|-------------------|--|
| June 1, 2020      | Policy reviewed and approved with no changes |
| June 1, 2021      | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



#### **MVP Health Care Payment Policy**

# Telehealth

Last Reviewed Date: May 11, 2023 Related Policies: Modifier Payment Policy Provider Responsibilities Virtual Check-in Payment Policy

#### Telehealth

Policy Billable Code and Descriptions References History

# Policy

MVP will reimburse for Telehealth Services, which are live audio-only or audio-visual services provided through electronic information and communication devices to patients at a site (originating site) that is not the same as the Provider (distant site), and for Telemedicine Services through MyVisitNow<sup>®</sup> or Gia Urgent Care. This policy serves as a guide to assist you in accurate telehealth claims submissions for Medicare, Medicaid, Health, and Recovery Plan ("HARP"), Essential Health Plans, Child Health Plus and Commercial plans, and is not meant to be an exhaustive list for every payment scenario. Guidance from federal and state authorities may be updated from time to time, but links are provided below to assist in maintaining the most updated guidance. Definitions related to Telehealth can be found in the applicable statute, regulation and/or guidance. Reimbursement guidance for Virtual Check-ins can be found in the MVP Virtual Check-in Payment Policy.

# **Billable Codes and Descriptions**

#### Professionals

The following Place of Service Codes should be used when billing for Telehealth Services on Professional Claims:

| Place of Service | Description   |
|------------------|---|
| Code             |   |
| 02               | Telehealth is provided at in a setting other than the home of the patient                             |
| 10               | Telehealth is provided in the home of the patient (including residence, shelter or temporary housing) |

### Modifiers

The following Modifiers should be used when billing for Telehealth Services to the extent applicable:

| Modifier | Description  |
|----------|--|
| 93       | Synchronous Telehealth services rendered via telephone or other real-time interactive audio-only telecommunications systems (i.e., audio-only). NOTE: Modifier 93 is to be used for all audio-only services, including mental health services furnished via audio-only. For RHCs, FQHCs and OTPs, modifier 93 must be used, but modifier FQ should be used as well when services are furnished in such settings. |
| 95       | Synchronous Telehealth services rendered via real-time interactive audio and video telecommunications systems (i.e., audio-video)  |
| FQ       | Telehealth service was furnished using real-time audio-only communication technology. For RHCs, FQHCs and OTPs, this modifier must be used in conjunction with modifier 93   |
| FR       | A supervising practitioner was present through a real-time two-way, audio/video communication technology   |
| GQ       | Telehealth services provided via asynchronous telecommunication system (store and forward technology)  |
| GT       | Telehealth services provided via interactive audio and video telecommunication systems.  |
| 25       | Significant, separately identifiable E&M service by the same physician or other qualified health care professional on the same day as a procedure or other services. For example, the Member has a psychiatric consultation via  |

|    | telemedicine on the same day as a primary care E&M visit at the originating site. The E&M service should be appended with the 25 modifier. |
|----|--|
| HD | Used with maternal remote patient monitoring; denotes pregnant/postpartum services   |

## Medicare, Essential Health Plans, and Commercial Plans

MVP will reimburse for covered Telehealth Services and in compliance with the CMS <u>List of Telehealth Services for</u> <u>each calendar year</u>, including audio-only services. However, audio-video services are highly encouraged over audio-only services for quality of care. MVP also encourages the Provider to notate the reason for the services to be audio-only and any Member preference for providing audio-only services.

## Medicaid, HARP, and Child Health Plus

MVP pays for Telehealth Services for Medicaid, HARP and Child Health Plus Members in accordance with guidance provided by NY Department of Health, Office of Mental Health (OMH), Office of Persons With Developmental Disabilities (OPWDD), and Office of Alcohol and Substance Abuse Services (OASAS). Telehealth Services include audio-visual services, store and forward technology, remote patient monitoring, after-hours services, virtual check-ins, virtual patient education, and in for certain Providers, virtual eTriage. Telehealth Services provided through audio-only should only be used in rare occasions to meet the personalized needs of each Member and in compliance with the most current guidelines developed by the NY Department of Health, which can be found on their website or viewed here: <u>New York State Medicaid Update - February 2023 Volume 39 - Number 2 (ny.gov)</u>

For Medicaid products, licensed physicians or Nurse Practitioners may bill for Telehealth Services provided in an Article 28 Facility setting; however, the APG payment for all other Telehealth providers providing Telehealth services in an Article 28 Facility setting are included in MVP's APG payment to the Article 28 Facility.

# Additional Billable Codes and Descriptions

In addition to the CMS allowable Place of Service Codes and Modifiers above, the NY Department of Health separately provides the following Billable Codes and Descriptions applicable to Medicaid, HARP, and Child Health Plus programs.

| Services   | Codes                  | Description   | Notes   |
|--|------------------------|---|---|
| Tele-dentistry                                       | D9995                  | Synchronous tele-dentistry services using<br>audio-visual technology; can include urgent<br>visits, follow-up visits, and new patient<br>screening                                    | Modifier cannot be used.  |
| Tele-dentistry                                       | D9996                  | Asynchronous transmission of recorded health information (store and forward technology)   | Modifier cannot be used.  |
| Telehealth Facility (including<br>Teledentistry)     | Q3014                  | Originating Site Facility Fee   | For facilities only; Only facilities<br>should use this code and the<br>Member must be physically<br>present in the originating facility<br>to receive reimbursement. |
| Remote Patient Monitoring                            | 99091                  | Collection and interpretation of physiologic<br>data (e.g., ECG, blood pressure, glucose<br>monitoring)   | Can only be billed one time per<br>Member per month.  |
| Remote Patient Monitoring<br>(Pregnancy/Post-partum) | 99453 + HD<br>modifier | Remote monitoring of physiologic parameters<br>(e.g., weight, blood pressure, pulse oximetry,<br>respiratory flow rate) initial; set-up and patient<br>education on use of equipment. | One-time billing of service.  |

| Remote Patient Monitoring<br>(Pregnancy/Post-partum) | 99454+HD | Device(s) supply with daily recording(s) or<br>programmed alert(s) transmission, each 30<br>days. Every 30 days when a minimum of 16<br>days of data is collected within the 30-day<br>period.  | This is a once per 30-day fee<br>regardless of the number of<br>devices used to monitor the<br>pregnant/post-partum individual.<br>NOTE: 99454 and 99091 cannot<br>be billed on the same day. FQHCs<br>that have opted out of APGs are<br>unable to bill for RPM services  |
|--|----------|---|--|
| After-Hours  | 99050    | Services provided in the office at times other<br>than regularly scheduled office hours, or days<br>when the office is normally closed (e.g.,<br>holidays, Saturday or Sunday), in addition to<br>basic service.  | Bill with modifiers 93, 95, GT or<br>FQ as appropriate. Please review<br>the MVP After-Hours Payment<br>Policy for additional information<br>on this service.  |
| After-Hours  | 99051    |   | Bill with modifiers 93, 95, GT or<br>FQ as appropriate. Please review<br>the MVP After-Hours Payment<br>Policy for additional information<br>on this service.  |
| Virtual Check-In                                     | G2012    | Brief communication technology-based<br>service by a physician or other qualified health<br>care professional who can report E&M<br>services, not originating from a related E&M<br>service provided within the previous seven<br>days nor leading to a E&M service or<br>procedure within the next 24 hours or soonest<br>available appointment; 5 to 10 minutes of<br>medical discussion.                 | Bill with modifiers 93, 95, FQ, GT<br>and GQ as appropriate.   |
| Virtual Check-In                                     | G2252    | Brief communication technology-based<br>service by a physician or other qualified health<br>care professional who can report E&M<br>services, not originating from a related E&M<br>service provided within the previous seven<br>days nor leading to a E&M service or<br>procedure within the next 24 hours or soonest<br>available appointment; <i>11 to 20 minutes of</i><br><i>medical discussion</i> . | Bill with modifiers 93, 95, FQ, GT<br>and GQ as appropriate  |
| Virtual Patient Education                            | 0403T    | Preventive behavior change, intensive<br>program of prevention of diabetes using a<br>standardized diabetes prevention program<br>curriculum, provided to individuals in a group<br>setting, minimum 60 minutes, per day  | Bill with modifiers 95 and GT as appropriate   |
| Virtual Patient Education                            | 0488T    | Preventive behavior change, online/electronic<br>structured intensive program for prevention of<br>diabetes using a standardized diabetes<br>prevention program curriculum, provided to<br>an individual, per 30 days.  | Coaches must be able to track<br>participant progress through<br>online modules. To bill, the<br>patient must complete a<br>minimum of three sessions per<br>month and adhere to the CDC<br>guidelines regarding coaching<br>support (no less than once per<br>week first six months and no less<br>than once per month next six<br>months); No applicable modifiers |
| Virtual Patient Education                            | D1320    | Tobacco counseling for the control and<br>prevention of oral disease. Billable only as an<br>individual session, greater than 3 minutes.  | Bill with modifiers 95 and GT as appropriate   |

| Virtual Emergency eTriage  | Base rate<br>procedure<br>code + A0425<br>(milage code)<br>+ modifier | This permits ambulance companies<br>responding to 911 calls to provide treatment<br>in place or transport patients to destinations<br>other than the emergency room. Providers<br>must be approved to participate in both the<br>CMS ET3 model AND the NYS DOH parallel<br>model in order to bill for this service. | Use the following destination<br>modifier as appropriate:<br>C – Community Mental Health Ctr<br>(including substance use disorder<br>Ctr)<br>F – FQHC<br>O – Physician's office<br>U – Urgent care<br>W – Treatment in place by a<br>licensed healthcare practitioner<br>either in person or via telehealth<br>(no mileage permitted with this<br>modifier) |
|--|---|---|---|
| All Other Services, including audio-<br>only and additional patient<br>education codes |   | See <u>List of Telehealth Services   CMS</u>  |   |

## **Allowable Telehealth Platforms**

Authorized Providers who deliver Telehealth Services must use non-public facing communication technologies and/or platforms that comply with the HIPAA rules.

## **Remote Patient Monitoring (RPM)**

Remote Patient Monitoring (RPM) may be utilized as Telehealth Services when medically necessary to monitor Members with certain health conditions and must be discontinued when their condition is determined to have stabilized. RPM must be ordered by a New York licensed physician, nurse practitioner or midwife who has examined the Member and with whom the Member has an established, documented, and ongoing relationship. Member health information or data may be received at the Distant Site by a New York licensed registered nurse. While ordering RPM, the Provider must see the Member in-person, as needed, for follow-up care.

Certified Home Health Agencies ("CHHA") are ineligible to provide RPM Telehealth Services to a Member if they are receiving home health care services through the CHHA.

## **OMH Specific Requirements**

Providers licensed by the Office of Mental Health (OMH) or listed as a designated Provider, must follow current <u>OMH</u> guidelines for <u>Telehealth Services</u>, including but not limited to obtaining approval to use telehealth. Additional criteria and information specific to OMH Providers are listed in the OMH guidelines referenced above.

Billing for services by an OMH licensed or designated provider follows the NY Department of Health Guidelines and the billing instructions listed above for Medicaid, HARP and Child Health Plus.

## **DEA Specific Extension of COVID-19 Flexibilities**

In response to the expiration of the COVID-19 Public Health Emergency, the Drug Enforcement Agency (DEA) with the U.S. Department of Health and Human Services and the Substance Abuse and Mental Health Services Administration have issued a <u>temporary extension of COVID-19 flexibilities for prescription of certain controlled</u> <u>medications</u>. Through November 11, 2023, or until further regulatory notice, authorized Providers may use Telehealth Services to prescribe controlled medications, including but not limited to buprenorphine for the treatment of opioid use disorder, without the requirement of an in-person evaluation.

For Provider-patient relationships that have been established and using Telehealth Services before the extension deadline of November 11, 2023, the DEA will further allow the COVID-19 flexibilities for an additional twelve (12) months (or, November 11, 2024).

After any such extension date(s), Providers must again comply with the Ryan Haight Online Pharmacy Consumer Protection Act of 2008.

## Vermont Specific Requirements for Audio-Only Services

For billing requirements specific to audio-only services in Vermont, please refer to the MVP Audio-Only (Vermont Only)" Payment Policy.

## **Additional information:**

Tele-dentistry: <u>New York State Medicaid Update February 2019 Special Edition Volume 35 Number 2 (ny.gov); New</u> <u>York State Medicaid Update January 2020 Volume 36 Number 1 (ny.gov)</u> Maternal Remote Patient Monitoring: <u>New York State Medicaid Update September 2022 Volume 38 Number 10</u> (<u>ny.gov)</u> Emergency Virtual eTriage: <u>New York State Medicaid Update November 2021 Volume 37 Number 13 (ny.gov)</u> More information on physician fee schedules can be found at the following CMS sites: <u>Physician Fee Schedule | CMS</u>

Medicare payment policies during COVID-19 | Telehealth.HHS.gov List of Telehealth Services | CMS

## **Exclusions**

The following services are excluded from services:

- eConsults, which are interprofessional consultations between a treating/requesting Provider with a consulting Provider, without a member present, are currently not reimbursable
- The acquisition, installation and maintenance of telecommunication devices or systems is not reimbursable
- Electronic mail messages, text messages or facsimiles are not reimbursable telehealth services
- Telehealth services during which all or part of the service was undeliverable due to a failure of transmission or other technical difficulty
- Services where the originating site and the distant site are the same location
- Facility fees when neither the originating site or the distant site is a clinic or facility
- Individual Practitioner Services for Individuals with Developmental Disabilities (IPSIDD)

# References

Physician Fee Schedule | CMS Medicare payment policies during COVID-19 | Telehealth.HHS.gov List of Telehealth Services | CMS New York State Medicaid Update - February 2023 Volume 39 - Number 2 (ny.gov) Telehealth Services Guidance for OMH Providers - April 2023 (ny.gov) Vermont Telemedicine Requirements 42 USC §1395m(m) 42 CFR §410.78 42 CFR §422.135 New York Insurance Law §§ 3217-h, 4306-g; New York Public Health Law §§ 2999-cc; 2999-dd; 14 N.Y.C.R.R. Parts 538 (Medicaid reimbursement); 596 (OMH); Parts 679, 635 (OPWDD); Part 830 (OASAS); and 585.28 (CDPAS)

# History

| September 1, 2018 | New Policy, approved            |
|-------------------|---------------------------------|
| December 1, 2019  | Reviewed, approved with changes |
| July 1, 2022      | Reviewed, approved with changes |
| September 1, 2022 | Reviewed, approved with changes |
| May 11, 2023      | Reviewed, approved with changes |



# Transitional Care Management

Medicare Advantage Products Only

Last Reviewed Date: March 1, 2023

### TRANSITIONAL CARE MANAGEMENT Policy Definitions

Definitions Notification/Prior Authorization Requests Billing/Coding Guidelines Reimbursement Guidelines References History

# Policy

Transitional Care Management (TCM) services are for a patient whose medical and/or psychosocial problems require moderate- or high-complexity medical decision making during transitions in care from an inpatient hospital setting (including acute hospital, rehabilitation hospital, long-term acute care hospital, inpatient psychiatric hospital), partial hospital, observation status in a hospital, or skilled nursing facility (SNF)/nursing facility to the patient's community setting (e.g., home, domiciliary, nursing facility or assisted living facility). TCM services begin on the date of patient discharge and continues for the next 29 days.

TCM services are reimbursable only for the MVP Medicare Advantage products. All other products do not include TCM services as a Covered Benefit.

# Definitions

TCM services includes one face-to-face visit within the specified time frames, in combination with non-face-to-face services that may be performed by the physician or other qualified health care professional and/or licensed clinical staff under his or her direction. Members may receive the following TCM services via telehealth as per Medicare guidelines.

Below are the two CPT TCM codes and their related requirements:

| 99495 | <ul> <li>Transitional Care Management Services (Moderate Complexity):</li> <li>Communication (direct contact, telephone, electronic) with the patient and/or caregiver within two (2) business days post-discharge.</li> <li>Medical decision making of at least moderate complexity during the service period.</li> <li>Face-to-face visit, within 14 calendar days post-discharge.</li> </ul> |
|-------|---|
| 99496 | <ul> <li>Transitional Care Management Services (High Complexity):</li> <li>Communication (direct contact, telephone, electronic) with the patient and/or caregiver within two (2) business days post-discharge.</li> <li>Medical decision making of high complexity during the service period.</li> <li>Face-to-face visit, within 7 calendar days post-discharge.</li> </ul>                   |

# **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must confirm Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into the Provider's account at <u>mvphealthcare.com</u>.



### **Billing/Coding Guidelines**

TCM services are only reimbursable only for a MVP Medicare Advantage products.

The CPT TCM codes can be billed only once per patient within 30 days after the original patient discharge for which a TCM code has been billed. These services may be billed by only one individual during the 30-day period after discharge.

The physician billing for TCM services should have an ongoing relationship with the patient and the intended use of these codes is for community-based primary care physicians. It is unlikely that most hospitalists will have the postdischarge relationship with a patient necessary to fulfill the required services.

Non-physicians who may bill TCM codes are Nurse Practitioner's (NP), Physician Assistant's (PA), Clinical Nurse Specialist's (CNS), and Certified Nurse Midwives (CNM), unless they are otherwise limited by their scope of practice as defined by the state in which they are licensed and/or certified.

There is a distinction between the discharge day management and TCM services. MVP seeks to avoid any implication that the E & M services furnished on the day of discharge as part of discharge management services could be considered to meet the requirement for TCM services that must be conducted within seven (7) or 14 calendar days of discharge.

The physician billing discharge day management could also be the physician who is regularly responsible for the patient's primary care (this may be especially the case in rural communities). However, MVP will not allow both discharge and TCM services to be billed on the same day.

The CPT TCM codes may not be billed when patients are discharged to an SNF. For patients in SNFs there are separate E&M codes for initial, subsequent, and discharge care, and the visit for the annual facility assessment, Initial nursing home visits are coded with 99304-99306. Subsequent nursing home visits are coded 99307–99310.

TCM services provided during a post-surgery period for a service with a global period will not be reimbursed because such services shall be included in the payment for the underlying procedure.

Practitioners can bill for TCM services only once in the 30 days after discharge, even if the patient may be readmitted and subsequently discharged two (2) or more times within the 30-day period.

When billing for TCM services, the following cannot also be billed during the TCM period:

- Care Plan Oversight services (CPT codes 99374-99380)
- Chronic Care Management Services (CCM and TCM service periods cannot overlap)

### **Reimbursement Guidelines**

Please see your provider fee schedule or your IPA agreement for specific reimbursement guidelines.

### References

https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/Care-Management

MLN908628 August 2022 Available: <u>https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/</u> <u>mlnproducts/downloads/transitional-care-management-services-fact-sheet-icn908628.pdf</u>

American Academy of Family Physicians Transitional Care Management ©2023 Available: <u>https://www.aafp.org/family-physician/practice-and-career/getting-paid/coding/transitional-care-management.html</u>

### History

| September 1, 2018 | New policy, approved                         |
|-------------------|--|
| March 1, 2020     | Policy reviewed and approved with no changes |
| March 1, 2022     | Policy reviewed and approved with changes    |
| March 1, 2023     | Policy reviewed and approved with changes    |



# Unlisted CPT Code

Last Reviewed Date: September 1, 2022

### UNLISTED CPT CODE

Policy Definitions Billing/Coding Guidelines Notification/Prior Authorization Requests History

# Policy

MVP requires all claims submitted with non-contracted unlisted CPT code(s) to be submitted with medical records that support the use of the unlisted code. For claims submitted with an unlisted code without medical records, the claim or claim line(s) will deny and it will be the provider's responsibility to submit medical records to substantiate the unlisted code.

### Definitions

An unlisted CPT code is used for a service or procedure that is rarely provided, unusual, variable, or is a new service or procedure that does not have a more specified CPT code.

# **Billing/Coding Guidelines**

### **Unlisted CPT codes**

| Code                  | Description           | Rule  |
|-----------------------|-----------------------|---|
|                       |                       | Claims submitted with records will be reviewed and, based upon the review, the claim will be processed accordingly:   |
|                       |                       | Correct code: claim will be processed   |
| Non-<br>contracted    | Claims submitted with | <ul> <li>Correct code but requires medical necessity review: record will be<br/>reviewed as such with claim processed upon completion of review.</li> </ul>                           |
| unlisted<br>CPT codes | unlisted CPT code(s)  | <ul> <li>Incorrect CPT code assigned: The provider will receive an explanation<br/>of benefits indicating there is a more specific or more appropriate<br/>code available.</li> </ul> |
|                       |                       | <ul> <li>Claims submitted without records: The unlisted CPT code will be<br/>denied, but provider can submit medical records for review in<br/>contracted timeframes.</li> </ul>      |

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

### History

| January 1, 2018   | Policy approved                              |
|-------------------|--|
| December 1, 2019  | Policy reviewed and approved with no changes |
| June 1, 2021      | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



# Urgent Care

Last Reviewed Date: September 1, 2022

### URGENT CARE

Policy Notification/Prior Authorization Requests Billing/Coding Guidelines History

### Policy

MVP determines urgent care reimbursement to be based on coding which specifically describes the services provided. Consistent with CPT and CMS, physicians and other healthcare professionals should report the evaluation and management, and/or procedure code(s) that specifically describe the urgent care service(s) performed.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

| Code      | Description  | Rule  |
|-----------|--|---|
| E&M Codes |  | The appropriate Evaluation and Management and/or procedures<br>codes that describe the type of services performed should be billed.<br>POS Bill with Place of Service code 20 (urgent care facility)        |
| S9088     | Services provided in an<br>urgent care center<br>(list in addition to code<br>for service) | Informational only as it pertains to the place of service and not the components of the specific service(s) provided<br>MVP does not reimburse for CPT code, whether billed alone or with any other service |
| S9083     | Global fee urgent<br>care centers  | Global code which does not provide encounter level specificity<br>MVP does not reimburse for CPT code, whether billed alone or with<br>any other service  |

### History

| December 1, 2018  | Policy approved                              |
|-------------------|--|
| December 1, 2019  | Policy reviewed and approved with no changes |
| Juine 1, 2021     | Policy reviewed and approved with no changes |
| September 1, 2022 | Policy reviewed and approved with no changes |



# Vaccine Administration (Vermont Only)

Last Reviewed Date: June 1, 2022

# VACCINE ADMINISTRATION (VERMONT ONLY) Policy Definitions

Notification/Prior Authorization Requests Billing/Coding Guidelines COVID-19 Vaccine Billing Guidelines References History

# Policy

Routine immunizations are reimbursed according to Medical Policy guidelines. This policy applies to Commercial/ASO products only.

# Definitions

Vaccinations are covered in the following circumstances:

- Immunizations for children as required by the American Academy of Pediatrics and the Advisory Committee on Immunization Practices (ACIP).
- Immunizations for children and adults according to the Medical Policy guidelines if not excluded by member contract/certificate.

# **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's *Utilization Management Guides* to determine if prior authorization is required and the *Benefit Interpretation Manual* for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

# **Billing/Coding Guidelines**

Codes 90460, 90461, 90471-90474, G0008-G0010 must be reported in addition to the vaccine and toxoid code(s) to represent the administration portion of the service.

For vaccines supplied by the State of Vermont, the vaccine or toxoid code(s) must be billed with modifier "SL" to indicate the vaccine is State supplied, and the billed amount must be \$0.00 or \$0.01.

Providers are required to use G0008 and G0009 when billing for the administration of the Flu and Pneumococcal Vaccine. The following G codes should be billed for all claims:

| Code  | Description                         | ICD-10 Diagnosis |
|-------|-------------------------------------|------------------|
| G0008 | Flu Vaccine Administration          | Z23              |
| G0009 | Pneumococcal Vaccine Administration | Z23              |

These services will be denied if not submitted with the appropriate administration code, specific vaccination or toxoid code(s) and the State supplied modifier, when applicable.

Please see your provider fee schedule or IPA agreement for other billing or reimbursement guidelines.



### **COVID-19 Vaccine and Administrative Billing Guidelines**

MVP covers approved COVID-19 vaccines at no cost-share to Members in all plans. MVP will reimburse Participating Providers and out-of-network providers for the administration of the COVID-19 vaccine when the guidance below is followed when submitting for reimbursement for administration of the COVID-19 vaccine.

#### **MVP Commercial Members**

In addition to the vaccine administration code, Vermont Providers must also include the vaccine code; billed with a \$0.00 or \$0.01 charge on the claim. COVID-19 vaccines are not considered state-supplied; therefore, providers should not use the SL modifier.

| Administration Code | Short Description                            | Vaccine Code | Effective Date |
|---------------------|--|--------------|----------------|
| 0001A               | Pfizer vaccine – 1st dose                    | 91300        | 12/11/2022     |
| 0002A               | Pfizer vaccine – 2nd dose                    | 91300        | 12/11/2020     |
| 0003A               | Pfizer vaccine – 3rd dose                    | 91300        | 8/12/2021      |
| 0004A*              | Pfizer vaccine – Booster                     | 91300        | 9/22/2021      |
| 0011A               | Moderna vaccine – 1st dose                   | 91301        | 12/18/2020     |
| 0012A               | Moderna vaccine – 2nd dose                   | 91301        | 12/18/2020     |
| 0013A               | Moderna vaccine – 3rd dose                   | 91301        | 8/12/2021      |
| 0031A               | Janssen/Johnson & Johnson vaccine – 1st dose | 91303        | 2/27/2021      |
| 0034A*              | Janssen/Johnson & Johnson vaccine – Booster  | 91303        | 10/20/2021     |
| 0051A               | Pfizer ready-to-use vaccine – 1st dose       | 91305        | 9/22/2021      |
| 0052A               | Pfizer ready-to-use vaccine – 2nd dose       | 91305        | 9/22/2021      |
| 0053A               | Pfizer ready-to-use vaccine – 3rd dose       | 91305        | 9/22/2021      |
| 0054A*              | Pfizer ready-to-use vaccine – Booster        | 91305        | 9/22/2021      |
| 0064A*              | Moderna lower dose vaccine – Booster         | 91306        | 10/20/21       |
| 0071A               | Pfizer Pediatric vaccine – 1st dose          | 91307        | 10/29/2021     |
| 0072A               | Pfizer Pediatric vaccine – 2nd dose          | 91307        | 10/29/2021     |
| 0073A               | Pfizer Pediatric vaccine – 3rd dose          | 91307        | 1/3/2022       |
| 0094A*              | Moderna vaccine - Booster                    | 91309        | 3/29/2022      |

\* CDC guidance regarding eligibility for a booster dose is available at <u>https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html</u>

The administration code must match the manufacturer code of the vaccine provided at the encounter.



### **MVP Medicare Advantage Plan Members**

As of January 1, 2022, COVID vaccine administration claims for MVP Medicare Advantage members should be submitted to MVP. Providers should not include the vaccine code on the claim for Medicare Advantage members, when COVID-19 vaccine doses are provided by the government at no charge, only bill for the vaccine administration.

### References

MVP Credentialing and Recredentialing of Practitioners

State of Vermont Department of Health Immunization Information for Providers: <u>http://healthvermont.gov/hc/imm/provider.aspx</u>

State of Vermont Department of Health Vaccines for Kids Program

State of Vermont Department of Health Vaccines for Adults Program

### **History**

September 1, 2018Policy approvedDecember 1, 2019Policy reviewed and approved with no changesJune 1, 2021Policy reviewed and approved with changesJune 1, 2022Policy reviewed and approved with changes



**MVP Health Care Payment Policy** 

# Virtual Check-ins and Interpersonal Telephone/Internet/ Electronic Health Record Consultations

Virtual Check-ins and Interpersonal Telephone/Internet/ Electronic Health Record Consultation Policy Notifications/Prior Authorization Request Billing/Coding Guidelines History

#### Last Reviewed Date: May 11, 2023

Related Policies– Provider Responsibilities Telehealth Payment Policy

# Policy

MVP will reimburse Virtual Check-ins and Interprofessional Telephone/Interne/Electronic Health Record Consultations to avoid unnecessary office visits. Providers must obtain verbal consent from a Member prior to providing these services and consent must be documented in the Members chart. Providers must inform Members that these services will be subject to all Deductibles, Co-insurance, or Copay's per the Members benefits prior to providing the services. The Virtual Check-in or Interprofessional Telephone/Internet/Electronic Health Record Consultation must be medically necessary and documented in the medical record. This policy applies to MVP Commercial and Medicare products only. These codes are not reimbursable or MVP Medicaid, CHP, or HARP.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into your account at **mvphealthcare.com**.

### **Billing/Coding Guidelines**

Virtual Check-ins are reimbursed only:

| Code  | Description   | Reimbursement   |
|-------|---|---|
| G2012 | Brief communication technology-based service, e.g.,<br>virtual check-in, by a physician or other qualified health<br>care professional who can report evaluation and<br>management [E/M] services, provided to an established<br>patient, not originating from a related E/M service<br>provided within the previous 7 days nor leading to an E/M<br>service or procedure within the next 24 hours or soonest<br>available appointment; 5-10 minutes of medical<br>discussion | <ul> <li>This code can only be used with established patients of the Provider. Members must have seen the Provider in person within 3-years of the Virtual Check-in by the billing Provider or by a Provider within the Provider's group who has the same specialty, and for Providers eligible to bill for an Evaluation and Management (E/M) services</li> <li>Patients must not have been seen in the office for 7-days prior to the virtual check in or within 24hours of the virtual check in</li> </ul> |

G2010 Remote evaluation of recorded video and/or images submitted by the patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related E/M service provided within the previous 7 days nor leading to an E/M service or procedure within the next 24 hours or soonest available appointment.

- This code can only be used with established patients of the Provider. Members must have seen the Provider in person within 3-years of the Virtual Check-in by the billing Provider or by a Provider within the Provider's group who has the same specialty, and for Providers eligible to bill for an Evaluation and Management (E/M) services
- Patients must not have been seen in the office for 7-days prior to the virtual check in or within 24 hours of the virtual check in.

### **Telephone/Internet/Electronic Health Record Consultation:**

| Code  | Description   | Reimbursement   |
|-------|---|---|
| 99451 | Interprofessional telephone/internet/electronic health<br>record assessment and management service provided by<br>a consultative physician including a written report to the<br>patient's treating/requesting physician or other qualified<br>health care professional, 5 or more minutes of medical<br>consultative time.  | <ul> <li>Consultation does not lead to a transfer of care or other face-to-face services within the next 14-days (or soonest available appointment date after the consultant)</li> <li>50% or more of the time must be devoted to medical consultative verbal or internet discussion</li> </ul> |
| 99452 | Interprofessional telephone/internet/electronic health<br>record referral service(s) provided by a<br>treating/requesting physician or qualified healthcare<br>professional, 30 minutes.  | (and not a review of data)<br>Only one consultation is billed (the service should<br>be reported only once with a single code if more<br>than one contact is needed to complete the<br>consult)   |
| 99446 | Interprofessional telephone/internet assessment and<br>management service provided by a consultative physician,<br>including a verbal and written report to the patient's<br>treating/requesting physician or other qualified<br>healthcare professional;<br>5-10 minutes of medical consultative discussion and<br>review. | <ul> <li>Only one consult can be billed within a 7-day<br/>period by the consulting physician</li> </ul>  |
| 99447 | Same as CPT Code 99446, except 11-20 minutes  |   |
| 99448 | Same as CPT Code 99446, except 21–30 minutes  |   |
| 99449 | Same as CPT Code 99446, except 31 or more minutes   |   |

# **History**

December 1, 2019 December 1, 2021 September 1, 2022 May 11, 2023 Policy approved

Policy reviewed and approved with no changes

Policy reviewed and approved with no changes

Policy reviewed and approved with changes



Viscosupplementation of the Knee: Non-Coverage for Medicaid Managed Care (MMC) Plans

Policy Definitions Notification/Prior Authorization Reimbursement Guidelines Billing/Coding Guidelines Notification/Prior Authorization Requests References History

Last Reviewed Date: March 1, 2022

### Policy

Effective April 1, 2014, MVP Medicaid Managed Care (MMC) Members will be following New York State (NYS) Medicaid's limit for reimbursement for viscosupplementation of the knee. Specifically, MVP will no longer cover viscosupplementation of the knee for an enrollee with a diagnosis of osteoarthritis of the knee. All other diagnosis associated with viscosupplementation will continue to be reimbursed.

### Definitions

Viscosupplementation of the knee is a procedure in which a gel-like fluid called hyaluronic acid is injected into the knee joint. Hyaluronic acid is a natural occurring substance found in the synovial (joint) fluid. Individuals with osteoarthritis ("wear-and-tear" arthritis) of the knee have a lower-than-normal concentration of hyaluronic acid in their joints.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into the Providers account at <u>mvphealthcare.com</u>.

### **Reimbursement Guidelines**

Based on the current available evidence, for NYS Medicaid Managed Care (MMC) Plans, MVP will no longer cover viscosupplementation of the knee to a member diagnosed with osteoarthritis of the knee. This coverage decision was based on research presented which included the potential harms attached to viscosupplementation (including joint infection, hematoma, inflammation), and the fact that viscosupplementation is only marginally effective in practice.

### **Billing/Coding Guidelines**

The following ICD-10 diagnosis codes are associated with the non-coverage decision:

- ICD-10: M17 Osteoarthritis of knee
- ICD-10: M17.0 Bilateral primary osteoarthritis of knee
- ICD-10: M17.0 Unilateral primary osteoarthritis of knee
- ICD-10: M17.4 Other bilateral secondary osteoarthritis of knee
- ICD-10: M17.5 Other unilateral secondary osteoarthritis of knee
- ICD-10: M17.9 Osteoarthritis of knee, unspecified
- ICD-10: M17.10 Unilateral primary osteoarthritis, unspecified knee



- ICD-10: M17.11 Unilateral primary osteoarthritis, right knee
- ICD-10: M17.12 Unilateral primary osteoarthritis, left knee

There will be no reimbursement provided by MVP when the following thirteen (13) medication codes are reported with the ICD-10 diagnosis codes listed above:

- J7318 Hyaluronan or derivative, Durolane, for intra-articular injection, 1 mg
- J7320 Hyaluronan or derivative, GenVisc 850, for intra-articular injection, 1 mg
- J7321 Hyaluronan or derivative, Hyalgan, Supartz or Visco-3, for intra-articular injection, per dose
- J7322 Hyaluronan or derivative, Hymovis, for intra-articular injection, 1 mg
- J7323 Hyaluronan or derivative, Euflexxa, for intra-articular injection, per dose
- J7324 Hyaluronan or derivative, Orthovisc, for intra-articular injection, per dose
- J7325 Hyaluronan or derivative, Synvisc or Synvisc-One, for intra-articular injection, 1 mg
- J7326 Hyaluronan or derivative, Gel-One, for intra-articular injection, per dose
- J7327 Hyaluronan or derivative, Monovisc, for intra-articular injection, per dose
- J7328 Hyaluronan or derivative, GELSYN-3, for intra-articular injection, 0.1 mg
- J7329 Hyaluronan or derivative, Trivisc, for intra-articular injection, 1 mg
- J7331 Hyaluronan or derivative, SYNOJOYNT, for intra-articular injection, 1 mg
- J7332 Hyaluronan or derivative, Triluron, for intra-articular injection, 1 mg

### **Notification/Prior Authorization Requests**

MVP Payment Polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.

### References

health.ny.gov/health\_care/medicaid/program/update/2014/mar14\_mu.pdf

### **History**

April 1, 2022 New policy, approved



# Implantable Devices

Last Reviewed Date: August 1, 2022

#### IMPLANTABLE DEVICES

Definitions Notification/Prior Authorization Requests Additional Exclusions Reimbursement Guidelines References History

### Policy

Applies to: Hospitals and Ambulatory Surgery Centers in Vermont, New Hampshire, and Massachusetts

Applicable **Plans**: All Commercial and Individual Products.

### Definitions

For purposes of this policy, the definition of "Implantable Devices" or "Implants" is based on the United States Food and Drug Administration ("FDA") description, which is a device that is placed into a natural or surgically formed cavity of the human body and is intended to remain implanted continuously for a period of 30 days or more. Implants must remain in the patient's body upon discharge from the inpatient stay or outpatient procedure. Implants may include but are not limited to metal anchors artificial joints, pins, plates, radioactive seeds, metal screws, shunts, and stents.

Materials, liquids, and allografts that are dissolved / absorbed / resorbed / remodeled, such as sealants, hemostats, topical thrombins, bone morphogenetic protein, bone putty or cement, catheters, staples, and clips are generally considered supplies and do not meet the definition of Implants for reimbursement. Single use / disposable instruments or supplies also do not meet the definition of Implants for reimbursement. Provider or vendor administrative storage and delivery costs are not separately reimbursable.

Cardiac and vascular catheters and guide wires billed separately regardless of the amount billed are not separately reimbursable.

Implantable Devices or brachytherapy sources eligible for payment by MVP will have a CMS Status

Indicator H (pass-through device) or K (brachytherapy sources).

#### HCPCS Codes That Do Not Meet the FDA Definition of an Implant\*

| C1724 | C1725 | C1726 | C1727 | C1728 | C1750 | C1751 | C1752 | C1764 | C1886 | C1753 | C1754 | C1755 | C1756 |
|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| C1757 | C1773 | C1782 | C1819 | C1884 | C1885 | C2615 | C2618 | C2628 | C2629 | C2630 | C1729 | C1730 | C1731 |
| C1732 | C1733 | C1758 | C1759 | C1765 | C1766 | C1769 | C1887 | C1892 | C1893 | C1894 | C2614 |       |       |

\* - This list is subject to change based on FDA guidance.MVP will use the most current FDA information available when making a determination of whether or not a device meets the requirements for payment.

### **Notification/Prior Authorization Requests**

MVP Payment polices are not a guarantee of payment. Providers must also check Member eligibility and refer to the Member Benefits Display to determine benefits. Providers must also review MVP's Utilization Management Guides to determine if prior authorization is required and the Benefit Interpretation Manual for MVPs clinical guidelines. These resources can be accessed by signing into your account at <u>mvphealthcare.com</u>.



### **Additional Exclusions**

The following circumstances will disqualify any Implants from payment. Providers can not bill MVP Members for these items:

- 1. Implants obtained by the provider at no cost or reduced cost. (See additional information below on use of appropriate condition codes, value codes, and / or modifiers.)
- 2. Implants that are contaminated or unused and / or were not implanted in the patient. Examples include:
  - Items that were prepared or opened during a surgical case but not used or implanted into the patient
  - Items opened in error
  - Surgeon "change of mind"
  - Technical or equipment failure / difficulties
  - Surgery case cancellation
  - Muli-pack implants when more appropriate unit size can be purchased

### **Reimbursement Guidelines**

The following condition / value codes and / or modifiers are required to report the respective circumstances they represent:

### **Condition Codes:**

- 1. Condition Code 49: Product Replacement within Product Lifecycle Replacement of a product earlier than the anticipated lifecycle due to premature failure, etc.
- 2. Condition code 50: Product Replacement for Known Recall of a Product Manufacturer or FDA

has identified the product for recall and is being replaced accordingly.

3. Condition code 53: Initial Placement of a Medical Device Provided as Part of a Clinical Trial or

Free Sample – Provider has been issued a credit upon initial Implant placement as part of a clinical trial or a free sample.

#### Value Codes:

1. Value Code FD: Credit Received from the Manufacturer for a Medical Device

### **Modifiers:**

- 1. Modifier FB: Items without cost to provider, supplier, or practitioner, or full credit received for replaced device (examples, but not limited to, covered under warranty, replaced due to defect, free examples).
- 2. Modifier FC: Partial credit for replaced device.

MVP reserves the right to request supporting documentation if claims do not adhere to coding and billing which may result in a denial or reduced payment rate. Claims may be reviewed on a case-by-case basis. When revenue codes 0274, 0275, 0276, or 0278 are billed, a HCPCS code which meets definition above of an Implant must be reported on the claim. If a HCPCS code is not submitted or if the HCPCS code submitted does not match the above definition, the claim line will be denied.

### References

<u>https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/</u> Internet Only Manuals 100-04,4,60.4.2 Complete List of Device Pass-through Category Codes

### History

August 1, 2022 New policy, approved